var title_f35_43_36528="Elbow fracture dislocation";
var content_f35_43_36528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dislocation with incarceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 396px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGMAV8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5kZiAdo465pq53BlVhnt60mwEgHO3rj1qUKocYLDsMdqViyZDjIGMmpYhtkO4dewqAAmTIBC9PepgHLg5xmiwFidB5oEQby15Ge9SR4D4AxnvUCjCjccnPrVjIUZHSmItx/dJJ+bp0q1HksuO3eqcHJBboasI5UYPODQBbHzMTk8DnPrXVeBCW1mH5c8jH1rkIiW3Z5zxx1rsPAi41WIL0JGfagGfTeiMgtkGMkio9Wz5mCygY5FO0QhbNQuCR6U3VmDRsMAsemaCTAmEUTnIIaqU6EqcRq3OfpVm74GSOe+fSqLFSCN+wZ+uaBlC9iSBjMseGBwc0qx5VOBjq3fNSXC+Yy5YYX171LbFWmZR0HGBTA0LKUBUHlDA6ZresdojBcdeayLWELAWbliOPpV60lHsAPU0hG+rAwHb36E1z+uL5pO88449q3ISWthwAD3FY2tqgjPPIByaAPCvHkK/aRkjIOcAd649gpXd6etdf4tVmnlOWHzZyfSuQ3KyOpIw3tQMglH7sdifapEVTGCMZ9aF4HTI6DPekaNJME5GOooAaGLH5OabO5GFHQdxTo1BjIbs2AaSUfNjGCfWgZA21kODgHjBqAowXgd8VM5ZcjaWPQ1XHCFlzwehoAidRkBs59qpzYyRjb2zV1x7+9V5QRkYzkZoGZtwhOCvX1qDy/lyM49DWhICuPeq7qpJVSfalYCsww+Rgr6UqgA7UU4PP41NsyRuHIHFQbJCRxx7UWAVk3Dk5APeo8hQTngCpnRQnDlmqEqNuSM89KAGq+Rk5OKYTlwBnB7d6fgb+OncCjCmYMPujvTQDXJPyr+fpTgw2jI3bTke9RyvtbuD6+tMbcjDHTFJiLaMp+ZhhmPTPShumVOT0qBpAwY45HSpI5MthsDIyCKBjnZ1YcjBHentyAewpigM2Xc+1KTyeDg+tAiNRksOGA6U8H5m55Bxz2qABWcKisCe9STyfPsAG7HzEUASLnzBkhlH61MhYfO/OegzUSKoC4JyByakVtuAOfqKYFgFWXpgk1Y2EcMB07VTj2hs847CracqpU/nQBLk7flAyPWnrI0bDoagB4HPvU2N+CpIOemKALFu3z+ZkfNxgV3fgJsarDtDMSRXCwr5Zy+Ce1dp4GUHUkJbjIwAe9AH03oew242ggEenU0upxpgEkD1zTPDysLGIMMbR3pdTdWfYw2jufWgk527Ugk7+/XFZoZQ7mRBxwcd6174I8ZVOfTPWsgoBlCQCcknFAGdeMBOqKXVep46+1C3RWX92QOcBT/jVmZBKwR5QccVHGkW7aFHyZOetMZsWsu/DPIMk4IrWtkQk7lAPb3rAtwHdQCOv5109pGinDNj5e9IRtRbVthgKFHQVz3iVT9mYYzkHn1rcjOEwMNWNrw80GLPAGaAPDfGcZjiY8g55B71xcpDJuQcjgkV6F41BeSUoBtA/WvO5A5Y4JGT0FMYxT8oUN0OacpCsBnjr9aREAjOc5FOULtYHhfU0gIgCJHwMqeeafgldrH5j3PpSoVJIZSfQjtUcpLSBc5HY4pgNdSqnbyDyc96ryqAoO7kjOPSnyFgSmCR2qJ1IbBPzY6etICu68d6gbIOc1PIS3UdqrSnIBPVelAyD5d3I4HOahnVS25Rgn0qdgGXk8+lQO+xCCMjOfpQAxsBxuJI56VGScZJxjgYp6uGO/jNMwNxZskY60ARquckY4HrTWYN901INrLghvekKbeEwB1FAES8DOSBjmotxA+XOPSpSVUNzjjmmMqs2VGABg0AJMqCLnPHTHrURUqFIY+tPO3adnUHkGhdzocgsc5z6ClYAdPl3hs9iPapFckdAAOOnWkjxGXBX/69NjkJ+QAFepAFMZIM7xlcD1IpQS7sJASAOMUiOxILBl/GlIViWDZA7UriGElVJXpjHFA27FBBOaRCdzqOQe3pUkeQWaQYHYDvTAVA3DkHAz0qddoQbckmot4YgKTz0FSxddrDgdqAJkLAgPgDtU6LggrjFV8YCkDKn1qcMN3r6UDFQfvNuB16VcXqdoxVZdwO4KNueatIyqu5ep4xQItRbcMJAWkxxiuv8AMv9pRhVLOWBri4mbOWBzXc/D4f8TSEoQpBHGOKAPpnR95s48qAcVW1ldxBDYP86saWGMEfORtHNRatz8oGMdfegkxDsDfOvXgY7VQuYt4YIMY5J9atSK4dgV+XHFVLjci/ewcZNAzPuIULR4fY3XANFrDi4cs/BqW4ERtS7knPcdqj01CB97ec596ANmwt/I+YoCQeOa01O9jnris6CTMu5s7eAQDitW3KMXXp9aBF6xc424/GsjXiyo+SSc4JrVs93ln+7nvWdr0fmQuuD8vINAHk3jmLbE2zH+17V5rtLMxdunSvVvF9o32ZuARjknivLbiJY2wc9wc0xkJdCRGOWI605t+0AqFb39KgLHny0yBzk09Gcoc5BPQUgHqWCZ35wO3FRFv4nIB7+1I4OeOOlOZeyDJI5pgQvy+Dn/Gq0xyxDHBAq1Jvx8zA85warMMHcce9ICs4yeG4xULgDCgn1JqV3y+QPwqGXaxyAc55FAyBuS24g88EVC2MEPhl/lU7j7wKc9gKidsJt2jpz70AV3wEHljIpoPQsvangBlBAIApCdp3FuPQ0ARHBIIBXPaopN4bLZ9hSyFiTt5PvStkcseo5oAi/iy+MntURYM/Bw3b0qXICgcbjx9aGTO0YOc0ANQN5h6c96c5CH03cUzDAMOjfWo3+8vmZJoAnIUpjOfxpVAIyDjPUikyqqG2j6etAZs/LgHqRQA9dp4HI6c00jGMHj0FIzFjlRg9KUAqQAAfU+9IYi8OxwBnj60BzuC5wenNMhYhMY3c4pWOASTw3HuKYiZRlgM4HYirOQoweABwe5qnGpXarc471aRcjJOWoAcAWUYzt7Vbj5QY6DgVWQnapbirCkldqYBHrQA5OVC8g9SKsRZIHHHaq20hvvc9DzU4YxDCkHPrQBYDsXBxketegfDfY2oxlshi2F9q8+RztCgf/Wr0n4XKp1OIuhK9sdjQJn0TpgZbMMeCF6HvS3b/ACA/3v0p9pHi2BY7VxWfczjATByD19aBFK7VvNJLAZ9+lUJIgwIDAgjk96s3wBcc5zVQqroAMADvmgCoIgu4Fcg9B6VXCFVLRsAQckjvV+SMpyXVVx9aqu2zAbo3A4oAu2LGTYG7dR6V0dpCgRT/ABfWuds8AMCBu+tdDZp+6VVbJ659KAJFZXmCBcL0NR34/dPvYDIxUobbLyASPSq1yWkidMZHr6UAeeeNTHJbMVJyowfrXj+pM4unCIcL617B4qBFvOhcHHQ+9eSakx+0P3YUxmcudxwPvd+1Oz91gMMDgCpAoZiFXHHPNOlYCP5cHYOfrSAQ7er5zVeYOGLEEJjgVIgc9TgGmSlhyxyo/SgCCQBgXHAOBUTptU56E8VLMQSFVsgc5xVR3PRjkA9B2oGMKseegHaoAc5BTqPWpiNwPJFVzwpI4K0AQz5DkgjPpUcu1lOcr/WpDyxYjr61E5B64yKAI1AU8sRjjB6GhyeFPzBu3tTJW3BeOvFNzsAI4xwaAB48bR0B61WcFWw547VPNlSSULAnio3yOGGSOQaAIGOXCknJ70g+8Blgo6+lOfJ2nII7+1MG7c3Ix1xQAP8AO7Ko9sikK7WEfBPY0YbcMSDmpG4bKHOBgkUASgMdpIA4qH5s/ePJp7sAqnOewpVK4woHWkMQKEkUdu9SZABZRk9qgJzIxJNSIcbgMdfxoEBQZJ6kkDHaonUEhRheTmnruLqSvA5xQQrNlsgHjFMByMzjII96l3Z74x6VXVNjjaePTNToCqsDy2aAJIWy4DZ9qtqT5h3HkdapwZ+UsPar7IAuGIORQA0kSLngLng1btoRIwA6gZwTVc5CMFUbRUiOW6DrzmgCwhCtgkE+1epfCePffrk9OcV5ZFwMDFeu/CZdl4j7Ny44NAme7xMY7dWyNvQg1mTODKdnRj19K05CFtgSAQwrEnO9iEPyjpQIbdfdG9csOg9qpyxxjBGc5yatM24DcM4/lVCSQkttAKE8c9KAIr8boyIUIc9OcVVEDxxjMjbuhzzWr5sYI35ZlGc+tVmnSTduXbzwT0oAuWkLErjaxA5x1rUjlaJGDHg8YHasSK48tAYTuJOPl65rSt5yrESLjjvQM04nG1Co7ZaoHlYCRk6e9RQXLFsMp2ngYqSQKqPnPTIoEcD4lkjjjmLIpLE59vevJ9aKC7LqBtYZ49K9b1eFZ2n/AHJyucnd1ryrxEESdtgAxkEYpjMZZACCo4Hf1pshYnaF57mo44yY8Ow55FKwYbS/r2pAOZ1kTZg5XrTG6qCePSnxNHycYz1NRyhlGO5PHtQAyQkHaFw3YVVlVkc4Xk+1WnbkM3PBGarOWOT/ABfyoGQ4bP8AOqzIAGOec9avDrwvSqruPmyCKAKrA7+FJH1qGRCCeoqebdtwp4x2qDgJsbhz3NAEbBVUZ+Y9qidcsRjknmpXQnlTkgc5qGPJyxOB6GgB0zuVVUOR/Sq8rMq5Reh5zVjG1s5IqBmAVjjNAEBZeN4HI5obBfG3tnrTnXzDz1Ht2oCgTde3egBqhf4hmnKqjeBknr1oKornJwo9OtKmwlTyc+tACIA+QuGUChSMY5GOKkUqhYLjJOQaTjD8/L70rDGhiwwByKRPmB7Y9uaGCjDJyMUpyMANgnnNMQiF8jc2R6U5XUZHoeKWQrgFcg1EI8sCp6c5xQBOMCUfMT/Wn5LZ5Bx29Krqx3rz1qWLqcge1AFiJVVk56irQZQoyM+9VI0bJZgCR0FWo9rLxnJ6igCVRtGC2QeeKkDYTAB+aoRk4UZ+uKev3NpyCDye1AE8KsHIX+Kva/hUpV4n3AqP4a8Zsl3zRgnv2r3z4ZoFt8Io2qAenWgGeiX103lgDHHb2qgG+8+AQaXVZOSVI6YwazoZ2aFNpbg8jGKZI64kdN2ARxyPWoVlLIpdMYP3RVqaQPIBgbiKzrpWViwYqCe3akMt+bHIcgYUcY9Kju/KkYRrgEDr71XV1MbJF8zEdf61XctGV8xlNAF+JBZhQBubGetaKTZkxID5ZAOMVhW29XZmcFd3Ge9aVjMWyXbd247U0BrRuO34fSpZWwq7csT2JqiuSpwW69h1q6ssaxKSCWXtSEcrr0Sq7LEQrMctXlPigbvNbGcHuOteoeMrqN13RrtdTzivOfEQ3wkhcZ6k+lMZxaEhAJFxk8EU6STLD+I4xgVCwZHx1A5zSsxClmGM9xSAlyoyT17A1G8zSOwbgdjULZXJTORRuLndJ25NADuxyM59KjmJVhgcDsaAx/h79KV1O0OTk+maBjC2DwO1V3Ax6inSsSvoarvk4UcZoAilYlto4FV5dwJ3EY7VakXkg9BzmqkqgOGBOCcYoARvmUEZU+oqJmyfUfrT8gkIxx6CkVY1DMxO7v70ANBXdhmJzULsvmcg4PSpAFKsVU5AppVSQ2ME0AR/x8ZweKZJtWQ4O5sd6eycsA2CfSowCZOBgDk5oAccIuRyD60FQCAG5PTiljVuchWXPTNKchtxABxQACPDF2I2ClEePmQDB5olXCEknrk0q8jCEYx37UhjGQqcjHPFLJkFVwuQOaVl5wOT3pVz6ZB70ANUZkJOeOnpSMGEmfQevFKOpzkY96Y7dj82eaYgKNu3jkDripPmYnp9KTZn5VOM/rSiMKT1JFAFmJfl3End0xVhD83OelVSJOAAA386nQu2Uz1oAlViW4OcVJneGXcBTAVQEYy3t2pQyFCRgE9hQBpaOu65RF25FfQfw6hK2xdlwuK8B8OR7rlASeemK+i/C0UcOjRh3KnGT2poGbGoeVJGx3YyMhRWWfMa3zuwRxz1o1W6UJGqY25zn0FRi7Uq0kREiY6HrmhCGmbYWMrjI4AqusiM/lhyB97B5pl0UwvmgliMgrUCyLJc7kxkrtx3FAGhtZIsRBSW4ytLLE8UO3cGdj1xUFstvZ/vZXw5P3SaQ3x3PkEgkDgcc0ANjYpIq4HynGPStezj8pVYfLnnHrWeqMFZmIDIcgH0qaOcCQ7H3SY59AKANu3Z2iKAjj+PvUnmYJyw6Yye9Z9nMzMwc8DuO9AuPMl8tQdgHPqKBHPa4WlknZAihhjLV5/rKh4zGWJOCCQa9D12NZEkTj1BNec30ihpA8eOqigZyMwwwHYenJqvKcAZJHoKnvpwJsIApWqsxZY+SH5yMdqQxwyysXYBc44qMOUkIZc5HSlG4qegJGcU0SKzR9j60ABYggj6j2pZMlSxOD/Oomb95noPSnhQoJbcSaABwcE8Hj8qr7T5nPIxwakbJB2dR1qOZyArZxzwMUARfNuzkDjkVXzhs4/OpWdd5Kjk96gkb5vm6dKAI5F/vAZPQgc0zbsxncc0rjG588VFuchmPReKAJMeUzYI55zUXz89AM0qscDcCc+lIzDGHPU4BFADJCVAwRkntTGQll6ZHQGnE4XI9e3NIw/ehjnp0oAJBIFyxA7jFNWQKARnoOM9KQMm4hmJ54pzIrM20Z/GgCddrwt6k9x1qEjZIQuefTpTk4jKgn6jtQ3Dk8YoGOwFyuSTjI96jG5VVlyMEinAl+dwA/WkiGZcbsrjvxSARhtJ4JIPalZR5o7GnsCd2CR6A0wlWXLZ2j0piF7Ak8g/lUiqSw3MATzk1GMBUI6H1pyhN5LE8n8KALCkk5OGHf2p6u6sdoGCetRh1AGAB61OhBxjkZoAXOSTtwMdaegXAwOSaWYrvzg06Nsyx5GF9BQB1vgu18y9jGAefyr3iEeTYRKTgcde9eS+AbLzLhJEJHTIx0r028uQhWJzuKjI2nmmIp61KN2zeOgJFMjeOKMSM2yM4BqtqZZ51dU4IH1pyvFJFskRgP4qYGlNElxCvksSX5BFYsSTWtySAWYnB4qxOXjXbbyADtg9BUcU0rKrRNnnBz6+tIC85JuUHlkhuSCM4q1qZW108iEEO5yRUelO0bN5pBckkZ7mptWzNbq7MiOOqjmgDCN8YbkKsjONufWti2RhJ5hHzMoJ9qypjHBECqjzuu4jjFPtNVMh2AdDhT1zQBv+c4PChVAyeaqTXDRzllGVbpUT3IblgAoHJ70XDrK0LIxUqe/TFAFfVZiJneRQFKYHPFec6nLuuZCSeDjBrrbycy30g8zljgE9BXManH5bM2N5JxnHShgcprEAjcYOC3OfWqQ/1XBwM81pamC24tnI/SsxGwBkg0hi55Yg/SkIKsu5RjGetA5YEAcHijfjsN3rQADDSHK8UsnOduQRxSpsLc5z1xSM2CNo70ARnI4I471DMoYAVY3Bgefu9KZIN4AXHByaAK6oEYDbzUDRksQ3Bz0qaYgMSucg+vFNmcrtJOWIoAqTIBkKDjvUaMykjbkd6nk3MpPI78VFu+U4Htx60ARsHHzY+Xp9KjfhR8gK9xUuARhvvdwaiZmzg469vSgCJzjlfkpryEnn6fWnyKCozkA01l2uobLKeVFADVVdr78fyoCbmARWAznOaHIYZIAUU6NMgEEgCgB4JXB6juaMq5cgEjNK4AXGTgmhfkl2kfKw420AEaBeAF6ZqLD+ZlVULUhyG4+alYtkALkjtQA9iVYEd/ekJywDEA9eBTRFu5X7uOAaRCScED0I70AOJbnjOeMGnHKtwo6cim/Iv31J78mkP+sIYHb7UASZV5Cx47VZTdsxkgVCEXJIzj0NWIwBgsep6UASfKFOWLEVd09FluEUY56HFVWRcE5GDW94ZtVmvYiUJORg+lAHqfgS3WwtjJIApI7jNWb+VhflyQHHIx/Kn27i0gVWXeMYb2NZc9xGZPNUkMODxTEaMdwA26Zcg1Pc7hG3y7Rjr6msyyzLuEiHJ5GTjFTNcSC62ykqq/wmgBbWLKvuILDqKUR/Z5FIZyhOSuO1SQTQ2jsy7WLHrnrU1vtKvKGJLHIU9RQAy1uJYi7ojsFyAHFMmkEzLNPKFlPIRe9JczXN1MI1AWEjvxVuO2hliaFNqugHzn1oAy9YdysbIRtIwQO1WNDtoxtmmfbj5Qp71TvI1hPlqd4zlj6mnteRLaLgDCkDpyKALxuERnManhjknoRTba5Nw8ksgCpjPXrVFriNrgJjOcMOwNSXalYHXC7XHVaAKF7IJpS0fC7uKxtbYgKVLA961yoWEKrbgvU4qjrMUcsKyhiWA5FAHM6mgOOSVYZNYM67HCgAnPFdFPiQkM+30GKxb+Ly5w2Mr70hlfeTjAxj86jZyFcYwPWpuVGSM/WhSTgFQfwoAYh+YEHinuQCOcE0khAGQAPeoxhyTg59aAJXGBgEVXY/N0w3Qn1qcqSFPHFNlzuwME470AV2jJ3DGcVAykAZ69uauNjO7gMaquCWYEj1oAhBDP3HHpTGUruLk4IqV8cEcY/lUQDH5c5HrigCvKuCPpz7VHtYMmVyPWrITGCcHPA+lRlGyecAjgCgCu/DEFsemOhpGHzgHJIP5U93XGADuPGM1Cz7m5GPQjvQAr/KMdB70qsc5xnIwKMA8tnB9adKpwApI/pQAvWLDAhqXZgnaMsOaahOMs270NSsCvJJ2+p70ABB/iGDioyXDcHr61IvzEkk8UmA2WU8nsaAI1Urg7jj2pSC0jKhxu71KoAU4YZPSo5eO5BPtQAsYJDZ9cU/lVIb5j60zlV+XkdamVsqWxtGOlACBf3qqMbcZznrVpOU44PaoODs29AcfSrAXYBjp7UATFdxUAHPpXdeDYY1m3yDbtXcPrXGabGXmCgAnrk16ZotssGnqxOCefoKaA1Wuw0O4jhjjOaoQj95z84bpRIytb+UqsMnJ5qo77VyJWRgcD3oEbwmR4QSOV67etROwnlLB8r0HqKz0uFgaPHzk9ae8ipucHafQd6AH3aBkkVD+8U5Ur2qa0uJI4UIOXPGDVe3uNtvtZQNx3Bsc4qaJ1MJymSOhoAvCfJcuDjqozUZumZmVFPmH+6ccVXspQjnzDu44qaWVFVHQqoXr70AQ3G6OIKGxuPVj0qlal2kcHktxk9qs6iHu4VeRlVB0x3rNs5pFfA6dOBTA0JJlCqFwzLxk+tX7PdOuHwEU5Ge9ZzOzoGKLt6YA5qVZpECrF93rQBLMWR5ozgKen1rKvdv2NlLYfv61pXTqQmSCGOTiql66oSPLIY/jmkByj5jlySPm6H2rMvhubkk981vanHEXRR8m/pWRqIVQActjgnFAGc3J4zj0oYiMYU8mmAbVOOBUiYDBmG7PSkMYyMdu4j3oZSEx0NTS7SF2/iajb7xIGaAGoTj5unakCktngj1pMY5bp1pSS3+rx0oAjbL8AYxULrnPFTy7gB27cVDNiMjrgDrQBDIQqbeeKjI447jFTuARkHoM81FkAHg4AzmgCARlVXt9ahdmDMRjjpViT7wYgsoOMVFKw3tsFAELDZj5Rz29KjbHQgKvXmnNiTJIIbtUZchSrDn1PSgBU3tgDbgZ4p6kYHy4bvQrBuWGBjtQVBOVBz6UAKy5Q7COOtKrEgAnI6cdqadzAYAz3FCxlOd4C0AOXYFIHalY7Tt7d+9BwMKgDAimgFUzgk59aQxg+8SeQDjBpwdvMIxxnHPekXZvCfw9SaUtvLLu+UdKYhWyTjBCn0qTB4JOB6UwOOVAYkjmlPAO1idvWgCaNPnGDw1WVGBjoM/jVUHEi7iAODV1IxK2BnaaANzw/a+fKhQZ5616DGMxKkY2kVzvhe1e2iUxsvJB+lblxIXnPOEA+bHHNMQ25zCxBGSOTWazeZNwMHnGK0Z33yKCwyV4z3rMldI5WCA7yOT70AXkJjZdpAOORTrhZrgKqbVK8nPeqsbLK6SPlSOMirDnhXjJYdCPWgB8UzsBBuG9OpxVmWcR2yRK6qwPJbrWdFOY5iyEAg8r3NPvpfnGAPn5G4UAWrS4jWTZKGdupI6c0y/nVCqplTu6+oqpFI6HaTtzjNMklEkzZIKe3WgDb2ia2XY4zyQuM1ltPITjbtcHB96tadcK03TaAODnpTdXRRGpt2DEnnjmgCKK4eVCACoXrzxUzDaciQmIjk1nQblRiemRketW7kqSpDYXHIHSmA29mjZwqHoByKlvGSNB5mWyAVrPYBmdkV1XualmlV7VO5X5ct0pAVZkM0e4j7rZ5rNu4tzMCCfp0rVQMuckHPQZpLkZTqMgYOO1AHISx7ZGU9qVQN2ORVq9iMcjMU5I61UDfMccmkMlUckEYHWpNpD5VcZGM0yFdwy/TpV9IsxKu4EdfwoAqNb4jJznPWqrxlXATuK2Ux5B9COKzWj3ZB7daBFYhs/MeMYqNl2p8wLVcaP5GYDG3jHrUPHA/WgZUfnkj8qgkQBPlPJq4RhNuNuTzVfG1TnmgCAqWwNv1qq8arJjdtJ65q2xyCQdoHeq8injJyT7UAV5FA9jnj3pshJOCOvtUzEMO+RxzUDsCAHJDDPagBjE5Xa3zGpMhSvmEn396ahHyts6GmyB3XB65zgUATs2VIYYGRzQehZsH2pGjygJPXqKUEcLjp60AH3Thc4x0ok4UDBApVkG47RlsY57UySQttDHkUAAXZ9QOPemMF3FlPGOlAyJNo5xn8abuIbG4fl0oAceSSpwelSx7gSR0yM5puGRAepPTipfMwhz1OARQA8kM4GBkc5rZ0OBZblSxyCcVjQ4acLjqfyrtPDVlh9yqCF7CmgOn0sraszZB42hWpNvmRvtboclfWi7gIwVH3RyR61EWk8lVIAI+83rQIrXErxuhTB56YqJo3lm3E85zg9qdFvmZpOiL3oMTs+5AOOTg9RSAsGJ85QjryaQmSJVAzySRjoaIBvmAXfgnoKsPbyGJg7lVDcAimBUL4YEgZXuOtTQuSuXwXJ4zUdwkfHlbs9c0z52XLryD1FAFwlgB521geRikkeMRMyouc4x7VDfSrsEsZxgYJx3qpFLIqZYZQ+9AGlaxeXF5xbIbjaO1WZMtaK2QDnj1FUkdZIdiYLDnPap5ZD5TK2DnlSDQBUdHkXcisV6ZNLAsjw7Mcg5+tTJcomFznjGKgFwwvAIx8gPIoAnX+JZDsz696bCYjK0TDKH7p96W9YsqO0Jxnjnmlz+7Oxctjd9KAI3tczFE3EjstMvInlhOFwF4z6/WtFb0o6MQjOBg+tSvsmTcgBQn5hmgDltVRjCrjGAOgrGijGwMn3z2xXV3sQMJVUwuSPpXPOPLlKjqOKAIY1Zl+bbgfwip4+H29VHOPWgIQd3U9PoKliUKuTw3vQwHFSIdwIHfHpVYY25I46j3q+q4yOpqvJGEcsRknotAFYBj5jEHHYGoTGcZYcD0rYixJCS4AI6471DLCBKTkAHsKQGLKoBGD17VA4XncGye9aU2A5UAZFVpYlEBYSr5hbGzHOPWgZkNuVgCRg0x/9cPyJqzLFvxzyvJzURIDHI60AV5OM7uT6ioGC4C5IPripnIQlQx3Z4BFMZAx6nI9KAIwNiM2QSP1pC2XG8Z46il24kHQgCnrtDHacZ68UgEblBgEH1z2pJARhuC2ORUjfPhWxgCmMRgBVwx9KYDfutwvzNSFWLAbfmz6052JbHORTWYptCjLHnNAEZwPY9xTQoBxyUJx+NSZyw5BppkbJz0FADxnOw889c1IyckKcgc5qODGDxx2z2qRY9y/dOc4yDQBd0yEyXCMB8oHSvQtEhEEYf7rDp7muS0WAJLHuHFdvDEEgRimEPJzTQi4hGxwzbyDyorPv5B5csa/fJB4rRB2xblUZIzx3HpWZqEqxR4SHDtyWoAq27yEbCwHbFWnjaNM5Dkj1xVVciVcrhiM49KkiileXLuoTOct6UgL2msROrFcLjkg9Kt3jBtqgluarieEAldu1OWIFQz3XmqyxjarfxntTAjuGzKFSTg8c1JCdrFXkJH8II61nx28iSmTgheRzUpkKzB3cNjkLQBNesjQhJvkYHOPWqPJiwpypP5UTMZ3JkAOOaZAqyAoehPY0gL7BldUjcDKjmrFuczR+bhggOW9ayXmEc8Sq+RnAFaKACUomDnnnsaaAuXHl5ja2UcdQRUcULfbtxwNw3dKsRJujYKvz49KtQWLLHG0jlT3HtQBUuVDIjo5YA/MDRIhHlyADy2AHHarP2cSq+4kQqeMDrULmNYSjSBUB6etABLbgyAMqqpH3hVnS7c+fLA4AXbuUjuaY0LSwgRMdyjhT6VoWc62yeYy/vFwre1MDMvIiqOrHOT27VzOoQoZSyrgHrXZ6vayNFJKAFDHcpBrnmgV4WVh84OT/ALVIDKWPjdkYHGMVYgtXkYLsUgDg1ZNsdx2LhSPwq7YRbSBJu29zQBk/ZsFSOCDyKUxruzICB0471u3URQ4RQwPIPWqk0DSRj5SetAFCzjV1zk8HBFNu0G0JGpxnmtGzh2q2xOntU00AFuXKgHHbvQBys8SiUZHzD8qoXKHccDGelb88J+8gLZHcdPas2aJ2PIAA7elAGHJGAoJPzVUkDYCkcnnNaN0NrMCD9apupKgDqOlIZUdMhtxzjvURRkJycAnmrqgFPmHHSomG4D5vlHH1oApCMLg5yM8GpJAEZdmc7e1PYjIVFIGc4okGSD3oAawIizj9eabtyFyxHv61KBmPj7wPFNbaDkg7h1A7UANC7MqMnPrTSCuNq5z3qSPa3zAnI6jNRl9www5B9aQFZIwOSOnQ560bdxOdw5pUBXcTt6/XA9qlXa5yucdM4pgRxblXD856Vo6eoLuSAFB71TWMsAVABz+ValqhDKpAOMZoA6HRxG06K3ccV09zMwQArxgDrXL6eo81Q77PpXQQ/M+C+dvXPPFAi6k8u5UQAHZ37VSucgL5rB2Hap4xudj/AAjofao5k3SABck8ZpgJFE08rErkYyAOtLdq8e7cANi9BXQWumNYWXnT5/eD5eK5fU5gJHKFgOdzGgCslyEyvX1NVTO7MwD4UnGDTHQpGJIyWHf3qSJDyJdq5Oc+gpATkusG3IOBkn2qNn3JlOnrjmp0gEyv5b5I46cVGlrKJMfNjOAB60wGI+YwGHI5zTi2zay4Kg84qzb25L/vAN3Qip2sXWdlRdy4yKLAZxiMj7wvIq3FLKpVgFOPTrUxtpfMAC/e+XpViDTyPknBBGRjGCKAL2kzM5ZgV5H51rafMoSXIZ2xxnpWVpts8U6AxjZ0AFdJo1tHMZU3MjE9CKAKttZglwG+8M81lajb7jHwo9WHaugns5rOQgNuH3cdM1n3Maqvy/KhGD9aAKNuJI50BYhOgYVsvJDLDsaE4Q8uf4qotGIShAIIGS2O9aLOpt8KcMSOPf1oAnBtJ7MwsrDnh/SubutOMdy4jy+Dmun8sxwlGX5Ou6kubZZYGKZ80d80AcilvIwLAgBP0q3a20jOWViw6mrP2QmSQtwAfXANaFvGHgCINrdQcdqAKMtsXCBB0pn2QBztHXitxbb9y7xKMDqT/SoxbZYDBz2NAGIsA3cEhAecUjwKysYvmYHpjmui/s+UyFVj2qTyQKdPpRtJmkRc5XBoA5GS2++zjHHHvWDe2rRyuVIKEciu4ubJQr78lj6dKxru0DuV2nbnBNAHB3toU5659axZg4kwTgn+Vdzf2RDtuX5R909jXMXluVPzc59qLDTMkjIPGSKrsz5GEwD1FaDrsGEGCaiki2ggHk80gKeGLDZ+WOlRtlXAbPPHSp3DLk7Tn1FG0sozwQO9AESjHXg5wDUbrhsghieDVhRtOw8kd6jZQGYjAz+tAEWT2ZgvQ8cmlO3dwDtpUJ4PIwOBSbTkOckknoelAyusTGTLEFe1PRWZhsbCdCMVGAC6jcSM96njHzY6AnJzSEW40AHBq7b427Y/vepqkjBAAB0PNX4AA27d8o5ximBvaZAW2liM44ArThUwuzSYGecDvWXDOihI4AfMbnPpVyKZuftC7gDTEaSOJYuf3eRxk10fhHSRdsruu6FRg59fWuTt4xPLvL/LnlPavQdEuhpuhzSJGSuwtx1oAxviLrMVuIbC1kwV4OK4XUrqN1SOPPq3NGsXL3U0kskZXPIJqjOqmONlXqOTSAfJMPNj8olVPXNWJZUYLkjGOcd6zUX597Hj+VPLBm2pxjmgZt2LguFRsDg4PSuitYGDBoySCMtXIae+SM8H1FdzpW37FgEkYyadxDmjXILR7X78daZKvyB0Odx7DkU9pHkB+Y4PA9qWWKXHyEZI7UAOs1VtyMQT1BHapUubNLwwOzM7/wAXrTLJmiDAct02+tZM0Ekeq73VgQcjPagDttP0xQA+7fgcLjtV+zsRHel4chgudp71Hp7t9mWRl27lwSenFaFqG8xd/JPK4oAlvbIXcYeTgryR61g3divmbTkBvurjnNdjFFIsYjwB65FVpbRPLeRkO5W4oEcW9i0UwiJJYkZDVcnswkRl2lWBwAehrSe3kNwGuGU4OQSORTdskk7AR5iHJyevvQBBalprZ0aMRq3TNNuSiW4A2mQfKABU0CBZ5HwTxge1JJbNJI0zMqMoyoxkUAYk0MiSorncj9+mKsxWriQAMGGcblGce1XpI1m8uUgFQR09aueURykWCf7vegCKOAAeWdxBGVx61ftrRQm6QEn39akt41ESkj5h61MpXBVhgH8waAEYDfzwveoZo4ikh3gbuuTVjJUFsBsjvWVPGzynC4BOOvA96AKVxbotv5YYEKSevJrFuoYljyC7A98dK6qO1jMAUkOVPJFUL2yUAkqVXOQO1AzkLi1Dq2xi3HAxxmuV1a0cgAjBXsBXdPCYpHeOT5CeFNZOoQb0DBTk55HagDz+W2AXAB4PeqT2mxiS3PSuovoyWIZenAOKypoM4LZwKAMWWAHK9BTJYMoDuOFNackJZW2Z4OOaikj+QKRu47dqQGWRtTkHmo9h3DcKumMgrvAI7j2qHbuLE9B70DuVvmJcHhQPzpuATgKQTyD61YIUAj72agw2Rj5QPWgCmvy7ucj+VPgk38OCCOhqBGbJDfKO+O9WYyRwwHXigC9GuU+UYyRVuI7mCqTWfA+5myvA61cik3ZK9KANGG4KTg4AOMCtGCUFfmY89c9KykZQUPGc1p24BikZvmVegoAvRXD27xOqZU8V32jzSXGi3Cbtq46DpXDI5aGIEZAGcY5xXU2cxWzEcCrggYUnrTEcpr0JXOcjPpWOQHt3PYV3V1ZecP3qjaqFgPeueudIZVLlSgP8PrRYZzrR7FUk8DtTlBEyEDAxzVw2kmwhlKgHuKWO3JDZycccdqQh9gu5juyD24612GkxypbA4wg5HrWFpmmEzIxJKgfn7V1lsgQSEqy4XkGmBEZmDKWOM9ABVmVJ5G8xlKYGTQRGpjJYOxHCjtVyCCS4VQJeG6g0AQWkDSkOdoC87qurZtOC5AY7unoKu29kgVImU5GenetnT7ZYLQZRmds9fSgDOt2uZ5FjACoBgjsa6O2gZLaI45TqKWzigS0yBh+uMZNXbVlUESLlewJoEWrWPzIVck+mCKa8IkRsfnVkqfIj2DGW7elTsggtyoU4Y5x3pAclqVsZyygfMMc5oYCGJYyqs2MErWtdxxsrHhQTg44rOngOAkRO7ODjtTAoG0WOVipJXGSOtQNCjWwkXcFJP3j2rSCS2nlb1yp6t1NQagEjh+V8bmzkigCjpsSFBHHlmDfMT2rXhj2oysxOOM1n2YBYIXAfqe2a14QY4whI68E0AV0haNAZDkbsfWpoImZsMOPWrUSsAA6hlB79KeUWRODx0wKAKgRQACRkZzg9Koup3uw5B5K4rUSBFJTHXrnvTZbbywrBduT2oAyEjkbcYsDvtIxUk1s+0bU3FvyFbVpYF3EgAKtwDWr/AGQCf3eVGelAHnzaO80z5GMdMjrVC60RwmQeh5OP5V6WdLYs2AeOMVEulSklsfu+4NFwPHb3QAVZkG/c2ea5jU9OeF2IAMR4wB0r3LUNNVySE2heMCuevtH86XasS+X3yKAPGZrQlHKqRznOapeQXBynzDnIruNd0kwXE0UYHljqR/KsdrRfKAxsAPJ9aBnLSRDYdnXpmqFxAqZ9e5rprq0VlYBTz0x3rLe3X5uMY9aQGK0eeemKimOSVwDV24jdxtU8CoVTbIynBHrQMwQhEchYEk9DUiHAQEEke/SmI5cjH3T2p6bVk3AcE9KANGAjBbJz2qygJj3gd6owkkHJ2knAq7CcRH68+9AFqJv3hNadjIEhkDc56D0rIQEOjE/L6Vp24YSqw+6RyBTQG/p03mgO6gHGA2K0gAJ1LTEhRkAcc1l2ciqgjfkHnNbRu7ZpI8Rb84xgUCNDR3WacFy0gb5dtdPd6bHOqrHGuVGPm61ydvdqjZhURhTzgda07fWnn3kZU9mNAFi58F+cBJAw8rqVPUGqsfhGJFcNIMdSR2q+mr3akqshIOOB0qWK/nmZERl5++RQA9tIht7GOOIAEDJbHes17QSq6udpGOnetO+upSAhB2dF2+tQ28TADaWG4c5HQ0AR21jDGI1LDfnOR3rQubNH2NCG3seVUfrVi2tnFyYhGWVejY4atsWuxU2Ljr07UAZUUEx28AeVjr6VuC3LQswPXjFJDmGIboxknn3FaUcLPAypkZGaQijZWcsOUZlDdQfWtcWgVUeUZYnOQKZZrJ5oLLnjAzW7b2o8tfMzkc460AVrS3BiQA8ckUt2pMe0McjkVowQsWYk5XPAx0pt8mYyVxuFAHKXEcn2lncjYBnB71GZFELMg2ZP41qakGlDbkJPYjrWKyEM4KgD2PNAFMsZJAy5K7v4j3pj2r3UpI25HqKtRFUOZANi5znrWjpqRyReYh5HIBFAGFLaG3jyi7mzzmr8PMKEqAD+lXNVUogjMW7nJPY0RRgKGbGxR24oAbJDI20Ljb1ye9SxLi4bHGVz0qezVV2lmZsjgelWjH+8QMvPQcUAVhb+YyjGcjnirg0/bDsK7z1+grRsoI1OwZAY+vStD7KoYBAWHfPegDLgt/LRI0UBGGelXFhKxnnAq/FErMF4CgelTeWpI2jPPPpSAyWjZs7DgdCTTSmYBHnKjvWk8ABKgDJpsVuSn3Bu70wMG6skKhcMB1OO9Zd5p6pHhE/GutaI7RwDng1WmhGTjqOeaAPGPGFgElAUAbuT6VxlzasjRqCrDOGOK9h8UWXmwyRvEOOQa8+u7ZS7FgMLwAKYzlLu0aJVL4CqT+ArBvbQFwwXIFdxf27OvC5k447Vg6jCIQwwfMPYCgDk7q28qZtqYx2qlNGM44B9q37qJt2XJ3nnkVmywBMkDcw60gOFDjYzAAdjTg+xSAMkDAB70owXwTyODnvUcjnC4OAG4oGWLZ87dwJIP4Cr5YLyTnHP0rLhdiSOx5NWoztTADFmPWgDStwGYAuc5zWrDISzBOSe3pWPHgMjJww9a1YSR844PfFMRuWpKj5eVxjB9a1I3ClJggUEYI965+zDqyy5OQcYrXhc7jE7ZyKANKFBK5cPn6HiiGaQTGNF/wB45qESLbsIVHLjpmrNunmyqQdp+6aAOh07H2OSVwFkI2j2pbGFrctIZAxxzTLeJgqrnkYJFbemwJ5TK0PU9RQBDZ2U99F5iy4jQfdJrc0+BHiUPgEjgY4qex09+AiqqbeSOlaMGnMAoUhtvG7PQ0APto0CnaoVscZqxCNj5wNrcE1GYJVZVdl29eamVA7HYcAdB70hFn7OhBdV3dsGi3bypUj8ptsvO5RkDHrTw7btq8kjt2NXrZ/K4aMvu6c9KAJYYMja3K5z0rQiXDqoX8hTYCqpzySelTQM4m5+UdKAJw5AbGWPTgVVuSoBCLlgOavCORiFYgK2ckVGLSPzBv49TmgDnZ47oIzMAUP6VgXciwkhVJkzyp713d7FGFK7uG6YFYN3pe92ZQA/Y9xQBy6W9zNIhkQqhJYHvW7pNi8UA35ZmPIHcVq2NisYAly7YrSt0VZFUx5z0JNAGJfQIsoVuQBkDsKljt0l2kBSgHPFa2oWbOcxBcjqaZHaEIfU9hQBUgs4QpdUK49TQYCspLgEZyuDWnDEjgqMkDjNSLADlZDtVf1oAis4EBB2475rUZQAuwgfrmqvl7eY2xzyKtqgHORjFIBiRDOD3OcChwxYqp6VOqqRlT8w703dknI5oAhKsMb6ayHIwe/OKnYExhieBz9KjSQ5KqfxNAEVzH5akqR1qm5DJgjkdWPer06M68tk1WKEHYQMY6+9MDl9bt5Jd2FyvtXnd/ZGFnBwWZs47ivY7m3U20rEcAGvNtSgaa4LFfnUnnsKEBxV3CVVlLMGPJJ/lWZe24eJnYHPYgV1GpWo8tn34I4xjIqlLCXHl5AyOpHBpjOIvIsHc2GPYVjXkSggLHgjv2Ndpd28QLh/vDgVzl7DmMgZ3Z5FAHjzZMmcDaaePkALAH+6KapHJI5xwKUk5znp7UhkkW1NzZClu1WoyByDwCAKogBlBfAqxGCfQAjk0AacTADae5yK0rc7yoGcdQKxFkIlA7Hua0rV35wCSOnvQBuLIdm7jjtmtaC6BSMGPMnc4rnoHYRPlgoPXI6VtQ3EG1CxO4d+9MRee7UhAEJZT1x0rdtGjdAXjCPjoO9YVoySSZjzuPXdWisUhc7mPTPy0AbKEeaHJMa4AxnOTWppUjiXKSZXOSCe1YlorSsRIRt6jNa9lcwwzqokRlI9KAO3tnAXYXABG7aDViFm8pTGyqc8jOazIXh8vzfMUheQAaBqlq5zEcOf4h0oEdChWRPMdSSgxj1psLABZgCRnoOorNhv5FYbJAeR0q+szSSEIwRsYOehpAa0YRQJZFYN7Usc6hz0APpWf9okJVS2O2TUsbKJNsfzt1JoA2I5/mAVSR9atrc8AYw2eh/nWbZgiYs/IPQYq+QhkBXrjHSgC+t7tztX6Zp81zv24xu7iqaxI4yGIOKkjG07thLAcNQBLLloxjtyM1EY8NvkA2+gqy5Bkwo+XGc0hyV47cmgBttCrckLzVtYMSAgZBqS1jEgGUwOtTKjNMuBhQeB60AMkUBTwAT6VEsQKYUnBPTHWtERB85GDTUiycBefWgDI8hYW+UlRmnE70cr+pq7dQgMSy9sZFQRwBD0znpmgBi4MShUGc8+1WGUiMccj0qNYsSrweD0qcwsuSR8tAENtJjJHOfXtRISqAc5Y06BTjnGfbtUkmdwJ+b2oAiYfKAc7T196iIEkhORippFBP7v9ajDI7BCCvr70gBshCQucDrUexHOWHPc1JzuY446AVLHHuiycDnpTAr3yZsGVRjIOK83ulUkowBAY/jXqM6KyMO/avO9atJI7t9hwc4AFCA527g8zegAwR0xWTdpGECPuJHXHYV0V7HhGPSUDvWdNGrE7SeRkjHemBymqqjsnlqAqjJ96569tVJJYYB5xXValBtuGYBiWPAHpWZdWyyfNKSI/TvQM+b2AO4g5YDH0pvUhWbkDk9qNwBYjlifwpAy9sj3xSGTICMlBz25yKmDHO0nHeq5U71DAYxxTmVtxJBBPBoAuW8isRkcdq1baXa+QRz1rEgfYxUjAI4HvWhbSFSQ5GccGgDd3F1GcAe1a1mIBGSFZpBgjcOK522mKoSxOAeDW1ZOHVTv5JyeadwNdBHMrmeUQptztA5Y+gqtNqd1ZgCLeUJ79hTnu4Y0AQBs9z2qjJdRopMnzE9AT1pCJn1u6vJCA+wY7DFPhv5RExDnPQYPOaxjcb/uqEBOTgVdsizKxVc8dxQB2Og6pJJb7PMbeB82TXZaFakBHkXKHJOD0rzrQm2y+Y6ZHoOleoaDexSwpBHtCryT3NMDcsbdQ5ZFwvUGr8UQ2lZDuJOQwqOydiuM9e3atGJY2O4sA392kIcLR9iFCGUnkNU0QaCQllBx2xViFd3V1ABz14FTusbxMytlsdc9aAHW+ZZN75VRwuKuKAxOWwc449KrW7xbVI4OOmetWVKK6FSOeSDQBcVVIwFz+NKoZeNx29qjWaOIMTyOuTSLco0gYMNoPHfFAFmCEhSfXrU8KjcWx9M1JEd4VgByOoqUKQRkc+vrQBYtRhRk4z+VTNErYAPzdc0lryGX+H+dP2YJ3jCnpQBKqDau4DI703jdz909CD0qSPhADjiqwA+YAjpmgCWVgRjHUVUeY+WNihqsyMdu3gAr3qsQVjGwcUAQmQhhkHFSCYlzGc4x1IqMMjZDAt6Ypu9SwGT9aAJShkIC4470uAoHykkDk0QkBwOcVZYqecAA9BQBUlVmceX+XrVcqwOQMPWhM7BtoC5xnmq8gIkGO5yTQBBuJyrHqOfapbYlR6miQAqy4AzyPeo7YngEE4oAnC71JGOM81yviKzEUvmcgHn6muwjBaIkAD2rJ8RwfaLLO0hl7YoA86lKTSNhdpX8TWayCR2RxtYHhga3bhfmzgb17jjNUGQmRmdFwDwCe9MDBvYF+7tyq8hq5+/hM6knAXOSR1zXYzxbwzOVC44yO1Yd1bJhokQPg5BxQB8nhCqhxhuenag7QnAAYdBTn2hQc/8A1qiQqu7LEN2PXNIoa7FWyCc1P5m5QQetRBd2Q2eBwacihQDuHTpQBLwcO4ye1TxkmPjnnjJqs7MpDAnHpipIZSV64z0wKANCKchSoI2nse1WVuypzgD8azI5O3BP86kypBLfzoA1Gu3ZeeF7c00TMxUnGemTVISARbVBLcEE1OhXA5z6/WgC/FITH8owy9e9aVjOu4BmOWHfisWJmBZMYzV2EqhBPOOlAHeadNEkSbUABx2rpdHVUZsPh24H0+tcn4fvIpVRTjsMV6DodgZ/nKhEB6etMRu6aLpLcK7rgdCDnNa1uw3Pndms63hlYFYWXah6d617baPnkTlR0FIRMsZaEneQDyaqXzi2gK+eV3e9Ra3rsNhaksw5GFrhbzVpNRnVxnCkc560Ab8OqXP2sRJK5PViD0rSg1G4kB/fMSeOfWue09CZRIAQCemavWvmlpM7eeQwbNMDehnunjYmUsM8qTW3osMjOH3bh71j6XDIcBCC2M+pNdXp0flGNQMZ5pAb1pu2LgZHTAq8iEEcnjrVW1QlflIC+1aUaBFIc57igBwQqAxPzelCvn/WZOO1J5+6LOMsOOacSQu8hSAO1AA5ckLHux69aYzhYmKkmToc0uVwCvbqDTMg53DGepoAVJGYknDccUyaTeSuTtApU67VHbAqG5UnaudretADdvO5eBnGagVDjduIIyKnZv3a9278cVSNzmQpkYzwQKAHorZJDNz3Jq7byEsoIOB37Zqi5znccKemKtQOgcDBDEdKQFvgsM+lRMMZyoY+o6UgcEDAIJp6sBheeeM0wIMHzAT26GkB2uTkDHNSK+G5wo5/GmOFdSxUA5xmgCaCUsxA+tJdDerbjnPGMdarp975T04z0qyTvIDDjGaAOG1G0FpcsrgbTkisC7PkssbBtrHgjtXoPiHTvtdsSjEMvoK4e7tSY2BJ+X1oAzpFZ0KrJlTxkdqzpFeBWRc5PUnmtjDAncNsZHXHOao3YYsqgN+AoA+L1Pytld3TNOYE/e4wKFdduPunH51HklwCaChxyNzDDKxxxSMVIGQQ3YUgYlyMgD0FBUEZABJ96QydlYgclDwPrTgQEwOOcZqAB1ZRuAb61LGCS2cmmIlQ+WAwNK3zAscYB4OKhD8gYyM1MxDKduc0ATxNkZOT2xU7EgqCcgjp6VnxL8uWZs56CrVuGJPzDgd/SgCxE7Ljr9TWraSqxAIxkcn0rJjOeM5AOaspxz1BPagDctZxE25M/L0Oa6rQfGN7ZgoXDKBwTXCxMWfABCYyQKt2uHkYAbcjvQB63p/j0hm22wMrDLEHg1ZufGGovaK0MaxRO5QSYyCQASPyI/OvOdIRcl1diVr3Ofw19n+Bdtfxrm5W5+3sSMko58sD6Fdh/CgR5lc30t25Nw5eTOc9sVbtMb0MfyAHoR1qrayMp3eUpz2zzVi2EvnK5A2k8c0wOns3Z3G8gA8DA61qWzRx5QRHPcjtWPpcdzHJL5ZDx43AH+hrdtMCMs+5WbkKexoEdZ4fgVYkbBDY59a6SyjcDzFXLD1rF0FlS2jLEMSOTiups4mJ46dqQF6yyqbwOSOh6VZY7uTyT6VSaRw5Q7cY4+tT2T7WZZAMDpigBjH1ABBx7mpEeRQB95Tzg1JPb4DPHjnnntVe2LJJtkyQe9AFjblxtbluafKm8LkfQCmiPL5UgjPr0p7I+TuHCjg0AVtwIyrHI7UjNmUbwS3TJp7qCxKr1GDntUbgNlHJHHBoAjuuTgcAj1rMR9spiKsR64rSI+XBUlQKpE7ywUYZTkUAMmUuVUAqw5yelJHKdwIDFlbB9cVJLkw5YjIalt0BJcZBPrQBogc8N09e9LkgK2DjpVeCXccMoyp5NXFAYA7TQBXfaZCGxt/WpCqtGRj5acoPmcqoGPTmpJPlXJ4B4FAGfsKyHGdvvT4yQ3JJAPan+WTtycj0HamvsRsHp9aALSjK4IJz2PauL8QWYium4OxjkCuytmznJJUetVdXgFzAQwGRyKAOBnj3IMnb3wazJROJMHBQ+h5rcvbZh1B64x6VlXqsHGI2C4oA+G+C7biMHmk3Drkcdc0vde7+hHSg4P3CMjqaCwX5w2cAegppwMgA8DsKQYDtyeRwaeisUJTORxmgQvl7VXJBJOcd8VJGrI7Mc4AwKaTgJ/k0vHALEk9vSgAI8skjIyOadG3z9eOvNM8zD4c7xjtTjIHGVG1enIoGSF8SfNwuc1MHGBgjn0qnuLs+0ZHoak3qu/cccADjvQIuRyYUGPFWlkDIvPfmsyGY4z1xxyKngcFgAcHrQBrwSFJcg9RzV5JPMAG/gHqKxYnAwQxBPXirtuenOFJoA6rR0aa8jt1kWMOyjezYUZPUn0r7Mvbnw6/ghrFdY0xdMe3NhFObmMR5CYADZxkDBxXxHaXAUrsBOO1ep3NyE+CWluQWzrcg9f8AljTEznbZkB2MWMjP1B+7WxBGUB3MSU7+lYunsskgwvIOPSt23VYmZ5SdjDt0NAG1plwzL80hDHAXjiuhtFDZcsWIGOmc1y+nyyeWmXXex4T2roLObZEpJMbjgj1oEdLoV55LqJuIc8DFdza3kUkIW3ZT+OK8zUqg8ze2W/hPSpFvHDgRvtYADrikB6oFcqC46dD6URDbIOwz69a5nRdeMSYupA6r1FdRa3MF3CrRkAYz70AaSYlY5OMDAFSNEFyyjJA6VBCyiIhm69atKQqZLZA70AQxklBgDOeQRipZHCDmkdVYZBIyOtQzBlVQW3ccigAMqSblIw3p3NV51O7A44qRJQhO8DB/OlKrKmYScD1oArBi0OCCD0wapMBC7YGWboBWgylWUOOKrTxJ5h5y1AEEpUOASCG6inKuUO0lSOxFLOiBwT270Qtu3Fz9KAHWsv7/AGcg55960hy/AI+lZELNFMzblKnkDFatvIrEOW5x09KADnIUZPNSPzGAR0PAPWkdRywPXpS7toDdWPNACGPCjPQjJNVJlAO1hkAZz3rQEgLAn7v9abPArsDtGBQBShyG+UnB/lU85V0+UEnuaTyz8xAwB1pocOfLU++KAOf1y14Dop2kc89a5WUN5jI479Cegr0maBXhaNlGMda4bVLIrP5QzuyfmHpQB8BIV37gQPSmo6AEFcA0pUbwxyR6CmmMFjjjnigoTcolU4yvtUoBBySQD0poJYbWUe2OtIpy4O72xQArkoFBODnI4qVwQuT68kVFu3SgsODxxSyBlchSQD680APzw2zqB09aR/8AVgqTnPSkXLLgsFYUsrbcEMSeOPWgBDKGTHoeD61I53DDY3nkCoJEfJ3DCikiJVsnJ9qQFwHC8fdB6/0ojZnBJ7n86ijKlCVyOduKdGcn5mBA7DtTAt5IcH5t3oO1XYnKcn6Gs5X5G1hgcZNWIyWXGTgdfc0AbFtOquAHO2vWZHH/AAorTT1/4n0mM/8AXEV4zF8hBwQc9PSvXJJDH8A9LYnn+35R/wCQRQDMO1uHMkflthWPzcV0Ed3vCI7fKOAoFcXZTksEXnHOfWtxLgrb7iAXU880xHZafEBMGVhuUbsZ71swO+SDgswyp9K4vS7yRGBUbSwz6100Vzlo/nTIHBFAG7bzme3Dt64/+vUhdRIpGR2B9TWRHdqXXdllP3vSrsk4flMLtO7cR+lAjUglZvv4C+ncmtDStYaCVlhkPHUE8VzougfmkBBHpU9qIGPmZIOMntmgD0rSvEkDgfaCNrcfjXWWDx3MOVJ9eteJxzIFwCW44A6Vo6Vr97aS70ZgnRvpSA9lO1VUDp2qCdcSHGenWue0LxJBcxKrOS3oeK31mW4TfExYdhQBWcckN+FRokschA6YyCKnlfHy9MjrUESTI2C2fegCRsliQQCfWonAO5gwz3q28WVy2CoOcg1XnUdYsjjGDQBXdVeI/Lll5470wkMUJBBxSkuhx1DHn2p0i71CjgjuKAGyk/dAGVPU1Ys2ZoSG6g5+oqmvBJJPPGCeKkiIUApnHtQBqrhs8nnoOwpWO3GRnJ4I6Cooj+5B5YHqB61Y42KoBANADkGR1Xp0xUhO3BwT24pgJ54x2oIPU42/y96AI5BhSQcE9RmqxVdhwzDnrVmXDZTkkc9OtQsuR0xjtQBLHH5i4bPFYmvab5sQdANynHFa9u20nJI9PrTtqujAigD8w0yrkHLDHQ8c0ijndITnPQUsfzTAk5zmnjliDyKRRBIRnAHfrTmQAEjPHvQVAuAo+6TmnqBvxj1pgNAU7ScqB0p4cCMk5LE8VFIcICAMg0JK2MccDjilYY9BublOvQ+lKy5AA5wetPPBCjoRmlZFEj44x6UxEUr7eEzx1z0phAXGAST1PpTmYpKFUDBxnNOuEAUMCcnnrQA0sFJAY4zy2KfEwKydjjA96R0CxfLxyKe/3VHbAoAWBsZzliRwB2qzE+4jcw2jsOxqohydvYdKdG22UgAAZoA2In5G1gcdzXQrruoyeH4NDe5zpiXBuhDsXiQrtLbsbunbOK5O3YhkHqcVfDEsBnHOKANu2uFjYKxwfati3ulZskFQRge9cwJGEgXjGcdK37IDylzyfftQBu2srNtQllHdq27O4kT5AMsT+NYCMQM916Vrac7POCxySAKoR0QuDHb7QeB3I61fjmHloC5A9T0rJh5ijzzg9627dVFkflHJzSAni8uXLRvv2naas87TuHy4/hrNsQGErd93OO9SXU8kC/uzjgUCNu1ZRD+6QZPAJpkqlo2j3H5cZI/lUaEtGBkgFOgqtDI4t1+Y/O2DSA0I5mt9jqcMDxzXT+HvFpjuFiuQQc9fWuPlcxpEAActg5p14A3VQNq5GO1OwHs0F3bXkLHdjPf0p7q0ZHzZXtXl3hC/uPJJ35w2K9L064klCB8EZx0pAWCwX778dlHegtxtXBzyBimTDlh6UxnJQdiO4oAfLGNgZxyOopu0sqkLx61LGS0WT129aZE7OMMcgdqAIniEbHI+U8jmiMbhg4B6g1ZXBRgQDg1A3EhA4HBoAtWjkO6yZxjGavKARtIJA7nvWZB/r1Xs2M1rIMDAoAGC7dpGQKZjD/7OMVL3oNAEO9Qx4PpShNoPOBjmn7RknHNL2FAFFVKNzz3HerEOGU8c5/GmSgeYopxO0NgDg0Af/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AP view showing a posterolateral elbow dislocation. The presence of the medial epicondyle within the elbow joint (arrow) prevented a closed reduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36528=[""].join("\n");
var outline_f35_43_36528=null;
var title_f35_43_36529="Bacterial vaginosis";
var content_f35_43_36529=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Bacterial vaginosis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/43/36529/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36529/contributors\" id=\"au4223\">",
"       Jack D Sobel, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/43/36529/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36529/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/43/36529/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36529/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/43/36529?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Bacterial vaginosis (BV) is the most common cause of vaginal discharge in women. It can cause bothersome symptoms, and also increases the risk of acquiring serious sexually transmitted infections, such as HIV. It may be difficult to know if discharge is caused by BV or other common vaginal infections, thus a visit with a healthcare provider is recommended in most cases. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40641?source=see_link\">",
"      \"Patient information: Vaginal discharge in adult women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      BACTERIAL VAGINOSIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     BV occurs when there is a change in the number and types of bacteria in the vagina. Lactobacilli are a type of bacteria that are normally found in the vagina. In women with BV, the number of lactobacilli is reduced. The reason for these changes is not known.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Risk factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Risk factors for BV include multiple or new sexual partners, douching, and cigarette smoking. Although sexual activity can increase the risk of developing BV, BV can occur in women who have never had vaginal intercourse. BV is not thought to be a sexually transmitted infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      BACTERIAL VAGINOSIS SIGNS AND SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Approximately 50 to 75 percent of women with BV have no symptoms. Those with symptoms often note an unpleasant, \"fishy smelling\" vaginal discharge that is more noticeable after sexual intercourse. Vaginal discharge that is off-white and thin may also be present.",
"    </p>",
"    <p>",
"     Pain during urination or sex, vulvar itching, redness, and swelling are not typical. Occasionally, BV causes an abnormal cervical discharge and easy bleeding (such as after sexual intercourse).",
"    </p>",
"    <p>",
"     If you have concerns about excessive or foul-smelling vaginal discharge, abnormal bleeding, or vulvar irritation, see a healthcare provider. Self-treatment with over-the-counter products (eg, yeast creams, deodorants) is not recommended without a definite diagnosis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      BACTERIAL VAGINOSIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of BV is based upon a physical examination and laboratory testing. The physical examination usually includes a pelvic examination, which allows the healthcare provider to observe and test vaginal secretions. It can be difficult to know, without an examination and testing, if vaginal discharged is caused by BV or another vaginal infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      BACTERIAL VAGINOSIS COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     BV itself is not harmful, although it has been associated with some health problems.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pregnant women with BV are at higher risk of preterm delivery (see",
"       <a class=\"local\" href=\"#H12\">",
"        'Bacterial vaginosis and pregnancy'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       Untreated BV in a woman who undergoes hysterectomy or abortion can lead to infection of the surgical site.",
"      </li>",
"      <li>",
"       BV increases the risk of becoming infected with and spreading HIV.",
"      </li>",
"      <li>",
"       BV increases the risk that a woman will become infected with genital herpes, gonorrhea, or chlamydia. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/3/36916?source=see_link\">",
"        \"Patient information: Genital herpes (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/44/1730?source=see_link\">",
"        \"Patient information: Gonorrhea (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"        \"Patient information: Chlamydia (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      BACTERIAL VAGINOSIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of BV is usually recommended. There are two prescription medications used for the treatment of BV: metronidazole and clindamycin. Both medications can be taken in pill form by mouth, or with a gel or cream that is inserted inside the vagina. Oral medication may be more convenient, but causes more side effects.",
"    </p>",
"    <p>",
"     If symptoms improve after treatment, a follow up visit is not necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Metronidazole",
"     </span>",
"     &nbsp;&mdash;&nbsp;Metronidazole vaginal gel is one of the most effective treatments; it is applied inside the vagina at bedtime for five days. Metronidazole can also be taken in pill form, 500 mg twice daily for seven days. The choice of pill versus vaginal gel depends upon the woman's preference. In general, there are fewer side effects with the vaginal treatment.",
"    </p>",
"    <p>",
"     Side effects of oral metronidazole include a metallic taste, nausea, and a temporary lowered blood count. You should not drink alcohol while taking metronidazole pills due to the risk of a serious interaction, which can cause flushing, nausea, thirst, palpitations, chest pain, vertigo, and low blood pressure. Metronidazole pills also interact with warfarin (Coumadin&reg;), potentially increasing the risk of bleeding. The vaginal gel does not cause these side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Clindamycin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Clindamycin is a cream that is inserted into the vagina at bedtime for seven days. A one-day vaginal clindamycin cream and three day vaginal ovule are also available. Clindamycin cream should not be used with latex condoms due to the risk of condom breakage.",
"    </p>",
"    <p>",
"     Clindamycin can also be taken by mouth, 300 mg twice daily for seven days.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Sexual partners",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not necessary to treat the sexual partner of a woman with BV. Treating the sexual partner does not improve the woman's symptoms or decrease the risk of the infection coming back.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Relapse and recurrent infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 30 percent of women who initially improve after treatment have a recurrence of BV symptoms within three months, and more than 50 percent have a recurrence of symptoms within 12 months. It is not clear why this occurs, although it may be related to bacteria that were not completely treated or lack of a normal level of protective lactobacilli. The role of lactobacilli is discussed above (see",
"     <a class=\"local\" href=\"#H2\">",
"      'Bacterial vaginosis causes'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     Relapse can be treated with a prolonged course of oral or vaginal metronidazole or clindamycin for seven days; the United States Center for Disease Control and Prevention suggests a treatment regimen different from the initial or previous treatment regimen (eg, oral treatment if vaginal treatment used previously).",
"    </p>",
"    <p>",
"     If you've had more than three episodes of BV in the past 12 months, you may benefit from a preventive treatment. This may include vaginal metronidazole gel twice weekly for three to six months. Clindamycin (oral or vaginal) is not usually recommended as a preventive treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Bacterial vaginosis and pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pregnant women with BV are at increased risk of preterm birth. However, there is no benefit to testing",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     treating all pregnant women for BV unless the woman has symptoms of infection. Some experts recommend testing all pregnant women who have a history of a previous preterm delivery.",
"    </p>",
"    <p>",
"     Pregnant women with symptoms of BV infection are usually treated. Oral treatment with seven days of metronidazole is preferred over vaginal treatments.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      BACTERIAL VAGINOSIS PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     The best way to prevent BV is not known. However, a few basic recommendations can be made.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Do not douche. Douching is the use of a solution to rinse the inside of the vagina. Some women douche to feel \"clean\", although there is no proven benefit of douching. The vagina is normally able to maintain a healthy balance of bacteria; douching can upset this balance and potentially flush harmful bacteria into the upper genital tracts (uterus, fallopian tubes).",
"      </li>",
"      <li>",
"       Limit the number of sexual partners. Women with multiple sexual partners are at higher risk of developing bacterial vaginosis and sexually transmitted infections.",
"      </li>",
"      <li>",
"       Finish the entire course of treatment for BV, even if the symptoms resolve after a few doses.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bacterial vaginosis (BV) can cause \"fishy smelling\" vaginal discharge, which may be worse after sex. Some women do not have this discharge.",
"      </li>",
"      <li>",
"       BV is considered by some experts to be a sexually transmitted infection. Sexual partners do not need to be treated since treatment of males is not effective for preventing infection of the female partner. Some experts recommend that male partners use condoms. Female partners should be treated with standard therapy.",
"      </li>",
"      <li>",
"       Do not treat yourself for abnormal vaginal discharge. A doctor or nurse should first perform an exam to determine the reason for the discharge.",
"      </li>",
"      <li>",
"       Several prescription medications are available to treat BV; some are vaginal gels or creams while others are pills that you take by mouth. Pills may be more convenient, but usually cause side effects (nausea, metallic-taste).",
"      </li>",
"      <li>",
"       Some women develop BV repeatedly. A treatment may be recommended to prevent infections. This includes a vaginal gel twice per week for three to six months.",
"      </li>",
"      <li>",
"       Pregnant women with BV infection should be treated. This usually includes pills that are taken by mouth.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1785010142\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23443810\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/1/14354?source=see_link\">",
"      Patient information: Vaginal yeast infection (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/56/22402?source=see_link\">",
"      Patient information: Bacterial vaginosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33570?source=see_link\">",
"      Patient information: Vaginal discharge in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/62/27618?source=see_link\">",
"      Patient information: Probiotics (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23443827\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40641?source=see_link\">",
"      Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/3/36916?source=see_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/44/1730?source=see_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=see_link\">",
"      Bacterial vaginosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link\">",
"      Acute cervicitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37876?source=see_link\">",
"      Desquamative inflammatory vaginitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=see_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link\">",
"      Pathogenesis of and risk factors for pelvic inflammatory disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/vaginitis\">",
"      www3.niaid.nih.gov/topics/vaginitis",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/STD/BV/default.htm\">",
"      www.cdc.gov/STD/BV/default.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Social Health Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ashastd.org/std-sti/vaginitis.html\">",
"      www.ashastd.org/std-sti/vaginitis.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/43/36529/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/43/36529?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36529/abstract/1\">",
"      Schwebke JR, Desmond RA, Oh MK. Predictors of bacterial vaginosis in adolescent women who douche. Sex Transm Dis 2004; 31:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36529/abstract/2\">",
"      Gutman RE, Peipert JF, Weitzen S, Blume J. Evaluation of clinical methods for diagnosing bacterial vaginosis. Obstet Gynecol 2005; 105:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36529/abstract/3\">",
"      McDonald H, Brocklehurst P, Parsons J. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2005; :CD000262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36529/abstract/4\">",
"      Riggs MA, Klebanoff MA. Treatment of vaginal infections to prevent preterm birth: a meta-analysis. Clin Obstet Gynecol 2004; 47:796.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_43_36529=[""].join("\n");
var outline_f35_43_36529=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           BACTERIAL VAGINOSIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           BACTERIAL VAGINOSIS SIGNS AND SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           BACTERIAL VAGINOSIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           BACTERIAL VAGINOSIS COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           BACTERIAL VAGINOSIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           BACTERIAL VAGINOSIS PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_43_36530="Dexpanthenol: Drug information";
var content_f35_43_36530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexpanthenol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/45/17107?source=see_link\">",
"    see \"Dexpanthenol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrointestinal Agent, Stimulant;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F158465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of postoperative ileus:",
"     </b>",
"     I.M.: 250-500 mg stat, repeat in 2 hours, followed by doses every 6 hours until danger passes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paralytic ileus:",
"     </b>",
"     I.M.: 500 mg stat, repeat in 2 hours, followed by doses every 6 hours, if needed",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F158466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 250 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F158454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection: Usual route of administration is I.M.; if I.V. administration is needed, may be added to a large volume of D",
"     <sub>",
"      5",
"     </sub>",
"     W or lactated Ringer's and infused slowly",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F158453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylactic use to minimize paralytic ileus; treatment of postoperative distention; topical to relieve itching and to aid healing of minor dermatoses",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F158489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Slight drop in blood pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, irritation, itching, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, hyperperistalsis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F158456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dexpanthenol or any component of the formulation; mechanical obstruction of ileus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F158444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Treatment of adynamic ileus should include correction of fluid and electrolyte imbalance, anemia, hypoproteinemia, infection and the avoidance of drugs which decrease motility.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F158457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women; use only if possible benefit outweighs potential risk to the fetus",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F158468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Panthoderm External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (60 g): $31.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dexpanthenol Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/mL (2 mL): $3.90",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F158458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bepanten (IT);",
"     </li>",
"     <li>",
"      Bepanthen (AT, AU, BE, BG, CH, DE, EE, FI, HN, ID, KP, LU, NZ, PL, RU, SG, TH);",
"     </li>",
"     <li>",
"      Bepanthene (ES, FR, PT, TR, UY);",
"     </li>",
"     <li>",
"      Bepanthol (EC);",
"     </li>",
"     <li>",
"      Bepantol (BR, ZA);",
"     </li>",
"     <li>",
"      Corneregel (GR, HK, HU, LU);",
"     </li>",
"     <li>",
"      Pantenol (PY);",
"     </li>",
"     <li>",
"      Panthenol (CZ, DE, HN, HU, RU);",
"     </li>",
"     <li>",
"      Pasquam (ID);",
"     </li>",
"     <li>",
"      Tentalux (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F158443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A pantothenic acid B vitamin analog that is converted to coenzyme A internally; coenzyme A is essential to normal fatty acid synthesis, amino acid synthesis and acetylation of choline in the production of the neurotransmitter, acetylcholine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9337 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36530=[""].join("\n");
var outline_f35_43_36530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158491\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158465\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158466\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796026\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796027\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158452\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158440\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158454\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158453\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158489\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158456\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158444\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299159\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158448\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158450\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158457\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158468\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323100\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158458\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158443\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9337\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9337|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/45/17107?source=related_link\">",
"      Dexpanthenol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_43_36531="Subungual melanoma - advanced on thumb";
var content_f35_43_36531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subungual acral lentiginous melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Destruction of the nail bed by the tumor is present in this patient with subungual melanoma involving the toe. Note the presence of pigment involving the periungual skin (Hutchinson's sign).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36531=[""].join("\n");
var outline_f35_43_36531=null;
var title_f35_43_36532="Speckled lentiginous nevi";
var content_f35_43_36532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Speckled lentiginous nevi (nevus spilus)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 309px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE1AbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDp0jHBAFLKORzwaTfuY9h6UkabvvnjPFcZ6SRcjX5CwAIA61WBMR8wAkdsU+BwpEfYnvVx0iL9MKBT3HtuVDKWIzn0qUA46kf4VBelY41EYzk/lV22j3RDnLHoMVNm3YdtLjvuRK23IPH0qPaTJwSSPSpmYZMTZXI/CkhjWB8bsE8nBo3BaEVvAnntIC5cHJFWpAdocuVKDg54b2p5C+YSgP3c8DrSvErRK+4MmcbadhuWt2OhcfIxRivUr61bELGEv5ijJ5Hp9PWq8IIGVJAAyRjGKtrhShLZjI5IGQPehMzluQ20qmVUzvRj2GBntV+QKkqFclMZ4/vdxVcALKrxqgcnjPTFW7jcwym0NwxUdPrTJlvoKZl2jaM7RyT3NIpbdIGbCuAcdfpzVK4lfEoboQOQvQ9vpVrTgAFG8PGRxyFY+xB9+9JO7Dl5VctBgAFTOAM/L/nmpIphKPlA3qoHGccf/W/magMjwSMssfzKSrNnIPTNMZk3Fo1UoDnDH9DT5rC5blmTy1WJgfmK4kXnIP1/LpRH5So+HmRx0d34x/X09KdbThZFEowMkbWPT8e4x60xHCANFI6bSQRt3j2IHbNHNpcpIhuyYhBLCrkA8nsOeOe3ariyrMkQjUEZLMDxz9e4qt5ri323EZET8EDgZ9vX61Y0+RQPKlISEk5ZuSPQ/wAqlb+o5LQkEAcybWkAYny8EbevQjt+HrVgyGBdySSEburD8OR69efzrPQERnbnhCSRwVPTk9x/jT7QO1sWkaVPMG0u+cN/jj/JoTJce5bQi3P7zYpBOc/dceo7j+VMnu5Y1jjtwmTz8+cr7g4/lTwTHB5UnQMCQwGQw9Dj26fzqaOCOa2B8t95PDoeGGeevShX2RN1e7IJWuEXdkDKh8Ehgc984+tP2lmEbojtJkdCAfcc46duP1oMhjaSOXIIONrALnPJIP8ACefpTkZwCkrdeNjqMkj09x6fjVJ6hqijPaBVREu/KCMXUL+fI47daldYWLNgK2QMLwD3DoT3B7cUkmzdEs0EvI3LKnOeepH9KkaOExKcj5X+eNm+XHOMDt/SpvbYu76jbeTzDsleRsY2kKCpPoQeRx7/AI1DFFsuQA21y20umQBxkYz0PHfrVuVII4VPk4LHJDNnd7H0IPcUhiFxEkkboshHJIxyOxB7dvSjfRi5upC7EklhJztyC2A3Xv2z+lJHsEZDxsgyPmPVcdj6jpz1FWwy/Z1jYqr53AlNv3eozk89se9Me3dZPIhdmWRCVUNzkdMfqcfyot13JUuhVLIzlJtpJPBzhj6EHpTJ5PLBXbuI+YbFw2T3GO3r7/oxY2ubohW2YGWUnrjglc98duv1qeEpNEwcMrgYLINuDn5Tj6UJ6aF7GdclwRICyGVSwYDO7Pr2z/niqVurxyg3DrJgqFkjbDIoPUEdcZ/Cthow0Plzr+5JJJUZOee/bnn0/lUckB8krweN+7pvHccdOO1SaKaSsQNL88gkKnqnmdN/Hyk9hz1+pp6N5kEMnCuvJYDkEdj7VLMo8omWNlnX93ISMbwBxkevHX8ajRjAY7gRkgLyGGFcHowP5fjR1M35DAsfl5LK6OFdkJ5PPOO2RiqsrxLI4RR5fUA5xjr1z1H+cd50LJiSEMiAsWXPQ9wfbjJFLIcyqwQYYBSi4XJ9D6E8YPrQLYfPNJNEiM0bOp3K+7aRwecdCPcflVX7W5i2niRCAM4yMjoQeo9x2x9afJC6lgY3YBuc8EHpyP8APSoZVP2kq4HmAmMhlwBjsR7g9e2KtyYkk9iAlfOSJ0aLAIALcZHTk/5NM8jasiIFjkjAkVR35Hyj1HIIpZjK0QBJeJAMYGQoJ45POAeKmMvnILp0QyJhZFU45zwce/Iz/hzKZTuhs0aPJK7upXPzR7e5HPPscfpUNxAHijbayo5MXT7rgcg47Hrj/wCtUqzBdjxgkBGBRsbm5A/Tg8VUBAjcgSeVIFYBgSHIIPPt/gKp2JVyKOVolWO4AMI3Rbl5OcZHvwQMH0pf3sjudm6POTt4DAkE7c/xDP607Uh5UZWdxICNu5Tnd+Pr6f8A66jQkxBt5ePYIy33cEHIDe/BH4iltoytLXQ3bGhhcSIY0BDPj7mTwSMYIx/P2qnPGkFyjkiSJgNyZ6rnkdO/WpbtmtbliGLIG8pTjOQACAfwNRAOLdApCjduQIwHGeo9O/H1pNjW1yrJDGJgCfkc8ORyM+3Y9KiuCJJQ7kcZXKHBUrySfXqP8irp2SM0KCOPLddo4z0OccjOQRVEpKsYmRn+cmNzt2lWAII/LPp2peg99yWPLMxI+lWI8bWUDPqaSJWJBI4FTRnY52n5a0BsreQ/mB84XNaKJvUFjkGo4nQttJBPrU+3aAGPHtQkkEpNkBhJ3HqBUiSbFHJQgYOKZKRGfnJ2N/dqK3uGLlWXKDueM0ikrotgbhlm9smqjb3uQWbKjgY4zU7sxdmjGFI71LPHuhVjw3ByKHcqOgNDNuZlfnsM9anRn+zCEA+YT8w4POait4n84YG5SMcHv61dihbeoO3eDgnPSjzQpPuOhVltx5m1jkhucEU63V7d5FkGMjHuo9RRbqN0kTFt2Cc4z+vpToWjZmMshyq4X5erelPR2ZGowy4YAHKk4CucZqXzmJUSDgfMzY5IqMQLKIg0YZkyMHuR61HG8s8bHIG0BQO5AGaluxSSZbuHczSmT94Dwpx9761Pap5sY2DdJzuwRtUVUDq1uSc4I+UnoCOtVZroQyMqEYYAcjOOc8Gi9ndiUW1ZF+d5XnKgkq3AG7j/AOtSwzDfKhQHncOMDr0I7DFLNG0lslzsUMQMIv8ACq9/aq4QzQlYlGQ3DZBA4/Oh3TLjZou2uGSQ3MbrvyygcjHY9e1WSoXCQqRk9zyRVaxlLWTDY6xqSDtbcMd/cdqswTyxvGZFjZSwYMgB474/Ang09LGck0ywsMC7QckNjOcgqD1waJYsJIEKuo+6f7w7N/jVpGjkOxyH4+XacE00D7K42xq24EkZ6Z6hvTrSat6GSmzOa1ljl8p32Ffm+RuhwDjP5eo/WtJZjcRlO+MhgMY4HGBkfjT3gDI8m5iAFO5eDxxwe3XGKqW0uJSqojYGcFOGx3Hv2xxR8LLcudehNJBI4KzJwo3Ac7uPp9c46/h0ns5lg3SP5qFj1VuQTz06cjvRGVXP2kkBgT5icg+mc80yMCQr85RVyN5P3SDnH05HFGzuiN1Zjrp/PDnak5xvzjDDjn6iopJPOhjGCXUYyRgjGMA+46ZNOkR7eX96pVm+5kHjPGQe47EU+XM6L5eDKoCMOpf39+wxnNJvm9RrSwsO6aIbeCMc4Hc8D69Of50sri5LidTDtG0NjGfc9x1/KqqO8UQ25Rx78rnpj2zVqO8F0gV2JIGMSLx34Df44pp3QnFrVFC+gkgk2+YDETgMOWXB/iU/hjB/pU0TOITHcgkjITB4De/198dakMMzQyLuDwjBIb+H6d/wqRDsZVuCrDbjzM8EH1+nTPoeaX4D5tCuzFiTllJwQGf2x/F/nqKWAoG2xD97G27C/OrD0+vp27GnLahoRhnRPU/OAR1HHr6VRjsstHMjGEA5WRRuBHcEd+vBo1GrPqWmWO4YvCgJ3AnkfNjp+I/P697USpKWZQUn3iQqTgHkH+Yz+YIrNlLxTDa5LNyfKz849f8A630omummCnI8vI+bAOzngkf/AK6FK24nFstXjoLon5oX/wCWiIBkDvjPGO/51C3mSTGWJ41O3c6bQp/L9OKG8wwrNsG8EjATr2ye20+3Q0sYSSyOUJeNt2c87c9u/r09KE7uwWsivNNHPHhz8ysAMcbe39Oo+tOu457CQxK5EByy71BH0we/uMZx61CwXJkGcqPmxyxA9Pxq01wbm3l81YwNmU2jAYdd34HqKV9+4ndehSmPlRbXHlyjLI4A68fKfUfqKqLNDvk3bkRgChIzt5wQR35rXuIvtVukbHcGO6JzkiRcD/x5eh9RWfLC6tvMin5uC3PHQj6Y9aGmhxkmtR0MjpIY2OfMGwjdkHPPftxx6Y6VDq32aWcN9nMbYw0RO38j2/8ArVYvoIwAluwYvnKKOh9gf8nHvUMs0jNHDKsby5+SR8BRxwDjvn29OlN6e6KO90ZtxcnbJJvV96lCdn3eP4sfQfiKiilkWNVQhlIVmUPlWI6E+361Znt4mj2KNs3zbx/dcnoPVT/n1qrDAse7gmQDyxng5HUY75BHuKjrqbe60JO7iQSIP3g+bceAfUfiP1FCbBsto9xKykxYGSVK5GM89atvIzRZ3KWQen8JA5x9cZqo0H7pQzAMMEA8jAPTOcj19apuxHQbGyzj7PMYdixbB1Hcnrg4IJ9OlQyRJseW5EjkYV2TkH0Pt0GPxq0bfMojmCF8EkscHcB9044wf8KrwTlZGhEe5njwyFThx9PXHPH4UX7i9CKaJZCokYeYX2sdw2lux9s/4Gj91GsLNjIXaPl3BwCePr2IqGIyeZ5auGMiiNAy8j0II7+9MY+WJInDKA+9gByrDggUJia6D71VyQItsZJL9/lJ4/Lj3qm4khVljUugIZ2DFgwA+Vvw5596sFlXyiT5j8lTtBU9sEHj0/M04SoiOS2SPmAZsL7j378Z701uK7SBQCMNnApXjwflyc+lNkJ3FTwDUsYJA28j3q7GnmJHDHFkjJJ5qwm6RDv7D86CgCElcH9ajTPHzZ9QKQ9xiqXcqOeehq1Cq7CNgBxxUMUkZLAYDDvTw7AlmUjtxTWhTTYm5grIqnHoR0qyB5yMhUg44yeKeEjeBi2QWHB9KdaQAKqSOQBwG65oQm1YYluQqshIAqwJngjLFFZWOAT2qaPGCoZhF33Dj3xUV3AGBw5KA5wvGfQ0LTYlO7swWQZR1BXjaRnANTSJEYs/cfI+Xr+NVYHWInYrFduCrDODTyTMhBYrIvVcY+tFyuWxOUkYSRF/myG+YfyqeO3jkWR1IiYALg9c45GPSs7zp4bsK8JClQxOOMeuavbRNlJC+/fnJGMevNTZXB3Q2SNDIpA2owwApzg1FPD5LAqu4dVY/wAI6VNP+7VGyBhip28g+hzVmHK5V/mOMEkdRTYublVxsFtvVhHkx7QgzwQT0/Kq/kywpLFHtCqSGJQnHVSfUVopIgVUdY9vB6dcdKj3APIwZZYw3zMAcgnuKGluhRm7jtNt4VcOQtwhX5WC43fUep61LbxmJ51UqUGRjknGe3vTtNCOAgODt27geAc/5/CrUA8yR0aSMFTjLHAJ4wB/P86LJpNEym7u5XtrYyTMcOzOMLlgAPU/zq6Zsxn5gwTkJJzkE4xn8eKTb5SBimV3DknhT6Y9/epJEjifPKSow6dHGeoI96NkZt3epHBslYAkAtkFJvlyv+92PbNLaq6I8TLuKygMh+9gDg+5/rinzBhMWidZFb2BJPv2pIV84iPHzFgcKc9OQQP060tUx30CaIjYyM2N42yA4O3sMZ6/4U1w3lpIECruKhlPQ/j0HP0q0z+XIrTLlCc5I5Ptnv8AjVdoJFhOD5kLNwuNrD0BB/r7UOPYIy7jXUDdHJuE4I2YJH1x6D+VRyJtkEis+0Y5Ujkg4I9M89MVHLDJmOQ5aNcH6YHp+PI9/wAnWscAaXy3aJmOCV5Unrj1/CklfQvRK5OuyWVmCATE8ZAAY9xjsc/h1oTbCxYER3C4BYKRu92B6/z4702GVhGwlQiIHO4ZBU49fx/z3UwIS7LOWlI2llOMcZORjn8Oe9PzQrdydSER2iYqSQNoweT/AEz+hFU5FkMQkEBdU5ZFG5Wx146g+3apHMkKKSxcAbl5ByucHPc8jIpFud8/mwxkbxukKEqQf4j/AFp36MlK2oyMeY0U0L5ViOSeQ3YZ/wAac4ScLGAqsGZi6gYYe4+vUGnXZSCB2KgkMD8o2+Z3GR0zz+NJfAZR0PmBhwc4OepBPr1/LFHL0GnqNCy+UVkj82BwOnJXHPHcdevTmmJFbzzAM+FIO6QjGfQY6HOB+JplveKHQO7Mi5BAOCB7Y5x6jtTr4Rs3nW8hWIk4ypUN+I4GfUd8UrK1x63sTLCptniJaOdRlRnIkAPTB/p+NRZ8iDdasDMRyjHBYHOSP/rd6gF6XRhOSU4YkDJX/awDx9Rx16USMr2/mBwwU9F/mM9j3pO26FZ9RNnz7otytgYZeCh9h3U0zzNxeJY41lVs7gSMHGTtz2JxxUlrersSGQBrfcdu7hlP17fT371Ne27jEpZniGIwZgOPQEj9D1otpdA97MorI0aMy5SVTlWx0PofTHb19amKRXYJLlJV+YNwA3P8f936ng08xI6AIpVhlMFvvc8D8RSWpJDkxksyjepG3cB0x6/X8KF2Jb6heW8oQb8N5a7PmO4HjjjtkcflWXckh9kwUxleX65PZwf5/wD1qvW0nkyGIjaWXALHHP5/l+VV3feoUvtLOzh85IPcf/W780PXYcbopSj5CZCMjIYooyqgDOV6E/z696d5PnLmPOxjvBHzLkcbvXnn/IqGdSp+RgnygqM8Omex/DODj/GNXcTiSNmMbD5yh2svI/r39x0qb62Zp00JX+Z2IYMxzgk4ye4z+uPx96ja5SV40lPzKgQFhwwGccjuPf09qe/lbyADjAYbgRjqCDj8OfWo7tvsaoViPlPH824bhz/n6jFV0uJK+hTuJlDDC7j/AHx3zwQD65GR9Pegzb7dRkHaCV6j8fpnNLcvsnl8z942MMx+YqDj069OtQRzIisCN7BW2DI6EHd9ecHH1qdi7JrQaJPP3gqsUUKZxkdR1GfU8fl04qG9O4sCuWPQJyzeh+tRmYGSRYmMQ3Bgo75HQeo46UyBWdX+VVcH5SAAOOtCdwcbakG6VbcoXI2kyZIJP+19AfT60qmJ1KS7gWHykc+4FSiT5Wd0ynKnnLCoZkaJo2CCNgcAdcHHX6GgW5ospYg5+lSIxjjzxuzUEMuSu4ce1WyVkAwcDtW97q4npoOSbdESeO3ShIjt+Ude9N+RUDbhz6VOM+WTxgUDv2I1gWN3K8yDk0smZhxtGBkgdqswx7iTgDPXml8grIH4APGKTV0CnZjLUbSVlyARjntU0ES8oXwp5B71Js3cAZPQZ5p3lybcumAOPpStYXNcWNWMSqzkBR2GaIcDKsT5JOQRyas2snlqGzhweAe9I6IWJCkHOQQaLCUivcRAgsiqqkDcAMHNQTJIh8xjlSMjGMtWlHPGrbPLPXgE55qrexNGSVAKSEn6c0T0V0XGWtmVLS5dpPKkyFIx1HH19q1rfCsBN84UEKBnJPsayRZkMXUhWAywJ6j6fyq7byl0LhdwQ/eHJ/L86yjdfEOok9izKmGQuATnODz+H51aEkDuS7GNkIAVjgj15+tVLi5gZUbcVbf0OGAGOlRkSu5dwJIlQnH+yD/n61rJ2ehkldalppRbZ2xqwDbG4yrD+nFSRi3EJCgoxJK+mPr3rOnm3uVt3VVYgYYnGOw/z0q5bm4Ns7fZyYSfnPABYdxjnI56VMZO9uhfLpceiywuFVmy4AI6blPT61pW8cZkZpMtLk/JsDKe3PTj+VY8TIkqsqlU3Zyp5U9e9aqMJIWVGG4EMpHZieme1VAipdFks8cgaMsy7QDk5BXPTnuPan3O+YDyUVkChQQep54+tVobySJ0OFKrnduAJAHIB/pV4hWj3n5ScMrkbSfb/P6097mT0IISzWzeYCWwSFIDA/QjkURxbBggyA/xLyR+P9P8KQM8Ekdxt3AqHboBg5yCex681bhnRZ5GExCOeoGCPqMdv/r1K13B3QibZoCJATk5+bHHpn8PShN2BCjkqVJKbuQe4H+HTFNfKzSMjMUJKnaMEd8gd+9Ch5IFETeaxYFHBA6Zxn0q9SdiKTaodFGCQTg9z689uufYn8cyZgLXs0w67c5ZB2J746eox6VpEq6bVJEgP3Ccbv8Ad9D7VDNFHcqmG2EL8xVcHIHBH1HBHrUtX2NYS5dyK182WITRyO8e3bvUZKnryO/1H/1qsRkx2rlfmtycupbGPRge3b2+lRRwvbssOWALgBjwG7DPuMHn8D2qZbzF0QUWOTG1x2PbIz+HB/rQlYbbexWtLgPi33MSpPDpwpx+lSO48xztRFzwFbcoPsR0Ge3aquo2TRyBoo/kYZ+RsEHqAP1/l3p32sOYp5FBb7gKnaGGBwe4OfX1/CpWnuy3K5U9UXVuYnEiOjy7sfdXJU9NpH+c1mXqhV8yCVjHuyyKckY7/wD1+o/WpiyxMWt95Zj8p6P/AIdunPTimrMzKJJBt2t5g29Uz3A6j6HrTeq1CMeXVENrCq7nPlzYcodx2nPZg3b/ABp1w5QFFaQKx+dABlvr6n3HXNSLaidisUxJmBQ+X8rJkHBHqOvH61bf93beRLHE+3gM45fHue/P1oS0By1MyGJSUEMkkWBuXABGeOmfqfUHHPs+Q/ZXaKQGOYMVb5fkdc44H9Pf2pIxhZFI2w90JOY2HXB9D/jVe+Q+TGN2FX/logycDORjrnn68d6SskVu7MSJ3hm2zodpwd2dw9FI9cdP8kVowTrhY5c+WzEnJA2deh449iBmsiOMqinznljXIAPQbuvB6E+o71bNyrwKssQRwfv4OQR1Gc9SOxpQdtBVI3NK6CNHCylmG0YYKPp68/T6Gs9JAJgZQHTeW+XtnuD1HT8M020lCSFXkUYJ2tuKF17EHp/UVTuTtulYl9zfe2Lzx7fhnP8AjTb2kiIw6El9KZJDIzZYORngH2yR6j0781UlkWSERu24u427R83147/oc1JeupiWWIbQOsi5GGzkZHbvUPnxuxk+UBuoAwB7fTg9P/1Q9zRRsh3mDygzlSCrKWwCcEYwR37e9PQ27SsIpDDAwLbeTjseT7c+/T0qW7QF/kcGF5ASwXHPPzZ9f/r571VKlWZWA5H3QMYP1q9mQ9QACWwARTGSVJU5aPnB49O4PSqrOryeQ5P+s2jaCfYjn8eKdggnbkyMByG4YdO/b6VXuBhU2BgGGSQD830+nPSpZUSsxEbQh/8AVqzI+BkkZyfx9vSk+ypukIYOqPj5GHzqeAVzzjnrSM/mcBg0YwAzDjI6Zz09KZI3lNkR5gcHBODt6H8/5g0XRevQry25LqzorKuQV24AHfrjnvj1pYSw3oo8qINkrnng4+m6rI/1fCBonBYYOT9R9KqmPLb1YEgAEjg//XpWs9BOV9GKqM5PlyfebbtXk5PQfTPSoLsKsaDbJ5gI4PJJ+mOnWnzMynPUEYJAzkfT8zSx3JDfvUDDpkHJXI6+4OaemxOu5MNsZGQcD0qeHDkEDAxUZZgqlsY64p8JYKHUDHoa1uVui1JAHjUk457VaCfwCMkHGD7VFEVIG8gFjwKsyII2A9eeDVeZm30HxIImCkfUZqaQiQFzyppXVXiDKcseTmmLEdrBm+vOKbVtOhHmPjJzu3DK/dHv71ZhIaMiXhup/wD1VUhyq7ZAOv3h2qTfh5A54wDz1NSgaZK0eWwOD0HoKniiiIK7iMKSPfFVIbjfuQksDjcR1q3G+3BUqQxI6dKEkgdwSJHLfL9wcnpz2wKju4VlY5BYnpzzn3qTIMoBRskYyKdL+6vFaPkqB2796OgJtMpeWu7c3JQDluQw9xTW8uOMSRACQH5k55WrLqpIZNjbuTnsaqmLyopcsRxkY5+tTy9TVO5DcSRA7ZYn2HADoRkevsafI3+hNLBIzEjaUOQSo4z6VXku9qL5yqVXGCFHyg9KxJ9ci01+JdkTnGDlSG6kD8h7VjKSjq2axg5bG7YSAgRTKWCElRjJJ9cVZh1CWyeS3Rt6tlWLqcqfVfQc96xlna6WCeHahlJ2buc/54q3ZKXfay73z9CT+JpxvoojlFbs1tPeJtoZuFBBkHRiT3Bq+6qq7WkIJAKsvzgH+6fTGeOtYsJ+zyYkjzHMxC4bGR9Omf8A61XYXQs0cuFHzbPMG0g/5x6VSlZW6mUld3L+yQBlYo5HyApwST39T2rQtpJUZCzl8jjIGRz2+hFR20wa3MjorIY9jhOdrHufrx/+uoROyMVkVSf7xBOf9k4/DnqKtytqYay0LAt8yK+ZFMgbI/hyT1+mMZFMeTyvl4DY7cEgd/y9OtMklZDGRJIsWeed20dCceoPUU26Dny4keCQZ+XawAIPT6dc0pWtoUk76j2aQxbIgGlBGMnDHtxng/z6VOkm1w0luDOpDlhlS31H+HofwqXBaO2IkVhJHgEtzx6H6dR+XSp7c/aLceVuyBlUUltvrgdSPp04oi9bA1pcll2NIjJPG4jwSdvKgnng/e9cfX1qK5lEMrpsJZM5dQcf73qMZ59uvrTEWUJtJPzruyDwwx1z6YH4YpzvIscLQbDCGYqWA3IQe5/zwardBsDRiWEMW82NQfkzgrnngdeCBUF6r5VllJJGQwO4r+PcdRznirKzCF2BiURE7lUjp04B7e1VSglyUfGw71Tuq57e3f8AOk9SokSLunR5m3xsMsqZXa3bOPp1FWjDGGErkziRc7CwBGOMqejcHvVQXAt5fMDhGJwMLu2nqPw//X61KsizBnw0ZODhDkHjk49f8mpVim3uQ/ZArMDIyBuSH4K46Y9R3/T0pjKxEZExYkEFZOcHuuf4lzgjOO3StzIvIEjQRu4XKqeCcf3eMj1H5Gsu7t3jwHR1V+FIXB69PQ8Ej8RVSXKtNhRnzPUieBs/abYsWjOG+UhgwHOf889amurtmKs8hZWGScZ3LggMPcdMf40CdVBYs25RgsFIYAcYI/z7iorh1nnfcUmXcQrRgKTx3HQ8dRS6aFb7kcl1GwkdXXzVAZZAM7exBHcf41CSrxqiFTGOR83HqOfrwDx/WgxkIGXmHBi3qO3p9cDIzVJY18yVowUUqSY2+6eecDt/Ss5T6FpIuJb4UAFhIT/q2+X/ADn+dShQYfNZmJbG0YA5Hr2z9KSMeZCF37CUyElyOc9j6dfy96fIIml8qM7xLyFwV5Pbr/U54qopW0M2yEMkNuGY7XEgcYxs+hH+eDTXfZCYyjpt+fG3pg9Qf88du9TSqqafGwbbIH56hSB/e9COlNgnFxHFb5VI2IADdVB4wPUe3FVboTfqVNUtZlQqQ+58OUIKlgOc+hHWsizhGJUk3rErH7vzMFx+o5+ordSdrYMpf5WIAVuMbSTtHp64zRKsQ3T28qxOuGVDjoe2f5gis5Q5tS41GlZkEa+aIZZCxDLtLgfeYL3/ACH51AitLuUK3ynkjGV9APXpxUqyKhCoAoVtwTd0z3H09PSlluVEokgDAlgSgHTnP9KpNNEO62Ks7SNaxhypSNsx4UDB7g9+c+9VAUd8ouMtjDDt2z/KrdwoYsEQtwDkEAFT0PtVR7kxgpJuYEjIK5OAP1xSv3KitNCKSxRij7f9YWxluQBwQaiZiyeUycIvy8dT6dv8mgSOGXAOwtu24yTkHPI9s/mKfcrHuKlFwSQ2MH/dPY5/SmrWug1vZlJ5GRSYmCxnBcsc49D/AEqDa4kQ4Ix97HbHOB+lZUdtfx65JLJOfsrk/J2BPXjtW8Q7BDndtGC2dwOPUD2IoVmaVIqFrO9yB3S5kYtjMnzqAfueqn0qpN+6wAcI3IOKsIN8iiJQrZwAecnsT65/pUBl3kxSEI2crx93PY/4invvuStGbscAlh6c46n0pViAQA+tMzJscoeD/KiN2IKGN/8AeNaJdCVcsCJcn5ju7GpLeMD52fdk45PSoVi2KTkkDtnpU8Sxs+YySVA3bqOoMv2RQAlunTkVPOhC4I5Pp2qiM5ATK88n2qwDPECVAYdTTW1jJrW5bhjjkVcjgdeMU17NVIKsMZHJ9KZuYsj78Ls5XPJJqwGBi2BOh7f0ptJoWqK6wpAZFO1mBzx3/GrECyFlURq6A9D1oQI0TcfOOijr9amhiaWPaj7m3DHTH51PXQG+4o/dzB1Xa3B+YZ6DpUchYylnwMkDbnH51YtIfKeRJXMmCW56g+h+lTPGw8zYwaNsEAjJ+v0qmm0RzJMpMEeQ7flckHOPw6j8KrSu2SpdcA4wV6VaDhGK7NoYYO3oTUdxK0m6VY1LoQSR0wOxHpUt2VzSLOY8QFrWN2jfKOhOAOOc9R6V4bql3NFeCQmae0lJA55jcfeXGCCM5x7YINfRl1DBPb+a8EboBl4m6MvfB9a8t8UaNaac98Y1UABXKsRnIOQV7N1HPvXDiI2al0PTwVaKbi1qQeBfEFvcXsVvLIUhK7GV1+cEnOfc+4616bb2R+y/aoJzMFmaJgIxkHGVJB9fTrXjek6jpKXUdxbgJdpEQ0b5LITwVOeo9xnj0xXrHh/UofJjEynypQORncMj8/fFKhJX5WGLi07xRuSKt/aqrzRkx4xnvgYzj07VUM7QuQ7sFKqwDHd7YyecdvX1pbaQHM0cjg7wodMjcf6Hv/jUt829hLLLuLFiQy4YZAyT29OR6dBXRLVc3U446Oz2LllcRwupiVwjKVdcgj2/Hk+lWnuIgqvsLKezD8O3vj/IrItonhTBA2OSFcdj9O/bj8qmtiHiniKhZQOobhh6+/v/AEpKTtZkyir3NeKMSwM8BadVOGViA6+uR1HtVaSER+aYp1dRh2989c/QE1FZ3UsDq0e1lYhfLJOcdhnr+HtSyRS52xhXPCYDAhs/NgHHHTPTj1ptKWqQkmmTfao1DeczmQcHJBzx3HX/AIEMjFMMBinQQONkoLxkNuAI9xj16/8A16pXLl0BiBQ5CY24KkH1HGeM9uh4qQLJayxXA+YKSS24MDnqDjj+WR2B6p6lqNi6JQl08My5J5IPr1HQ9/8A6+atWyEs5Knb97arcggZJI78fnUDIzwKyukjIT8yYDN78dR+o468imxlc+aZRC5+6QMKV/P5SD296pXiyHqOlfJYKSEPykBTkJ6j25P+eaVkY7GRgArZJDf5x/nrTFgnmidAY3eJcj/aAz90j0HboRipLWXBG6IFPlDK45Hc4OP19OO1Wtdwemw4W6nCk7EcgbjgjBPf157j07ZpJFUkRuiF1OMjqOcYweoz+PoadeSW6SME+aBzkrHwBzjcuehwBkd6rNvjdA7+XIGJUsM5BGDx34AOPqPSjRCVy1CYnDqzss4+ZecsT0I+o69j1oublrhEZvKDL/Fj5Tjp7H36VHMv2iUSMqjIJDKdwf0+vQnsRVeRJmhBb92wYLkchgenzdMg/Q4696bulYEluWpIi65KAq/Uk5IPbB/Tn6c1FvJO51hLKoiIK4BweNw9fQj8arRIcOY42QN825c7G9cjsR/kVbQxmHyyihyThivf+6R+f5ilcHoTHa0UU8pURyfJvI3EDngnvg+uD9aoSK0U0mwqGCl1JXeH4wQOOh/p2rRCC3TdEyujYbOcjqMfQ+/4Gob5YWO+MZ2nexiOB16D0P0/GnKN9SYy1sUTGdn7tTsQBlwQMD1Udvp0/pWmnDSlmiRYyT1XgDPp1Azzn681dtWeSOQq5EkfBIbOVJP9R2+tNnjQrDLHKqSFTlefkPoT055/Pn1qXZrQtOzsxFmS3uAHbMcq/wCsDBxzxuH8j1/WqRQt5nkMDggsC2RkjH8xjH09qnmFsXK2/wAo5AULjJI5BHUd/XtTJDGoiCBBPEMFR0YDkfpx78d6TYaLYryRkEiYfPHsIjfnHPT/AD9PeqjSSRMksKqy79wLEY49f/r4q3dyRC6lMJLIxOd/IC9gR29qrFBEDLGxy4wUIGME4wf8jikWmNcZVSdkUxxhscNjqPanPIwTbIpwo2nAyR3/AB/+tn1oVSQZ41wFxlRyARgjH6Z/GpZJFkhjmhKrIqgEDA+Ycg49vXvTS6kyZU3FI5CdvlvHsIz24Ocn0IBqK6DTkgFTPt4LHPHc8fzqRx8s3zALuJBxxn69uD+NVpbZxNHMkY4GQ+eQeoPvRYEQzCQTL5i7XQH5gdpPpj36/nTUuA52yJnbgHK/e7Gp5SrxIp6gkv6gY6e4qlO5ilWQ4dBglSM5Hqf0/wA5p7BbmHyyJLOYnRCSvXOOMdf/AK9RiYW9wyrncBjAGAfXn9fxqNlb52VcBX2Hac/5BHNCYkLqCADkI4GQSp9/6e1GocqRJCkTQzp8qsuGjY9x3XHeq16A8Ylx8/p6H+nFOhkA+V1BBztYjoetMbdH5iJIrB+qn065pp3Qknc3Am1dhHtinxxgbWVmbjnJqFYxKHJYkgj2q7GVXcCPlGAO/FapX1B6D49mAqKOcc5qw9uNymNlLE444/GqpiypZMjBwCOlLabxIVD47AH3oWuhNuqZZ+YoA/AHTip4gqozEseOqnGKY67JGjQbGONwJ5I9Ke6iQoIQytnPI6nuaNUIXh0PlHjptNSwTBSqMmen40wjy5GcEt/tDuaW2VZH2EEHPXH6Um3fzCyaNKKFZNzRLhyNwLcbfpVZEeEK6kMhIzz09vrSb5F3KWzsG0BuoFTyOhjBjYnaqnZjGDnn605NPyIs0T+biRg+HOe3G4d6ikkeK4WaFsRhgCSMgduRmmzSBFDEjk545wafIAbZZEKgPxgdRjrgen1pNsmKM+4kkMrGHCEnKlWyB61GpmJ/en5SpUHOCv19q0o4fNtvkCFhwFzjjjnPfPpVG7YxsI8MhXIBY5GPTFRJOOrNYtPRGeb37BcFIhHLFL8myYDDA989vrXNeJdL8+0iUOWjOW2tgqpHAyfXGfwrp7qFZYSBEOMZHOB7fzrL1m4lt9IZGYrbxOSFk6K2O/pwR7GueULp82x003Zpx3PMJ9Jh0cNNeJEXQBgoG0tnnK5zg/z7iksfGSSaeFIgktlBCyIwWVCcY3Lnsf0Jwaw/EXiufUbtYLlkhERdA8pZhkHPzbeR168jnNQ6DYJf3s3mrCLiVmaNoSrZQjlQ2cFfQMOcEZrn5bLQ9Xlur1D1fS/EbvfRIIn3y8FDJ8ynuD6nnIzgj9a6yO4M8EsU215d3ySdRn2x0JxXnui6WkkaQOzgpltxz8x6Ag9eRxg5wfbmvRdOtGsbNlZ3JlGdhHyyDPBBP3SOev51dGcndPY86uoRfu7k0zrb4hmdTGjfK6Jjd/n09qyYdbtvt5haYMVJQqT1bs6//WPB471pa9Ytf6NJbRRp9oHIPA3MD9316cYry4aNfS30Fqd5gjLyozckMwxhT1xkLuU8grnvyq9SUZJJBh6cKkW5M9VSVLkKXUxocOjxgK2PfHBPHDDvU0crI8ciIjE8Z5GeOScd/wDJzWdogMduDdNlSuBJnIQ9SCPqPof1rajmMym4Kgsh2qAR0weNvXGPr0FdNNOSv1MJvldug65gea0kkgw0AIZlQkHjqcHOD+XPSqkR8qNgjgFsMq8/OR0OOzdcjp6dqkS4itzPv3JkHIVujY6/4j1x0qvepDHP5sVxGO7QsDkgj0OOP5dQamXdBF9GX9MkV1ki2rBLy0bDK8HII7g+nT9ajEUhAIJaQn5gGB57Z/2jyD69s1VdWSGKVXZY5BuHzZG72PY9Pf6jmpRGoLTYcw8ffAbYD2J9Mj+XejpZhbqW7QnyFkgILDdlTktgcHGeoIPT+VOiudpUOjMAMDa2GUjpjPbGB74qhBKVk3iZY8FmIRcFefQ9eP8AI5qOKWMXqmdRJCzbWf8Au5HTHr0P4HrTUrWsLku2aU9yrxxO8SrnjeyY3HODnHQjH4VC+NpZsOG+7gj5WHVSB1H5eoqKK8htL4x+aJrckOGkHKkDHOP1+lQ3otvtcrW5VSSHxHwqZzkEe/H+eKbb3Eo20L1sf3nm27tuB3KNpOTjn2yPTuKkMkflhZtpL4LAdBnoR69f89smK/tmneNfMjm2ZYqflBB9+SAMe4rTtt8kUkbrG0YBlLAAkL6xseufQ+4xVxaa0CSa3EjmeC42R4Yod24ADjvz78jmkuJ2MTR/fQDIZSBt/wAevPrjtioLuWRQjRyLc4J+Yggg9wwPOcdAf1qpJMxkKuu1XHBU5AGf6enalfSw1HqXXnURumAQ46rk4Oc8+36j3xToHZssZEZ9p2I4wW9wRwfx/Sokv4HtpBNGFmbngklDxg5HI6dc8Zp5ESGRQ7NGSWAK52kd2A6fUf8A1qa01FbpYRFUlg25Npzz06YHI7irMUqxpsk3KdoIPXODn9MmqUUwjYtw4xghgfz+oGPwqzNc+YRHK535HLjmPtzgc8Acikn1RMkyO4iPl+ZkFM71kB657ce/p0zVNi3nqz7SxDBmIyM9uO/UVoq4YKvmBQJCsgTkY6E+v4jNCjbPC0rApgqxA4zyOe3cdfWi19hKVtynPDEzLMrMFIKlTzsHGR7jkde1Z8iNFIrO7DYeCvYdwB7HtWzKVsnn8hWMLoQQ3oRwSP6//WqvJEi+XcQKQeMMRkHjnjvkHp7e9DQKVjPXcVdUXc4QgsDjI/rj+WaBbCNiww8LDYcgE5wDxnrjOKuyoihSgCqx3DB6D+oHX6VWlkWKRtjFk+bawG0YPfB6U7LqPmb2KxRQQWYLGrEF8ZK8dcemQPpUXntEvlqR5b8ggcEZ/lmpizuu5cFQeWXoPwqp5LK7xuRsxhR3X29utG2wepJJ5RZA/wArPwDjPbr/APW96oXkSblJPI6DHJz6n16irbptiKlRu2hQx7EDofbvVWR90eZBliMZxj/Jp6bMa7ozEuPKl/e/IAMDAz1/w6/5xSKwZ5Bt3kdCDjp0OatzWiyKxMgABAJbp+fUDrVWVI4GVg4JzlcnKgjr9O31os16Gl09is8zecYyCTncwHY4/lTTcYAJTe5Y7iRkkEdP6/hUEwcvlSqqScZGCfb2qKVxtVGfZ2K5x/n60r3K5UdyYVV2YAgY4ohcqAH3cdcVGplI2hsHsOtJEshmy4JVugXrmt7djNLuaDlYscgKwHBFCBQzd93PTgH2qONw8Xls3yA8kevvU8R2jnC+hI60bkNWJoFIZZw+455B7e5qzLGyN5gY4HPHPWoJI5Uy8SBkU4LA+vtU8ciyxBXLKxyXZj/T3oaId9xVcmMCTBUfNkDqfSoYtzhRF/rFPAH86srKr28gZTlSNvJP5VWijKDzFKoc4LdalvYpImiZchSkjep3c8eg9KsIqyDIJA6sNuKjAVnRzlT1wOn1zU+JEkZsqUfBye3+FHKS2PdI5P8AWEBshQ3QnnuOhpsi/Z5Nr7fl5yRxUrBGfATktuwp3EY96mKrPMIOY9wAG7B5GT7e/FDRKZXTeilgCjfd8wD7uf4T7HAqsy+e2C+yRj8x7H6/THSr8e9Y2iRd28YO84x2GfYdjVNoN8uUCLhvmB4z/gKGm7DWjM2WJsEwkF1y+QQpx/X6fWuW17Tjc2UqOJBBIfLcL/DzzgdM8V3MoRECumHUZBXqee/06VTuIbh/3LlGi3YG89wP/r4rnlT0szpp1HF3PmDxPpS6RqktvFKZnEgdQg5YbiQQoGAwyQVGOCeOK6Twtokn2qz85J4ZZG+UqcpjJ5BAz+fP1r2WHwxp17dlXs7csTlPMB3A+mf61Yl0RrK0jYN51s+VVQ2NjHgE578Vm6M5R12OuWOWy3ItGsRC5ElvA5kQoPlKBW9frxWuqmCPyJCqmM45Ide3bnP0/wAKdZOXTy5mDNkclwML/Tpz/XNWpLadDJJIuRkKxBDcDseefxrZRSXunnSld6kMg8rbIYztY42Fsgj0z+nqOxrH1S1tw0dxBIrtKC0of7yEHkH9eevFbaNiQfaF82Mr26suO30HP6fTK1WyiRJZIpDIynanmLgt/ssPzwfw44qZpOOhVJ2kVDqUJUPI8HnoCr84Z1P8W3vg85/l2ntpYLoO+mk+eNoKK3JznjHU9M57c9a8R8TPczX7tbzQ2WpRY2q2VMozxIuR97tkc4xnNReG9d1KG+ilu52LPLsjkUhV3H7ylTxyDkY4yOOprn+sNK7Wh6TwV1eL1Pdr+VWgaLYwnjyFjf7shPBBzypwcZGex9645tQ16KWIzyG4tH4CSN84C8dBntjOMdD2rftb03R2/IXK7WZFKiT325+U49Dg47Vdm0WK6aIiU5yCwK4dJB78f/XB6GlODqu8Gc8JxpaSQ6KCOO2V42eSNwrbWVvlb09GAHfr+lbEcYmX/WHzidvlAj5wR1BPB+h/Sq48+zRIpgxUYG08qyg9s849varBVnZmijjDEbh5RDKR1xj17/0zzW8IqOjOecrlfy5POcGGJm3hSGGwLnopI+77Ed89e9W4tirGTawTpKpYHcpPAJ4Bxxg4/KrMzPIzFmLyldpYjh2HZh3yM++RzWNctPHczvLIzRkqoXrlucc+hHTPIIx3pTaRUEyjreqJpyEyzZSNSpkKfMEyeeeo7cjiuTHipRfWk00qSWMreWk9u3IGMbXHY5wR16bT1FaPjrSZNQ0iKeF502HcWAHAB6KQcg8dDjkY6GvELi2uNJvS+8AODvWEEpJ6jaeq/wB5TyM5GR0yesrP5Ho4elCcL9T3rSvEMUeoIJLh0nbKFoxtLehx05wwKkdVI9K7TSZWvbUiF0/dpz2OCSTt9evTpjv0r598OQ3WoX1mbhlkReY7u2lyNnBUYPIYFcjd155717pZiQMZLhPnOAWbA5IyGPpnJ9s/qUW1Jroc2LpRha25uzK8nmMygODuyvX3+o647/kaqSQukRaNUkYIT8p5ABGD6/1HSpY7mKdSFYW868MgJxkdQO2OPaia5ZyRhWcceauQwHQgnjI7c8/Wut9ziTZRhMKzoDDkSnO5CQ8eBk56gr7+9WEzFmTJftnoCB/Jh09KgvIg4ieHiSM4kx/dIwePrg8emKntlDPsZvLO0lvMGQDxj3OeemfxpK/UtuxYuE8+JGyRLwoHJ385/P2/lULwiO5i2zoYnHL5+aMeh47Z9OlTNAqM6yIc5DI3I57g5/PB96dMp3gzneYwUWUZGWHQE/TPX1707dTPm6FcAee0YljKfeVznDn1HeqdzPKqMQzqpwPlH5Z7dPzxVx8EBUQZByGB79gR+mfaqo3oRvz5WOTnKnOcZH1/P8qGio2K8EshVWGwDkMA35H/AOv/AFq3G7yW0pVQx+9Ki5AGO5x2znkVXWJZI1MTj5xubfjhsnP/AOqoniZhvZWG9M5UleMc8flUrQcrMbM8kJKXHmxDlhk4xx1GKheUSyeVIjLhgCccjtjH0wRU90WeCPzHLKyZzkZGOMmqkzGZXllchlH975tvb8P06Cn5IaXUmtJIUkZZ5FMYIH91sHP8vTNRXEu6465kAwxBx06HP0xVNrdydqF3bYXDBeg+pP6802Z5ZImQRiGRSpDHHUdePei+lgcVcvFsbZAcfNsfoePXBqpcAwOxi5Q9QOcexPr9Ke0aGEZ+Zwcsh6/nT12PaElUVowGBySW5/z+VMnYzr2dGVnBZXD5XaBgA84xVC4LGPzcgj7pweSRWhMBkFuZlO0g9zzyOO3XmoGjKExGRWBAI74IHT60PUuLSRkODIo+TDMcBfWoZrdgu0rvkHVifoeP1rcdEmjZvLIZX+YqMA8cA+lQPbsY8gKxkJUA8kFcHH45xQolKodOEbg4O4cNxjB9qkkT7p+cdPmB6GnFjEoBBGSSBnrViELJH5e7gHOSeTW976GN7aiWaYjKsqkMeuen/wBerEQ2gjPB4wBzSQooXD7vlGAo4z75qwpADcrwMcGqtsS3cIfLL8BgpAPI5/8Ar0jlAwKkA5+6fWp4F8iQbCUkXg//AFqtSRJDdgyqm1hlucgfU0raakc1mZ0TN5mSxCnqR3/wqxGyRyHy2ibIPEilsf40+WNJPMdC+44KsgwPfNQPE6LubDk8YHbHTFJpxKTTJXiMPlF937xTkbcEHsR61MsjQSLJ8/zrsaMtkMPT1FRW4k86NY3ZljwVUn7p68elWGUqxfYrsfn+bIwO/wDKkrdAfZiW08PnossbFGOdvXA7dKueSrIHQpIOFJI5HPHGfpVWJZQSVU+W/Ixz9OaeiySRkkFcDv0z/j0qt1sQ1roxzIPObEZ2nn1xiozbQPIrEDcDwckZGP5Zq1agSxtlCsiplccjrzn/AApFcTuUJU5wgB457YPY+lJIOYjkiSNDJCcbTyGAJycZHof0qhe7oUaPYQoJBcjKkdh9MH9K07qAHa0TFJVGXiBxvPt2qvPtklEZC7cELv8Alzxwcjr9aUr7IqD7mRc/Ls+YZU7dx79MdM/nWJrd7MYnjhuYrchOVlHLZPA9/qK6C9Rlk2hSRwSq4yfXnHDVnX2jxajDvTejxAjKHh/YemR6cVyVozkmonTTcU05Eei3RvIY5DDmUJuPlnv3/LJ/w9dmO8aAoYyhwMqQMde3sfbp6VgRrFp9rGsSSZjOcg4fGOce/T8vSqmoayggEjBZoj/DC3zEHqCOxGD9CPSpjU5I+89Rype0lotDqXMcpaRJI0YjcgDZBODkfXH9acHSeAxMN0e0Eo67wR2yR+WRXn+ia1NPeGM3CuMbgQDsdc4zzyCp6j7w5I3Cust5QF3O6IU3ZR2xn1x6n/Cqp1ufVImpQcNGcJ8QNFS7uoTNaGdA+flcqY8nluOuBkgnoc561nS+D90KxwBhcMp3B2Ueaf4Qc9SCDyCD0IweK9VllBXPliRWGQ+AWUdwD0Yc9+fp1qoIAyshQSQNgbGHHAHPPNZSpLmZ0QxM4xS7HG+FJ2tDEJCTOuY5FY53A+oHOff/AAru1u7UiMJKQWADBxgjH+13HX8OMVlyafaxX6XDo+GyS565JHIOPYdR1z61ZFnE8wkkgDozBFeNioz/AEJ6c+31opRnTXKRVlGo+Y1UlimiIkLLtJQRkE89yD/T8fSppYozAWPLhzuYLwBkA/rk/wAqpJDHbw/upZfLYAAuQCpX3Hp68H+VTJP+8/0lUPzKznpkA9fyPP51va+kjnatrEhujBChlwk5Aw6sOn+0OfmHfPbv3rBv7yN7ktnhxx5fQdyrZ+o/OtnXIdkjrPGqEfvMoT8y9Qw9COuR15rzjWTKNQW1Vx56sVQrg+YDkjH+0M8qeoYenHNXk6bsjqw8FPW5uERTxEgZ8tvn8tsOFxxkHhhz169j1BrE1Hwql+rfJG8jcBx931BIP6MMEdOvFP8ACD7pFLOUWTIAcnA5weDz9R1HOTxz3aWiiP5BnaM4I3A47e4x1B9PSpppVFdo0qTdGVkzhfDXhRtLmW53MrsxTdkEIeDhj0z054yPcV3OjTNhrS4UuCBt2dMj+6D1Bz09DSbYkIQxbSMNtzk46ZU98f575p6gksak2sZkw2V2jHPrj+Y/KqivZ6oxnOVZ+8akybSqGJtyleOVcH1H1HHfkA1chBkb5fnZBkBuqj1PqMelUbS5eeBTeKpdFbaxbHAI6En/AOv61IRJbW7JOpzGdwDKehPOD+tbxfVbGDT2e5YkljW22rmIodpYDgjqM+h4xnv9arNjzm2joQMBvvcZwPQ9D9aabgvKRPH525S248nGc5PY/wCelVEkaGZXjA57EbgQe4z1H/6+Kcp7DjE0E1MzQIspLvnlieTj+f8AP61bilEkMLSE+aQV3EdfTn9MGsi4RJAgt5VzJncZOMEZ6+/9cc1FayssRE7rtLD5SeQfXHf0x+PahVGt9SXTTWhtzKZUWRUzlSP3YGWA6g/5zWcpAOWHyE9QTkdsn/P86mEzMM7i0QfeyK3UkdfUcd8dvzZHamHBjd2BIYiQd/w/yat+9qiY6KzI0Cxq2VJaPkAYHHfPrn2606EQSI7DEgHzbDww55x3xg96iKymNDgYUhd65zkev1qclfODMh2lcqy/wt05/rREbKivHFMWRhG/UcZ5/wA/pVZoYlVw4BGfu5/h9c/U1bmYiSTZhlIwVKgjrz+XbFVWULIS+4kKME98Ecfl/KguIkbusJ2gGPBVdpwQSOufQ1NKiT5Emd+0Y7Z/z0qOKRS3TY5Vh8w+VvUfXmq4mBPzBgV459ad7EtNvQldvs7l7dNqAYIJzxxx+Y61I8kMM8jK2xJAjcAEjjOPTGaqmUqv+rPzEnj+EGoNr/Kdw8px8oxwD3zTTFy9xtxG6HHKgj6bTilmkL253IjSxsd5H3nz1P4dKJ4w8jx+YRsUbd3VjjocdKpTA+ZukYBhnL56fX8aXwlfELJdyi4aVPkbcGDLwAQMZqpMseDJuy2M49/8KgXU02oJMNGTnA6k47GnyMGVXQ/IxwvYcDkfXmlzcyuXytbncwwrMG3NwvIzxT7a1E0o3EeXzk9CMU+ElQRHx7elTRmNQTHJyBjgZ5rp9TmbZJGzI5bOGHBPSldVfBMW44wx+vrQR5cieUQM84btzVhYwQDHJtEmd0Z5K9uaLtk3sVtiQW5WOQSITkg849waljTaY2Qjy3HOMkf/AFqbLGETI+8p2sM5LD6Gp0jWVQ0KhUKhShbBc5pWuVfS5IilIDHhCHPBZTlT6Ckby4jtnTO0kFlJG32PtTSWaLDKML0Knoc/5FSR4uG+YnP8e3uP8aE+xGxJGiOSqCN2Yjy23duwznH50k8EsJeCcxlSd245+Q9hke3apYbZREhMiNxjY4/z+dEgeF3ViArNkDqp/Gna61Fzajds3lqEIywxkHG4f41K6DzSzoWZumBj5vSk8/ZbiUhgzdATnGOMY7UouNzIxBB4yw5T8f8APFHMkGoxZXBBWQOwX7ufTj/JFCr57LklWI+U569x+v8Anirjs0rK/kptjU8qc5H49qpLlpMxADB3Fc4/n3/nSkUmToHETmdGGeHJx9fwP1qlcQRzLF8xDL0bJAIxn8KlkR/lmik8xyPmBYgj0yT9OKijVJt3mgxuzADf936gjv7ik7NWKjpqVBHbhxHcNMjAkBoyNw44P9arSs9rumQ5dG2iReB68+mfy688ValljnCxttt5lBQsM/OPYAHH4evpUI3oqI4AGMqSDgrnIz2PNYN6GyVtyrq9sby1eZTslA3fOMAnuAe3HSuHuNLupLk+RFmQ/OBG4UhtuMgHuQMEDrjpkc+jWrPDG8TKAyjdgqCwA7qPUdwe1UtTsEmmd1WNd3IXHBB78/w5P4YrCrS9p76NaVZ0/dPGNQXV7DWEksleNc5aDBdVPQ7gOR3wRyM4IxXomn63G1ibi6c27FS3759wJHUZA7+/b161ck0yF5gRF5bFdu52BRgABtJAyCMHk/jWVqmiPbWiwPESHXajq3UE56jgnrx0PseuEY1KSutjrnVhWspaM3bK+tLmJDZ7tshOCOdxxgjA79vcdOuK0RfeVErRIQq4DFfmRgcjd7g9Dn+dcPpWi3miNm3KPaPtYBOnYgYPCj/Zz64x0rr9MZ4lBVvLVyWxjcjIeDhT94cfXjp0NdFKUpOzVjlrQivhd0Wby4iWFJYGKvtJYE/c7cj0x36EHsRWXFqAUz48tCBsdAeMdDn9DnjrVDxHdGOwfywcbTnyxzt79epGfrj6V4fqms6nBqU5+1SRgELBcMv7s8fdcjoSD1OR6jBJClUfPyo2w+G9pG9z6Pila3fEwZoHxneuOo/XHYj2zVtbhZ0EdwY2kX5WEmdxXtyO3off8a8x8A63eXdmBKNqBRuCHfGr4w3ByVPQg8/4d1HIjnEfySDqpGc+49vb8qqNW+xlVouDsy7tiSZMqJ4lJQxzdVHoT2I6ggfhwa5DUPDaXjXKbLgRj5s7dwBycbh7c9MdOPSuyZP3hOZNzYX724cDsT3z0B+maYsoWY942b5u2D6c8g8ZHPX8RSqU4zsmRCpKGsTldA8PS2szNcMlwhYbJskMWHPI6k46N3HrXTRs3lENtVEYZ2jAB/p/LHpVLW7iPS33mT9zgtwenXpjPrn86tRzW81oJIZ8ynBC9Dj1BHUexz7VMVGD5FuhzlKfvsdfIHgXDoSpOCqnKk4zx6ccjvTbNxcTN55YHJViOWDH09f696p3epQ2qtul2uARGemTjOPY+lTWMkN7DGNqiL7/AJmcMMjAGe3PT3+tPmTloTytR1Lcm1mjG5cyYbjHLY659fUd6SNmKSCZ9mD0xuUnofce1NjRzJiUJvyV3OPlJznOR69PxqJUZ5i1uQ0ZG8r/ABr2OD369+1U+5PkTLBK8WA+3YzMvcBh/dPuMfWoYZ4rmJEmhUJvJMicGPIII9ME4Pp/RIZz5bwktsftjP6f/rqMhvNAUsr9UOMZI55B/wAn3qU+qKS7lsSbWjaUxuhIjkYrkenI+nf+uKiniJIQBN0TGP1zg9AfTHrVaK5hS7a2uI3EcqkhkztTHXIxkY78H8qVWSGTZHcBUJ+Vt3ysRkKfb/6/NO6YuVov2iqUMc0e085yPmU+nHr0/wD1UkTGRxGqllZgRnqfbioWczKGhG1gpMij5cc/Xp0x+lKJSku9ySVbLMnUHoOn07etbRasZtMldVMbyK3ykbQD1GeR9ehokxDKwTYy5B6YwcDPuPpTJ4zCMxEhymAD+f8A9eqdw7mdQMgg4O4kZ9Dz0/8Ar1WwWuTXDqQDkYUYyB2PqOn5VRkePfsfzF2Nko3zD/P86tLIjjYV+Y8Y7rUXkldoCOJCdrFiO44I/wAkUmio6bkc6ExbkTMJwTtJIx6n061WVE3MYxtVeRnoKsW+YkdMjH3l9c+g9PpVO9Dx25lKZAJwezY6gn8qPMtLWw6WUREhw5DdC/Bx9frUiA7shwFyW9l49OmazrSaWeVo5F3PKSA3T3z/APWqWOQxxL5ZTaxzg84P0pJr5CnCxNdSKwUJgfN685xgH/PvWW0sk9u29VEiNySvJOQOtT3UvzFkGQcAhjzj1/8ArU23Ih85pD95CUK85b1FN6uwoqyuYRA8zcocsQdyH7uQccfhV6AlgRjBXB56+9I2YnEkWGzyW9Ce1Ku055O5u57H0rOCcTWTuegIpV2cuylm27h2z1qzLEyleC20bW96iWVpEd35yMY7E/Sp4iVUOm9XIIIB4P8AhXburHGCKJA27KMq7hx978alhcsgU+WpPAY8Zz2NSRvG+zyztfAQJnnBPWmXIDSHYdqvgkYxz/Sh90TvoWLqNv3UuSYThGGQc8VWVjFLgCN2HG105Hv/APXoeNHQOmVI+UgHPTvUiRGdcoEyMnZ3/DFDdwWiHhZHjkkRdm3qMZGOOfTn0qGAeTI0cmCpO7eD0qeBi8yspTeeeRuz9R61dmtmZGmlWNyQJGWPsOlS1dXC/RjZ0WHyGkJMMp+XnJx7471PJAwMjITtGMZ5yR0qlFHGVLxLu8slnJJBI+hq3BcYHyPgdcEbefwpxs9yGmtgCpJhGZ45QeVII5xnj/DrTY12SNv3q38O19m3HUe/pimyOzE5RlIP3s8g565pIpjDITJ8yA7s7cjnqDn+dJ6Mau0WoplhUQMpRM5yVHPfHviozGJGIfa2WPTnI68e1RhMXflITtbDBgOfb6/pUrFkZjKpBOcgnP5Hv/Ol67A12FYI2wb1VMkAvn+dVpbZlV8YYHAwDw39DVt4w6CdW27SAylc4Pv6/WohOB8u10QqQuDlDz39KNHoxxbWxnTQxSqpt5EEnO7gjB9Dj2PXpxUd1HO1sFmKoW+6W4HAxj2ODj39B1q7FEkc4R12yMSBnAwR2z070l9aC5iba+yRcfK3OR2I/XP0qHFpNrc25tUZAkPkLC4HnLIWXIxuB9x34/yadDNDKxibgDIVnPRj6/3fTI/KlSIzxlJo1jnjyN4PLjjjHf6j/wDWk9vHKM8xzKMbjnnsUb29+o+mK54t7mrtsLE8sEiPGFyp37SM568n+R+lLf8Ak3luGhtUVpDyANoH+yccH8gao6ndytCu+Ax3C8FsEMT2z644/X1pdPuPNi8yUKc5VuAx9wfX2/KnGtHm5OgODtznN+L9bm0rTJIY1E6527s5ZD1BwMluAeexrzOH4ly3LDzYysKtglSc8ZwV/PJHBHJGea7zxtpS3DJKvzRKzKwDmMqSBgg8becYPY5HQ15JqWk30eoyfY5LyZJMCcyJtc9Mh2HDDuGHTPOawnLV8zPRw1ODjtqetaBfHxBp02NzKoyxADnGM/Mo64z1Hbn6chqeiFb4sJ4iz4BTaX8xfvYZP4wCOccjr3rqfCGiPaRWl3ZBUZlC+VGNsmevzgHk4yM4HPak8Z+FpdXv47mzwJQMg7SA+OhIUg5Hr2OcHtUODlFPqhQqRhUaTsifwRa21tCZbcJGjtuVI+QBnqrcggf3fSu7eFAI8BCcDcQwGFPIIHsRzjP4VyvhjRf7KtmQSiR2OSHQgg45yc8k+pOen1rrEjDRosxkU4H3kyQQPYZzW9G/LytHHiJXndMbCA0biIK2MsQFznHU+3v/APqpmGdmK/dBHJAOe457jv8ArXKeJdTl0K4juEDYBBDAEdP4l9x6dx0xiqWleL2vLyNUaPbP9wqDjJ6qVPufu+4x1FZyrxTs9ylh5uPMtjsbqxivIXeZSzxtuMJGHIHfPf8ApVCNVt4pohlmDfu/l+bgdGTuMdxmr1vJHKoYqQSQfLLHcpA9TyOelP8AsDOsjybpI0yWXIDADuPp39u1Va7ukZKVtGeL+Pr2/sPEEeoWUs4Viq+SHOwqOdoBJOfT8x6HvvB0l1Nowu5ZFaOSYLG3HpxuHbkEH6VuSWVvEZPPgS5h6OrqNrL1xjnB6EH2965+O/sbfVIolt50tsbHLAIYySOcDg+o9c1jZUmnNnY6ntocsVsdnDcB7cB4yV3dSeM8cH/PaouVbOWjUSbVfHzLnsaisf8AVbVdmV22Hy8EP3BweSOenYn85kBljnEe9mQhSwHUZ6MCd2OPfpXVfmscFuVlf979pZXJwj7TycIRxnHp7irKQx3cpXzkVscFj8pI6D6VV2o10MrJvGMsG+YH0H8x+VECxzB2i3kDaeuXUkkBuwI6cUKxTJSrgP5ZZDw5DH5gQeq+v+R9YJPKkaUSxqokGGQJgMw+vT1x1FWnSRgiDbvU/KQckH3B59/pTLtfOkZ5JWEshwQ/PI7j1/Q4ocUxJ6ibXuH2Mpad1UIVfnp09/SlDSN/rAAWULnnIxjP+f6ilWMKkcbAMDyO3fqP5f5zT1kfeyFJGHqjDI/DvjFXGIriyMYs72BH8WTkE56/5/OqrmN5EExYDJXpjAxwc/XFPIViAZA6sdrHuD75/wA8U26tpcBJOFCgo3U47VeokkQxwF5GUspIXPXGSO3vUbsIy/RgRgYGM456fzFPSPasu5C+MMXz0qu6sEKod/OSCefelsWtWM88NIiMQDnIKnn86iuCysV2lX/h56e9SJCAjLuwT19B+fWpJIg+8SOTJw2/GQf88UrN6lXSZm/Z1hRd5KsfyI9RUimMRBFbKFuCR8y/59qtxStGY1lUlF4G4ZIB6jB9+aGMJS4DquV5jfpgdcAe9CXYUpt7mVPGhZ0zuVDjJXafrj+lRKpVexUDAHpzmtFV83eLjLDpuz09KguYvJMTksFZSQBSaa1FzdCngr8sgGJBuXac9/0qERBc5OUxnIFXpESECQY3AcbeevTPvUE2VgTCnO4rk9CMVQr32O+jhbYio4YSbvlz745FI8wi/fEOhX5d65wT61IZQrLuj+8CCRzgDtU08YdGSKRCrFcIG5Pv+BrpXkc68yO1AliLrxg9R1x61aiWdgNsJ24xvK5wOnJ7GqdvIYi8YVSrLs+YEAL6g9RzViCZYEMYkZhjcWRiueP89aFYJJjpM26FtrDd8gIPyv6np+NTF0YskMyLI64Ow/K3t7gj8qFminRImYxtnjCgMx7Et0qqYvLlZAFBBZSf7wHt/CTTbSEo33L0gNw/nhGSVWBG3oVAxwPr79KV7toScxqQwxgZA/GkyTGohZX3jBQc59x781K3zLHE0YfAI3KcE+mR7Ur2FbuVoZ445Q7ojAAgqVyR6H86tyQRy24kg2KAAflbKn1PqPpVLayiQxglwNxz069Qf6Gp7Z42gMUZkjuMbWCjKtz0PpUp30Ka6oswA3KhV8zKcsQRyvHP19Kb9pVh5EsW4NgB04YejEd6Y6+XKvlSLNGwA+YYIPPGP8+lX2KGGOURrgDa/GQGx6f4UaslpIgnglV1MbhZFwMn9D9Kc7NIyh4/3jHDAZZTx1APGe9AXyoY3b5v4TxyM89O4xT1WNinluWjbrzkA/7pp3JvYjjLxloSMl8KS/6fp/ninFSHVZIlOARkfLjjOc/TsaJypHzHepONv9D/AI+4psdwkhZDIwkXG0PknjkdOtJKw9XqQ3MLIFn+WSMjkMASR+HT60QGUwDySd6klckAovXv9f8A9dWzckOFG4vuHy7s49gO/wCffmqrRbwyiPbgcqf4fpn09DRZX0LTutRP3UzFp5tspGVJG3cfw9j6fhUFzbq6CSIsXUYOehGcZHofrx+lFskgBRlBEny7T3OOCPf/AOv60t0xuFwwj8wjG4/Lx05A69qiSurlK6Zk3MckkRBOVkXGGOcgHAI9xyMehqou2xWTcCYX+chT39T7dM8Vb8lg6SBmSRDuVn6D69ucHnv3qK5jSWzKbmjkVjtXGQuev0HsOv61z2s+Zbm/l0MDUtR0+SQxpMwmJKbWUlfTBPQA+nPt6VUCwRbVtwvkgDbGw8tge6kDg+mepGOtcv4g0a9GsCWAyo2cl1m5A6EDHBU9QcA+u6rd1p2oXmkSxXCtJccESKANmB1xjng5wpHXla5PbSle6O9UYqKtI7LSp7OS1821L+UOUIBBjOcFQegIOeuK1l3q+VYn5txAGOQM9McHvn659a818K2ep22qtNeTMrSqjPGTlZZFwA6knuB1yeRjnNeiLcNMojuFIlBAA6Mpz0I7dvY47V1UqnPE5K9JQlZO5KzefcedOXkJGDuwSR2Pv9asx28cjRBN5kf5Nu7g55GPy7//AKufi1xyTDcQoHLlRtbDqRkcHoVOMYznP0pLHWUv7l/s5ZZo8KwcbC4J4zn37/8A1qSqwdiJUp2K3jSwmuTIkc0yIo2FD94gnJIHY45x35x0rz+08NanpmqwzyhXVnEolicOH6YbA6EdTj1PevYrpvt77ZlRWbCFSu0kDPB9MVQNpGm8OiZU7iG/x7H/ADxWNagpSckzejiZQhyENk/mWcckqkSFjz1zjqQfTrkVZu7kWqMZGIfP8P8Ad78+nsRinQFSrNGZFcPnaQOnY4HXqR/jWZq1u1zDJErGMOMkr84AP5dulat8sbmSSlLXYZDrEN3ceTBIVlVSeFIYEdQQenbjpip1sUvrNN6JKkJLblUFlB6e+PboO2KwNJ0+9XUGkuHixEuxJNuHI6Yf1+pya6GeTyXjuIVKyLyTjIkxwWOfccisYXmrzRrOKi7QZMnl2sUrb22Beg+YqR0b1qtqF+vzXjzIzSLueRfu8HnP6GtD7XHduNsEe9pD1baQSM4BPQda4/x5aNLBMLLdEz9mxg9uce/BIraa5YXjqkZU0pzUZaXJbrxDaNcKonidZBgMvUkfzz+fWrWlXlvdRGS2uCxI3KcYIzwykfiTmvFA8lvfGOeDbKGw0RYemPyx37ivS/hjY3CM4nfekz71WX5QPbI6VywnKdRJ9Tur4eNKnzJnfRPLLKokYFyRgkdeOv8A9f3qe5QkcgsepIOcD/CoraHyNolBiQkBmIyB6Hj+f41aJ2s0YwZFbJK5IYY9vzzXoqOlmeVfXQji2bG3gZI4Yjgnp+FPlRCUkCAIwwVBBwaZIuOjEZySG4B4/Q+9QIGRSH3MdwPDcgelNA0JLb4YuzEYOGJ6qB6j8uaZ9tQkDccj5CMYx+P1p+d+9JW4PII4OMVmy2zRTAlVcYyOc5o22LUU9JFwFDIjSM4Xpnp7Uy+SSAMCvLNhR0+lQsNrkF02lQ2Aeme1SPmW3BcEhO/HHpTezQWsyPcnkjIIYnoOQf8AA0gYREFyRETtJyDkdacxYsM4Ybep659PpVd137sozZOQB39sVO2w7X3GSMj3AMbkhuOu7Jxk01otzBW2oeqt0B/A9KNsQij3FlkckE9gOx/xqv5sjHzHw0g656g+4PenddQt2BgYpf7jK2WYHNLOY3Xb0ZPTktSSPHK6gOCxxwBjAPHX2qF1KO33vl7Ac0mxOPURlBYNnKjqKgvJEA2KSQTkZ61ZUrImdq8A7s/0NVCm58qu5v4lxkAfWhrsJeZ6A43T8NiPI2uDwAcc/wCNM87y5REjKGk4G7hfqT36mmRTeSYnaIFVznjv7dsVZgjiuLc9HcDO3gDHtnqc10XTfmYrTct+aFcrcusgx8kseSMjsM9BSJEvmbgCzA54Xhh+HSmyWhWBywG7ggAYIH+QRjrSQ5BTZOrRk5Ddt2O4NX1sxadB9usTFQdqufl5+6PrnoasyeW6N5rIrEZ/vZI6YNQTwkzyfaAqvgFtg49+n4UixhJc4Euzlc/LgH17VK00Y9HqW4CU8sylogeFZjkemD6dfxqzNCY5fkO5kGWyM/L6nHX/AAqrLKzDDJsKjOH/AIhjkYzg/wD1qsWU+bjACbMBcBse/WjTYzae4vkIQZ4wVBGX8puh/qP/ANdV4baMTZUuG3fKRwR/hn8qtsux/MhBRgDvRW3cflwKZFIm2N4SR65Pvxjtj6VLVnqF2Tq6ZVblBuHyuSpJx7en659aihlIuWjypQZXPQY7VdliFwcSBwByH6gD6evNUHYiXEqDgY3BcZHr+IpyutRRs0TgAMPLxg9d/GSMflUyIrbh/qyuOGPGO3NJE8BUIXwT6nge9RDMUwwQpjOSOx9/pz+FD0J3ImyXIZAfm+YHnHvjrjHpUCCMXrLBIG2n7zdwB/L+XtWgm0zmbYAqEDKDv+PXvVfyI53fzJsOMhdw247jt74waixrGSIpQVdSQuCSDzge4Hcfr7VPI0uxGd2eNeAc8hc+vr25qONAFMcmdwPJLYBGef8APsaFkaB2XcQmPmG0Nn/EelO4xYvLkKuUPL/MuNwZc9iOuBULROThE3qD83fOOhq3HCjWqGNFynzfLwR+X5etEKKxIWTczDO4NtK+x9we1LfcXNbYoSKGT523ZO0KfvAH1P8AWqFzassgaMZdsAAgt2xj37/lW7LCZVCOxd84+bAbP17/AI8H2qqwLqSXbjJx1/8A1dOvrUSgupcZnPzaU7rl0RMYZudyjPcdx/npSw2aggIDu7YOdwzx9R/n2rcNvt2i4dZIw27KOGbaTnj/AOvVAW2y5ZQ6hQzFHIPB7Hjke4/TFS4qLvY0U3JWuUGs4kiKqFKA7yhGVU/+y9evQ+1U9RQTQSRwb2PQeYwyByNufx6jg1qbpPMSNWUKinDElT67T2/oagv4mZs3EYAK43KAoYe/bNZz2sjSMtdTyi+S5N8II5DG7Ha6ORuD4+YEemfUfQiuv0HTpftMTXEjySLGUJY8ke+fTkfStPV4VAeWZHkk2E5wGOeMHnv17+nSm6NqtxexBbpBlDtV/u78dM+jduf161xRpqE7NnXUrSnDRGpFEkhQF2jycZPzZHTnPceh/Orr2Yjl2uxDA/KUHBP+e49Pxqs5USb2JJZQ25ecDHOf9of4+1aVtOIbaOTAeBly6NkheuCO/wD+uu6CTdjz5ya2KFzsk+QFvOkPy4b77e2Oje386pgFMBlj3bc4b7rj39+xBqPxDbm8gLZKF/3gXBBGOh+br+BzUOjW8sMRVZi4B3rG7Ehj6AnkZ+tQ5P2nLY0SShe5ZEasUZo+GwMLglccZ/8ArH86aB/o0iOX2RsWQJ8y5PXPdf60XDGNA7oAW55IBHqMjuKrQzqszpMzBpFI3twQc5/z9abtF2GrtXILmQQPtcbVT7roc4HUEe3t9a888U+J3tzsSVVUPwMZIPfHYj2/lXe6wBKFUMGB6MoPB9en5iuE8S+FJb+F3gIkbo0LqD26qf8AP41hW5tlsdmGUN5nFab4mjuNct1vBHcx7/LzgDAPIO729D6817Noc6tCo2lQox+I7Edv5V4/ovgbU7XVIpbhRDGpDfJhy49u34GvXPDdu9vbeVIQ8a/Ir4OQo6cf09qKbSnZGmL5WtGdNazyNGIIzxIwwrnjP17fj606KcLISg8sDu3C57jPb2qUwLJKDMGiUqAZUGUY9iR2zUIzAxxtGcHB5Umu7Y8xWY6WcqpEalowOpHGc9KgkdZVAd8fMCMrnj2p0xUoQcq+eB/C309KgaLeN/B2kbQCFx+dS+xaSsPUh4uG+ZTgb+p+noahn3A4ZQW/idfQ9iPWiKTy5GKkrgnB756EYqQqm8AnKtyADjJPv2otpoLVMh2rEqnYrE5IZef8/SokkePMaqCpO47/AF/xNSEyKmcJjOAB0B9/enqw8klcYZeQQOf8PrRfUH5kMr71LlH2qOhPIH1H9aoOr7gySZxyD0P0q+eQdhCsc5yev0qsI4lUM20EkoTnoR60McXYpIZlIVjnJwMnirGFlgHygSBeoz83502RkZSSgJwcEcZqIkFVIBGeOPX0pLcbKciOpd4iACcFe/4UsFwomBkGSeGUGrc+0NiMo5XGGXjFUVYDhiXP04o5eVj5uZExdXiLLjcvHpVOe7mA3LxhSuRxke9PdFG4LjKnp2IqtdbtuQOD0I64oba2FGKPUWk8xVdwQAgCgR4AA6fr3qONGuJohDGS7qSQucADr/8AqqzbzQrG8YZfLLMy7jkgjpge9LDHHIPlkCELvZlH6fnxXW1exyJ2FtnV8LIIgxONzttb/wDV+oq3cWfkFZY/mck9eOn8R9uvFUFjEf3gSeHDBvXqKueW0cSEKVVvxH0x9KS21E99CSGUW7eYCpJ5OzawIPXOe/tiohEFnxjCOv3cEFc+3p7D1pJ/KJRUDLEwHUdz1zU00DQ4fe5APyAgggdiD6UrtjQ6aBhEqbUbORwRkntz39vyqOKMk7DwY+dw4OOxB/ofpVy1kL2exHDhshgV4P0Pb+lMkieOUmWJ9xHzhcbvrj+L8Kdk7NC5nsySG2aWNZ4WQuh4XHcdefQj1pPsxmmOwnDfMSBjJHUEe1EMnlzM0BEpIOcrxj2pXkVpxjgHoyngHHH+FKSutRa3HqRGSs0chBGMjIK+v4d/aobxpZI90Tq+35QQMHJ7e9WDOZ9wILAgEMoP4nHQGopLmZtySkMGyQQB1H86TtawR3JkeKVQWViSoDRhQQDxzk/0pm4AFTxjjB7D6/0pBBICsiKoSQZyv8ORn69M1M6ZZgztuTG7PJHuP8/nS1sJpFQKxxLtYx8AOmBg/wCf8inCd0R1Ys7Kd24A9T/e9jxz2ohUOssRCpjknn5hnqPbp9KkmUeYxm2syDGRx0+n1FEdroryYxds+0SZUHkgZ47H8enSrAcratEzZjI+UkdBmoGDG2il8twD0Xf82emcj6f40+MlIkLOVJxg7eCc9z279+eaV9RNEYNxDdBY4wyk9eMqecYP6/hT4QgJZwA/HLZ6+/t79RSyMs2A5BA4BB/l+NP3kYBK4HJj/Td/9apDcYWIT5yUkyeGPH59j71GoIJByuPmHTP4Hv60pRWB5Dr9xkYc+x/lyKZcISqqAdyjBBGOPcdce/40/Ma7CTSMAwjkVY+DgjgN3BB6D3qLgxYYMWGFwzcj0yP61JIc484uAg4LYz+B7j61BDGJFCqRnnIfjHpj0/lSb1sWloQXJ3qC4X92QQwHzN7H37fhUaQ2t2reXiF+o/eZR/bnkH2NX8SAHPyOcB2Ixgn1+tV0smTzCse4vkmLIZfqO4NRy3fcdzMe1cvsuAz+WQcHn5D6Z/kfwqMW8EfI+UngOBjPsR/n+lXpYVyyN8hQfKjA8+q+v/16laJGtypeLKEHuSe3cf59KhR1L5jHlzE3AP8AsujcD/I/z2pY52eNkSQx/wALg/MmD3Hp0FJNbPFLI+0FAMmSPJA9M+3anQ/vMhgqsV7DqP73uKxTalY0drHO6iupi4wPKMAO4mFgQB/MfTnHpWlpxRoHcuqlOqn+L2FMv5fscISRNrxklX6YHfHr64rBu9VaBpJI0O9fvKOQR3rO6hK7dzdRdSNkjqHm3QyJv2rnfh+dpx61FKLeRI2XCsoCtnJDHrj6fSuI1LxHNGqPGi4HyvExyWBGfl9R7VoeGNZnuLQ4icW8rYj/AIgfY+uKFXi3ysbw84x5jfkYMSihoxnPzfNz6ZH86RYhEw24wf4m+6R6ZoiQpLnggHO0f0z3FXYx5vzMuBgjaB8x46+4rSN2ZN2I4bGORiHJXPUsO2D1/HHPvVm3RFALpuwDllGSVP8AUU4rF5WEXehG3oachEUe1DgqM89fxrdJGTbZIzCKAoJVyDlc8hgfeqm5+A+MA/w9Me3apGSJnRVyGbA3AEYPpTZmZJArhAD9/ByvsfUGqewRQkipgEZXHQsOfy6UozJGSqhdnUj7v5VKVEsQUsCyjIHc+2aiBSGTG7IxnJFAmU5bd1LMT8pAPAz155pkx3qy/NnGVB5zjt/9etGRwGyJHXGGBXnI/pVK4iwcMuUP8Q5B9+KVuxcZN7lEzFI1Z+CflP8AjVhZR5Y9G4ORVa6h2HYWZolOcYx19KEceXlTvkB47HApa3LaTV0E7SxXAQsNinORz+FMl2/aGOX8kndwe/rTQSUEpIjB6ZPce1MjEzHcqnIOCKZNupDOjtIke5lUnJ7596bsCSldxOCRnGQT61ZuQGjjwhVl4JPUmoSAkmFJyecn/Ci2o+a6K8qkMwGCW9OoqIFuQdhbPXNSC4UOdwIIbqDUW4sMgBiOQuP5Uh2K0gkaXCMNzcgNTUVWyoY4I7noakby2yNuOT196hACqVyR6ZoQz0u1lVSMsCjccj0qxIpWdCkqKXX5TjAJ9CP89qZLHEULjaJUP8PHJ4z71YVmc7JAsh6KTyRjt/8Aq611W6M479UWLaRJUUFcOCcKVyCMc59/arC3CQxIDOrvjHlyLvXb9e1Z91E0UiOQqF0BysgIOD1/+t2qRJn35lg81JMAqDkn0HGeeTzVJvYnkT1J4pFlAjKCQKc/JyD2JBP0yPrUG4LC6ygCY5UFjgf59vpTUkhtHXzYnwCQwD/MR29OR+oqadVmQGORWDDLbm3An0ycdux9BSX4jtZ+QscyhkkjbYQdr9cKfcf41qSTwzwL5pRnDDbGg5Ppg81jROylY51L5XavmH7ueeG/Xn86ma3xbxyZkPIJ4wOOuSDx9eOvekm1sKUVcuyINmYZGxj5vM4LEe/rQ4jHysQ7cFm4DjPv0NRCMOvmoz+YfvAtnjJ/OiB9rH5VYA9yCuPp1/w/Sh6MRZtT5IeUZMf3ZEbhs+o7gGob1TcwboGOQS4Uc7ePXtj3pUCNCQyvhCSjBsj/ADjvSRwNIGkTh1HUHBYeg/z9am7egKydxttdsCFGVKD+7ke4/r61ahSOZyVdS3U/MMn2AwOKguIVV+DuXb1x88f16Zx60Q28WVDLlivzHByo9eO3vzTTa0Y3Z6oAHjldHLKOSjD19x+lLECr7d+edu3djP0Puf8AOKmlRoplTzRLE64BYnGO2D2xnrUZgZnaNgQVU8kf5/PpUarQLoIoo5Zpfs+9Q3VC21j7bT3GKchlgY7gZAw6HoCe+D79RTVWSZ2XYrFckgLhvTIz1+meakSYDa8p83GAoAx065HrjH5d6rzE2PE0b7HVypPyy7hkY9fw/OodydVAODgIeO/OD2/GluvLAVoX5AwQpHX+ePakjDSQOwMYK8+Xuwc+3pn8vak73swS0uSbwGEY5GOQ3UfSn+SWVTBuDAEHH8x6VRySQCNrDPIGKduJ8zDNnHPH8/Uds1KlYOUWaZvLZeMfe2dSPof88VXWTcqygAheORnb2IK+n0/KrSjgoqxzK2CNzYPPTkd88f8A66pSxKHKSRhW5O4gDBPb0ofc0j2LFvOqRlP+WocFJl5wPQ+tPaUG4LZZXOMmMe3of5VTjUIDsBJYbWDDII7Gp5ZWkA3A+YANx9cev5UotpailHUja4O4MYxNuG1o2H3l9j6g/iKacsq5VhG5+UykcHsd3Q/Q0+5R7hCWiiE553jjfjtjoSMj35qO3OFKyl1B4Yc8E92Hf60PcfQrSFAcFXhmJKOOisOu7H17VXa3TDLINhOSrL0J6dPQ1bnHzJFlWUZB3HjH86SONXjLBwrrxtfPPt/+uoaTZVzm/FMYe1EM4Ur081icBux3DoeO4rzO7iuLacPK8gTkFgRskxjt6+vr1r2ya2hmQryoIIKkAflXNXXh62LN5cYaNXBkjIx9cenp+NcuIouT5onZhsTGC5WeQy6sV1JIMoDt2k7cqV6gMOoxn/A13WgQTxWxnDrJbE5ZFUhoz6n1GO9bll4Xs7SW58gbJJcEtIuTuHTPfj1/nWlaWog3L5bJMRy0bAAjuOBzUQoyT942rYmElaKEtIZNQiLGVBKCTz1PvSpHIrbXBBB/EHrxRaIRdkZIGflJxkVemk8st5yGNiwOCMgn1Ga3Ubq7ONvXQRIypROrEblK+9MjJRiJPU/ORjI9KRHBbPBC5wp7fQ09SZMK5PHOCf5VqtyGQy7Q4UlcZxwenuKY07E7WPlnOckZ57k96bPH5fmDaVZW544A/pVaMqTsJJY8kk4A+hovZmijdXLWyUfvV4IP3l5x/hSsjiMZydxwOeR6VFZrLaXck0MjAngIT0P0qckyquFCnOPcn6UImRBGgc7SzYHL4B4Heo1baSEJXb3BqzMm9yzHcwHQ8H/69VpixYNtJjPtT2EtSu5LzZc4HXI4/wAmnMieWyyAg89ODUMrfvMYVQRw2c1YS43x7fLRiox+AoTsVLyKKIyMm5ywAB47VPsIDuDt56jpUmEIBU5YHAHtSIwQOyNtGO/RvalcmTK8m393yFb+IgcfWoLphJJkoGQdR/KrrGKVMqPLfoQRVaWMhNvuQMdQabuTFlCXdHC0MiLtzlWYcrVVZN5JRycLz6mrMx+XbIueR14NZ87A7jkhs/dHYUN2N46oa8iqT8u5TyexFQoTIgO/OOPepWlO04RW254PcVXY5dVjRRnpg1PUq2h6/EkaMCAqtEB855wT9eMdqlgtDlsqpfaX24yCB1qFXlUxnAHyfxDrz6HrVqznjZXM7tGVyB8p6eg/Wu73Wec72GO3mQurJ/rCMgfxc/8A1qQPNEITEWeMHcoYYwR7jnFWi7XBiYYUjJZewPYY9OB1oswJVKFginnaSOD6/nxS2Yr2IIJLW5wJ1ZC+A5c5DHv2646VUCmGcrhGAGVbIyR/L0rSmhIUrHCWi5YbBjGeue/XkelQLO0xHnxpKVYFsjDFQMYI/wAKmV+pal2IkaWdwuBmPg7xjPP+eDWjaSyIwSVcBQCW2ksB7c4I+lQ7YC6guF28rIc7gP7vOAR71J5bMpPmZUHb8rA4b1HQ4PqP1o80S3cR0zK4t2ARgQoAI3D+nTrSvLIJGjkV4iT8vHQ9MflSESwttJxESBtIyF9x/gKGZDIWMuJDgYwVBxj1ouCJsySEO0anjgqRn3yM+n0+tTCNHRj/AM8xuzng5989f8KW1jMrOVk2kdjwWz6dsHFV2EsMjgkMoHOASGGOM479RnpwaUl1F5FiG4ZSxYgnoQ4yQR39x/nmmxld77JmAQjAVe59u3eoUAli3rLGwYYAU4P4fpTomILNGH27cOMHoeo+lCbukwsObeytGjBsLnHY/wC0PT0P/wBenM/7oI8LBl4DLgkHvn0Pt0NVkLKWMTFWHIbOMcdPY+/OaljnLSJJMN0u4ZXABIzn+fvUt2KsOicxxqYWUjOOOjD+n0qaWNZY3kjkYhQMfKTuHfHepYhHdgOSqzg4+UYx6fUc1GS9tOVZlKtxgKQGz6+nfpRZpa7E3u/MhIYKsw+ZG4IHVGPP4g/nSoSAuxxlxh/fuPYn9DRI8cqSRhQjrkqSNjA9cH15/pUU48qUOr7icHOwAcjuOn44o6XRS10EWZoZgY3BGTjjgcHjFIfMkGUVN6cYU/Nj1HqPWiHcEUbAyqSd4zlfx9vf86kubfEMboDuGQWUY78Z/wAfekr2DS5SePzYVkibD9Tn0+n1/wA96W4eSQRnOWxj5scd8c9+anjjeMEqCASRyPm9wfUio2gMkWUYZVuUJ5/DPX2qLWLTuOCq+xHBTI++f4T6Zpgid5vLeRFznaXbHPsfX2NFtuSSPzSkZHPzrwfY/wCe9Ssik7SoVCOeMgj/ABp76iehWQyK7Rk7Zoz3x1Bwfbp+dF6iONzBxIpyrIeCp64x0xTZ7cLKdpcliAPb2NSDcAVbGBks/fPcfU1HdMLpaorOJCoKSmVlHK7fnA/rTY7gME2x5bgc8BxnoRVsRgqphJyCVyhwcYz1qs4+dS6lST8xPr603daj5kyVlAjDSBVRx90jIHqB3qnIgklAU5xwB0P0H+FaEhY27LjcwbGAe/8Aex64qjwEWVGw6tyucE470PUUWMJAAWQE8d/SpYVjdGC7gx56jn/64puQ/wB9mQe69KYyKknzfjt9aV2tR+RWmViTvjDBT1AwBSeU0qADa20ZxnBq2kmSAWUDpllyPxFU5FU5HTB4HPA+tF0y0yMldgHVs5APUf8A1qldwEB3bj1DL0/GggLnZyCOrLyM04xlUDRPkkdMcflUK43IiMiSiQZxwCOeM1VktyjMzcZ56d/WlliPOVAOcYHSpJHZInVkBDAAsf4h2qt9GVe2wqshAPCsAAWX+oobCJu3KeOdpwRUagIVEZLbhyM5zSs4YbV69zjIo5raMl66oY8yFVR8EA/eHpUBcq53cjoCP4vf2qWYIoBmAbtleCtVpHEfWRgehDUXZSSFlhViQGy/Yev1qq2VJ6KSMZA4FTZcsGfG08A98UsjKqlcEsexx0pbj5raELM6mM7RskHGPX0+tW4nCI+04AOCp6mqaJtHmR4ZUyTzU/mxsP7xI4B7043ImNuAME45Xk+9QPKpTCgrn8s02WR3YJuyCeOP0pGURruPQH7uaObXQlIp3AL535xjntWbNtjkBRRkjPPatlyroV3cjlfes68gRMBPvDrQ09zaEuhUYK6YJ9enWoTAdxBXKYyGHapGIPygYGcg0353O5clfQUkabHrVoR8izkvEhKooIycg4x6jP5VO0fD7ThkYENnqMdfr0qp9nLQhhjOQo3HHP8AkVatZvKkCvu2ZwQMEn2967NtGee+6J2hkaZhJGQwIDbcH3456H1qHy5HaTy4mUA7VcjaD/T+lTxzrJGFDYkTKtuJBIzjHPX1+tTxyeYoKr5mwlsdOpzgf4DrT0loTdobaySvtDO25hsYsu48fj161DIpkmMrOFLSZ55x6nI/z1qYEzzucqBJ2ZeG6Y6cZ70/7CCxhmYK5BMat/F7ZzzS5W1YSkkMW3eM7YpAW5ww7jvkf/W/xqJYk81ghjK8sp7P6j2z1FTJGyx7lzuT70bHp68jB4x3qbzhPEx8jdE7DfhgNzfoePTNKyKuyiq9Ahym4khiNydeM98gdelPlfCFCGVTtwpUgkenPHepHtw8Mb2+6Q/NuG0kbfQ02J3MJwGbA3BPvAr646kVDuVoNhgKNhGMY5A83DKT3A6YPse9Wk8084kY7Sp4zlT29Rg+tMtroqzMQcFcPFKM7x7Z/rUEhEMw8hzHuO4ZGAfbn+R496asg1k9QgljlmKTRIC/ygKPlYnjOO1Wgio22WQbWztkZTnI7Z659fpTW2XETedIskz/ADbVIBDd+DyOOlRKbs7Aj5A+ZA3PT29fai/fUHrsSTgJJuYs8JXBdSGO0dfTIH5ioZHWVMjIRFC70Hy5zwfbI/lVh41jjHm7PNHzb0bg+xHBH1/OqjMqw+SmHXceXXouex9TUyQ46j1bZOoMh6dWBU47n6e46+lWJLh0BeUCaIEEkjaWGcD8M1TD/wCjcj5BJgp0Keh9hz604TlHAk3EKNuHGCV9COh/D8KSdkNxLCKJYyFYEjJVGGD09fWno0gkEcjunbJxgH1/LvVRtwlClXUjpzsIHv6ip40cL8wRmGOGOCBjp+v+FEdxNaAQ0ErESgqw2h0PB57+nSlRzH6AZPzbsbfqvI/Kon3RoWDkErjB9D61DPNuZQcKUTLfKMD6+o96PhFy8wsjOGEkUhZy+Tt4z69+tFxIrqjD5yOjjBKD3FIqbULlQqk7cg5U9857f5xipXjHyMFYM3DMDjH+eKXSxWiGKIjmVZs5YHnBB98+x4/GnOWCvhSrKcEBeRUToHLuSDgjBIAOPXjqf1pykgyCMnkYAJ+8n90+tRbUGQWdw7ud5UhuhAxipJsj5kyC34cf56VKXgeU7Bx05BGGHUZqEDa7ZbI6N3K+xpJOKs3cW7vYbHBtk+/s7qccfn6VGXlUEbpGQgknO5cg4zjtVsGMIcYI4+YHr7GkmgUTNGrAEdDERj64ppW2Dm7lVbgxty2COVKHqKSeIgl1c7eu7aB+eKjuomhuNkgUS7Q4GOG+n+FPZ0lKknZxnBHQ+lEX0ZTVtUGEZFcgpKMYI5H4iq5RdxZsYY/eTsfSphcKqFZoCccgf1B7iofMWRgoXax5HXqKJJdwVxmSxbDBvQFccVEwQrkt82cbG/xqckQhZFXjJ7/0rPuGBmk2ZIPKjbj8KlmkVc0Ay4G8fd6f/rp/7vKgEht3UHGPYiqEcoMZwF2PjIPY+1K7LtXg5JwT1Bp3E4WZNOig7TyDk5qk8oWRlxmNxwGGce9PlmPygtkZzg/0qpOwZ2IUBR0PYChvoOKfUHdkOG6H25FTR7cbkYBz0z3qmzcAryO1SbtuGwB6EVCKaJJXyDngkcr6VCESViJiQpHBIzzR85HmAgg+h6UjDK4RgH64Jpq/QNiozFCfLOCvGDzmrHEkALkeYBwen61XuEOMzKV4+Vh0qEmRflUhxjpQnbcpq+orJIu7Dbk/iANKNxA2Kc44FMViDkYwaJJWQZIwetGgO+wgfEirIMH61FcM275vudAw9KqyncSwUkjqc5xT4ZMqUlHPBAJ7Ut9B8ttRDOQpx8wH4U2RvPOWwEP5UyTYzNu4jz1XtSKg8rbvweoJpptaDstyBlVJCshyMduc1HJvRV2E7QTxTJ5VEvGc9+KVZwYm7gj8qEVZo9RN0ZVEbAAruycdz61Zs2SaQiVhHnDls4zgdfx/pUUhjleN2IUxryGyC2Tnn8MflT4IASMKZAcbsDAFddnc4bqxowwW7xKipukkYbVRsEfX39agmSWxuRtLsrZC44JweR/PmoEcxsjLKQ/3cjHOMc+o7VdjuRI7pIm1pCOW5xjpx2/+vTbT8mTsSI8LQyMjqrkhskdAP/1ircUqTRAzRxo2PnG3PbqKppaIuxuWQAHZj5gMZOD7VGIpIoGeMjYzHAPDYHcnBHfNNSaepLjF7FiV0jlVlhwjfJwc5B6HA5BH60y1XG5RsOGww4Kn/aHpTrq3Jijfy8SA8gKCjn1GPzqujkOZLZAjIBkGQHae5Ge3Pak3ZlJXRPIlxaRkoV8hiQ2FwMZ7+n17Vbt0hnVVL4ZRhRjBQ/n/APWNKJSYozBKgbaEVRkEf7w5B/GoDb7nRHKgyKdoVQOc9iOh/wD1UWs9Cb3WpLbBZgVlRmYZCoTnJHY56H+YqG7jlgWNCwKMM8H7v1B/zxRJE1qHWeN5FwRGT1B+v5cU/wA2KccPKrOPmYHPHTjPP+TSk76Pca7oZDDIFY7iAh5yOB+Ocip1RO7kkrzk8YHQE9qqTRZAeNi6IDvKjcVHAyMYBHt6VZs2aND56hgVyrx8lfc/5/OpjvYUr2B42jdAiqUfgFujccfj71SaJUBIYhiDwO4/wrQtXIjaLHmqWIBABBGM49ajl8p5Gj4/eN8u7PynvkUOKaCMmmVDApQupE25eSBhwccgiomnmhAjmeKaI445DLjuM9quxR+UpxLyHwCem4f5FRFPO8zblj02jkAE8j8PwqdVoaqS6kC3OEZwN0QADlySQfX1z71MwUNmEs2B65cL2PuP0qpPZeV85b5UGzJGcfWnJI8ACFVMYJYAds9h6dqm+vvDdvslh0uYC3yZU8BSfl6ccfyNZ6+azqFAQjncO2eufX6VpRzutuygqUIGN6knHqKgWWMTKrkhtuQMZUj2/wAKUo3tZii32G277/uIImYfwHapI9ulSRNJtZQWwBh/UDrggdqWN0klKz4VWGVCLxkegpyIEn88A7s8E5PT/PvVLYGwhlRlbds5XGR0z2PtTVVHIWUqMnkjjd64qSRmEnmso2EZKhshs4zULRrgEAgtzsIwCO2B3ofYgdKJVSfyZFlIIDdO3Iz6/WoWaNwH2AbhglThkPce470ZbB2s3PUDrgUzcQzKwTacFXXuD/k9ahlIRCwQwuUKZ3IcYwfr1H0p7ecCfM/1gOe+T7VD5T5BClvfPJH+NSJcFFIwwC8cjkfjRfuN+RWuS07Dkhc5VSxOCfc02ORm2LKPkJwSehqS8RJLcSxsPMLfdweffNUYZCu9MOQ3LA9PqPeok7O5otUTn5V3qML0HtjtRLEzQ7lOQQGx/d+n+FOUxzEKjKpIyQ+cMaijcIGRQSAcYNU7WJTZXuLg+SRE/wAvcMMgGqX2ppIQspOQRgdq1D++SRF2HvjHU1QaAZcyIQeMZGMe1TqaxkhsBCMcSqqEYAbn86n3IycD515BTj8aqOm7G0tx0+lTQwMULRsCeMDoaSetkhya7gil3AjwWAzn0psqkhii7Se6nj3yKUHZlwMMep/+tSpcIVKEMHz1ppoi7KUZYsfMXCLwCtK2UYsGOOxFWZSu0FjyRgY4NJGkMkToc7xyP8DT9CubqZ0kjqNzZyfTv70yRlMYZTtk7VauNgXay4B79zVR18td0RyAeB6VHUtNMhMjFMSktnp7UQlAQH6fzqYJC0bMTtfGee9QuRNwqgHuT/Sqae47pkn7sJwDuB6dqryNtcndu/WpVzGm4sVOOARnNPjeB4ykkWH6A+vtRa/kRexSZB5hOQAfSql0MLjdnHcda0LmJVYFMKO2aqXLiTqBle9LyLi76lLCLD3DH8jU9s4MbI+SScrjt7UnLEbee+Ka7fMeNpz+dGxUtR9xbq6sy4JAyQe1Z+1iSf4fcVbM64IdsAdarySFQpULsJ4HendbhG56jvbym3MAwwrHOSp7GpIpTEwCnzFK4IPBH1HpSyGFS+xl8hsEE4IBI6fX/PWgmMLkSIZB93ABIHcZ7/8A167GtdDhQkci5BYq6hWxhc8noOOn41oIiR24QnAVcyADILe3ccEdKykhbzm+zr5a/eK9D152+h74rQhaWNkLOs5B3Yx94dM5PX8aE+6HNdiaGVjGVJcqFwpV+Bz0NNZpCWdXYvGMhSPmHvjv/hViC0S7kkmjbYqYZ3B25PX7vpVWeNoCJZGQCT5kkYHP5dhStoQrXNDT7hX2oWjJK4G4Y465/pTby0En7yMM2T8oxkkD+Ij86zOFcGKEouMjBH6ev9a0ov3tsPJEJdvmB24IHbHt/I0RfMuVg1yu6GxZi2ysFdGyvY5Hfr9O9W2gE4DW/mqR86LuGBjuB/Sq0DCRGXaUYclVyCGHUhuwPf3FNtr1rNZkmEhyAflx19fbg5+tKyWj2E0+m4ocSK6ToWkLABm5A+ozx+FRxXC7VRFBD/MHZSCMds4xjvkYpk9wsr+bZ5HyZZX6qR1PH4ZpbZxPlnZ946YPX3/xHrmlpsXZ2Ltq6eSUyUOTlo2BDAjkEdP0FNkVlnBh52knehGeOpPOO9RMbdivl7lmzuz90Y9h07Uhk8wLsOZRwVACknt04P1FErLQizvccjMJHk8wKCwYAD7xHcevXPX8+lJI7yMXcFiOGYc5OepqeAGRCJD5cmcLhAScfw59frVfyJQPMt9sin7yg/zHr9KnldroE9dRFlcxF3YFAQSGGD+HGM1LDsa4CozHLbtwOGx/8V2IqNljkhUkvFM/G8tw3tgdfpVJEkLbpG+cZ/gzn0II/Wk29LlWuX7r91mRpMlfl4HIpkYaBsTqYyRkHblSPY9R9OaibzPLKyOrNu27z7e/f8asRFJAqylUOBubBHA4xk9TVxJeiGbkO9Ymyigd+Pp+fT+lRybjCplD7SflBUEAeoNSHLYyxDbcBuhPTg+uPfrTULbkDsNvUL0zz0x6+3NZ9SkCDfCU4yp6H+Rq4MMgClosEN5bNkfh3qHDIWcKx2/dIGMY56enX6U7ejxnyyCh+6Seh+vb+VNaEN3EZd5YIpGG37VJKjPbH9aVWWRVjfaUPyhm52frwf51FHKqum8NGDw2PvKR7+lRuSCzPhwxyHHGfrS80MS4ULhjG+VO1tuQeO4Pb19KpAupKjEkfVGAwSO+atLcJkht4DLjGfun1B9P5VEYmbbjHm5x8j4zx6f1qWr7FJ23HxPmI7Dgj5uRnI/xp1xNH5qu8Y2OPmVWO1sd19KrybmQFFG4c9MH6+9M2sHPlIZAnJKjrn2pa7IfKtycIQShA2qC2cn8yRUciiJuVEqkdhg/WiCQeZmMlH/hxx9R7Clx8hJkwuTnd2oQFcxxsi4Z8kEEEdf8KiZGA+ViQPX09KnkVVXzQ2V5X5Tnafp6Uy3ZQSd4z6HkClbWxd3a5UljeElmAwedytnIPSkMzMn+s4fjDDj6VJIwUurA7STjaentUUkCtuaNABwCAOKV9dCrdwdQow20Ecqo5BFQvK0YO1QfUd1NTeQQwG5lPYnmmmNmD7xllGTt9PWle4tOpA8+SQQpI5znBzSKrTh5MKwA5G7B+tOaNCCc54zu7iqbjjj5XHVvWl6lxXYQysSFdiFXkHHIpGlcsQDzjrUExkfB3ZxwW9qj3rE/JLIRxj+VJs15SxOGPJyF9AKpSsQNqgZJ+Vver3mDOckgjOO9UbyZRHuiDM4OQBRJ6XJincgM7MrJNzIDgEjFTwqVRg6k9+PT2qnDcG5Mhmj2MvUkVYimPGGyMYK0RknqaSQSvkDa2CeNrUyNjkK2MjoSasPCGAI5jP6VE8ZQ4YY9M1TWpF0QuWGM4AYHNRSj+EIB7mnTRsclecdPQUzO4Ksg+bPWlsUQSHavv05oypjDBgrg8g1LKyLB8yjOeoPNUrhlCkgHaentT1W40uYjlhU7mzuPY0GJDhWyGH8VQqCThSSPftUjwvzuY8ilp0G7rqej28jMYgTkt8p9OtX2wkhSEBFJ4HXAPaiiu6OxxPcV5jlWCj5jjB5+7WvFtNuJQiLuAZlUYHPQD6Y/GiinB3ZnPYgjBhtROp5EuzaQMEAcU+K6F5cr5icFtv3v8+lFFTezSGkndl1LZJLZsAD5lQZA4z34x0/pWfLObV08nK+YDkjGfx45ooontcmGraYsM0isy7stKAGY9wccH/GrhghkR1kQt5JYdevI6dx19aKKmOqdypblNomtLjy0cNyMllznOBTlUKrS4BBbG1hkZHeiioW9h3vFMliQXLMDlSWUBl4I3D/9dSXLfZSIwAyouQSBk/XsT74ooqvsc3Un7VhbVkleUMhBypBVsY5xTpd1vcKqtzGxAKjFFFNP3bkvexVvWyJpSqgDazKBjJPv1H4VUt38+PMf7qRG2q464xnn19KKK5226iRvBe6WLMM7pBuIJJy3rnkce39aTzmBULhQcgbeMEd/89qKK2WxDWo9J2eYFVVDhQdo4P4H60zi4uPmBD4ByDxk+xoop76MVrK6JoJC78kqRxlDj8asunlMF4YSjDZGD9eKKKUNYXZnP4rFa+X7M8YU/ewQRkYHp9KrFiSpU7Sw5x049qKKhr3rFx2uR7y0bJgbV5wf88VDJM4J54OF7A49KKKzuzS2pK8xDqqgKynaWXv71FuYS7ixJxjjiiiqeuoJE0yRn5gpGQG5OSM9eaYBv+bPJyDRRQ/jJWxUnRdwwNr9Cy8Z+tRqQsqLjLDIJz1z7UUVmzVD1KyPIu3BA3Ag06IDbuI+9yQPWiimnfUUkQXsrI2zgjoDiqoYs6upK8kEDvRRS3bKSVht3KY1z6YAxx1OP61nTMxmUu2SOmOMUUVE2aU1oSsqkgMAeefenG1Vwqg7QeeB0oorSCvuS20V3RTaSbhlk6H1rO8kCRmDHA5AooqXqkaJ6FjG2QAdDg/nTgEjO9I1GTgr2NFFNdSCdQCHCghRjjOag1EeXgAkgjvRRVvZiXxFEKUYBWO0jpSS5LbW5xRRWfQ0fcguIUKdOCcYqq2ANmPlPrRRTejGmNVAjEDoeKbK7KNucjpzRRTemwXu9T//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple brown spots are superimposed on a background tan patch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36532=[""].join("\n");
var outline_f35_43_36532=null;
var title_f35_43_36533="Serum anion gap in conditions other than metabolic acidosis";
var content_f35_43_36533=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Serum anion gap in conditions other than metabolic acidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36533/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36533/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36533/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36533/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36533/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36533/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/43/36533/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of the serum anion gap (AG) is primarily used in the differential diagnosis of metabolic acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31432?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Serum anion gap and differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the serum AG can also become abnormal in other conditions, a finding that may be of diagnostic importance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13442173\">",
"    <span class=\"h1\">",
"     CALCULATION OF THE ANION GAP AND NORMAL VALUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum anion gap (AG) is calculated from the following formula:",
"   </p>",
"   <p>",
"    &nbsp;Serum AG &nbsp;= &nbsp;Measured cations - measured anions",
"   </p>",
"   <p>",
"    Since Na is the primary measured cation and Cl and HCO3 are the primary measured anions (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/17/1298?source=see_link\">",
"     calculator 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    &nbsp;Serum AG &nbsp;= &nbsp;Na - (Cl &nbsp;+ &nbsp;HCO3)",
"   </p>",
"   <p>",
"    Historically, the normal range for the AG has been 12",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    4",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    However, the normal range for each of the individual measurements varies depending on the specific analyzer utilized, and, as new technology has been introduced, the normal range of the AG has decreased over the past several decades. In several reports, for example, the normal range for the AG range was reported as 6",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, many European countries include the serum potassium in the anion gap measurement, resulting in a normal range that is approximately 4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    higher than the number calculated in the United States . If potassium is included in the formula, the AG calculation becomes:",
"   </p>",
"   <p>",
"    &nbsp; Serum AG = (Na+K) &ndash; (Cl + HCO3)",
"   </p>",
"   <p>",
"    As a result, we suggest that each laboratory determines its own reference range for the AG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The way that anions and cations in serum are interrelated is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef86696 \" href=\"mobipreview.htm?42/60/43982\">",
"     figure 1",
"    </a>",
"    ). If all the anions and cations are included (and their concentrations reported in",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    then the total anions = the total cations. The anion gap is could also be determined with the following equation (",
"    <a class=\"graphic graphic_figure graphicRef86696 \" href=\"mobipreview.htm?42/60/43982\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    &nbsp;Serum AG &nbsp;= &nbsp;All unmeasured anions &ndash; all unmeasured cations",
"   </p>",
"   <p>",
"    This demonstrates that an increased AG can be due to an increase in unmeasured anions or a reduction in unmeasured cations. Conversely, a low or even negative AG can develop if there is a reduction in unmeasured anions or an increase in unmeasured cations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/2,4,8\">",
"     2,4,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major unmeasured anion in serum is albumin. Albumin has many positive and negative charges due to ionization of various amino acid side chains. The ratio of albumin's positive and negative charges changes with the pH of the solution. At &nbsp;pH 7.4, albumin carries about 20 more negative charges than positive charges (therefore each molecule has a net charge of -20). Other unmeasured anions include phosphate, urate, and sulfate. Unmeasured cations include potassium (in the United States, where potassium is not included in the anion gap calculation), ionized calcium, magnesium, and certain abnormal proteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HIGH SERUM ANION GAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated serum anion gap (AG) is most often due to an increase in unmeasured anions, and this is almost always caused by one of the organic metabolic acidoses (eg, lactic acidosis, ketoacidosis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31432?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Increased anion gap acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Much less commonly, the AG elevation is due to increased levels of anions which are not acids. For example, hyperalbuminemia, hyperphosphatemia, or, rarely, an anionic paraprotein (usually an IgA monoclonal immunoglobulin) can increase the AG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/1-4,9-12\">",
"     1-4,9-12",
"    </a>",
"    ]. Although a reduction in unmeasured cations could theoretically also raise the AG, this generally does not occur because reductions of potassium, ionized calcium, or magnesium will have a trivial quantitative impact on the AG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A small elevation in serum AG occurs in metabolic alkalosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. A study in dogs showed that chronic severe diuretic-induced metabolic alkalosis, which increased the serum bicarbonate to 40",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    was associated with an 8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    increase of the AG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. At least three factors may contribute to the increase in serum AG in metabolic alkalosis, although these factors may only account for a portion of the increased AG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An alkaline plasma pH causes albumin molecules to release protons (a protein buffering effect), and this increases the net negative charge on each albumin molecule. Thus, for any given albumin concentration, the anionic charge will be greater with alkalemia.",
"     </li>",
"     <li>",
"      Volume contraction, which usually accompanies the most common forms of metabolic alkalosis, will raise the absolute albumin concentration and its negative charge contribution.",
"     </li>",
"     <li>",
"      Alkalemia increases the generation and accumulation of organic acids, such as lactic acid, which mitigates the increase in HCO3 and decreases the severity of alkalemia, while increasing the AG. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lastly, any artifactual increase in sodium concentration or artifactual decrease in the chloride",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bicarbonate concentration will cause the AG to artifactually increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LOW SERUM ANION GAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of a \"low\" serum anion gap (AG) must be determined by each laboratory but is generally a value less than 3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. The most common cause of a low serum AG is laboratory error. For example, in a single-center study of 67,740 consecutive measurements, a low serum AG was noted in 304 patients (0.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/15\">",
"     15",
"    </a>",
"    ]. Of these, 285 (94 percent) could not be confirmed upon repeat measurement and were therefore attributed to laboratory error.",
"   </p>",
"   <p>",
"    A verifiably low serum AG can occur in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decreased concentration of unmeasured anions, which is most often due to hypoalbuminemia. The serum AG falls by about 2.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      for every 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (10",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      reduction in the serum albumin concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/1,2,5,18\">",
"       1,2,5,18",
"      </a>",
"      ]. The expected normal values for the serum AG should be adjusted downward in patients with hypoalbuminemia. Alternatively, the AG can be \"corrected\" for hypoalbuminemia by adding 2.5 x (4 - [serum albumin concentration]) to the calculated AG.",
"     </li>",
"     <li>",
"      A severe normal anion gap (hyperchloremic) metabolic acidosis often reduces the AG. This may occur because protons bind to albumin as the pH falls, which reduces albumin's net negative charge. As an example, when chronic metabolic acidosis was produced in dogs by the infusion of HCl (reducing and their serum bicarbonate to 10",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      the AG fell by 5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. However, the calculated change in albumin charge only accounted for a portion of the change [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increase in unmeasured cations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/3,5,19\">",
"       3,5,19",
"      </a>",
"      ]. The latter can occur with hyperkalemia, hypercalcemia, hypermagnesemia, or severe",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      intoxication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/1,3,20,21\">",
"       1,3,20,21",
"      </a>",
"      ]. For this to occur, however, the increase in the unmeasured cation cannot be accompanied by a proportional increase in an \"unmeasured anion\". As an example, if MgSO4 is administered, the increase of magnesium is matched by an increase in serum sulfate, and the AG does not change. However, if MgCl2 is administered, then the chloride concentration increases without a change in sodium or bicarbonate, and the AG will fall.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another category of unmeasured cations are monoclonal proteins, especially immunoglobulins of the IgG class [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/3,12,21,22\">",
"     3,12,21,22",
"    </a>",
"    ]; thus, patients with IgG multiple myeloma may have a low serum AG. A reduced serum AG has also been reported in some patients with polyclonal IgG gammopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/12,23,24\">",
"     12,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bromide can interfere with chloride measurement and cause a spurious marked increase of the \"chloride\" concentration. As a result, bromide ingestion can generate a substantial \"pseudohyperchloremia\" and thereby produce a low or negative anion gap. An artifactual reduction in sodium or artifactual increased bicarbonate will also reduce the AG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NEGATIVE SERUM ANION GAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases, the serum anion gap (AG) has a negative value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This is usually due to a sporadic laboratory error or a systematic laboratory artifact in the measurement of the serum sodium, chloride,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bicarbonate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum sodium concentration is often underestimated when severe hypernatremia with a serum sodium above 170",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      exists. Displacement errors will also lead to pseudohyponatremia when an accurate quantitative volume of serum or plasma is required for the assay (flame photometry or indirect ion specific electrode methods) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/25-29\">",
"       25-29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The serum chloride concentration may be overestimated (producing pseudohyperchloremia) by one of the following abnormalities:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Marked hyperlipidemia can falsely elevate the chloride measurement when certain colorimetric assays are utilized. This lipid effect on light scattering may cause a marked overestimation of the plasma chloride concentration, occasionally to levels above 200",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Salicylate intoxication can falsely elevate chloride because the high salicylate levels alter the permeability of certain ion-selective electrodes used for chloride measurement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/31-33\">",
"       31-33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bromide ingestion and accumulation can cause marked pseudohyperchloremia. Bromide ions are measured as chloride by many chloride analytic devices. Furthermore, each bromide ion reacts like three or more chloride ions. Therefore, a serum bromide of 5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      may be measured as an additional 15 or 20",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      of \"chloride\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/34-37\">",
"       34-37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This phenomenon was seen more commonly in the past when many sedating medications included various bromide salts. These included over-the-counter medications, such as Bromo-Seltzer and Miles Nervine. Bromide has been removed from most medications, with the exception of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"       pyridostigmine",
"      </a>",
"      bromide, which is used for the treatment of myasthenia gravis and some herbal medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/3,4,34-37\">",
"       3,4,34-37",
"      </a>",
"      ]. A study of patients taking pyridostigmine bromide, for example, found that their AG was 8",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      lower than in normal subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36533/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13442298\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum anion gap (AG) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/17/1298?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) can become abnormal in conditions unrelated to an organic metabolic acidosis, a finding that may be of diagnostic importance. Furthermore, conditions that reduce the anion gap may mask the presence of an organic metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An elevated serum AG is almost always caused by one of the organic metabolic acidoses (eg, lactic acidosis, ketoacidosis). Much less commonly, the AG elevation is due to hyperalbuminemia, hyperphosphatemia, the presence of an anionic paraprotein (usually an IgA monoclonal immunoglobulin), metabolic alkalosis, a sporadic laboratory error, or a reproducible artifactual increase in the sodium concentration or decrease in the chloride",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bicarbonate concentrations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'High serum anion gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A low serum AG is usually caused by hypoalbuminemia but may also be produced by a severe normal anion gap (hyperchloremic) metabolic acidosis or an increase in the concentration of unmeasured cations (eg, hyperkalemia, hypermagnesemia, or IgG monoclonal proteins in someone with multiple myeloma). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Low serum anion gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A negative serum AG is usually due to a sporadic laboratory error but rarely may be associated with marked hyperlipidemia, salicylate intoxication, or bromide ingestion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Negative serum anion gap'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/1\">",
"      Gabow PA. Disorders associated with an altered anion gap. Kidney Int 1985; 27:472.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.583-588.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/3\">",
"      Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol 2007; 2:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/4\">",
"      Emmett M, Narins RG. Clinical use of the anion gap. Medicine (Baltimore) 1977; 56:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/5\">",
"      Jurado RL, del Rio C, Nassar G, et al. Low anion gap. South Med J 1998; 91:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/6\">",
"      Winter SD, Pearson JR, Gabow PA, et al. The fall of the serum anion gap. Arch Intern Med 1990; 150:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/7\">",
"      Paulson WD, Roberts WL, Lurie AA, et al. Wide variation in serum anion gap measurements by chemistry analyzers. Am J Clin Pathol 1998; 110:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/8\">",
"      Oh MS, Carroll HJ. The anion gap. N Engl J Med 1977; 297:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/9\">",
"      Murray T, Long W, Narins RG. Multiple myeloma and the anion gap. N Engl J Med 1975; 292:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/10\">",
"      Thatte L, Oster JR, Singer I, et al. Review of the literature: severe hyperphosphatemia. Am J Med Sci 1995; 310:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/11\">",
"      Kirschbaum B. The acidosis of exogenous phosphate intoxication. Arch Intern Med 1998; 158:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/12\">",
"      van Hoeven KH, Joseph RE, Gaughan WJ, et al. The anion gap and routine serum protein measurements in monoclonal gammopathies. Clin J Am Soc Nephrol 2011; 6:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/13\">",
"      Madias NE, Ayus JC, Adrogu&eacute; HJ. Increased anion gap in metabolic alkalosis: the role of plasma-protein equivalency. N Engl J Med 1979; 300:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/14\">",
"      Paulson WD. Effect of acute pH change on serum anion gap. J Am Soc Nephrol 1996; 7:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/15\">",
"      Adrogu&eacute; HJ, Brensilver J, Madias NE. Changes in the plasma anion gap during chronic metabolic acid-base disturbances. Am J Physiol 1978; 235:F291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/16\">",
"      Wall B, Rinner S, Emmett M. PSEUDOHYPOCHLOREMIA AND ANION GAP ELEVATION IN PATIENTS WITH RENAL-FAILURE DUE TO ALLOPURINOL AND PURINE METABOLITE ACCUMULATION. Kidney Int 1989; 58:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/17\">",
"      Goldwasser P, Manjappa NG, Luhrs CA, Barth RH. Pseudohypobicarbonatemia caused by an endogenous assay interferent: a new entity. Am J Kidney Dis 2011; 58:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/18\">",
"      Feldman M, Soni N, Dickson B. Influence of hypoalbuminemia or hyperalbuminemia on the serum anion gap. J Lab Clin Med 2005; 146:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/19\">",
"      Goldstein RJ, Lichtenstein NS, Souder D. The myth of the low anion gap. JAMA 1980; 243:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/20\">",
"      Figge J, Jabor A, Kazda A, Fencl V. Anion gap and hypoalbuminemia. Crit Care Med 1998; 26:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/21\">",
"      Kelleher SP, Raciti A, Arbeit LA. Reduced or absent serum anion gap as a marker of severe lithium carbonate intoxication. Arch Intern Med 1986; 146:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/22\">",
"      De Troyer A, Stolarczyk A, De Beyl DZ, Stryckmans P. Value of anion-gap determination in multiple myeloma. N Engl J Med 1977; 296:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/23\">",
"      Qujeq D, Mohiti J. Decreased anion gap in polyclonal hypergammaglobulinemia. Clin Biochem 2002; 35:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/24\">",
"      Keshgegian AA. Decreased anion gap in diffuse polyclonal hypergammaglobulinemia. N Engl J Med 1978; 299:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/25\">",
"      Turchin A, Seifter JL, Seely EW. Clinical problem-solving. Mind the gap. N Engl J Med 2003; 349:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/26\">",
"      Krish P, Jhaveri KD. The Case  Hyperbicarbonatemia in a patient with Waldenstrom's macroglobulinemia. Pseudohyperbicarbonatemia due to paraproteinemia. Kidney Int 2012; 81:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/27\">",
"      Bern M. Clinically significant pseudohyponatremia. Am J Hematol 2006; 81:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/28\">",
"      Weisberg LS. Pseudohyponatremia: a reappraisal. Am J Med 1989; 86:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/29\">",
"      Aw TC, Kiechle FL. Pseudohyponatremia. Am J Emerg Med 1985; 3:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/30\">",
"      Graber ML, Quigg RJ, Stempsey WE, Weis S. Spurious hyperchloremia and decreased anion gap in hyperlipidemia. Ann Intern Med 1983; 98:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/31\">",
"      Zimmer BW, Marcus RJ, Sawyer K, Harchelroad F. Salicylate intoxication as a cause of pseudohyperchloremia. Am J Kidney Dis 2008; 51:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/32\">",
"      Mori L, Waldhuber S. Salicylate interference with the Roche Cobas Integra chloride electrode. Clin Chem 1997; 43:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/33\">",
"      Jacob J, Lavonas EJ. Falsely normal anion gap in severe salicylate poisoning caused by laboratory interference. Ann Emerg Med 2011; 58:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/34\">",
"      Faradji-Hazan V, Oster JR, Fedeman DG, et al. Effect of pyridostigmine bromide on serum bromide concentration and the anion gap. J Am Soc Nephrol 1991; 1:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/35\">",
"      Wacks I, Oster JR, P&eacute;rez GO, Kett DH. Spurious hyperchloremia and hyperbicarbonatemia in a patient receiving pyridostigmine bromide therapy for myasthenia gravis. Am J Kidney Dis 1990; 16:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/36\">",
"      Danel VC, Saviuc PF, Hardy GA, et al. Bromide intoxication and pseudohyperchloremia. Ann Pharmacother 2001; 35:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36533/abstract/37\">",
"      Bowers GN Jr, Onoroski M. Hyperchloremia and the incidence of bromism in 1990. Clin Chem 1990; 36:1399.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2347 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-197.136.42.3-3357F5F93E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36533=[""].join("\n");
var outline_f35_43_36533=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13442298\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13442173\">",
"      CALCULATION OF THE ANION GAP AND NORMAL VALUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HIGH SERUM ANION GAP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LOW SERUM ANION GAP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NEGATIVE SERUM ANION GAP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13442298\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2347\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2347|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/60/43982\" title=\"figure 1\">",
"      Anions - Cations and the anion gap",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/17/1298?source=related_link\" title=\"calculator 1\">",
"      Calculator: Serum anion gap",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_43_36534="Anal Rectal Fistulas Parks classification";
var content_f35_43_36534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Parks' classification of anal rectal fistulas, anterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 491px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHrAgMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopKWgAzRmkozQMWim5o3UCHUUzfSF6B2JM0VF5g9aPMFK4WJc0ZqPeKTeKLhYlzSZqIyCmmUetFx2LGaM1X80etKJR60XDlJ6KiWQHvTsj1ouKw+jNNBHrRkUwHZpKKDQIWgUgNKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKaTTqglcLQNK5JupS3FUpbhVJ5p0c4khBB7EVLkVysnMgpjTAd6xJtRCkjPIqpJqg9alzRoqLZ0LXAHeo2ul9a5iTVeetQtqee9S6iNo4ds6lrsetRter61yz6icdahbUDnrUOqdEcI2dYb0etKLwHvXJLfEnrU0d6fWp9qX9TOpN2PWmm8HrXPC6J70G4PrT9oT9VN43g9aje9x3rDa4PrUbXB9aXtC1hUbn273o+3+9c+bg+tIZzS9qP6ojohqA9akXUB61zHnn1oFyR3p+1JeEOrF+PWpFvlPeuS+1H1pPtrL3qlVIeEO0S9X+9VmG5WTgHn+dcKmokd6s2+rFHVs9DVKoYzwrOzeUIRzweRTxKCM1lzT+baNJGc4XzF9/UVSs9SWTC7sluPx7Vamc6pNq50qsDTqybO9D5UnkVqRtuQMO9WnczlBxHUUUUyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigANY2s3PkpJz93BrZrm/FKEMD0WVCp+v+TUTdlc6MNBTnysyLzVMxxyKwOQRj3H/ANbFTaBqfnLKjMMK6sCPRvlP64rhReM1pcxbv3sTBxz/AMBb+an8DVjwvqBTXIIZHTy7hTAcHoSOP1ArlnUPUlhV7OXka+v3TW2oSpnAJ3D8axZNSb+9V/xwHJtrvHLAo+OzDt+e78q455Se9ZymXSppxTNp9QYn71OS8Y45rDDk1agbgVDkzpjTSNpbgnvTxISetZ8Lciramlc3UUWkY+tWY2qmhqxGeKLjsXEkqUSVUU07NVchwLDPUTNmmg04DNFw5bDeacFNSKtTxx57U0RJ2KhU4qJwRWsYgR0qvNDTaIjNNmYWI71G0hqzLHg1VkWoN0kyGSQjkGq7XTL3qSYcVnzA80cwnTR3HhbVDNZlXb5rdsnPdD1/r+VZF7dvZarcWjMUWNzsII6dR+hFZnhe7FtqypJzFMPLYfX/ADj8aXxzFJDfWty4ZvMUwuB3dO/4qQfwqudo4o0Uq3K9mdFaaqBdwSB8JMf16Efnn9K7bR7nzg6E8jkV4fDfBrKVV4aGQPgHOFbg/qF/OvRfB2redJaSseJl2N9en8xXRCpqjPEYT93K3Q72iiiuo8MKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKyPEsBm0yRl+9H8/5df0rXqOZFeNkYZUjBHtSkrqxpSn7Oal2PBdZK2Wvh5CVtrgfMR2BBDfjyT+VZEjyWl2wTcLmF8HA3FGU8EH6iur8daeyW8wK/vLZ8jI6r/8Aqwa5a8lWaK2ulDfvF8uQA4y6gDPHqpX8Qa86R9dC101sz0q+Ca5oLSRqAZoluEA7MRyPwYEH615s2Qea7TwBeiTTpbVwytaSFsMesUnX8mGawfE9kbLV5lxhHO9fx6/rmoWxwUl7OcqT6GYhqxC3aqq8GpUPNI6UaUR6VdjOazIWq7E3pQaJl1TxU8bVVQ8VMhoGW1NPBqBGqUGmBItSLUQNSKaaJZKvWrMTYqqKepxVIykrl4PxUUmDUQagtVXM1EilUHNUpUwTV5zxVaUZqGbQM+VM1nzp1rWkWqcyVBqZILRTI6/eUgiuq8UoL/wzcyBcusSXkZ9CvD4/4Cf1rm7lMV1nhxluNIt1lGUDtA49VcEY/PbQ9jjxPuWmujPN7EytdGBQcSoY9pxnJ5Ue43Ba6LwTfN9jKA/PbyblPseQfzzXLMkllfE7mSS3kKq2OrK36citzQPLg8QX0MRxFIvmxj/YOGX9DVp6He7OXk0e9wSiaCOVPuuoYfjUlZHhSYzaLDuOShKfgOn6Vr16UXdJnx9aHs5yh2YUUUUzMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoNFFAHFeO7JWljlZcxzIY3/z9D+leO28OyS8sXz5i5aP3ZM5H4ru/EivoPxLbfadHnAGWQeYv4f/AFs14Z4oikstVt7+34ZmDf8AA1x/MYrirR5ZXPpcuqOrQ5eq/wCHRB4f1E6RqtvcyB9pJWYE8NEeCMD2wfqK73xhYC70rz05kt+47jjn8Rg15zfoqXbNHADDNh41wCQrDcB+R/SvRvCGoDVdEEU6/vbdRbTK/df+Wbf+yn8a5/hZeLVuWvH5nn+MGnA1pa1pzWF9JCQdvVCe4rMIxQWndXRPDJg1fhfNZQNW7aSkUmasbVZjNUEarUTZxQaItqalBqFKkBoGTA1IrVXBp6tTE0WlNSA1VV6kWSqM2iwKQ0wPRuoJsKahepC1RsaTLRA4qpOOKuPVaccGkWjKuhW94Rlzpt7CPvofNH4YI/8AQaxLgda0/BbhdVeNvuyJz784/qaEc2JV4NnM+M7fyfE+oImSsrrKigYDBlDH9c1HaP5WqaPLjbmIwvznkMygfkUrU+I0a/2hp865R5LRF9uGI5/OsDeqWdqyMHeK5LbhxkFVP80ojsb0XzUoP5foe4eBmJ0+4XPAlz+YH+FdJXJ+BGObxM8fIf511lejSfuI+czBWxEv66BRRRWhxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQTjrQAUUA56UUAFFFFABRRRQAUUUUAFFFFACMAwIIyDwRXi3xB08xQXES/8ALvMCD7dB/MV7VXmvxLiAe+Ixl7fefqB/9aufEK8bnrZRUaquPdfkeY7Fls7Gd5GVcPGcdcqQw/ST9Ku+GtVOj6ks8kjyQSAxzx7c7o89fqOtULZydH2bQ2y5Qj8Y2z/6CKYGbzHSNRH03ZY4Hp61xSPeUFOLhLzPWNU0+HWbJfLkV3xvgmByJFP9fX864S+sJrSUxzxsje/Q1H4d1640cSRShLiwY5aEsRg9dyHsf88da7eLxBoupW4E11FgjPl3Y8px7ZPyt/nmlfuec4VMO7NXieeuhBpYiQ1dtLp+g3ILQ3KL7Ryq2PwBNMPhW2dN8N04HYsvH64p/MpV4ddDAtyWArRgTgVeXw7NGu6GWOVR3H+TTYrWQSGNlIYdqdjeFWMtmMHSlrQi0527VYTSyRT5WDrwXUyaUZrYGl+9B00DuKfIxfWIGQM0oJrUOn+hFRtYkUcrH7aDKQc0u81YNqwpjW5HalZj5osi3mjdmnGI00oRSKTQhNQTDg1OVOKhk6UmUjPnXIqTQHMOsQEdyQfyol6Gq1m+zU7Y9B5i/wA6FuZ1FeLRc+JFr5lhp0jHbtnnhzjoCdw/Ra4iRgbCWTcSPNjAO3H8Mlei/EMZ0AAKCVv14PvET/WvOyFbTptqFBvjbGeOrDj86UScG70F6/qe0eA2zdzgHIMQP6//AF67SuC+HsmblR0D2wP8q72vQofAeJmatiH8gooorY88KKKKACiiigAoopCQOtAC0UA5ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqNzxTyagnfArOcrK5UVdleaZoiShqOHWIN2y4Pln+92qO5f5SRXPajNC5KggSZxgHn8q86pmMaL9/Y9Cjh41dJI7hWDKGUgqeQQeDS157BeX+mYaCQiMnJXqp/Cuj0vxLa3ICXWLeX3+6fx7fjXbRxVOsrxZFbL6lNc0PeXkb9FIrK6hlIZT0IOc0tdBwBRRRQAUUUUAFedfEsgvdjji0IP5NXoteR+P75Zl1CYNuVyI09xkD+WTWGIdo2PUymDdZy7I4CBX/suZkXJ88EDpnar5x/30KgKqY8rv8AMb+IHOT9KspK0em2qKRwXnIJ6lsD/wBkNWdD0ptZv0trZfL2/PJMekady39BXDI+iUlGLlLYpwW0t5OsFpBO8xOGijBYgevfFdJp/g2+uY3S8nFohAAjZfNk+uF6fjXaWsOn6FpxMeba2x8zscSTn1Y9cegH6VzGo+MZyTHpsawwjoSOT+HT+dLfU4Hi6tV2pKy7kkngNygEmoSPg5H+jAfzcU+PwIMqw1BoyP7kaIT+TmsF/EOqOebth9FA/pUJ1nUGJzez8+jkUadxXxD3n+B3el6DcWV2JZNXuJowpUI78DPcfMTx14xTde1a1gvkELozAncFPT/PNcE+oXkgw91Ow9DITUAJpp22FGi+bmm7ndf8JGijjFQv4nIPyiuNBPvThmq52aKjDqjqn8TydhUTeJJjXN4pQDS52UoQXQ6EeIpRR/wkMprn8H0pVQmjmZShDsdLDrzMfmFWv7XDY4rl4oj6VaWM0czHyROmhvVl9Ke7g1iWgZSK1Y+nNHMHIkyVmG2qsvSpmqCSky0rFKc8VUtRu1G3HrIv86tXPeq1gf8AiZ23/XVf5ihbkVNjc+IRH9gzgjGLyI59f3Vefxqn9mXhTdt2xvg84+cf416D8RnEeiSZxg3cQ5GR/qjXn1kM6RqTbgURUXj03rRDcywf8D5r9D1X4d/8fNt/16j+Qr0OvOfh+4jurIPwXtwo/wC+Qf6V6NXdh/gPIzVfv/kFFFFbnmhRRUc80cEZkmdUQdSxwKBpX0RJTJpY4ULyuFUdzXNaj4oXLR6em49PMccfgKzYpZryTzLmYt9T/Idq5quLp0viZ3U8vm1zVNF+J0raoJG2wKcf3j/hVmBieT3rGtUUEbe1atq2RiuenjPavTYmrTjBWiX1paYtPr0EzjYUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSN0oAa544qhcv61LcTGMkjr6VQlmWdS0Z+ZfvL3H/ANauXEp8t4m9Ja6iTMgiYlvmrnbhBLemQN9wAY9Tz/jV28lk3BUTJPcnishkks3keWXzFkO5jjG0+v0r5LG1nLoe1hqfKnrqzSN1iAxSpx9KwbmGZZgbdBIjnG3OCv8A9atB7sGMMZIyv97cKrW9wshkKnIUgZx1zXnLE1ITUoy2OujF07tIltn1Cww9vI6AckKcj8R3rbsPFjAhb6EEf34+D+VQrdxC0KEDOKwrtkELvxhWHP1Ne7Szp0mlPX0/yMfZQxN1Uhr3PRLLVbK8wILhCx/hPB/I1drzI2gKB4pVIxmpoNS1K0x5VzIVHYncPyNevSzbDzWsl+X5nFUytP8AhS+89HorhU8Uaiowwhb3Kf4Go5/EGqTrtV/LB/55pg/nXX9bpWvcwWVVr6tHTeJdSSxsHRX/ANIlG1AOo9TXi3jmYg2louSzAyso9DlV/H71dtDA9xPuuXJYnncck1weoXMd54sv70nNvaEuoHQhMKo+hO38zXIsTHESfI7pHqYWksMuSOr3f6Io6kCl2IokGYEVCwIGdow3P+9k16P4X05dM0ZVuMCaUC4uS347E+gxk/j61wPhjT/7W16zglV8tJ5khYHlF5Ix79Pxru/GV4YNDfafnupP/He3/jqj86T1Y8XJ+7QXz/r7zkvFOsvqt6QpP2eMnZ/te5rEpTyaVRQ3ccYpKyExTgvtUipU8cdItIgSMntU6wE1aihq0kftQUkUVtjUi23tWikXtU6RCgqxlraH0p4tPatZYhTxGPSmFjIFp7VLHZ89K1FiB7VMkNFg2M6O0GOlTpa+1aKQj0qVY6dieYpRWwXtU4TFW1jpHTFOwlMpuKryVblFVXFSzRMzro4BqPRl8zV7Yf7efy5p9/8AKKs+DYPP1tWI4jXP49P5ZoW5nWlywbLHxIlC6cEdvl+2ryOuFh/xNcQZG/srUN235xGuQevzZ5/75rqviQ5lg0+EbRLI00xBPYkBf0/lXKALJo0m1cb7mKMDb7PkUoCwqth1fv8Ar/wD0SGOSzt7GaI4aOOPn0IA/wAK7rRtbt9QREZhHc45Q9z7etcexZ4yxICDgL2qA2uVDowB7CvOwGbRguSpoY18PDERSno11PTqo32q2VlxcTqH/uLy35CuAmvbyLZFLeyLv+VVMxG72AzzVS5JggmlcFjGQCAfX1PoM16dTNaEFdP9Tjp5VFO856eR1N94sdsrYwhR2eTk/lXM3N/NfXGJZXnmHY9F/oKksb6JUlm8hjb+QrpxhmbcA2Pb5lH4GqV/qBYwSRRtEZWaNlKbnOGxzj8TXk4zM60lamrX/rb/AIc7sOqNJtU4/M2VmtNPhAkVpLlx8oXoOQOT2GSKz4Lq4n1hPKVjbEBZArYCNnoT68H9KbpFoVjU36DIRkCbyxwWzyfbitK5ncLtgQtKxBVBxwD1NeS6/PJX1fcFGTk33OjtIv3OUAAq5bEqaxrC73KFOUbujdRWtbEs3Fe9gpqVrbnl14uN+Y1IzkVLVWOZW4Q5HrVlelfQRVkedIWiiiqJCiiigAooooAKKKKACiiigAooooAKKKKACmv0p1I3IwaAMq/bKkHrXJajdy202+N9kg+6w6H2rqNWVo1J7HofWuK1lg6srcisKjsejhYqRo2OqR6nlTtjvU+9Fn7w/vLRqLCWMAgZHBrgboS5zFIVuEO6N1OCD2ro9A8Q2+sxR2t63k6iRgdlmx6e/tXh4/A+3TlS+Lt3/wCCeioOjaW8fy/4Bf0mKJkjGF+YAlvWr11p8UL7kxlhggd6peQbeURDKgD5Cf5VahDlgZGBAr5hJRvCUdTeo25c8ZaFd4AOC5AqYWiCEPuHynIHv61BfSbdxALbSOB35pj7lT7xCe45FZcyWyuXaTSdxoZC21eMDdgdOtX4LcSr8mC1Z9vbeewlV9pH3fTH/wBepWMkB+XOKcfds5K45q+kXqOkAWTZ37e1ENwQivsIyOhHSoIg004Lcdq0dT8mCFSp5HU04r3XPsTKyag9ble4uDa2dzdtjMcbSAfQZFeWW0ciaW8ictPKFxnkqg3H9WT/AL5rq/iD4w0Hw/pFxaavf+XeTxrttoF8yYgkHO3IA4H8RGa8G1z4n6ndxw2vh+2j0qGEsVm4luGyc/eIwvb7oB9zX1eVUHChd6X1MoVeVuyvqvw/4J7/APDqKO3n1HU7oiFIoVVHmOxcnJOGPH8Iqr4x1nT9TFrDpeoWd6kA2yG2nWUKcAAEqTjvXzFcWeq6xJ9p1S8nuH6+Zdzlj+bGvQvhdEtvpN1ECrN9pOSpz/Cv/wBevQcFFaE8kpVXVkdr3qVFqMDmrcCZxWZukPijq3FGPSiKOrKJmmWkEY9qsoopiJVmNTigoRRUgpVjp4joAAaevNIEp6rQA9BVlBUKDFTr0pomQ8U4daZSiqM7FhTxSN0pqGnnpTIejKcwqs61blxmqsx+U1LRrGRj6l6Vt+DoTDpt5doP3pyqfXov6mud1Bvnrt9CjWz0u0STAUAzyk9gBn+ZH5VGyMMZK0LHn3ja4E3iKeMsGhtVS2UbiD8oyenuTUFpAH/sa0ViweczEEc7FwB/Jqy7qZbi6kuTks8jSSKxyG3c9/rXWeEbMXniCZWA22VskCg8hW6sPzLCsq8nCjJrex1SSpU4xfT+vzZ0ikOBg5HQVN5BIzVa4U2s4QjCrxVqS+MqKi44GOK+N0u1IiSlo47HPTyeVp9zcu370z4JxkjbJ8oHsAP61Yu0vTHIdPUXEMvysR99Xx1ySBjGP8mpp7ULcrc+QoI+9JgbjxjP5VfguJEj2KCc+ner9sk1zL+uwOLUfdM2Gzui6NKPLRdqrH1IVeQM/Xk/QfjbGli4chURXdsyMqjJ9s1NBLulYE5w2D9aumZ7dwygnIpRkp/FsTKUoP3dylPavbx7FldWxwTg/wA6XRVBIaUkkjLE8k0Xc7zPucHJ4A9TRCq2Fkbi+kWKCJfmcnr7Aeta4ejKtW5aSv8A11FOfLS996s14tm8yOVWNASzN0ApP7TW4bbbkrb+p4L/AP1q4ebXZNYlyiNFYxn93H3Yj+Jq6DSckK78HsPSvs8JQjQjZavuefUpN+9P7jsrBiQM8e1aqHIrDsH3YA6VuRjC89a9GJ5dVWY6iiiqMgooooAKwPiBrc3hrwTrmtWscctxYWklxGkmdrMqkgHHOK36z/EOkWviDQr/AEjUQ7Wd7C0EwRtrFWGDg9qAOU1r4jWHh3wLoGv62n77VkgWKCKRI1Mske/G+RlVFGD8zMAKxrf44+F5NKj1CWDUYbd7K6u1YrEyu1u4WSFWDkNJypGDtIYHd2rYg+Fuhx6KmmTXmuXMEMsU9o9xqczyWTxqVQwNnMeAxGBx7VNqvwz8P6xYaVa6z/aGojTrv7bFLd3byyM/dWZicocD5enAoAzNZ+LmlaN4l03R9R02+gkvWt49zS25eF5gpUPCJTIACwBbbjIOM4qhovxeM9lqs2p+HdSinh119DsYYvKJuptxCx5MmFcBSWJIUDoxroNX+GHh7VNfn1e4/tBLie6gvZoort0hkmhxsdo84JAAH/1+aWf4Y+Hpv7TBGoIt/fjVMJeSKLe7yW8+HB+RyTyR9OnFAGePi3pTRaYkWka5PqF7dXdj9gghjeaG4thmWN/nxnHQqSPUit3x54zt/B+kWt9dWcs/2iQRLF9oggIJUnBMsignjGASSe1UG8IeE/CcGl6xdStZQ6HNcXQu7m5JzLcDZLJK7feLbupPXFbHivwjpviefTbi/a8hutOkaW2uLO5eCWMsu1wGUg4YcGgDjZPjVo8mn2V1pmi67qP2nSn1nZBFEDFbpIY3L7pBgqQemQexNb3g/wAZweJvE17b2U8r2Y02y1CGN7URlUnVmU7/ADCWJAGV2Lj1OeGaR8L/AA3pNvHDZxXQRNJm0Ubpif8ARpZDIw/3tx61qeGPBekeGrw3OlpMspsbbTz5khYeTApWMfXB5PegDpKa/SnU2TpSlsNFG7KPGySjKnrXBeJ7KWx/eE77ZjxJ6ezf41292pJ4Ygd6pyxfuXDAPEwwyNyCK86eIUXyy2/I76LdO0o/ceQahKI5UdeAx2keh9ax7+PbJ5ikhHbduU4KP6113i7w35KteWW97AcvGp+aE+vuP5fSuOErRDy7gB434D/wuKUu62PoMNUjUjeP9eR3XhXxGurD+z9WdEvlH7qXp5w/+KrZuFlim8s5Y4znOPzryiSNCCuSy9RnqPxrrvCvikNKml62/JAEF23U+iuf6/nXnY7Axxa5o6T/AD9fPzMZ0XQfPBXj27en+R0yBjKodQq9RznJqe6miMIVfvCpblXwqOowOh9arTwLFKgJJLZr5icJU24NW7hGUZ2kVraXyXZP4d3GO2eT+tXpryNrcrtG71qSNLaKA7gdx54rOkubS0t7i8v5YoLS3UySzSHCoo7n/OTQozuox1bHKUZXk1sWLb5YmZ8KoBYknAUDkknsB614n8RvjI4uZtN8G+XMV+R9SddwBzz5Sng/7xz7Doa574i/EG98bXkum6Estn4fXhgTte5x/FJ6L6L+Jyemb4Q8FXfiO4FnoluCkZH2m+kBEUP49z7Dk/TmvpMFlcMPH2lfVr7kZNufvPRHHeRcXl4015JNc3lw+5icvJI5P5kk13+gfD2/EJm1VhpahQ4j8rzrgj1KZG38Tn2r1XTfB+neCLvQU04NPqVxI/nXsoHmMBt4UfwDk8DnnkmspvtEMiI0y7mGCdvKgdvevV9pdKS6m+HhGotNv+C1+hq+DPht4VutF/tK5s7nULgS7B9ruCy/eAJ2qFHc8HNS+MbS0sNZittPtLa0gSIYjt4ljXqeygV2HgUA+ESAWI+1Y3HqfmWuV8ec+I/+2Q/malSbvc4oNutJPo2Yi9au23SqS9auwdKk7Il2M1ai5FU46uQnimWWUHqKsoBiqyHFTIaBlkYp3FQg0uaAJeKUEVFmjNAE4YVIrVVBp6timiWWgaXdUKtxS7qozbZOJKVpeKrFqQtmgmw5nzVe4OENS5qpevtjNSzRIz4IPtepQxHozc/Qcmul8X3YsfDd86cSy7bNPx+9/NvyrO8Lxg3M92y7hCvA9T6fyH41S+Id0qT2OmSOW8qPzpdrYy7Z5/D5j/wKpfRHNJe1rxh2OOshGbyPejbYzvkyfvqoLEY+grsvBLz29m1zKhzcyNIX7E5wf1zXHQoI7OeZQzyPtgTPO5m5JH/AVx/wKvTtMhitdIgtlGXRQp9/X+teXnFTlpRgnZt3+47asld3V+hJdnzA0jck0tjHCYyztgjoKq6es0qtvYBASoBXmnzweSeHIB7V85qnzNXM3FL3Lj7662R4X5j0Ue5p2nQho8Mx49e9H2DzrcyBufrzUIikD4U89xnGaburOSBcrjyxYOiW0pAO1WbIx2NTfayxC5Vj7cmnQqu/9+egxxVbVL6y0W2F5fkjJIhiX70hx0rbDYWeIny0/n5epE6kV8Su/wAye7lt9Ps31DUn8uGIcKOSSew9Sa841rWLvXb1TMxii3YggB+WMf3j6nHeotZ1W+1ucTXxyqnMVuh+RP8AE+5qurJaIXc5lIwT6ewr6vD4enhoclP5vv8A8A1o4dp89T4vwX9dzodM2q8cMQACjv2A711tg5JVVBZieABya4bw9De3V+qQw7pJRwmeUX1b0FetaLpyadCCMS3JGHlxwPYegrsjJRXNI4sbUUXyrc1tNtvIRTJgyY6f3a00Oay4C+8Arye+a0oulb0qnOeJUjbVktFFFdBiFFFFABRRRQAV4DH4S8W3/i5J9QvPFEdnc+ItShnCalKkaacVJh2gNhFLYAIwe3HFe/UUAfP+jL8RNK0XwnPfWHiHUJW0O7sLqCG5XfFdGT9zJIGdRkKB8/JH1651npHxC/tnwpNPb+Ib6VLawS4juruWKKEgAzSCWOcZY8hhLG+ccZBFfSNFAHzV4p8M+KdS8D+JNO1HSPFN74ruDN5lyL7fYTxeeGjWOPzCowm3ACAghsntXQa9o3jl/ixNePca2mnjULeWxksUMsBthtDxSD7SiICd27dEzHqCeBXutFAGfrcuqw2qNodlY3lyXAaO8u3tkCYOSGWKQk5xxtHU88YOL9u8cf8AQveG/wDwfT//ACHXVUUAcr9u8cf9C94b/wDB9P8A/IdMkv8Axtjnw74c/DXp/wD5DrrailOBUzdkNbnDXOoeMATv8O6D+GvTf/IdUJ9Y8VBSreHdHx7a7L/8h1217IhQjvWLeHb7V8/ja/I9Ej0sPTUtzl4dR8TJIXTw5pZJ4K/29Jj/ANI65rUtI1Mw3d1H4ZsnjPzSWttr7Hb7qpsvx4P0ruxdyKpKjIPB9j6VQE80d0rxHEjHoemO+a82hm7ozUJR93rpt5o9BYad3KErP1/M8qhUKw2scEZUZyCKtTQ+fCrIMyxknb/eXuK7DxV4VM6nUdFiCzj55rVejerJ7+3f+fHRFm3TQFjIPvRnvjrj3HpXuxaklKLumejRrRqx00a38jpvDPif7Nbraai7SWGP3c2Nzw+x7lf1FdgYZJRDIksbow3Rupyrg+9eTSkJ/pMHML8ug7e4rf8ADGv/ANkOsE4aXTZnGVXkwk/xL7eo/wAnkxeChilrpLo/0f8AWhjVounepSXqv8v61OzuXSJZXuWEUcKGSR2YBEUDJYnsABmvm34keOZ/GupCw013t/Dtu2VUnHnsP+Wrj/0EHoPcmt/47+Nn1DUrjwnos4ayhcfbZ42/10g58r/dU4z6sPbnivBHhW78T61HpVlmOJR5l1cYyIYwRk+55wB3JqMvy+ODi6tX4vyRgpe195/Cjc8A+ELjxdP5Nqr22iW7YuLkD5pG67FPTcf0ByewP0Hotva6Bplvp9pbpZW8QwqKSyk9yW6knuTU+g2Fpo1ja6dp8XlWVugRE798sT3YnkmrmqRJIDsGA3FeTj8c8Vfkdor8fMtW5lGSMLxepOp+G3X/AJ7Pgj6pXD3gdLx98w3OGwSvGPSu38aSeQ+gPn7szc/gp/pXJ6xBDHqFyLttzq77V6AfNX0ND+BD0X5G2Cfu29f/AEp/5noHgH5vByAYci65x/vqa5Lx3x4jPp5S/wBa6f4dup8H3RRcBLknCj0VDXPfEGPZrsT9mjx+TGtI9Tzo6Yifqzn061dgPFUF61dgPFB2xLkZq3CapIeatw5oLRbU1MlQxLVpFplCgmnUoU+lOCGmAygVJ5TelHkt6UWFdDKcKeIX9DR5TDqDRYV0AbFO3VE3y9qYzOP4W/KnclpE5YU3ePWqrSMP4G/KoHnk/hikJ9lNFxaGkW4rH1a5w21TzUmNQl4jtJ/qUIrR0jQJfOS71Fgqod2wDPPb8fYUrEzqxgrtm14bsGtra2hkwHb9/KPp0H54/wC+a828U6i+p6zdug3xvL8g4+6mAD+OM/jXo3im/wD7H0CafPl3d1iKMZ5QEf0GT9a8nKjLLHGi+WoO4E5I7fXpUXu7kYCLnKVZ+n+Zr6XGZtV0iHB+VTcv/vHLA/8AfKpXf+bGke4YUDlmNcl4ViM2uahNj/j3UQj6DgfotdLZW5luMuT143c7a+fzeblXUV00N5Wau+n66j9JvkkkkcD7sh+UjBx2NWtTkS4OQNtQ39uBcJ5RIlzt3DuP61kal4k8PaW7RarrunW844MLzrvH1XOR+NedGFapelBXMpOndVNjRhkZQPmG31NOjdhcrKFYqFIBA6kkf4Vz0fjPwrcP+68QaVvXkF7lE/D5iK09f8RwabaxPZvFd3c6ZhKMGjVem4kdfoK6MNl1erLlknFd2glVV7QV2yzrGtW2iwGW5HmXkgzDbDq3ufQe5rza6ubnWNUe+v38xo+BjhVPZVHoKgmklubti8jS3Up3SSvzj3P9BUnRRBbD93H95j79/cmvpqNGFCHs6e35+bOijh1TfNLWX9aIhuZGU5QDHqauaHplzqN35NqgluiMvI33IF9SfWnaLpVzrep+RaAJHFzJMwysfv7n0Fd/a/ZtNtRp9ghWOMgyyEYaU92NRiMRTwtP2lT5Lv8A11YVqzb9nT1l18vX/IuaRbW+jWhtbImSTP7+cj5nP+FdPYXK+SFrCjlgKKAvzfzrUsFRgCoxXm0MZPEVedv5djy61NKOu/fua0Td/er8R4qpbxqcZ7VbUY6V9Fh1ZHlVGiYUUi9KWu05wooooAKKKKACiiigAooooAKKKKACiiigAqvcnCmrFVrnpWdX4S4bmPduBk7c1kXchlPTAH51t3EJkDbe1YUpxJtJwScV8rjr316nsYexXhgjXcW+V2JYk1kXv7mYyRHJXkjPBHcVq3allIYk+9UY4IWbazZ9j3rxKt7np0ZW95sktr4Rtu549ayfEOhxayXvdJCxakvzSR5wJh6+ze/51s35tkhAjzuHXNR2Qbb5qZBHp2roweNnhJ8vxR6r/LzIlBNe1hpL+t/I8uZzDc/dKbyQ8ZGNrjrx71keLtd/4RbQmntMpqN4TFZcj91/flx7dB/tHI+7XpnjXTtP1C0k1JrqGyubVPNuHf7rRLyzEdcgc+p6V82atqT+LfEVxqNwWisIRsgjY/6qFSdq/U9T6kk96+soShViqkHdBKu5x5LWfX+vMqaHp8ztBDaQma/u38uBO+T3/wDr19ReEfDdt4S0O2srFI5mnVZJ7xTn7RJjkk/3RkhR6e5NeSeALIWmnzarKrJd36mK2JGPLtwcMQfViMfQHs1d94X199FkMF0Wk0uQ5ZephP8AeX29RWeMo/WKbpXs3/Vn5A6c+XnirpdO/wDwx3ixuylgM464pGLNjJzipRJ5UayQSLJbyjcjryCPrTYfnLO33cda+Mq0ZUpcklaS3FGfMuZbGD45tzJ4dtZRy1tOpz7FSP54rmNZV21aW4kRZEL7wu3dww3ZI/EV2/iaLzfC18ueVCOPwcGuH1UREWV1I0hEsK4VTx8uV57/AMIr6zASc8LB+X5No0wrtJp93+KT/wAzsfhtKZdC1qJQBGshYKOOSg7fgKz/AIkR5uLGb+8Gz+OD/Wp/hLMs17rQ3HlYvlPf79S+P49+jwttw0bIT+RU/qK6o7s4Z+7i5L+tjhV61ct+lUhVqA8UHXEuoeav2wyKzYzzWnan5aDRF+ECrkYXA5FZhYgcVGZH7E1SYSTexvAxKMlhTTd2y9WFc5K8rfxGqxV885p8xn7NvdnWjULYdxThqNtnqK48o59aAj+pp84vYrudumoWhH3hSvfWuDgrXDFXHc1GxkA6mnzkew8z0XQ1t7p2kODyQPr6VV1bUr20m8uDSmnUKCWUjr3G3O78cVw9hqd1YSFoH69QeQa3oPGcoXbc2wcf7Lcfkc1Ld9mYToy5uZaotL4sWJR9s0i9iJ9YDgfiWFH/AAmlgzFY7W4yOoMSf/HKltfF2nNjzIXiPqFx/wCgmrn9saNqe2OS6jI7JcRq4/8AHhn9al8xDik/eg/vKSeNLHyd5t71FHfyY+fflqjm8c2UUy+XY3ctzj5TO6qBx7E4/KtC68NaReof9GiG4Y32jmE/98/dNczq3gu8jWd9MnF2RljFIuyUcY47N9eKl+ZdNYWTtK69f6/Mxte1y91a+E90FaIfJEiLlFPcDPU9OaqWdtu1SONh5ayGPCo2R97GP/1etVPKlIEa+Z+5zu4wVPoQe/Xir+htH/aVm88Z3NNEUJyDt3Af/Xqluj1uWMKbUFsjpvA/MWoz4+aWTGPzP9an8VeLNN8I6W2o6s7DflYYEH7ydx/Cv9SeB9cA42h63Z+G/B2pavqTEW1vMcgfekYgBUX3J/Lr0FeC6vea78RfFkTvEZby5Pl2ttHwkEYycDPRRySx9ya8r6l9YxEqlT4U/vOOrrNwiXfE/wASPEvim8kX7ZLp9jIdqWdmxXKnszD5nPrnj0AqbQvhtruoLGyaK0Eb8h72URE+nyfe5+le4/D/AMD6X4P09PJRbrWXH729K8g91jz91f1Pf0Gt4i1qHQkKQbZtXkTCIeREP7zf4d66aOL9rP2WGiuVbvov8zPSHuwV29u7/wAkeEa78ML/AEopFcppjzuu/wAu3vMOo994A/XmuTsdR1nwneSw2kskIR/39jcqdjH/AGkPQ+4wfQ17BljPJd3rmSVm3lnOSzf3j/QVh+NdB/t3R5bhVCalaRmSA4+aVACWjb8MlfcY/ir0FO7sjeVBxheWrLugara63pMd1pgMTyP5dxG53NC/UgnuuOQe/wBQa6fw/osmrSmGFjBYwnM056/QerH9P0rxv4Q3cUPjm0srp2Wz1UfZJdp5DEgoR77gB9GNfT1ysa20VtaoIbWIYVF4/GuTG4qnhIc71b2X9dCfbVH+6W/fsv8AMlgjtNMtEtdOVY4F5wOSx7kk9TWc8vnXYEePlyGb1J7VPZ2ougQH/M9aYbOSB22nI3ZBr5OvXq4iXtanU0owp0rxT1NBbZxCTFhHI4OK2tMIUKDwMDFY1lJIcCXnHQCtq0HttzzxXfgErqxxYlu1mbMPsatxiqtuvA44q2gxX1tBaHiVCUdKKB0orsMAooooAKKKKACiiigAooooAKKKKACiiigAqtcDINWarXB25rKr8JcNzIuZzGGAznvWFMhlc9RznPvWvervY4zn2rLuZ3j4K498V8rjdZantYdWXu7laOcM5jkALL3qO/hClXUYqnLHcmQzx4CKCCG4LZqaO9aWPaYyWHY9q8aTvpI9D2bTUo/MqvHtZS53EnpnpWrpsKOp3uFFUhBJgvt3fX1pwWZcKqMxJwACKwj7kk7XKqPnVkzy79ovX/sGgWuh2kn+lam5aXHUW6Hp9Gf/ANAIrznwd4Un169stGtkfDqbq8ZMZSJewz3PCjPdhVHxnrMniz4iX98zA2cMhgtxnhYYyQv58sfdjXr/AMG7X+ztHl1m48xbrVX/AHOFztgQkAf8CbJ+gWvsk4Zfhlzrbf1ZzQjOSbjuytczo77XiEdpxHHF08gKMCP2wBgVUZpLebyzmSNvuk9fp9a7rxhoou4JNWsIMSAE3cGPvj++B6+vr/Pg5wzRjySWj4K85Kn29RWynGolOLumd2HqKcdFZrRrsdJ4U8QjSma0uiz6ZIcMO8BP8Q9vUfjXocLLEQGKyIQGVl5DDsRXkNvJHexAyZWUfLuHVT6H1FdR4P1cRuuiagdvP+jSZ4Qn+HP909vfj0rkxuEWJhePxrb/AC/yMK9LlbqLZ7/5/wCZ2VzD9ts7+1GR50Lr9MjivPPOb/hG7cx8tDMykk8hWAI/rXpFuFimiwMPu2n8eK4IWiomu2BGBBKrLjqFDlRj8GFZ5S74dxe6b/RmdGSjUdvJ/p+pa8AXC2njCKGNtwuYXjbJ6kfNn/x0/nXT+M4N+j3q/wBxn6enDj+ZrgtKmh0nXdNvbdQixygOc5JU/K36E16rrluJBco4G2SMH8iVb9GFd63RjjY8mJUu6PGYzlRViE1BsMTvG/DIxUipojg1TOhF1O1X7U8VnxmrtucUjSO5oqMijywabGcgVMtMsi8oelL5A9Kl5zThQIhFuvpTvsy+lTLTwKYFX7KpqOSzGDxWmiZp/l07ENnNTWWDwKqSWpHaurkgHpVeS2U9qTQaM5R4SO1QMnrXS3FmMHArMntcHpSFYpW17dWbZtp5Ix6Kxx+Vd74P1qfVUeCfAmiwVcep74/D9a4GWMqTXZfDyDyo7m5I4LAdOygk/wA6a7HPiIr2bbRF8SNMjMdrqVuhSa6xHKoOAx2kg/Xgj8q5TSmRtRs1ljbeJ4xkj7uGHGPXivQPiIRD4UsyRyJo+T2+Vv8AP415yl3Z6cV1K4LOtrm4lw+C6oNxGOnRSB+FTDdGuDm3hZX6XPMviPqz3d9BoCyYsdPc3M4B4ad1HX/dXC+xL1618GvCI0LQDrF6uNR1OMFUI5hg6qvsW4Y/8BHrXjvw801/Fvju2F9H5q3Nw15eDsUBLsD7E4X8a+ldZ1VdIsXu7gI8rErbxdN7ep/2RXLjpTqNYalpfd9kRJtLzevq+xDrmtR6FAiRIJtTlBMaMeI17M3+HevOLi6Pmu7u091K2XY9WY1YkM95NJd30zM8p3MejP8A4D0rOiZWuC0SKTnEajoB3JrelShRgqdNWS/q7OyhS9neUtZPd/ovItHMZVpQJZzwiDkA/wBfrW94X0a41G9WXzNttbsGlnZcgkc7VHc/yqn4e0ebVb4wpLtAGZ58cRp6D3Neib7extEtLNUhtYxhcnr7+5rLFYqGFp88t+i7/wDAM69WTfsqe/XyX+fZHx5cSf2N4kle3Ug2F8TGD28uTgfpX2Zd25SElVxG/IJ718feP7Y23jjxHCc4+3zuM+jOWH6EV9YaZfyXGiafvYFmtYmIz0JQE1xZ04ulGT/q5zwUm4tdiJN0TERHPfFWog1xIFY4A61EMglkJJPFW7aWGJTIWGSOQa+bprudVRu10tSzGkcH3m4FadkWYhiCAegNc212JrlF5K5644B7DNdPp7o0agjBr2MC7yscOJg4Ru+puwsCgFTrVSDt6VcFfW0dUeFPRj+1LSUtdRiFFFFABRRRQAUUU2SRIkLyuqIOrMcAUAOooooAKKKKACiio1uIWZVWWMsxKgBhkkdR+FAElVL37h9qt1UuRkmsq3wl0/iMeVwjknpWbfTL8zdKv36bcgYNZqQxvzIAxz3r5TGN35UezRUbczIoLYyEEgb25+lRXMbRS7Djd2q88q26lt3QVji5+13TsW/drj8Sa8mvypKK3OulzSbl0LEBE+0pnaR+tcx8YdaPhHwNfXccgS8ul+yWuOvmOCCR/urubPqBXWeX9nVWiX5AOgr56/aP12XVvF2m6KD+60+ASuAc5klweR/uhPzNd2VYeFSt7621M6rbaUdmcD4V0yTU7yz0m24ub+ZIc/3VJ5P0Aya+qbm2hsjbpaRGO1g2wxKOiIF2j8gBXj37PehLc6/e63c4Edin2eAesrggkfRc/wDfQr3i6twI96mujOqnO1SXTVnRCahOwzT7yODKyrzXCeK/D6WMr6jp7H7DK3zr/wA8XPYj+6fXtXTSXS28/lSIQv8AAduQR6VpW8gc+TLbq0EvyOrYIIPqK5Mtx0qM1Rn8L/B9/wDMdSnKk/bQ3/NHkZhZpN0eEnHGD0b2z/WnsRdRGNwUmjPQ9VNbPiTRZNE1DyMs9nJkwSHt6qfcfrWOx82VI5yIrhOElHdfQ+or6aUXF2Z106qqRU46pnoHg3XF1WNbS+IGq244Y/8ALZR/F9R3qLXLbyfE+pMqcXlgzjHdlXgfX5K4u3lnguYriDCXls+5fTI7fQiu1fWLXXZdFvIsLJuaOaLrsJxkH8N2KqlCN5SW7tf/AD/zPMr0ZUaqlD4Wn8uv3aaHBMYZmD4KHqGBwM/417Fp18dY8P6deg5kdWik/wB7BB/8eUV5AfL80wsgS4ifYwPRsHGcV3/w1vVOi6lZFgLmCY3CR/7OF6fip/Os3ob5jHmpxqLo/wAzlPEEBt9bnH8Mv7wfj1/XNU14rpvH9qI5IbhOQG259VPI/rXMKelWyabvG5dhPSr0HSs+E1ehNSbxNCHoKnXrVaI1PmhDZITSg1H3qRaCWPWpFpg605aYyzHU6jIqtGasqeKtGUhrioXFTuarsaGKJBKBisy5Uc1pTNgGsm7kxkVDNUZtzjdXoXhi0NtoIUriR1xj3c/4Yrh7C1+3ajDB2dufYDk/pXqFnHtaGMcKoMzD9FH8z+FJu0Tixs+WKRxvxR1AQ3mn2o/5ZRtMR7n5Qf0avIvibfJbeEJFZz9r1OVbdUHZFIeQ59eEU/79d945vItR8SSyw/NEqi3DnoSpJOPbJI/CvH/ijdF/E1jYybdljaCVlBz+8l+f/wBA8v8AKqpLU6KcHTw0IPd/8Odz8BNMi0vQtY8SagfLgJW1Ru5VfmcD6sUH/ATWlql/JrOotfXibIlG2GHsijoD/M+9VLXNtoOl6QpxaWEQZwP+Wk7fPIT9GYqPpUZxMnmXBZLXqFHBk/wH86UoxUm1u9zahSs3Vnu9vT/giTO97u2sRDnDP/e9h/jVmxs57uaKz02IGSX7ueAAOrH2HrTeZRGiRFi+FjhUdfQYr0XRtKg0O0ZHkzqE6gzyf3R/cX2H61lWqwoU3Vnsvx8i69Z07Rj8T/q/yL1jptto+ix2kEgdvvSP3kbuT/hWV5UbX+9FUYAyMdyTz+lWpnRRl5Cw/mfSp7O1JdnABY/eOP0r5HEYieMqe0kZUl7CLbd7nyj8Sgf+FieJR6Xj19V6Fb+XpVhEi5dbeIE/RAK+XfHaLc+PvF74OI7yYfir7f6V9Y6ZItrPtxlUGwZ9BxXu5vb2dOMtFf8AQ543UE12/wAhGUoSjKvzeoqu8McxwRkH071dunFxMQnGfTtVIMbSaEP8yj5d1fPTtF6PQ0g3a63LCW5ij2Ivyn+BgP0rX0sR4BUVC0qzhSoFOtY2iYkNwTnGK9XCpQmnHVHJVk5xd9GdChAAxVhDzWfbNuAq9HxX1VCd0eRUjYnPalpO4pa7TnCiiigAooooA+V/g/4V8YWfgePxTpkTabdW2i6kioJZJbnUbktJ5G+B12rsIG3727C+uBZ8e+Lde8YeDNbsI01KaxPhS0mnil01oS+ofakEpUlAW44wvy8HHSvp+igDwGbxT4u+y62+m6nrN34bXV7GFdZk01RdQ2roxu2jj8oBgjBAG8s4DHrjNT6Prnj3V77wrpqavfWFpfXOrR/2lJpsZlntodhtpXR0ARiC3ZQeuDXdXfxb8HWuqT6e+oXL3cM81qyx2FwwM0Rw8SkJhnGDwuc/lWppvj/w1qUdi9nqQkF7YSalDiGT5rdDh2Py8EE4KnnPagDyzT/FPj5/iVdW91ceQkeoXEMelTQS+XPbAN5LIVtsDOAxkM+DyCF6Vz3iDVPEus/DzzpvEnig69DJb3Oq6eNIESWZFwilUIhDYUEnAZtwTJ4yD7TbfE7wveXtpbafdXl69zFDPutbC4lWKOb/AFTSkJ+7Ddt2PfFYvjL4waLo/h3Wr/R47jUp9O3KpNtNHbTOrqjos+zYSuexPSgDhvEfjXxVb+ONMi0XUNalso7jTomF1ZgR30Eqp5koRbYbQckljIpBOAowKZ4RbVdO1vw+sNltR9e8QyPJLYCVox5btGysV3oCcfcK7hxz0r16++IPhyx8RLotxeSi8+0R2jOttK0Mc8gykTyhdiuwPCk5rrKAPG/gX4j8S6zq2qW/iK41K+SG3RzdvEEtGkLHKxqbeKRGA/gO/juOM+r3R5OKumqNy4UHNYV3aJpS3Ma4G9zk5qtcW+xM/MhPcGp3kwScEEHuKoanf7I/myzY+VFGST9K+VxMo633PYpRk2lEoWYaSVjO24BtoJH61Z1O2VE3wneMcgdahs5kktoi/Tbg9sN3pZioBCuSPSvHnKKi1Y7Xfnv2KiaokFrLPNMotoEaSUnqiqMtx7AGvkk382uavq2v34zLPI0xHYFjwo9gMAfSvfPjZqsWj/D7UHhAF3qZSwRwOQrZL/misP8AgVeKeD9GOrXui6MCVF9cjzSO0Y5Y/goY19Hk1LkoOo+v5ImVnUbS0R7z8PdMj8O+C9HgKn7TcKL24IGTvkAPPphNg+oNd7HIs9ttyM+tVVeNJXRIlVXXKqo6D0qCGILIyg7eR8p7V4Fau6lWVTv/AEjTlTir6ND3VWbauDtOc1oW9iHiWQHBBFR3NqkdnuDjf7dqr2V6yviQYjRS7H2AzVYalH28YTV7tGVSUpU3KD2OP1DUFu9d1TTtQOIHmJiY/wDLNhwGH5c1g3dqVd4LhfmU9R1HuKZdtJdszscXSsWDdmz/AEqYXf2y3TzARPF8jZ9O1fXSlzano06Pskktv61KcLtvw/Ekfyt7jsf8+tanhYlLq+QYKxzRyhT2LBlP/oVZ88ZcpKvVflb3Xt+R/nV7wv8A8hi/jH3ntg4/4CwpwepOIX7tlLWRHJPevEcSJOzq/faxyP51reCGktPGWneY42zFoyy9DlDwfxArK1S3aLV75eSi7UYd1AUANTRNNH5csTATQsHSRT0I5FKW7B0/a0OVdUeneLNNE+mTQ4y0eQn06p+nH4V5lGcqPUcV7KkqanpFpfhQFuYV3f7OeR+R4/E15b4kszY6tJhSscp3Aejdx+dKOqPKwk7rle6KsB5xWjByBWXGea0IGoZ3xZoxnGBUymqqNkVIr/Oo9aSLaLS9aeDxUO7D4pxbmmQ0TBsU5G4quX+YD1p6NjNFyraFyM1YDelUUcCphJVJkctyZ2qFzSNIKrTS4FDZSgMupMA1i3MmSas3U2c803SdPbU7zy84hT5pG9vT6mp3YSairs3vBGnZDXkwwHyFJ7IOp/pXR65eSaZ4bv77IWeQfu/9ncQqflkH86s2lsu1LWNdsaYMuOgA6J/j/wDXrkfiZre6VdJgAdU2vMMZ3N1Vf5E/Ue9KTu7I8lXxWIUen6HB26TXEqQwJvy4VWbgEnivK7IDxP8AEF7mc77W81ID6QK3T6CNQPwr03X72Sy0PWL5v3Zgs3246o7Dy0Ix/tOtcF8L4lFzE5BY29tcTYHcsBCP/RlbU1ZXPVxDvNLt+p30zeaxMuNrEySeh5zj8TUwQSL51yMuR8qHoo7H61EELTCNsFEG+THTjt+daFoiSSme7/49ojuk55b0UfWszqbSV+xo2MsWi2cep3CB7qTmBGH3V6F/x6D8a7u4iaaZpMDBAPI5xivMZrh9V1BJrjGwsNqjoB2AHoK9VeZUaTkDAwQa83N2nQUXtdfkzgrRcZxn9pp/poY4soTdeZIpLDGMngH2FbFmuyJi3B/nVW3iku1ZlXgGgmbckZOBuCknjAzivnaUXHW246knP3W9j5djiOreN9ajkGXv9XMZA777jkfrX1PcpG0jPuyWJOBXyt4FnXUfHenzKSoudZilHcgGYNX1Ta23msVjySOp6V7md6uEEr7/AKGcfdSbfQbHcRQx4VPmqGKE3zlCNwLZOD0xTdQsZg+FuHQZ+ZQBnHsasWTNAgSBQAOOK8G9pKM9jR2UeaD1Y2ffp2MFiucEZzitOweS4jV2G0MM88mqUsfmHFxht3GBVzQrhDEh+8ANv4jiuzCWVS2yOetrTvbU2rYlSKvoc1RRgTkdKvQ42ivrMK9LHj1e5Y9KdTR0FOr0zkCiiigAooooAKKKKAPPrD4Y2dnrVrqK6hcM8GuXmuBCgwXuFKsn0GeD1rJg+DVvZ6VoNppviLUrKbS7K405riKOJjcQTOWZWDqwByeo5/mPV6KAPI0+CGm/bNAml1e6K6PHbJEUtoY5j5IAGJgvmBTjJXJ6nGM1ZvvhCs/hjUfDMHibU4PDd0ZGjsPJiYQM8vmnD7QzKG3YBPfvivU6KAPNb/4SaVP42n8R29wkUtzcx3U8U2n21wfMTHMckkZePO0ZweuSMGuy1zw7Za1LFJeT6pG0alVFnqlzaAj3EMign3OTWxRQByh8B6R/z+eJP/Cj1H/4/VK68F6ZGflvvEg/7mPUP/j9duazrzAzu6Vz4mTjC6ZrSSctTibnwtpyJhdQ8S78/wDQxah/8eqnb+F7WR2Dap4kAzwf+Ehv+P8AyNW7e/LM21jtHb1pgVvLLgj6V8niMbXVSym9PNnrww9NR2WvkcnqPh9IZQIdV8Sfexg6/fEHP/bapf8AhFzMv7vWPEanvt16+P8AOatDUZiCjHJBcZx2APNaFldm3OCAVPQ+tcCx1dy1qyS9X/mdksPCME1BX9EeCfGvVdT8M6loml6PrviO1upIXuLlxrl4+9S21BhpDj7jnj1qz8LW1rxD4ivEv/EXiWaxtLRWZBrV2oaViAuSJARxvP8AwGuM+NWqf2t8W9VK/wCrtDHaL7FFAb/x7dXq/wAB4Ps/hm/vdo828vWycctHGoC/+PM9fTYmtPDYO7k72363Zz06MJLm5Vq+x1b+HB5gI1XxIqDjB1+++c/9/uKcPDsbygjVfEioP4R4gvjn/wAjVt3d15ygdMdfaqtrJIPvKRyWXI6ivl/r+Ibdqkrer/zOhYaDjdwX3Ionw0gP/IU8Sfj4gv8A/wCPVWvNCjis7xv7W8SLJHCzKR4gvjg8AH/Xdq6g3aNAVKjd6+lYusyD+wNQkdtu8LEremWFd2AxVaeIjH2ja1e77GfsINawW6Wy7nnbLe22XuLzUL+If8tLq9muSn08xmK/hUqgS/voSBJjBHZh6UFp7MhnIZDxvHQ/WlYL5iy2wCK3DoOgPqK+hbb1Z68YqC5YqyGvMAoY5CNwT6H3q/4aBHiRNvJktZVP4DNUdqsWDDlvvKfWp/DZa38SRKpLR+TJjPO3Ix/hTh8RniNaTF8QxSSeJb6SCRVYgfK33WHPftVFJXdTbMv2eRV5BHJ+nbHvVnXpmg1+VsZjaNAxHY804+TdRhZRkDlGBwyH1B/p0pz+IdC6pqx6b8ObyO/8KraOvz2pMEqnuDyD+IP6GoPFmjfbLWRDzMmCHPc9j+PQ+9cRoUmpWfhfxVLYyH7QiwruTg7ctlsduD1+tTfBvX7/AFe0n0/Ui80kW54y2cgAruT9Rj0I963p4WUqUq6ei6HzVessPjHBbP8AUx4yVkKOCrqcEH1q/Aa1fGWl+RN9shXuBJjuD0b/AD7Vi27ZkP0Fc7R7VGXMrmjbtnPtT1fNyB2AqrE+12/CpbMl5pG98UrHQ9S28n75fQ1IW5qpcNtlTHTNSO+FJoElqLHLvucf3amEy+a49BVCz53vUdu+biXJ9BQUagnzIqipjLtcAmsu1YteHHYU6WQm+Rc8DrUlKJp+Zmq1w/ymmySFWUDvVS6lOSoyT0AHc0XKnZXEtrea/vFghHzHqeyj1NegaNpq6fbRw2qhpm+bcw/8fP8AQVW8P6XHp1jvlMYmfG93OAW9PoP1rz/4ueKdd0TxDZ2mjSvDCyCXzF/5bH1JHX0x046V1YfDyrz9nDc+cx+NUdFsexKINJ06SSaQ+XEGkllfknuSa8Ou7iW71O8v5mKySSvIqnsG6Z/DArqfE3iWfUfC2jwTZSe7BknUDl9jFVAH+0wzx6VzK2yJvl1M5LfdtVPT/rof/ZR+J7Vg6bhJxl0O7Kqdoe2erl+RyfxCvmHgO9kjQmK8mgtd/TPzGTj1/wBVj8ah+GNqItJvLnHJ8mEH2G92H5+UaZ8Wroz+HbNdy7Wvl2qOAAkb8AenzirvgjP/AAiVpApAee5mkJHZcRp/7IfzrXaJ0NOVZ37/AKGvZSFhMxP3n/QdP51YLFotrkiFTnH95qhjAQyEcLu4/IVc3C2iDPxL1wf4f/r1id1rhZmR9SsothUzTIoz7sO1el3fzLI57HNcJ4Uh8zXLW4uQd27cinqAATn9K7mX97IQeE649a8XOpWhCPm/0OWq71fRfr/wCayuWiQ+Ucg1V1KeaOOSYKflRpM9RkAkCtO1ERhLM3I6CsDxpdfZvCuvTx9Y9PuWGPURNivJoJupTV92vzOaUl7zSPm34NDPjTRF7ibcM+ysa+q7K8+zsQeDXy98B4kk+JOjLNzGqzsR9IHr6hm8ky4C59zXqZ3JxqwaeoWT91roFzdCaYOcYHJPtVKzlmMYLxOOPvDv+FaKRIACQNvcVYvXt1hAj+9XjODmnOTGpqPuJGStwZ5WiTevZmbgj2ArVtbFbRAYAY88leoNZVsw+3SZ+8ApP610ULGRR3HrXTg0nuTiZONlHY07NNyfMc1ehGDiqFsSCoHStGMYx619fhF7qPDrblhelLSLS16ZyBRRRQAVT1i+GmaZc3rW9xcrAhcxW6hpGA7KCRk/jVyqOuw3lxo95Dpr26XkkTJE1wCYwTx8wHOPpQBy/h/4m+GdW8NW2u3N6ujafdM62zatJHbtcBACzICx3AZxx6GrSfETwrJ4h0zRotaspLvUrf7TaMkyFJV3bQA2eWJzgdTg+lcZ4N+FepaVb+BLfWL3TbuDwxLeHbHC37+OaIquQ2RuDsT6YA703wh8JtQ8NXfhaeDUNPlOmW93Z3StA3zRTXJmBiII2uoOBnigD0CHxt4Wmmv4ovEejtJYKXux9sj/AHCg4JfngAkAk9DxTbzx34SsoBNdeJ9EijO7DNfRc7Tg4+bnBIBx3rySH4D30Gg3ekLqdhMi2M1jaXkpu2lVJGDYMZmMSDPXYgyQDxzXcar8NobvX7O9hFhFaQaJcaX9n8gY8yXb+8AxjHBz35oA6a78a+GLO/srK68QaVFdXqJJbRPdIDMr/cZeeQ3Y9+1O8KeJrbxJJraWsM0R0nUpdMl8zHzvGqEsuD935x15ryHVfgn4gvdFs9KPiO1ks4LGytljkWZVheBgWZFVwjb8fedWI6DHWvUvAfhibw1L4mae4jn/ALW1mfU02Ajy1kWMBTnqRsP50AWLTxx4VvJ76G28R6RJLYo0l0ovI/3KKcMzc8AHqeg70tv428LXNnqF3b+ItImtdPwbuaO7jZIM8DcQcDJ4HqeOteSSfBPxBdSXT6n4jtbyd9OvbBbiRZi7+f8AdZlZyiBRxsjCgY79ug1T4V6k0+oz6FrFvpc9zpFlp6vDEykPBJuZiVIIDABcqQw6g0AdY/xC0Ga98Pw6VdxapFrN1JaRXFlKkkcbpGZCHIPHA6deRW7f8g15X4T+Eeo6Nr2n6lc6lZv5Gsy6o8cQlOQ9uItgaRmYkHnLE5r1W9ODzXNivgNaPxHLXxKSkNjB6HHeqUsr4xgitPWJoihAXLVgA7G3bcA9PavhsckpuzPo8OuaN2iSeCSWIKu3GOppunXDJcwW1yCGLBM9QRmtGK4i8jbjmud8ZXIsvCutX6Eq9vZzSIQcYbYcfriuWlTUqkIp3u0a+091qSPk7WtQ/tPxPq+pg7hdXss4J7hnLf1r6l+FmmC38C+Hg/yt9mMvBxkyOz5P4MK+SbRcRKO5r7btII9P0+106DhbOFLdSPRFC/0r6fOppUku7MoJxhFL+v6uN1FTCc9QDkr61ZgkSaIA4KNyDVdpBJOkYO5j1PpWhDZloSVIVVHAr5qmnNvlRU5KMUpblG8tQp/dssmay/EaQR6CsF8rsk84H7ptpXAyOorVeTy2BbkBtprnPH92Lax02NlY+ZI7kgZxgAf1r0cos8Q5JdH+gO8nCEtr/wDBOej0uZG/4l1yLuPvC42SY9MHhvwP4VSeEBybVGjkX79u3BH0z/Ko5boShWt5T5g6bT/Sr41B5YkXV7Riw4S46MB6Bu/0NfS6M7XzQejuvx/yK8LRXCfNlT2cdVNaXhOMp4ikE6qSsHUcgguvNUZ7VY5PNgkDxydG6c+47GtHwopkvtQk5DpbhR7HJI/lTp/EZ4pr2TaZW1idI/ELfKuXgRtrd+TVLUIFheG4sxthk4ZOyt6Cp9egW71y4UELJGiqh7qeTj9aqW9wZIpIJflbow7qR3qZ7s1oL93E3/BGofZPE1qrgGG8BtpARwc9M/iAPxNO8d+KIPh94gtrTQtOgjEyhpiVLls5O3k8KOOBjrXPXE0toILqMqJYJFkU9sgg06Ff+FsJuuGistas8/N91JEB6Hg4Iz6cj6V35fTTvOp8HX/hj5zP4qNWLju0eltNB4h0CO6gBWO5iPB/gzkEfg38xXmtrIyzsrAhhwR7g16jpWm2+l+HbW1tbmO5CK4aSNgVLEhj09MAV5bJJu12/bs08hH/AH0a5KiipSUNru3oduWTc6a5i+WxIDnhhVrSDlmJ/vGs24fDx/WrelyhSw7bjWfQ9S12WL9wJM9hzSTyYgzUOouPnI6AVHM/7pffFIC/bjbbE+1UIm/eyfhV8MBZ++KyIZcTvTDqadocTOw7ACoN+L0nvVrTVzAWPVuaz52xfnHpUGnYuiUvPk/wirnhuD7ZryEjKwqZOfXoP1OfwrLgkG+XPXArpPh8gN1eyN/ejUH6bjVR3OfFy5aTZ5n401fUfE/jFtO013WGJxEm3kgZwMe54PuTivZPDVrocdjY+Hr+SzvdStkZmidRJsYksyg4xxnp7dK5ebwAvh/T9W1rT7t7rUFi3Rqq7ShwASSCeQuT255rkvhTZ3dldX3ibUxIUsomba3G5yCqoPTJb/Oa96s6VbDt05WjD8+n5nxEVN1bNXcjovF2oqninUmjKRpAEtUwANqqOQPQZJ6Vz5hmugskuY7c8jsz/T296ss3n3U19dIst1PIZTu5AJ9BSzzEgvI2WPrXgXPvqFL2dOMOyPOvitGsNpoMcYAUzXTYH0hH+NdT4SCp4R0chcNJDIzH1/fyf0xXGfFe6El5osKrgJbSTbvUtKV/9p12mi5Tw5osOcE2qcnsGyxP/j1bS+E5qetR+rNGNdsYuHHyg4jH95s9f896kQhG3TgM45wegPvSRZk2S42xrxEp/nViztp7qXyrKAzTdSey+5J4ArI6r21Zs+C9t1rMrfM7Rws2QDjJwOv4mutkbLZjGeMGsrwnp4sGvmku457hkQMIzlU68bu5rctWjVPnXII4r5/Ore0hHy/U4ZT5qkpen5FaFZHbYm4+1YfxPjFt8OfEMjjLizZVGem4hT/OuiVik26NtpXniud+LKyP8M/EbuCf9F6n/fWuHLor28O90Z15PlfY8U+AlqJPH9szD7lpM6/Urt/9mr6Mmikjljwo8vn65r57+BLND45sSAD5lnMPy5/pX0d5gnLebwPSvQzpJ1o33t+rK5mpX6Ak0bW4RzhqpzywwguxJA9aZqLmKPdHIMggcgEnP9aqwWpklEk25sYxv/wrw5N6I1p0425m9CTTMs7SMrB3zyR/Wuk06ciPYaqQxIYyd3NSW5w/GCfeu7CRcZJ3OavJVb6G9bnp71oxVQsVDYJOa0YwBX2WFXuo8Os9bE4opBS16ByhRRRQAUUUUAcX8W/EupeFvCYvtFFh9skuY4Ab2REVVbO4qHdFdwASFLrn17Hy5fjHrFzYWBg1XQrNJtMvbxrzUbB4t8sEu1YwgnK5YcZVn55GcYr6AuraC8haG7ginhbqkqBlP4GsS78H6Ld+ILPV7izje5s7VrOGMqDEsbMGPyYxnKjB7UAeF3fj3xhDe+I/FGnNZ2/2fw/pepXOnXySyIC4YssYDjYTk5JyeB9a37vx9rdn4i1S30S306O5vfEljpSveG4nRUmtDIW2+aACCo4QKCM5GTmvbZrG0mMxmtYJDMoSUtGD5ijoG9R9ab/Z9kX3/Y7ff5gl3eUud4GA3TqBwDQB4pbfFDxG6afpeoXWhaZevreoaRdazcQv9lj+ygFSEMi4eTOAC+PlP0rNi+JPibStX8d302r6JrMVhpdneWdnbI6pPujYmSDMhPlj7z/eyMYK9T76+nWUkEsD2ds0MrmSSMxKVdicliMcn3pyWNokyTJawLKkflI4jAZU/ug9h7UAeFaf8VvFkmnxqqeH7m4uNY06wtp/MiYNFdbwS8cFzLsKsnBLcj+HINezSanLpGjWk2vCSa7IWOY6ZYzzqZMEkqiB3C8Hk+wzkirUWladCgWGwtI1EgmwsKgbx0bp94evWrtAHMnxppf/AD6+IP8AwQX/AP8AGap3Xi3SpAcwa6ProN//APGa7FulZ15kdBnNc+JaUNUa0r82hwF5r+lu5wdVGezaJfj/ANoVTk1rTWXBl1BR6f2Jf/8AxmuweJ/Mdnxz0xUF/LFFakEAGvk8T7HWUofiz2ac6mijL8Djv7Z0wdZr7P8A2B7/AP8AjFY/j3VdMuPA2sWrahNZ+fD5Qnu9Kvo4U3MB8zeQceg9yK7JImlMcoHyKM89T+FcB+0TfR2/w0S3Bw91fQx49QAzn/0EVll3samIilCz33fQ2rupy25vwPG/DfhrSm1zTVPinSLpftEZaC3tb95JFDAlVX7NySM8V9INrWkuzssmoq7nJK6Nf8nv/wAsK+evg5ZrcfEDQRwNhlmJP+zGzD9QK+nzblfmUZau/OKkOaMZRv8AMdprTn/AzIde0WPn/iYA9iNFvs/+iKlk8VaXsKRy6iCfXRr7/wCMU653mNjGWWQEcA9ea0NKjjVAlwSGxznrnvXkwrUvgULX82KdKSXO5X+RhWuu6T/y2kv5HJzxo18R+H7isfxjqenXX9neXdXNu0Xmc3Gk36bgdvT9xz05/Cur1Jfs0m9MtHnOV6j8K5fx5d/NpWNzjymkBUccn/61ejlUqftJqMLWXe/VFRhUlUhJS3fbyZzM93opwLnUod3bdpt8D/6T0kGoaRA/7vXF2H+BtPvj/wC0KJNSSaPypwXT0YdP8KhhCo/7lg8R/gfnFe3ePY7/AGdX+f8ABFoXej/8stVAX0GnX3/xitbw5f6VA2oOt5PcGV4l/daVfttA6g/uOCc8Csi4SExGSONYpV5+QYDfUV0Hhh/svhTUb85Ad5ZB77U2j9a0pON9EcuMhUULOW7XQ5me5sJ9Qub1NZQxyOW/5B1/hQOBz9n9BUs0+i3aBn1UCfHEsem32T9f3HNUtJle3CwzDkrke4q3NZtDmezBaPq8Y6r7j1FQ5RvsdKo1FFLn/AzbppJE+zxlp/M4idYnTzPorqGH0IBrQ+KNvYeDdlloKyRX+oJunywIUHsOM9j1z29Tl0GoPbywXtm4FxbuJEOfTsfY9PxrtPF3gyHxZrWj67HcCOKaNDtbOVG3dkdjwOhxyO/SuvAV40qt5u0Txc+pTkoWV/M5n4cafqGhaBf6pqUshieJgiueXbIPHsMYz6tgVhaeZLm9bDDzGy5J/M11PxE1ne0Wl2vyQRKoKjso+6v9fyrmtDjPmSyDpgLWWJrutNzZ1Zfh/q1FJ7k1yXjuUR/TINW7DzJGKQqXbPQU3Uo2PlSgZC5B/GtXRYjb2ZZhh5Tn8O1czdkd6nZXKF+k8ULedGykjAJ6VA0n7uMZ71u6qPN0y4U9QhYfhzXP6YvnX1opyQWBI+nNNO6HGd1dmjJHdpbb2iYRgZ/D6VjGTDuc9K7IgmXnv1ribtRDNdqOiuyiiLuEZ33Om0y5jWzTcRnFZUsu7UAc8c1uaRb+TpUUbryyAvn1Irk1kzczDP8Aq8r+tSlqWpp7GvaqXWd/VsV03gpmI1C3jcRzErsYnuVYA/nWBYhodL3bCUI5arXhK6X+27hAcMYgwHrg/wD16cH7xGKhz0eU868M6trei+NiiyziUTFTFjhlz0Pr6f8A169q+K92trptnpsIWNLmXewUYyEwen+8VP4Vi/EfxTF4Ve1lsNItJtSlkYi5khBKjJxg+vv9PwyvGeot4im0a4GIZxaHz15wrbyOP++SfpivTx85V4Qr8tlsfL5VRSxfs3rbUyridIF67m9BUItJpWEl5lE6iLoT9fSrVoi2mWUbpv8Ano3UfT0qGaVnfZHlpD+leWfY631PNfiuE/trSI4027dN5x3zcTf0xXf6Tb79L0lmQmNbC2AX++TEp/LmvN/iVKzeLGhZ932aygjHoNyeYQPxkNeu2kn2HRtJtbeQm8FlbrM4H+rHkoNo9+uT9Petp7HDRfv373/M0ltoLGPzNSdZLkjItlbhB/tkdPpUUurmSLyElSOEdIo8Kv5Dr+NUQVUhWVTxwCM0syxSR7ZI0x/sqAR+VY3O1Qtq9Wdd4ShH9lSz85kuCCfYAf1re2oMbB8x61jeEYseGrWMMSrvITnv8xA/lWxBiKQhiSQe9fMZrJSxLXZJfhc867bk/N/nYZNE8QZgCWYD5T7elZHxCu0uPhf4iQgEfYZD+mRW08zT3AVfvDoKx/iFpSQeAPERUBT/AGbcNweuI2P9KywClHERlDa6/MzrcvJae54p8DojN4xsMOUKWM7Zx16D+te/NHK2VLBcHG7HWvn34KTMnjTQwnSW0uEb2wjN/QV9EEvIAI8YruzuN60X5fqzRNplD7P5c4ld3kONqhux9vwq87sYseWRj35pjnEqg9VXP49K1Ut4/sKvkFjXkU6bm2l0Q6tW1nIxkkkPRuPpWtpqHqysSaoAbLkD+A5Oe2a39JjV49xPNdeAp3qJGOJqcsbmhZjGMVpxA4qpEuMGrkZr7TDRsjwaruySlpO1LXac4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAjdKpXYyPerx6VUm24O6ufEK8TSm7M5y/uvJO0qcnpx1rJvLSa6QuWO0c7QOPzrW1FVknUE/cBb/AAqATywKRtypr43FpOfvbHuUZOCThuULe4VJGEn3T0rxX9p6aMWXhu3iY7ZZ55SMcfKqAf8AoZr1+/jkdzJbELJ/dbkNXhH7SMrjXvDtnKyl47WSchRwN77f/adVk15YheVzetFWTT3ewfAa08zxbcSMAVt9Nds+hZ0Xj3wTX0NpsxkXazZYZFeD/ABGbVtdIwCtvFHuI6AsT/7KK9pET2Mi+U7SIxySeuT1NVm039ZXkl+ppyKScb6lm7Xy5i38KkFvpUivGR+869mFRs0l0NoA/wCA81DIridVD7B3GAc/nXlT7oErqz3JJGUMMEkE4BPqa5Hx3NHaatFJcyxWtlBbIglnkWNM5JwCxAJ5Fcz8XfiGfDN4mkaERca6VDu7gMlmD0+Xozkc4PAGM5zivEbqx1bxDqhudWuLvUNSl52kNLK3sFHQew4FfR5Pgp0oSnU05rGSqtTUqetr+h7SfFvhwEq+taYSOCC279QCKhOreHLwg22t6ZC+ev2pEB+ocivMB8OtbeMFdJu0/wBmVFjb8iQaIvhrr3Jm0W8Knp5QDn8gSa9j2cTZ4mrvp/XzPVY5fNBWCSG7U8LJayrKrf8AfJNdZcWtza+A0sYYJpLlrfLRIhZgXcEjH5186y+A7+MnzNM1aMjruspBj9Kz7rw5Na/diuww9YXUj9KqMVG9jOpUqVnG62dz3220m6u4Fja1uI5l+6WiYYPvxRGLm0O2+j+ysp2kzMI1P4tgV88R6XdEkPFdAHr8jc1ImhyMRi1umHciFjUezidH1ir0SPada1LRY97trGlxTDkmO6SQN9QhNdUfjN4H07SbKyt728ujb2wh/c2rH5toXq230P514Np3g2+uBlNF1eQf3hasFH4kYrZb4aeIriGM2Hh+6XcAQ8siICD0PJHFPkicuIvWa9o0rHZ316up38t3Hu23Db0DfeCnoD+GK1bBPJhC9+p+tZWk2zW0UaTx7LhFCOMg7WHBGRx+VbEXSspGrnfRGtaMCMEVbGao2fatJB61ky09BCgkRkb7rAqaqaXpP2KcSNJ5hUELxjFaagCpVANUnbQV7ERB3ZrBm0KSXUndmX7O7+YfU+1dMqg1MsYOKa0J57EGzbH07Yrz17eQavPa4IklmODjsTnP5V6g8QKYrNuLdVk3hRvxjOOaL8o6ctTOvgsOmSogwqR/yFcxoeqRafe/2ldMy28e4yFV3EIF547+tdfJGrxukgyrDBrkpfDst5LNpttcrGlwjorspbZlT1A60QZq5Kz5tjq7X4nfDvV1MGpanGBuVkFzayrtIUAndtwOnrWHrOpaTf63eT6XqejvaMUS3WO9hBCKgGNpYEcg9q4e6+BniONv9EutLvQQCFWZo25BI+8oHb1rnW+HmtNgrpcEi7c7o7+Ag/m1b6NW6HDh6UaVR1Kck3br/SPUI4bm6YLbCIp18wyrt/PNUrzVNE0WKVrrWbJnA/eCCZZpWx/CqKTz9cD1IrzQ/DrxAx/d6Tgf7VzCP/ZqktPh1r+/5raxhIOC8l9CdvvtVif0pKETtdao+qKojufGfjRBFB5EmrXSpHGDnyo+AMn/AGVHJ9jXrU88SazqPZftDhfYZ4FTfDHwla6E7X5uft+rGZYDMEKxxKRyI88892IHHGAM5ltJnU3IDctM5YevJpVHoPCp8zS6DQ6TRhZBuXsw4I+hqrdl7aPIPmxHuByPqKkZI45jtYxn+72NOnI8o4ORWR22PQfDW2Pw3pTpyGiL/mxP9a0bqRJRkJhgOxrL8PI0fhrTG/h8o/gNxIrUV4zH935j0Ir5XMm/rM16fkjyYL7Xm/zGWqCFsocsecnvVfxckk/hHXldwC2nXKgfWFhQvnG4byk3R98nHPtVbxBI39i6pGY3/wCPKc5LcY8tqwwkmq0V5r8yq0G035Hz98EmH/CcaBuPBW4T84Xr6glCQRbtvQV8qfA6TPxB0ENnaPOP/kF6+nNRuXuf3Nvy7DA9vevZzlpVF3t+pKi5yS6WFCtOplxy36D0qaIzkCMDA9TVa0lnjBUptfup6Z9qlmLhd5Dk/wCzzXg6b9TSSd7FtwsMQUkMTVvSvMidgqkx54OawbWY3M+ED7VOGdxjn0ArrLIxJCqqMn1r0sClKd9rHLiU6ceV6tmrbsCBVpKo2w+cE9DV9elfYUHdHh1FZjxRQKK6zEKKKKACob6VoLK4mQAtHGzgHpkDNTUyaJZoZIpBlHUqw9jQB4p8LPip4k8R+Gr/AF3V9Pt7qG2szciz03TriGRiHwdksrmOT5Qxwpz/ACrR1j4wSTaJpOr+EtDudR02+1uDSop5isQuQxwxiDOpB3ZUFsLkHOBzXQaT8KfDWk6PeaVYHVo9Ou4DbSW/9pzlBGWDEKC3y57lcEgkdzVmT4ZeF20u406KyltrGW8j1BIba5khFvcJ0ki2keWeM/LjnmgDDHxj0s+NI/D/APZt5u+3Jpks4kiJiuWA+UxhtxQEhS4GM+o5pkHxjt7nRdN1O38Ma5Jb6lfrptmcwL9omLSrhcydAYSCWx94e9beqeEfCmg3Nx4mu5bzTo4Xjurt01G4jglePAWSaNX2uRgZJBz3zzSz+F/CWieGNCt51MGk6TqCX9iWlc7bh3cqSepBaZuDxz7UAYNx8YraLw0upHRLhLxL6406ewmu4I5I5ofvqpLfvOo+7n8BzVvwb8QJfFXj2zt7EFNCvPDUWrxxyxgSrK1w8ZBIJ6BcY6VqXnww8L3UnmPbXcU/2651Dzre9mhkElxjzgGRgQrgAFc44qzo3hDw14OeHU7VBZLY6cumiae4OyO2WQyAEscfeYnJ5oAxdd+Ktho3j228NXNhLIJ7yCxF1DcxPslmC7N0Ybeoy2MkA8EgEYJr6R8XrTUdW063bQdTtbDUJ7q1t7+Z4fLeaDcXXAcsBhD8xA/mRt3fw28MX2vjW3t7r7U17DqW2O9lWBriPGyUxBthbgc45/E1Knw48MrZ2FqbBnt7Ke4uIo3mcjfOGEueeQQ7cHpmgDzjxB8cWufCPieTRbE2WsabYx31vI8sV1DJG0yxkhkYgkEkY6e9ez3mccAEmuLT4P8AhBLG7tGtb6WG5sU05xNfzSkW6OHSNSzHaoKjAGMD8a7a5rnxGsTSluc5fW7RSGYMzORgg9CPSstrxWBCSfgQc10GpNmEqfwrnrcKsknu5ya+NzBWloe9h3zQvIqJc77pkAYfITlhjJ4r51+PM/2r4nxxjnyLOGP8yz/+zV9RXVtbmNXUguOh7ivlH4sSi4+MOsheQhgjHtthQH9Qa6cmouFaTfb82aSnGo42Vjv/AIAwlbDxNdNnZJJFGD7qrk/+hrXrQZWsvM3FZVAJDDGDXCfs/wBpH/wgNzLKQDLqMrqPUBIwP1Bru5JVEyqwBy2Afw4rjzWX+0tf1sbRd20ujLdleGNQ204YZGRyK4L4veNH8I6Is9oqtq18zRWat0QgfNKR3C5HHckds13kbQ+S7zyLHGilndzgKAMkn2Ar5M8Z+IH8YeLr/WnLfYIv3NpG38EKk7fxJyx92Nb5VhXXlzz+GP5mE9ZcsdG/yDwRoF/ruux2tmfN1K5LTTXMxLCJerSMe55+pJA6mvbLyytvDtzLpGnLsghCB2xhpn2gl3Pckk9enQcUfBvSYfD/AIdS6uYwmp6kFnlZ/wCGI8xp7cfMfdvYVY8XwW48TX7XUjEFlIXOBjaK9yGKVac4L7Nl+Z00IuNZK2ln+mpmPd7RzJ+tNW4SX7r7j7VXmeyXHkCIe7Dd/WofMRuPNYj+7GmKux6Ny406oyoWGWYAD8a6bxwjpYwNDIyPJdEggkYwZP8AGuQn3Jau0UCwgDO5jlzXbePD5mg2kqDmGQM/HPIP/wAUK1p/CzgxP8Wnc5NNTvrRV8+a5Udm3tt/OpZtU+2RhZ5nkHYlzkfjVe31bylKpJgdweQfwqC4mspfmMEZY/3F2/yrO518qvshs7LFE/lyh0wcrJyfwNereHFZNHmgcfPb28cec+mB/QV5A8SvLGPKEQZgoznPJx0r2HSmZ4NUkXhCygD15wP60djix2sV/XVHllwMaldj/pu4/wDHjU8faotR+XW9QTBBW4k4P+8akh6jNORzxNK0PIrTQ5ArLtu1acfKismbIsRjNWEGKrxVZTpTQmOj+9irkK1Sj++Kvw1SM5FgLx7VSuUFXR92qtweDTZMNzJuxhc1xHjfUbrS9GvbzT7yWzu40HlzxNtdSSBwffOPxrtr37tZmmRR3GuxxTwQzwlWLJLGHUjaeoIxSh8RtO1tTyDSviv48iQxnVoLxCNuLuCNjjBH3sA9z3oPj/xJGozZ6IABgYhx/J6968R6DoVtbS+RoOh7jbeYrjT4Ttbaw/u+oBrgRaaddKjxaRoeGUZBskHP4CtvaLqZ4eiprmpq3zPNpviL4iZ+IdJQYxj7KCPrySap3XxB8Uyx+XHe2dtH1xb2ECfrsz+ternSbQ8f2do6D/Zs0P8AMVZtVtLDDQ2lirDqy2kS59jheR9aPaJHR9Vb3/NnCeAPijqNhqUVr4jliuNNuJFD3CQIktu3Z8qBuGTyDnjOK7NLKeCR0R9k8bFHRjwSDg15H8SrGGx8Y6lFaQpBazLHcxxoMKgkjVyFHYAsQB7V7VdR3Mt41wke/wA2OOVgp53NGpJx9SaKmqFhbRm0tmiuk6s3lXcQDjqrU29tUWIyWjMh7oWyp+hqWREuotsgIYdD0ZTVVorqJSoxNH65wfyrE77X3PTPDoL6BpUIbj7OrN+JPFWri3WOXYrdDk7eAR71neEufD+nsSRujdfoQ7f/AFq0lKmRwW5B5r5XMv8AeJ33v+h5lP3b28/zNK3lt4rXBA3Vy3jG5+z+GdeuO0enXLDjv5L4/WtaRo0BLEHHc8CuZ+JNzHD8OPEk5OF+xvGD/v4QfmWFRhJOpXpx7NfmRKHJCUu54f8AAKJn+IGnsOkVvOzfQxMv82FfS9su5pJIQMA4JJ614D+zpZb/ABVezMMrFpzY+pkjH8s172ERE8tWYIeQoPT2rvzqf75Ly/VmqXT0HRTGRdxONzEfkcVtHyPsgxjdislbEpB8gAjzlR6UgjmxtLD8K8uE3Tvpe5FSMZvR7DjIqyLkgFiRz3IrcsHAHCnNZFvpv2ll3nKJnj1PrWgkAhUopYbe2TiuzBRkpKZhXcJLlT1NyFixXbzg81oRnIqhYgBB7VfSvsMN8KPFq72JRRQKK7TnCiiigAooooAK+f8AxboPi6P4j6rq9ra6lNpuZJTcXdz5cVrCsJ5gaOfJy3/LNoevU9x9AUhAYEEAg8EGgD5Z0bw54r8T/D+6utNsdY+z33hZLeb7dfib+0rwujLJGrSNtAQNydvXGK6rUfBXivSpvEFp4bXWPsFwdJmg3ai0h8xZf9JKs7lh8o5GcEcDsK97RFjRURQqqMAAYAFOoA8Kl8HeKT4gfWl/tf7dH41WSL/iYP5Q0k7N+I9+zafm4xu4xWPd+A/EmqeBte0nVdE1u48WTWtwZtVfVh9lvX84PEqIJehUDCsihcYPWvo2igD5x8UeD/GF3PpzadZ+JbXSV06OKzhgvFlubG5V2LF990oy3B3lpMLhcDGK9I+GPh3V7XW/E2reJJtT+0yarcCyimvWaH7KyxFWWIMUHzBu2Rj0r0aigDndTu/Fcd7Kum6LodxZgjy5bjV5YZGGO6C2cDnP8RrOlvvGg+94d8O/hr03/wAh12Z6VUuVJBx1rKrtoXDc4K91DxUSTJ4d0P1O3Xpf/kOsFdQ11JWi/wCEf0vLfNzr0mM+3+h16DcJuYisHVrVJFKkDdngjqK+Sx9VxbfKn8j2sLGPwtsxY73xEcY0HSce+vyf/IdfPniDU9Hn+IOuS3nh6/bUlvJknMevJ5O9SVOzNnnbxxnmvoUSzwsI2IdidoDdfzr5YnP2jxh4gm5wbq5k9f42rpyWt7TnfKla23zOiphuWavJ9T3j4ZXF+ngeyfQ/D9v/AGfI8rp9q14+bneVbO2zx1Xj2xXRx3Gt3BB/4R/S+DjB16QYPr/x51W+FbpbfDHQYHTDNC7/AF3Su39a37VSbl9rYyoyMd683GYhfWJWgm/QuFJ2b5mjgfir4iu9F8JzRa7oNuLbUj9i/wBC14+cdwJYjdZ4xgYJP973rzfwhpOl61eW+mWHhu9IKG6k8/X1ChF7OVss4JwvHdh0q78eNTbW/iFYaNCwePS4QjAdBNJ8z/8Ajvlj6g12XwL0OY2Wq6wwG2ecWsWTj5Ixlj9CzD/vmvfpc2Hwt6cPeavZLq/I54RWtSUmvmdk7a9Ihm/4RzS0Vuw15xj8Psdc94plu01dZNS8NWLXEkSMCmvMV2jgdbPrxXopDgeWZECd8HP8qxfF+l2epw280zXCtbjZmPAyD67vf+dYZbCqudzp8t7dLagqkVUj7za12ZwSXzFgh0S2tFPWUap55X/gH2ZM/wDfQx156U5roswSJTI56Ki5J/AVppZaTavhUE79g8hlP5LgfnUs+pvaRtFaRRwI3X5VX/x1f65r0Gl1Z6lOc0rQTfqyK200wIt1qRVWXlYm5CnsW9T/ALI/HFda/lal4aWOeX53UfvG6/7LH8+fpXn0kk19K2wPO46s33UH16Cuk8FXKRpNpryxySIDKhI4xzuX6c5/E1cJdEc+KpOym3dp/cc1LcT2Ny9tcWiCeM4YFAc+49QfWnGW8uuQkcSD+I4UCu71TSrKWJVu1Vo84UygjYf7oYcj6cVwnjddC8I2yXGrXM26VS1vZxXAeW4/3cL8q5/iPHXqeKn2b6GkcbC15bkFqsC3vnXNxGtvbfvri4lbbGirzyT0ycD1Nc/4s+Ll3eSR6P4Mlks9MLqk+olNs056HZnmNfQ/e78dK5FptZ+IOrRWVtZN9ljO+DTrU4jjHTfI56nnl2PfAwOK9b8LfDez0TT2vdZjt7/UUhd4rdRuggYKcDB++3ueB2HetIxUPU4cRV9tL3lp2/zMWyTBB5P15rVhArKhkOAI0/OtGFJ2UZdV+lYM0iatttzWlEVwBmsW2tST80pNacVquBlmI+tQzRNl+Mr61OCKqJapjgt+dSG3x0ZvzoEyyn3hV2HpWXFA+eHNX4VkA65pollsNxiqs54NO3uvUVDcSgLk02KLSZnXp+Q1T8Pc+ITntCx/lU15MpU881W8PSAeIlB/5aROv6Z/pShuaVNjZ8UBRHKkDhhLbruHo+CCP5fnXB6cltNAm7cr46o2DXdeI0nkubZNnzzRMkUhAG7GQB+BP1xiuCtIrMb4LoTwTRMVDxkZx2yDVWNsK7R7lo2q5+W7kx6FB/jTDawj7zPJ/vHA/SkaEIMx34cejR4P86iinit5Xu7mbzILON7qVQMZVBux+OAPxpJXdjqlJQi5PoeW/EVzd+NNYVACbZo7NVXkZjURkD8VNe269DNpupybwzWpbYkwHHyjGPbpXj/w2thrPi2zm1Al992b+6YjqkeZW/MjH417jDrpu0kW+SKcSfeGNhYfy/QfWtp2aszho+0jJSir2Wvz/wCGMbekvzNgn+8OtQzpKwIhZCPQ8Vsf2HY3hdtKumhm6+Q4/p/hWXe6RqEGS0ZYDjdEdw//AF1k4NHbDEQlpszsvCILeF7NG+/5smcH7vzdAf8APWt6W1VIFfIzXO+A0ceHpA6ygR3TD94MHlVz+tbMgPmbC+5BzXzGbaYiTkt0rfcedH4mk9m/zM2aMzOd+4qD1PSuJ+O18tn8OLm3/wCf+4gtlA9AxkP/AKLH516fC6ojLgEt3rxL9oydPI8OabGcyyzzXDIOwAVVP4kv+VTlNLmxUX2uy61Tmjyk37PNsyWut3BUr/x7wqfX/WMw/wDQa9ZlhljkEkowpG3H90dq5f4L28Np4MnlcYee+lZD6oqog/VGrrL6R3VVAO1zgn0A5/pVZraWIkrjpybk9CVZpvL2k4UdTnilspN+0jo2cH2zUlkIxByQD6Uww+XygKrklSO1eaotJO9xNrWJdEssLkRg4PpUqOxXL8s3FYxv8FlBZmHBAXGPzrQ0tHuGEkp2/wB1RXfhajc0jGpS5Y80jp7I/Kue45rST2rMthtAHP41oxHIr7DCvQ8OtuSilpBS13HMFFFFMAooooAKKKKACiiigAooooAKKKKAA9KhlI71MelVpwccVE5OKuioq7M67MQJLFRWbNFbsfmC/nUmpmVM1lKWZTkheeM14GIx65uT2Sb8z0aWGfLzc7RcFraSsFaONuR1r4jsZvOudVugcmTzHz/vN/8AXr7C1e68ixupcnyYInkbHfapJP6V8a6Myrpl4c8sgA/OujB14VYyUIKNnZ22Z2YalKE/ebd+59keC4rSz8F+HoX8nemnW+7jJyY1J/Umtn7dZxcs4RByzbSAAOp/KsPTIBZ29raSpxbxJCcf7Khf6Vz/AMV9UGk+ANeuoCFka3+zpg4OZWEZx+DMfwrgp5tVnX9nThFa28/Uzng4Nc0mz5xgvn1HXda16UsXnmluBu7F2J/rX1B4HsV0Xwfo2neTunjt1eX1Ej/vGB+jMR+FfOPgHTF1DUtE06XHlXt4glU94lOW/QGvqyyiaRmKrlmJYn1JrfM8ZUocsaTtKR1Spw5VGWy/r/MIbncxjZFU+hyaTVoPtel3Vsdsm+MlVx/EOR/KotShlKDyoyzg4q7ptssYHmMPMHvmvOw2LxVSrHmbavr0Xn5GVSnSpx546M8llvSmEiHJ4CoOT+VTDTAi+bq8rRk8i2TlyP8AaP8AD9Ov0rpfEMVtoF8X061WOSbL/aW5xnqFB+7XF3U0t0ztvIjB+eQ/5617zSW2p69Oo68VPZP7/wCv60LE1495LFZ2SpDFnAVeFX1J9eOSa0vDBhg8SWqxLuiCSqSRy48tsk1QtoEstPDsMXNwMhe6R9vxPWtHwbAZtauJQMi3tZD/AMCYbQP51UfiSM69vZSfQv8AxH8YW3g3QBe4W51G5Y21tZPyk+P4nH91ARyOTkDjOR4b4Z8L6l468Q3Fzqd27ykh729kBZYFPRFHc4GAo4AHoKXx/q03iv4lyw2RMyWsi6bYxg5DOG2lh/vOSc+mPSvbLm0XwR4JuLDSVUvsVvOHLSyHAd8+pP5DHpWzbTUFu3b5/wCR4rlyRdR+vyNHQPDeiaJpS2GnNBboMFmE+JJm/vOSPm+mMDsBWmrLAjZlWSOJdxYHjA5NeQfC5tYvPECNO8rQud0qyLxjv1/zkivRvGmoJZaTJFFxJc5hjGei/wAR+mDj8faoxVB0MSqbd9L3/C1icLX+sQcttTz+05xWnGDxWdbMqck8VaS6VztHasWd6ZqwHGK1Ld/l5rBhvbePhn3P2VRk1ajubyYfurG8I7bYHY/oKnlbL9pFbs3kk4p3m1k266w5Ah0PU3HqbZx/SrUthr3l7m0LUV91iJP5dafs5diPbU+rNCOUZq7E/Fckb3UrZitzpd7x3Nu4I/SpIfEMIfZLuhf+64IP5GizW4+eL2Z125SOaqXO0g1nxapDImUkU/jTo7gTglGBpXGoplK9tBJllYqapaFFOviW1AAYLuYsOw2nNatwcCk8MFf7Yuc/eMHH/fS5pwd2VUilE6q/RNQ0lbTYyXETeZBKVO0MOxPbOSPSuJ1OwFxdGWUCyvSNsizRkpJ7n0PvR8RvHE3h5ks9PQfaWUHeRnGewzx0x69at/DbxLqmvwsmqFd+3ch28EZI6dO3pXRChV+r/Wpq0fxt3/r7jzqWOhTrOjHfX7+piQ+H7ieVlzZgE8NGQ2f1rE+MlvF4X8DxWMJJvtZmETMepijId8e27yx2Fe4L+6k2BY/MPO1FAI+pA4r5d+M+vnxH8RbiKCQy2emAWcIXkFx98j1y5I98CiHLa6Ot151pKHQ3fg9by6bpmpa2IUePelgoZchlPzyfyjH412l3Yq0X23TMm1P+sizloT/Ue9P0qyXw7bWmhXCfuoIBHdKP4pHAaRvqGPHsoqKGW40XU5IgwJXjnlZEPT8CKzk+jO6kn8S3evqiqJmBAbt0zWpaa1cxYWVvOQDA3k7h/wACHP55qLV7SKS3/tCxBNsT+9jH3oT6+61lHfGoZsPEejr0/wDrVGq2N/cqL3kekeF737baTNb5Ty2w8bcYyOxHBH4VsLuYjCK2PUA1zngaMx6FPcAkG4lwvuF4/nmugaG5hj85TgH1rz8dmEqE1TUU1a7vqeNKjGVSVnbWyJwkeTvWJP8Ae4/rXzn8ZpVu/jJaW5ZfKsrSJTtOQM7pf/Zq95tpWu5mExJKdVHHNfMvjG++3fE7xXeE7lhmkt0PtGBEuPwWtMtxMcQ5NU1G3VLuCoOnUScmz6Q+HukQ2/gfQ1mX52tlnIz3kJk/9nroZtPhmC5LrtORtPSsnTrLFvHDgAwxrH0/ugD+lORCs20Oy/QkVxVMyw7k+fDp+ff8CXh6rblGq1/XqXxpUYbKyP8ASpnsyRgS4/4DWfO8kDYFw+CP72f51HHdznrM7H2wBUfW8tWkqLT9f+CL2GKeqqf19xaXRlMzyPMW3dguBWrZ2nlnhxj6VlWt65bbI5IJxu9K0oZpFBySCDiuujPL3adOm/v/AOCY1VivhnL+vuNmJM4y36VfjGAKybWYkjkmtSI5Fe5h505L3EedUjJfEyYUUgpa6zEKKKKACiiigAooooAKKKKACiiigAooooADVefjmrB6VXn6Gs6mxUNzD1QtMpUd+9c/fAQPEAeh5re1EmNDtzj+VczcxvdMcOQOm7pj6V8bmV1K/U9/BpNa7GRr1+n/AAiHiZwQzQ2F2CB7ROa+StEha5ktbRBueeVIwPUkgf1r6k+JCrpnw58RtGAqixkjBA/v/J+u6vnP4fQB/F/hncAytqVspX1/eLXoZL/u7b7/AKI6Hy+1bj2PrqVfNlm54Lk4/GvIP2j5/sXhjSdPQKHv7wykjrtiXkH8ZVP4V7RIsC2YYH56+cP2hr9rjxdo9nklLay8zn+88jZ/RVrzsqpJ4pSe6Tf6fqRKTlGy2uTfBqyMvje3mCF006wkmYAZ5fEf/tTP4V9CWtw0I+TrXkH7OsSmLxDqEvV3gtl9gAzN/wCy163fLDOSEX5cjHfFGc1P36cXqkXpJuMloVZr8PfwjDGMMd8gHyg4wBmtISReTtyVc/eNI1un2LjaMDG3Hasu2abznj3KY1xjcuTz2ry3KVP5lcsKq00sWL63tdQt2s74F4XPyt3RsdRXG3vh97NwL8bdLgAYyJyJeeFHpnue1dj9llEy3EkjGNM/Ljrx0HvVqO8P2YeWFaJ2IC9Rgf8A669fL8c6MOSvstu//DEtyp/wXe+//A7Ox5hezNNPJLIQWc546AVs6ddLoHgvWtTLbbtbOW8T1BVSYx+aj863L/QdIuIZJTp4SY8KI5GQFieBgHHWsH4wJDp3wn1+S3jRJGt4ISwHLAyxpgn6E17eFxVGpJODvfTb5meMxHtKfIo2+48W+DNg7+JLO7iwZra3uLlS398RkIfwdlNdz4at/E154kxfNK0Eknz7ucDPU/hnrWT8AIBJql2xHTTJFHsWmjx/I19A6Xpk942y3DLBnkt91fp/hXcsRUhzU4QT5lu+n+ZwV8PGbVRytynOy3VloOmm4uxBbKwAYRRKru390Y6n8q4p9L8S+LNTe5tNGuhGRtj8xfLjROw3NgH1/GvonT9OgsoVREDMOS7DkmrtFPCqK1ZhPG2dqa0PE9F+EOpTlH1vUoraPqYbUb3+m44A/I13WmfDXwzYMrfYnuWA63ErOD7leh/KuyoreNKK6HNPEVJ7srWGn2enxeXYWkFtH/dhjCD9Ks0UVoY7hRRRQAVVv9Ps9Ri8u/tLe5j/ALs0YcfrVqigNji9S+Gvh27y1vBNYSn+K1kIH/fJyv6Vx+rfDrW9IP2jRboajGOWiYCOQD25w36fSvZKOlZyowlujenialPZnzu+qMszW2oQyW10nDRyKVYfgabaXwtNTgugdyKcOB3U8GveNb0PTdctxDqtnFcKPulhhl/3WHI/A151rXwpkj3yaBqP+7b3YyPoHH9QfrXLLDOLvE9KnmMZLlqaFLXNC0rWjbzXsLSyrgRtGAdw6jOQRjnrWAPFmnaDraaQkZiAO2RrcfzJBJxjHUdOK29Aj1zSZhp2t6ZcxICRDcKu+Mf7JYZGPTP0+mNrHgK2vfEsd8ksymaT54gucEnsfqfw960w7jzezxEnyW030f8AW3QxxEZfxMMk5Pd6G18RvEyeEvBF3qVs6pcTL5VmepkmcfKR67RlyT/dA714R8C9BfWfHli8iF7exb7bcO3PKkbAfUlyv61a+NuvL4h8dLpNnL/xKtFX7LHg5UyDHmv+YC/8B969e+COhjQvCrXUsXlXOqPHclSMFYQcRKfqMt/wMVjGKpRUb7HXBtU3N7sTxzGY/FFw4+7KquPyAP6g1l3ifbNLEijN1Zj5vVovX/gJ/Q1u+OGWeW3nVlZlaSBseoOR/OuesrwWdyszgMoyGU9GU8EflWctJs9ainKjG26/Qj06+ktpFkiI6YKkZDDuCPSrEunuW+16LE0sEhCyWq8tEx9PVTVWXSbxNSNvp9tNdwygSwPGuQUPTJ6DHQ5rufCvh9tKkNzeShr1kx5at8kQ9z3PSonKNJXqOy/rYzrYiCXNB+92/wAzUtYUs4bazRVAt41Qhem7GT+tXJTLInzMAgqnclReBhExWRQS6njNMvJWt0Xh5AxwpBGCf6V8tjZylVm2r3f4dDlp07qKW/8AVx0U0NpfhzgKUMrD1CnJ/Svk3wMJNY8W6es+C2oahGJPQ75Rn+dfSfjZlsfBHiHVZADPDYyqj9NjMpRcfQsK8G+Btkl58QNFikGUjMlwT6FI2ZT/AN9Ba9fJ1yYeVR9X+SKnbmbT2R9LC6ZLm4KdM5bn1qt+/knMgcqem0LkVYvrSGBmZMbieWB61PFOIbdiFG7NfNu9+VvY2UklzQW5AVYoTIATjrin6cUaT94eKtW8DXMJfIGPSsWaV4LvyvKJZjwVbAP1pOLg1JhD95eK3N2/+zxKXTGACWxU9lI0jKgOcqOtYcsZuYDExZQ3Xae9aGmGWF1EmC44yP4veu7DVrz00uYVKKUN7tHT6eApww5Fayc9KyrNw+OMGtWLoK+wwXwng19yQUUlLXecwUUUUwCiiigAooooAKKKKACiiigAooooAD0qCTB61OahkRj0FRON0VEx9TAzlRXLz3EdvMyMdvJwCPWuzubOaQHaB+dY1z4ennctshye7Hr+leJjMrnXd07Hq4XEU4K02eX/ABtutnwr8QDGGkWFB+M8ef0Brwn4Xjf438MqBki+jf8AI5/pX1F45+G954q8LT6Ot7b2fnSxsZNpfaqtk/Lxn8xXMeFP2fh4e8Q6dqieIzc/ZXLmJrPZu+UjrvOOvpXRhMFOhR9m3c2WLoqUnfc6tyBhWB56d6+afjNcfbPirfoPuW8UEK/hEpP/AI8TX15H4VGf3l2SPRU/+vWLP8IfBt3ql5qOpabJe3t1IZJJZriQY9gFIAAHFZYHKfqsnJPcmePpXT3PLvgFAsXgK4lkU5uNQlYH1ASMD9d1eh27NGgDksepya1/h3YeELjw8Y/CkSPp9rczQMhkZjHKrnepySevIz2I7V10djaxEGO2hUjuEGaqtk1KtUdSb1ZDzOKukjgRLIy4VCc+gzUttpt67FobWTLY5K4H616CAAMAYFLW0cow0fsmLzKX2UcV/Y+rS/fiwPdloj8M3oAx5S85xvNdrRW/1Che7ivuRl9fqrRWRxreG75ipZ4MqcjLHg4x6e9Utf8Ah7H4l0STSdYuWSymkR5RAfnYK4faCRxkgc139Faww1KDvFETxlSaszhvCHhbwTouqX+m+H7SCPUbOKNLqLzXd1R/nXduJyDjOfau3RFRAqKFUdABgCvhX4kfEjVfD/7RPiDxF4euQsltcizaMkmOZIlWNkYd1JQn68jBxX1p8K/iXofxG0VbrSZhFfRqPtVhI372Bv8A2Zc9GHB9jkDZJI55TlLdncUUUUyQooooAKKKKACiiigAooooAKKKKACiiigAIyMHpWXq2jw31vcCJ2tbqSJkS4jHzRsVIDAdMjOR9K1K80+OfxRsvhv4ado3im1+6UrZWp556eY4/uD9TwO5CaT3HGTjqmeR3H7P+raV4psI47kanoE0m66nUbJUUfMVZcn72MAgnk84r2ESGC4yq7V+VSm3G0Dtj/PSsj9lrxLP4l+FUMl9cNcX9reXENxK5yzszmXcfwlH5V6vPbQXAxNEjj/aXNc1bCqrFxTsd8MfLRVFex5vfaVp1xdvG0KYlmEvBK5Oeenquazj4Y0iOUZthIxP/LSRmx+GcV6Pc+HrKXmPfCc5yjf41Sk8Kxn/AFdywPbcua4a+CxMlanO2/Q6aeNp7Nv8TGTyrWxESMqRJgYjGAoPsP8APNV7iFME+awJ6YwRj2Nby+Ff713jPUBP/r1MvhaD+K4kP0AFcdTJq1dL2s9V/XcqOMo03eL/AAObsZ4kttjDcFORu9ahuWSVhxgbgcAcCuxTw1YqBuaZj7tj+lSr4e04dYmP1c1Usi54xUpbC/tClGTkk9Twz48aibP4X3dsCMXlzDb8H/aMn/tOuA/Z4tTL4qv51xutdOdlz/eaSNcfkTX0n428DeFtZ0N08RIyadbP9qZzcNGEKqwyTnphjWb4a+EmieF9RvbrQri6hW6hWFopSJAuG3ZB4POB19K7aeXulh3Qi+j/ABFHH0rtvS9iE5e2Ekp6jOM9KZGreWC3Q9/Wull8KygHyrlGP+0pH+NV28O6gg+UxN7B/wDEV4k+Hpp6S/D/AIJ1Rx1JrRmVDJJCpCMQpqFlDTBmGTtOCfWtJ9C1CNw32bJ9VKn+tRS6VfuMPazH/gNZPI69rXX4/wCRpHE0r3TRHblB1xxVxWQqe4qmbO6jHz20wx3KGiCzkEwkkMvUHleKdHLMTTdmkTKUJa3Oq05QCqj05rYQYrH0/txWuhyK+owtOUI2kjw8Q7yHilpKWus5gooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADZpEhieWVgkaKWZj0AHU18qfAP45oPFuq6L4ouRHpuq3811YXMpwLeSWQsY2PZGLcHsc9jx9BfFGx1nVvBOo6T4bWMahqSfY/OkfYkEb8PIx68LuxgE5Ir5ysfgR4d0T4p6L4W8QXF3qFrqukSzR3CP5LC7jfLbQM/L5fY569aAPris7xJqsWheHtT1a4IENjbSXL59EUtj9Kr+EtBXw1okGlxahqF/bwDbC986ySInZNwUZA7ZyffGKZ4z8N2vi3QJtG1GWeOwuGT7QsLbWlRWDbN3UAkAHHOMjIzQB8LfBL4ja/4L8XTXllb3eqWN2d+o2cSljIuf8AWADo4J4PTnHevu3wn4k0zxXosOqaLcedbSDlWG1427q6nlWHp/TmvMPE2k2HgT4ufDzUdGtILHSr2Kbw9NHCgRV3fvIRx1Jkz1547k17PQAUUUUAFFFFABTJxIYZBAyrKVOxmGQGxwSO4p9FAHz58Q/hZpvgf4ZTa5oETXfiXSL6HW5dRmA864eN8vkj7qYZm2jjjnJ5r3bSbq01WwstVtFR47q3SaKXAyY3AYc+nNP1Wwg1TS7zT7xd9tdwvBKvqjKVI/ImuY+EWg6v4X+H2laJr8tvNeWKvCskDFlaIOdmcgYIUgY56daAFT4iaJLr02l2ialdmC8Gnz3VtYyyW0FwSB5bygYBBZQT0GeSK6ZdSsWSJlvLYrNu8siVcPtzuxzzjBz6YryK7+Fusz/EWPX7D+ydEH9p/bLi9027uVmu4AxPlSW5HlbmGAz7uTk45rKsPhh4t0qHRYbmfRrjSfD41Z7f7MZjc3C3UUu3Kldu4NIBgHp3JoA9vtdX028eZLTULOd4VDyrFMrFFIyC2DwCOcmmWut6Td2y3FrqdjNbtJ5Kyx3CMpfGdoIOM47da8A8KfCLXNc8GwnURZeHpJfDK6TFHbxuJ5HZ0kZroFVwcptKjcfmJz2rUsvgxqUv2QanbaEIv7Zsb+8hFzLPFcRQRTI42NEqgkSqAuMEA5Y8UAehan8T9Cs9bvdKto7zUrmyt0ubhrNUaONX5UbmcAkjB4yORzXUahrem6fP9nub62S8KGRLUzIJZAAT8qkgnpXk3iv4PT6gnxBXRoNEs11y0sLXTQEMYthD/rFbanyKcLgLnO0ZxgVo6n8PNZ/4SbxLd2lv4d1C11udJ/tWpCT7VZlYwgRMIQQMZU7l25PDUAd9b+KNIe00+a7vrawkv41kgt7ueOOVgewG7k9uCadoniOy1jV9b020EwuNInS3uS6gKWZA42nPIwR6V4l4p+DPivVvC+kaNFeaHJFa6JDp7CSWSLy7hGJLhliLSIeysVAPOM16l4D8LX/h/X/FV9fTW8kerXEE0IiZiyhIFjO7IHOVPTPFAHaUUUUAFFFFABRRRQAjAlSFODjg4zivmT9oD4T6Rb6Z/bM+p6xqnirWtRttPtpryZCgkkccKiIoChVYBe1fTleTfEYf238afh1oIy0NibjWrlfTYu2E/wDfeR+NAFX4OfDXVfhb4q1axtbr+0vCupoJYpWwsttMnRXXoQysRuXqVGQK9joooAKKKKACiiigApGYKpZiAoGSTwAKWqWtaVZ61ps2n6nEZrOYbZYt7KHHodpGQe46HvQB8f8A7Tfxlj8UzN4W8LXBbRIJM3Vyh4u5FPAU941IznuRnoAT9XeAdcXxJ4J0LWVYMb2zimfHZyo3D8GyPwrxfxH8N/CGt/G3SPCtroFjbaVYaLPf3q2sYiMjSMIkDOuGJXAYZPGSfWvVfhd4Nl8BaFPoUV+99pUU7S2BlGJYY35aNscHDbiCMZ3HgY5AOyooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8m+O5Gk6j4C8VDj+ytcjgmfH3Le4GyQ/otes1x3xh8MzeMPhtruiWaq95cQhrcEhcyowdBk9MlQM+9AHY0VS0T7YdF0/+1FVdQ+zx/aVU5Al2jcAe/Oau0AeZ/tF6bPe/C3UL6xH/Ew0aWLVrZv7jQsCzfgheu+0HU4da0TT9Utf+Pe9t47mP/ddQw/Q1NqNnDqOn3Vldpvt7mJoZV/vKwII/I1Q8I6Ba+FvDWn6JYS3EtpYxCGJ7hw0hUdMkAD8gKANeiiigAooooAKKKKACiiigArD8dXt7pvgvXb7SmiW+trKaaFpPuqyoTnv6VuVHcQRXNvLBcxJNBKpSSORQyupGCCDwQR2oA+efCfi/wAQaBYafLdNc63qdx4RGtqlxqb+XK8k8SquHAAbDjgd8qucippvip4r1P8A4R7+zbjR7S4fWzp19DPBLABmHeqSCRWKj7xLISeFx1Ir26Tw1oUsaxy6LpjotqLFVa1jIFuCCIQMf6vKg7OnA4qI+EfDZ0hdKPh/SDpayecLP7FH5If+8E27d3vjNAHn8fxad76KyFvY/bG8XyeHWgE37xYF3Yn29c/KPbmuJ0r4s67onw20WWGW21bVjbajf3K3vmPK0MV1IgO/IUDC7eSTwAFNe8v4X8PvqZ1J9C0ptRMqz/ajaRmXzF+6+/GdwycHORUNx4N8MXNrbW1z4c0Wa3tt4giksYmSLeSX2grhdxJJx1zzQBf8P6iNY0HTdTEflC8torjy852b0DYz3xmr9R28EVtbxQW0SQwRKEjjjUKqKBgAAcAAdqkoAKK8y+JGr+INP+IvgfTdI1k2en6zLNBcQ/ZY5MeUhfcGYZ+YELjtjNZ1n8WdWutWs4k8L266fd6rdaNBOdSy7XEW/aSvl/KjbOTkkZPBwMgHr1FeFeHvi/ry/D3wpf6po8F5rWvTTRWpgaZkdIwxZ3SKF3U8bQqq+cbiQM46LQfifrGsa7pelR+Dri2uZ9NTUrxLu68iS0T7S8DjY8YLEbN6527gR93rQB6nRXh8fxyu4tL1m71Dw7BbXlhFFMNLluporoK9zHAN4eALj95nchccAHrmk8VfEnxJ9vtNLtLC3s9bsfFFnp1zBBd+ZBdxTW8kqp5rRgrnChvlyMfhQB7jXn2ieG9UPxq8SeJ9SgVLAabbadpkm9WMiZMkvAOVw4HUDOeK5mw+Kd5f61o8d7ptxZXcMus2t5aQXiNA0tnGhOSYizA7vlIKYOchhioYvjhdWun/ANo654YFrZ3GhnWrP7Pfee0gDonlv8i7clxzzgfoAe20V5B4r8beO9KvvC1uNC0SOfUtREDxx6oZFkRomZU3GEFDlWywBHyjGc8Tab8Wr3UvFlzY2fhe8m0aC+uNPkvkScmJ4gfnc+T5SoWG3HmFhkEgdKAPWaK8dsviXqWsWHgvVbrRrjSbHWb9I4Rb6gkvmoYpGbzFMJO0FBgAqTkHIxg9T8N/GGreMLa21SbR7Ky0K/gkns5Fv/NuMK4XEkewAZBJ+Vm24weTQB3NFFFABRRQenHWgDyb4TH+2viZ8S/Eh+aMX8WjwHsot0w+PYsQa9ZrkPhV4Qk8E+Expl1dpe3slzPdXNyiFBLJI5OcEnHy7R1PSuvoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8Z0Lx54p1b4uazoKKg0jT782wMekyyqU2bv3lwG2xn6qauXXxbuLrR/Fp0bw/ONV8OWM898l3IojtpkLhYyQf3mQjP8pHyjrkgV1kfw68MReJ5vEMVjcR6tNN58k0d9cKrvjGTGH2Hj2o0/4b+E9P8AN+x6QkZntZbKc+dIxuIpWLOsuW/eElicvkjPBFAHP+H/AIlalqF54e0ubwvdSatqWlx6pKLe5hEcMRkVDIdz/d+YNgEtggYJzVPTvjRbXWs3ti+h3MixWlzd28lhMt0LkQfeRcAKWPbazDPBNdr4e8D+H/D17a3ek2UkVzbWbafDJJdTTFLcuH8v52PG4DGeQBgYHFZll8KfBljK0lrpDRkxTQKovJykccvLqil8ICecKBg9MUAczpPxqh1LTLS5g0UTT3WpQaZFb29/G7CSZJGXzAQCmPLIOR34JwapXXxV1u+8ReGLfQtEmknln1Wy1HSDNEGa4tRHgCZsDaNxOR16Yps3hf4f+J59O0vw1qM0csetR3lzMhup5LxreKVDF9qZsrhWbDByFxgcmu+i8KeD/CyaPem3tdNTSWlSznmuWQI9wQr7mZvnZyFGXyc9KAOIt/jNbTxS62lvfHTk8NLrBsSIxhvtLwth+u7KkemMHGavv8YPs02oWWpeGr611eKazhtLL7RFIbprokRfOp2pypzknHvXRQ/C3wdDp72Mej4tX0/+y2T7VNzbeaZfLzvz99id33ucZxxTYvDfgnxXPrrpaRX0olj0zUCXlBSS3wyKORtZN4O5cHnqaAMS7+IHia18f+HdDvPC8dpbX0E810Wu0kaMRsoLowIBVVO4grk5wOQaztL+Otlf2eoXw0DUEsIbCbULebeG81Izyr4GI2I5AyR754rt4Ph34Zgn0ueOxn+06ZM9xbTteztKHYqW3OX3SA7VyrkjjGMVXi+F/hCGG8gi0p47W7ikhktkvJxCEk++EjD7I888qAaAOdk+Jz22sRXGs6fqOlaeNFudV+yyeRKZYoyhD5RiQxDEBcj3xXZ+C9d1TX7RrnU9Bk0iGSKKa2Z7lJvNRwTyF+6wAGQePmGCecSz+EdCuLuC5uNPSWWGwfTE8x2Zfsz43RlScMDgckE+9J4V8IaL4VFwNCtZYBOqI4kuZZgFTdsVfMZtqjc2FXA56UAXfEOjW2vaXLp97JdRwSFSWtbh4JODkYdCCOnrXzx8ONT1rSvhP4F1nS9VuH1zxNrS6ZdXGpSy3kax+ZcgFY2cAEbF+6VzjrX0zRQB8++LviV4i0D4hWWixavFOba70+yvIJ7SOEXPmhBJLEuWfaSSd24BThfm6mW1+IHi9dQ0/UZ9TsH0251++0b7E1lgKkYkKSGRSWJGwcAfgTXvtFAHzNpXxY8W3Hh7XJW1awa/tlgIuGjhNjGXkwQkynCPtzhJgMdSfWynxY1l9P0NrvxCukW17b6g8l/fWERLPCUEfl7GKOCSQGXhugGea9f+J/jyy8A6Na3l3Abme7uUtbeEP5YZmPJZiDtUDknBrHi8U+F7i7j8S+JBaWOqaXdTaTbmK7e4bcyI8iBEA3N0yNpIAzkZoA8ru/EvjF9R1XxNFeRaPq9t4PtNRuraS08xZGEkhK7Wb93uxk8EjIHatkeONbjvtUfSTY2N5qHiPSdPaY25kAW4t1LEqWG4gnjkcDHvXpNj8V/Cd74ln0WG/bzorMXxnZMRMm1nIB67gqliCBx3zxTvGnxK0Xw54XuNWt5Y9RlTT01SG1jk2NPbPIiCQEg/Ll1oA83j+IfiiAjTNZ1y0sbW38QX2lXniI2KhY0hijeIFCSiM5kYZPGF9arp4x8Sad4v8R3Np4h/tpz4fgvtMsGtHjjv28t8vFHuyuCN7beW6dhXs13438O2fiNNCutTji1R5UgWJ0cAyOoZU3427iGBAznkV0dAHzhpXxR8WTaFPJDrOkX0sl/p1vDOIldofPcpIkqIQByAQMhhyD61qeI/E/iPwz4g8XrC9nd6laWemLPqSWLARpJI4kmaIMSVReQuTjqcjNe90UAcv8PNUXVtEmnj8RQeIo0uGjW+htxEpACnb8vysQSfmXjt1BrqKKKACiiigAooooA5/XfBnh7XtWtdT1jSoLvULVQsM8md0YBJGMH1JqWHwnoUP2fytMt1+z3j6hFgH5Lh87pB7ncfzrbooA5X/hXnhH+ypNN/4R7TvsD3H2ow+UNqy/31/un/AHcVe0fwloGjTJLpek2trIlsbNTGmP3JdpCnuC7Mx9SSa3KKAPFvGPh74fLaa74P0zS7q2vpIbeW9bR9KlunhjWVZY0JVSFDGM4TPTnFehW3hDwppdtb2tvpVhbxWt1/acaKMFZ1BHnepIBIyc8V5n47+FF9q978TbzTtPsPtWu21lFp0rMFbcpzPk4+XcVQ++BTdb+F2s6p8UbzVBYaY2k3s7Ndy37RXRkh8rZtiBiEsR5xtEhTr1HFAHpOi6B4R1a3t9a0mxsriG5a5uYrmMHDtcACZh/v7QD9KgGneDovEtp4bOm2p1CDRnEMDwlkWx3qjJk/LtLbflNea+Fvh14o8NaT4Gn03Q9GXU/D15dG6gF9sS9E0Ai+0GQRnB9QQThR9BD4X+F/i7S9MZDDpYuz4Z1DSts0nmxGee+aZVIxypjbqRjPUUAepwfDzwVNpDWMOg6ZJYNOtwUVdw8xRtDA5yCASOvQkVdk8DeGJNdbWW0Ow/tRmLtcCIBmfBG444LYJ+br71xHwN8Eax4Q1XxPPqtpBZWmoraNBBDLEwDosglO2KONFySvRR9TivWqAMWHwtokFnpNrFpsCW+kyCWxjAOLdgCMr+DH86j0Xwf4d0LVbjUtH0eysr2dSkksEYQlSQxAA4AJAJx1Iya3qKACvJfjze6pav4dTS9btLKIvPLcafJqv9mS36qq4Edxxt2FskZGcj0r1qq97ZWt9EI722guYwchZow4z9DQB4J4a+MJ07R7FJ5PsmnzeHrzUbSXXbgy3E14lwypCJtyiVMZ28biAOfVmq/GXxDDp0l1HN4etpodF0zVEtJoZDJfS3CgvDF+9yME8YDEcZz1r364sbS48v7RawSiIEJvjDbARg4z0yOKx7Xwhott4kudcjs0+3TQww/MAUjWLOzYuPlI3HpQB59cfEXxBFb+OtSuRpVno/h2aS2X/RZZrgv5aMhKiQKcM+DyM+q4JrlIfjJ4pOk6tFu0KS7stQt7f7WGhG6GWFpG2x/afLkkUrjas3r3Br6FFnbBZ1FvCFuCTMNgxISMHd68cc1574s8YeFtA8Sw+Fho9neX9xbG8lgVrWGOOOMcFzK6gtjJAGSFBPAGaAOAvfjRrTadHPZ6loNvGPDh1pJL6xkie7mW4lj8hE8/5SwjAGC/OSCQRiK+8c+LNH17x14hs2tVsbSXRXudMvlkdkE8EKtHEQwEZDSEk7Tkj8/SHvPAg8R6N4g1i+0qz1q/0uCC1trm8hYCEt5ibAGKk7mIDqSD2JrQ8PeNfBPim3vJrHUNJlV7xLKYTPEGmm3FYhgn5txQ7P7235elAHAWnjfX01+70jQo9MgnvvFt9pnnXguLhUWO3SQOFMvBz/Cu1PRRkks0z4qa/qNn4btby88P6Dc3v24XWq3sTNbFraXYEjUyJhm6nLcDOPSvR7vxN4etvFui6Paw2t3e6jeXUXnW3luLa4hh8yQSEHKuVwPXkZ4qzoeteDvFEc9hol9oeqxwnzJLe3eOUKSfvFRnuevvQB4/afErxPpC/EfUbrUdI1htMSCe0sIUdcLIsOJky+fIVZNzZHJ53KOKuaZ8UvGFy2n2MS+Hbi6vdVisobpnjdWikhkfc8dvcyhGDIcfOdy9gcmvdFsrVbhrhbaETsnltIIxuK/3SeuPaooNK0+3CCCwtIgj+YoSFV2vjG4YHBx3oA8Wv/HusaDd+J02aZDeDXLDTJr+Zp2tbYSwKXndHlIVQeAFKDlc5OSfWfBeoTaloST3Gq6Zq0gkkjN5pqlYZNrEcDc2CMYIDEZBrVNlakXANtCRcf6792P3nGPm9eOOadbW8NrAkNtFHDCnCxxqFVfoBQBLRRRQAUUUUAFFFFABRRRQAUUUUAFFFeJ638Q/ENj8I9V8bwXFqDc6iI9Pt5oA0dtbC48kFsEMzsAXOT3AAGDQB7ZTJ4knhkilBMcilGAJGQRg8ivG9F+K2rW/hy/vdUs7PVPL1Y6fYXUO6yW/jCFvMSN97MQRtwm7OfQE1q6D8XE1/wD4R6PR/DmoXVxrFrNdCITRJ5CxT+TJuLsAQCCeOSMcegByngb4eeJPD2neBI4rC5tntJtXl1VI79Rt81JVtz98jJzHjaDg8kZzXLr8KfGFz4Z1a1utFabZJaT2/wBqvES7uZEmzICyTNG3yFvnfY2ccDrXf/Dj4tS6tBeWN5bz6rqthHfXt59lRVaOGKZ1ijVBjfIwUAAexJ5FdX8LPiHF4+hv3is4rM2vlkxi8WaQbw3DoAGQjHcYOeCcHAB51408MeOmt/Fln4b0K7az1vTNOjs/+JrGrae8C4eI7nyWOcblODj7xzUmt+CPFUmma9ax6It1bX/i641JkW4i802rQqqSoGkCZyGGH5HXbnBG34Z+LmoNor6l4s0NLGy/t06R9qhmXy4QXdA0gLEgKVVWbgEsCOM1bj+L73dnp8umeGby4lvtOuNVhje4SL/R4pNu4k9Nw+YDnqPcgA6D4MaVrWifDXR9N8TrKmrW/nLIssyzMF85zGNykg/IU78DjtXbV47f/HbTI5bX+zdF1C/gNpa3lyUIEkKTjcqqmDvYLkkAgccE11Xxe8cJ4G8L/aYntRql25t7FbqQRxeZgsWdiRhVUE46k4UckUAdxRXj+n/EDVbz4Y+EvGqXlpIhuoIdYtYFUoyyyCE46srozo2M+oI9PYKACiiuA+NMsh8NaZp5mkgstV1ez0+9ljYqy28kgDjcOm7ATP8AtUAd/RXzp8TdO8Q6t8W7/QfCTX0c0WgW72Qt9TezhsXE+3zSqkBgF+Xbg/Tji3rvxL8QaX8UrDQ4NTjlgXVrHS7q0ubeONpFlVA8sYGXKliWDkgcgYOMkA9b8ceF/wDhKY9DT7Z9l/szVrbVM+Vv8zyWLeX1GM+vOPQ1xetfCA6jZarAur2wa+1yfWVaewZzCZI0TYrJKjgrtzuVlznkcVxPiDxF4n1v4eWeu6jewXMQ8SwW1vY2tt5MhMd4VGZC+DuCgYwo9TRrfxZ8Rx+DtK1FNUsLPUJb29i1OzMccdxaNEQFt4xL8jMNwJ3Hc2RtHXAB3+mfCqewvlkPiW6u7efRP7FvxdQeZNcLiTDrJu+QgydCG4UDPeufuPgbf3ulS2Wo+MBcAaEug27DS1TyYUnilRsCT5iBFt5POc54wdD4ra1rJ+CWla3p+p32l3Zewnu7jyDBKEZkD70Vv3YywJGSMAr0OaqSeOPFKfEPSPClpdW1/Dqws7+01SO2AjexETm5bAOAxZBt9BIPbIBqa/8ACS41jx3D4hm8RFoYdUtdTjt57MyyReSVPkpJ5gCo2DwE4Jyc16vXz34Y+KHifU9asI7S7tdYupJNSS60eC1CtBHB5nkyNIDkFmVF5wDuwBnmtr4HePfEPirXpbfW9Q065ifT/tMltGqpPZzh1Voyg5VMMR8/zZXuKAPaqK+f/ilrfh9PjHoVhY67c6Z4ht723uNQupb2VYIrcKMWyxZ2M0m5Twv8RJPOK77wx/xLvjB4s0uwYnTriytdTmiB+WC6dpEbA7F1jRj6kZ70AehUUUUAFFFFABRRRQAVwSaxqWofEfxHbRXbQaZ4f0+L/RlVT9ouJlZ97HGcKqqAPUk13tc8/hiEeMpfEFvcPE11ZiyvbbaDHcqpJjY9wy7mGe4bHpQB4t8Mfih4svdO/tnWbgaho8ejT3t5NdWJsoLa5RyI40nCYcMAM7Q2M8ZIIroLP41X32PVFu/DIOo2V7YWqxJcSRJMt2W2OPOhR1xt6Mozkc16pa+G9GtfDn9gQadbLovltD9jK5j2MSSuD2OTWXp/w78JafFJHZaDZQpJLDO4VT8zwkmJjzyVLHH1oA85u/ihrGifEu70jVrJTdXqadb2emNdKIIJpTJvZrjZ0woPQknAAro9L+Jl1dfEtvDF7pEOnQG5mtoJLqaZZbkRqT5sQ8nymUkY2iTdjnHGK6/V/B/h/WJL6TU9Ktrl75YkuGkXJkEZzHn/AHSTjFM0/wAFeG9P12TWrPRrOLVZGeRroJl9z/fYE9GbnJHJyc9aAOO1Xxp4ps/id4h0ix0ez1DS9P0ddQii+1GKWRsOeP3bZLOuzb2HzZOdozrX42rqWkS6po2hLd2IutPsUla92B7i5VS8f+rOPK3KGPcnoK9NuvDmk3HiC312SwtzrVvEYYbwp+8RCCMZ7j5m6+prioPhDpEXw/s/ChuZXtotQXUZ5jGoa5kEm8hlHABGF46ACgDFu/jJe2qHT38Po3iEavPpJiglmuLfdFGsjOGihaRshgNojznJOADXonhPW7/xH4NttVfS5tH1K4if/Qr5GBhlVmXDAhW25XPQEgjpUTeA/CraDHozaDp50yOUzpAYhhZD/GD13f7Wc1qWGhaZp+hjRrGyht9LCPH9mjGF2uSW/MsST1JJNAHnnw51jxL408BeKFv9VS11y31O8sbe7s4lRITHjZhWByoP97JI6nPNdl8OdffxT4F0LXJoxHNe2iSyIvQPjDY9sg4qjH8PtG0zRNWsPCsCaDNqURilubZSzgHIJAJxuwTg9ic10miaZa6Lo9lpmnR+VZ2cKQQpnOEUAD6nA60AXaKKKACiuB1mefUfjJomkS3E0On2OlzaqIY5CguJvNWJd+PvKgJOPVgTXmHw71LxlqXjG51GO91uXR9P1vUY9SmubhZLP7Kg+SKOLJfzAfRR1HJ5wAfRtcD4p8By614x1DWkubeNLnw5caKqMhLLJI4YSZ9AOPWvK9L+OHiKSz16bOkXy2+hNrFq4gEe1hMkex0S4kIB35AYo/AyBmrnj/xv4q8J+KtN1O8S3u7k6FcTfZ7MTC0iBmiCyyruLEICSxHOOmOtAG5N8IdZFx4ffTtcttOex0+xsbm7tlmWaZbdQCrJ5nlSKxHG9OM85wBU7/CnWItGvLGx1XS4nh8QJr+mStavkOJWk8uYBuVG4AbcdD68VNW+KWr2PxH03R2vdHk0meWygSazgFw1y0yKzllFwJIQQ2U+SQYIJJFbfjrXNd074x+DdOstZsLDSb+2nDw3cZKzSK6AqPnXLkMoQDoc5DZAABS0D4V6zZeJLTWb3W7N7uPV9R1SR7e3ZBm6tUhGxWLY2su7BJ44qb4ZfDLWfC/jJNd1nWLfUHXSW0wspnaSQmVHEjGR2A4TG1dqjjArm7f4w+Kp9D8UXJ0zTIbvwxp7/wBpK8Muz7f57IsafOP3flpuPJOSBmjUfi/r2n2HiExNo+rpaT6fHFqVlHtt7cXOd4kDTbSY8AZMijLDcVoA9+orh/hT4n1LxF4avrvxB/Z63FpeSW/m2c0UivGqqyuwillVGw3KbzjGehFee/DPUorz4s6zodp4o1DX9AuNF82POrG/Ut5gVpHcbfs74IAjUd85HAoA96orhvg5fXd34Pkt765lvH02/u9Nju5W3NcRwzMiOT3O0AE9yM13NABRRRQAUUUUAFFFFABRRRQAUUUUAFcNp/w505NB1Pw9qzjUfDs98b20syHia1zJ5pj8xXyyiTLDgYzg7q7migDE8UeFtH8URWset2rT/ZJfOgeOaSGSJ8EZV42VhkEgjOD3qp4e8CeG/Ds+nzaPp32eSwgltrY+fI/lxyyeY6/MxzlznJyR0GBxXTUUAcdH8M/CMTQtFpHltElzGrJczKSlwSZVYh8spLE4bIBPGK0vC/hDRPDEl1Jo1o8c91tE801xLcSyBRhQXkZmwMnAzgZrfooA8+8VfC3SNV8K+I9G0c/2UdemSa7lO+4TcJN7MkTPtRic8rjkg4OBSa98KtG1vXdJuLxpBpGnaW2lpp0TyRBkJXGZEdTtAXG0gg55r0KigDktU+HXhXUriCefS/Kkht0tFNpcS2wMKfdjYRMoZR0AbIxxXSajYWuo2sltfQJPDIpRlYdiMHB7celWaKAOLv8A4f2MmleHtD02RbDw5pV0l1JYqjSNceWd0aGRmyFD4Y5DFtoGRXaUUUAFUNf0ew8QaPdaXrFstzYXK7ZYmJGRkEYIIIIIBBBBBAIq/RQAyCJYYY4kLlUUKC7l2IAxyxJJPuTk0+iigAooooAKy/7A0z/hJj4hNtnWPsv2IXBkY4h3b9oXO0fNzkDJ9a1KKAM3w9oWneHdO+w6Pb/Z7XzZJtm9n+d2LMcsSeWJNaVFFABWbpOhadpN3qV1YwFLnUZvtF1K8jyPK4UKOWJIAAACjCjsBWlRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZGreH7LU9Y0nVJvNjv9Md2t5on2na4w6N/eRgBkHuARgitK3toLZXW2hihV2LsI1C7mPUnHc+tS0UAUF0bTEEgXTbJRIpV8QKNwJyQeOQSAfwqxLZWsr7pbaF28sxZaME7D1X6H06VPRQBTh0vT4Z45obG1jmiXYjrCoZV9AccD2qa4tbe5eJ7iCKV4W3xtIgYo3qM9D7ipqKAORf4faFJofiLSnina31+4kub9zKfMkd8Zw3YDAAHQV0dnptlZ2P2O2tYY7YjDRrGArcYOR3J71booAhtLW3soBDZwRW8IOQkSBFB+gquul2kVtcxWUKWJuFIeS1RY3yQfmyB1GeCavUUAZvhzRbHw7odnpOlRGKytU2RqTknnJYnuSSST3JNaVFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parks described four types of anal rectal fistulas that originate from crpytoglandular infections. Fistulas can have a complicated anatomy with one or more extensions and accessory tracts. The original Parks' classification did not include a superficial fistula tract.",
"    <br>",
"     Type 1 is an intersphincteric fistula that travels along the intersphincteric plane.",
"     <br>",
"      Type 2 is a transphincteric fistula that encompasses a portion of the internal and external sphincter.",
"      <br>",
"       Type 3 is a suprasphincteric fistula that encompasses the entire sphincter apparatus.",
"       <br>",
"        Type 4 is an extrasphincteric fistula that extends from a primary opening in the rectum, encompasses the entire sphincter apparatus, and opens onto the skin overlying the buttock.",
"        <br>",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36534=[""].join("\n");
var outline_f35_43_36534=null;
var title_f35_43_36535="Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors";
var content_f35_43_36535=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36535/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36535/contributors\">",
"     Theodore V Parran, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36535/contributors\">",
"     Bonnie B Wilford, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36535/contributors\">",
"     Robert L DuPont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36535/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36535/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36535/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36535/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/43/36535/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H268753552\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abuse of prescription drugs is common and increasing in many countries, including the United States, leading to increased morbidity and mortality. Prescription drug abuse involves the use of a medication, usually by self-administration, in a manner that deviates from medical, legal, and social standards. In addiction, the use becomes chronic and is accompanied by impaired control over drug use, compulsive use, continued use despite harm, or cravings.",
"   </p>",
"   <p>",
"    Medications with potential for abuse and addiction are regulated in most countries, restricting whether and how they can be prescribed. In the US, these drugs are referred to as \"controlled substances\" and include opiates, stimulants, and anxiolytics. Their potential for abuse and addiction results from the \"brain reward\" they induce, mediated through dopamine pathways in the brain.",
"   </p>",
"   <p>",
"    The likelihood of prescription drug abuse can be influenced by characteristics of the medication, the patient, and the clinician. Understanding these factors provides a foundation for efforts to minimize abuse of these drugs.",
"   </p>",
"   <p>",
"    Clinical features, epidemiology, and factors contributing to prescription drug abuse are discussed here. The identification and management of prescription drug abuse are discussed separately. The diagnosis and treatment of abuse and dependence to specific substances are also discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=see_link\">",
"       \"Prescription drug abuse and addiction: Prevention, identification, and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"       \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=see_link\">",
"       \"Treatment of opioid abuse and dependence\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753559\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753567\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753576\">",
"    <span class=\"h3\">",
"     Prescription drug abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescription drug abuse involves the use of a medication, usually by self-administration, in a manner that deviates from medical, legal and social standards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/1\">",
"     1",
"    </a>",
"    ]. According to the DSM-IV, use constitutes drug abuse when there is a maladaptive pattern with recurrent and significant adverse effects, such as failing to fulfill major role obligations, legal problems, physically hazardous use, or interpersonal problems. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753583\">",
"    <span class=\"h3\">",
"     Prescription drug addiction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chronic, neurobiologic disease characterized by impaired control over drug use, compulsive use, continued use despite harm, and cravings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753590\">",
"    <span class=\"h2\">",
"     Types of drugs abused",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four primary categories of potentially addictive substances among prescription drugs:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stimulants (such as amphetamines)",
"     </li>",
"     <li>",
"      Anxiolytics (such as benzodiazepines)",
"     </li>",
"     <li>",
"      Opioids (such as opioid analgesics)",
"     </li>",
"     <li>",
"      Other drugs (such as dissociative anesthetics)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753597\">",
"    <span class=\"h2\">",
"     Regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescribing drugs with potential for abuse or addiction is regulated by the Controlled Substances Act in the US and by similar statutes in other countries. US physicians who wish to prescribe these drugs must register with the Drug Enforcement Administration and obtain a government-issued registration number. The drugs are assigned to one of five progressively more restrictive categories or \"schedules\" for controlled substances based on their relative potential for abuse and addiction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H268753632\">",
"     'Drug characteristics'",
"    </a>",
"    below.) These schedules, summarized below, determine whether and how the drug can be prescribed (",
"    <a class=\"graphic graphic_table graphicRef66064 \" href=\"mobipreview.htm?4/37/4701\">",
"     table 1",
"    </a>",
"    ). Some US states have implemented additional requirements.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Schedule I drugs",
"      </strong>",
"      &mdash; High abuse potential.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There is no accepted use for these drugs in medical practice.",
"     </li>",
"     <li>",
"      They cannot be prescribed.",
"     </li>",
"     <li>",
"      Drugs include heroin, lysergic acid diethylamide (LSD), and mescaline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Schedule II drugs",
"      </strong>",
"      &mdash; High potential for abuse and dependence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There are accepted medical indications with severe restrictions.",
"     </li>",
"     <li>",
"      Generally require non-refillable, written prescription.",
"     </li>",
"     <li>",
"      Drugs include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      , cocaine, amphetamines, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/27/32182?source=see_link\">",
"       secobarbital",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Schedule III drugs",
"      </strong>",
"      &mdash; Abuse potential less than schedule II drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Compounds with limited quantities of controlled substances.",
"     </li>",
"     <li>",
"      There are accepted medical indications.",
"     </li>",
"     <li>",
"      Generally require prescription refillable up to five times within a six month period.",
"     </li>",
"     <li>",
"      Drugs include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      , acetaminophen with hydrocodone, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Schedule IV drugs",
"      </strong>",
"      &mdash; Abuse potential less than schedule III drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There are accepted medical indications.",
"     </li>",
"     <li>",
"      Generally require prescription refillable up to five times within a six month period.",
"     </li>",
"     <li>",
"      Drugs include benzodiazepines,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      , propoxyphene,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/48/29446?source=see_link\">",
"       pentazocine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"       phentermine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Schedule V drugs",
"      </strong>",
"      &mdash; Abuse potential less than schedule IV drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Preparations containing limited quantities of certain opioids and stimulants.",
"     </li>",
"     <li>",
"      There are accepted medical indications.",
"     </li>",
"     <li>",
"      Includes non-prescription antitussive and antidiarrheal medications.",
"     </li>",
"     <li>",
"      Drugs include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9094?source=see_link\">",
"       diphenoxylate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10946?source=see_link\">",
"       propylhexedrine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753611\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abuse of prescription drugs in the United States (US) is common and increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In 2008, an estimated 6.2 million Americans (2.5 percent of the US population) reported using prescription drugs nonmedically in the past month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/7\">",
"     7",
"    </a>",
"    ]. Of these, an estimated 4.7 million persons engaged in nonmedical use of pain relievers, 1.8 million abused tranquilizers, 904,000 abused stimulants, and 234,000 abused sedatives. A 2003 US national survey of lifetime abuse of prescription drugs among adults found pain relievers to be most common (13 percent), followed by tranquilizers (9 percent), and sedatives (4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonmedical use of prescription drugs doubled in the US between 1992 to 2003, from 7.8 to 15.1 million [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/5\">",
"     5",
"    </a>",
"    ]. Increased abuse has been observed worldwide as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/9\">",
"     9",
"    </a>",
"    ]. Many factors contribute to this rise, including the misperception that they are safe when used outside of medical practice, their relatively low cost, and their growing availability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/10\">",
"     10",
"    </a>",
"    ]. Studies of opioid abuse reveal additional contributors to increased abuse, including the increasing prevalence of chronic pain in an aging US population, wider acceptance of opioids for treatment of chronic pain, and the rise in potency of some agents.",
"   </p>",
"   <p>",
"    The growth in availability of prescription drugs comes from several sources: increased production, diversion from healthcare, and manufacture of counterfeit drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/9\">",
"     9",
"    </a>",
"    ]. Of individuals who reported the nonmedical use of opioid analgesics in a 2011 survey of US adults, 30.7 percent reported receiving the medications directly from a physician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/11\">",
"     11",
"    </a>",
"    ]. Older age was found to be a risk",
"    <sup>",
"    </sup>",
"    factor for obtaining nonmedically used opioids from a physician.",
"   </p>",
"   <p>",
"    The internet has created a global marketplace for prescription drugs subject to abuse. One study identified over 300 opioid \"no prescription\" web sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Although many of the US-based sites have shut down through law enforcement, internet pharmacies in other countries have increased. Diverse sources lead to distribution of drugs of inconsistent potency and quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/8,15-17\">",
"     8,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2005 survey of 50,000 US high school students found that while overall illicit drug use declined among adolescents over the prior decade, their nonmedical use of prescription pain relievers and sedatives has increased; 7.2 percent of high school seniors reported misuse of sedatives and 5.5 percent reported misuse of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of prescription drug abuse can be illustrated through comparison to illicit drugs. The number of Americans who have abused prescription drugs exceeds those who have used cocaine, heroin, hallucinogens, ecstasy, and inhalants combined. Only cannabis use among illicit drugs exceeds nonmedical use of prescription drugs (",
"    <a class=\"graphic graphic_figure graphicRef73465 \" href=\"mobipreview.htm?16/57/17309\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753618\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all substance abuse and addiction involves the use of substances that produce brain reward. Brain reward is a key concept that has replaced the older notion that a drug had abuse potential because of its ability to produce withdrawal on abrupt discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/19\">",
"     19",
"    </a>",
"    ]. Many brain-affecting medicines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , do not produce brain reward and are not abused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prescription drugs that are abused directly or indirectly provoke an acute release of dopamine from the mid-brain (the ventral tegmental area and nucleus accumbens) to the forebrain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/20\">",
"     20",
"    </a>",
"    ]. This dopamine release is responsible for the brain reward, which can lead to abuse and addiction in susceptible individuals.",
"   </p>",
"   <p>",
"    Although all people experience the dopamine surge in response to these substances, there appears to be at least a qualitative, and perhaps quantitative, difference in the surge and resulting brain reward among individuals prone to addiction. The nature of these differences is not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753625\">",
"    <span class=\"h1\">",
"     CONTRIBUTING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three interrelated components of the prescription process determine the potential for prescription drug abuse: the drug, the patient, and the clinician prescriber [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753632\">",
"    <span class=\"h2\">",
"     Drug characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug characteristics that determine abuse potential",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    street value include rapidity of onset of action (faster is preferred, ie, more likely to be abused and thus has higher value), magnitude of the dopamine surge (higher is preferred), route of administration (intravenous &gt; inhaled &gt; immediate release &gt; slow release), and purity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/23\">",
"     23",
"    </a>",
"    ]. Prescribed drugs with the trade rather than generic names are perceived as more potent and thus have a higher street value.",
"   </p>",
"   <p>",
"    Drug availability also determines the magnitude of the abuse problem associated with specific drugs. Historically, hydrocodone products have been abused far in excess of other opioids because clinicians generally are more willing to prescribe a Schedule III medication than one in Schedule II. As prescribing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    products dramatically increased in the late 1990s, oxycodone abuse, addiction, and diversion surged as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753639\">",
"    <span class=\"h2\">",
"     Patient characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the vast majority of patients with prescription drug abuse or addiction, the onset of drug abuse or addiction precedes their use of prescribed, controlled medication. These individuals typically start using alcohol, tobacco, or marijuana in late adolescence or early adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/22\">",
"     22",
"    </a>",
"    ]. Individual characteristics that suggest increased risk for addiction include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Past or current substance abuse or addiction",
"     </li>",
"     <li>",
"      Use of controlled substances in non-prescribed doses and routes of administration",
"     </li>",
"     <li>",
"      Use of controlled substances for reasons other than indications for which they were prescribed",
"     </li>",
"     <li>",
"      Patients of younger age",
"     </li>",
"     <li>",
"      Patients who work in health care settings",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753660\">",
"    <span class=\"h2\">",
"     Clinician characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians can have countervailing influences with regard to prescribing controlled substances. Underuse can result from clinician discomfort with prescribing drugs with abuse potential and the regulatory burden associated with these prescriptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/24\">",
"     24",
"    </a>",
"    ]. Evidence suggests that appropriate medical indications, eg, chronic pain, may be undertreated as a result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    However, controlled substances are also overprescribed by some physicians (though most physicians prescribe them appropriately). Overprescribing contributes to these medications' abuse and addiction, both directly and through diversion and resale. Clinician characteristics associated with poor management of controlled medications can be classified by the \"eight D's\", described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Difficulty &mdash;",
"      </strong>",
"      Clinicians have reported difficulty in identifying which patients will misuse controlled medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/29\">",
"       29",
"      </a>",
"      ]. Clinicians often fail to recognize aberrant medication-taking behavior in their patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/30\">",
"       30",
"      </a>",
"      ]. Most clinicians lack formal training in the appropriate prescribing of controlled drugs, and in the treatment of pain, anxiety, insomnia, and addiction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Dated &mdash;",
"      </strong>",
"      Clinicians may lack up-to-date clinical knowledge, leading them to prescribe the wrong drug or dose, or use a controlled drug when another option is safer and effective.",
"     </li>",
"     <li>",
"      <strong>",
"       Deceived &mdash;",
"      </strong>",
"      Clinicians may be misled by patients regarding their symptoms or behaviors related to controlled substances.",
"     </li>",
"     <li>",
"      <strong>",
"       Distracted &mdash;",
"      </strong>",
"      Some clinicians, including those under time pressure, may be less than adequately attentive in their prescribing and record-keeping behaviors.",
"     </li>",
"     <li>",
"      <strong>",
"       Defiant &mdash;",
"      </strong>",
"      A clinician might believe they have greater expertise in a specific area of practice than everyone else and may engage in clinical actions outside the bounds of usual care.",
"     </li>",
"     <li>",
"      <strong>",
"       Disabled &mdash;",
"      </strong>",
"      Some clinicians",
"      <strong>",
"      </strong>",
"      have personal problems with psychiatric or medical disorders, including addiction. Although physicians with a drug addiction have been characterized as more lax in their prescribing, research suggests that most disabled doctors are not diverters of controlled drugs to their patients and their communities, but rather tend to be diverters to themselves [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5562?source=see_link\">",
"       \"Impaired healthcare provider\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dishonest &mdash;",
"      </strong>",
"      Dishonest clinicians constitute a very small proportion of all physicians, but may prescribe large amounts of controlled drugs for other than legitimate medical purposes, often for money. Inappropriate or excessive prescribing of controlled drugs is one of the principal reasons for disciplinary action by State Medical Boards against physicians [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Discomfort &mdash;",
"      </strong>",
"      Some clinicians can find themselves contributing to a patient's drug abuse through \"pathological enabling\", or facilitating the abuse due to the clinician's excessive need to be helpful. This problem can be compounded by what has been described as a \"confrontation phobia\" among clinicians who are unable to directly address abusive behavior with the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753667\">",
"    <span class=\"h3\">",
"     Practices that promote drug abuse or diversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain clinician behaviors, even among honest and well-intended clinicians, substantially increase the risk that controlled drugs will be diverted to nonmedical use. These include:",
"   </p>",
"   <p>",
"    Prescribing controlled substances prior to obtaining complete clinical data (eg, without a full history and physical examination, without reviewing prior records, and an assessment for substance abuse). A 2004 US survey found that 43 percent of physicians did not routinely ask about drug abuse when taking a patient history and one third did not attempt to obtain a new patient's prior medical records before prescribing a controlled drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concomitantly prescribing multiple controlled drugs, from the same or different classes.",
"     </li>",
"     <li>",
"      Prescribing controlled drugs for extended periods of time, without reevaluating the indications for use.",
"     </li>",
"     <li>",
"      Lack of monitoring to detect concomitant alcohol or drug abuse after prescribing.",
"     </li>",
"     <li>",
"      Failure to consult colleagues (pharmacists and specialists, particularly experts in pain and addiction).",
"     </li>",
"     <li>",
"      Continued prescribing despite aberrant patient behaviors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753674\">",
"    <span class=\"h1\">",
"     IMPACT OF THE PROBLEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in prescription drug abuse has been accompanied by increases in emergency department visits, accidental overdoses, and deaths involving prescription drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/10,15-17,33\">",
"     10,15-17,33",
"    </a>",
"    ]. Emergency department visits involving controlled prescription drugs increased 79 percent in the US between 1994 and 2002, with the sharpest increase (168 percent) involving prescription opiates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/32\">",
"     32",
"    </a>",
"    ]. Emergency department visits for accidental overdose and admissions to addiction treatment programs for prescription opiates have risen sharply in the US, particularly in rural regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/33\">",
"     33",
"    </a>",
"    ]. Prescription drugs play a role in many drug-related overdoses. In one study of 295 fatal drug overdoses, prescription drugs were associated with 63 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prescription drug abuse has a large economic burden. One study estimated the direct and indirect costs of prescription opioid abuse in 2001 to be $8.6 billion, including workplace, health care, and criminal justice expenditures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36535/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/21/7506?source=see_link\">",
"       \"Patient information: Prescription drug abuse (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268753681\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications typically regulated by nations because of their abuse potential include stimulants, opiates, and anxiolytics. In the US these are referred to as \"controlled substances\" and are subject to restrictions on prescribing. (See",
"      <a class=\"local\" href=\"#H268753559\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abuse of prescription drugs is a large and growing problem worldwide. Over six million people in the US have been estimated to use prescription drugs nonmedically; the number has doubled since 1992. (See",
"      <a class=\"local\" href=\"#H268753611\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prescription drugs that are abused provoke dopamine release in the brain, which is conceptualized as leading to brain reward, abuse, and addiction in susceptible individuals (See",
"      <a class=\"local\" href=\"#H268753618\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug characteristics that determine the abuse potential of prescription drugs include rapidity of onset of action, magnitude of dopamine surge, and route of administration (intravenous &gt; inhaled &gt; immediate release &gt; slow release). (See",
"      <a class=\"local\" href=\"#H268753625\">",
"       'Contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinician practices that promote prescription drug abuse or diversion include prescribing controlled substances before obtaining prior medical records, and lack of adequate monitoring over time. (See",
"      <a class=\"local\" href=\"#H268753625\">",
"       'Contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increase in prescription drug abuse since the 1990s has been accompanied by increases in emergency department visits, accidental overdoses, and deaths involving prescription drugs. (See",
"      <a class=\"local\" href=\"#H268753674\">",
"       'Impact of the problem'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=see_link\">",
"     \"Prescription drug abuse and addiction: Prevention, identification, and management\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jaffe, JH. Drug addiction and drug abuse. In: The Pharmacological Basis of Therapeutics, 6th ed, Gilman, AG, Goodman, L, Gilman, A (Eds), Macmillan, New York 1980.",
"    </li>",
"    <li>",
"     Principles of Addiction Medicine, 3rd ed, Graham, AW, Schultz, TK, Mayo-Smith, MF, et al (Eds), American Society of Addiction Medicine, Inc., Chevy Chase, MD 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/3\">",
"      Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003; 69:215.",
"     </a>",
"    </li>",
"    <li>",
"     DuPont, RL. The Selfish Brain: Learning from Addiction, Hazelden, Center City, MN 2003.",
"    </li>",
"    <li>",
"     Report of the International Narcotics Control Board (INCB), 2006. www.incb.org/incb/en/annual_report_2006.html (Accessed on January 16, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/6\">",
"      Friedman RA. The changing face of teenage drug abuse--the trend toward prescription drugs. N Engl J Med 2006; 354:1448.",
"     </a>",
"    </li>",
"    <li>",
"     Results from the 2008 National Survey on Drug Use and Health: National Findings. Substance Abuse and Mental Health Services Administration, Rockville, MD, 2009.",
"    </li>",
"    <li>",
"     Results from the 2003 National Survey on Drug Use and Health: National findings. Substance Abuse and Mental Health Services Administration, Rockville, MD 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/9\">",
"      Kuehn BM. Prescription drug abuse rises globally. JAMA 2007; 297:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/10\">",
"      McCarthy M. Prescription drug abuse up sharply in the USA. Lancet 2007; 369:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/11\">",
"      Becker WC, Tobin DG, Fiellin DA. Nonmedical use of opioid analgesics obtained directly from physicians: prevalence and correlates. Arch Intern Med 2011; 171:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/12\">",
"      Forman RF, Woody GE, McLellan T, Lynch KG. The availability of web sites offering to sell opioid medications without prescriptions. Am J Psychiatry 2006; 163:1233.",
"     </a>",
"    </li>",
"    <li>",
"     Anonymous. You've Got Drugs IV: Prescription Drug Pushers on the Internet. Center on Addiction and Substance Abuse, New York 2007. Released at the US Senate Judiciary Committee hearing on \"Rogue Online Pharmacies\", May 1, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/14\">",
"      Wilford, BB, Smith, DE, Bucher, RD. Internet pharmacy: A new source of abused drugs. Psychiatr Ann 2005; 35:241.",
"     </a>",
"    </li>",
"    <li>",
"     Emergency Department Trends from the Drug Abuse Warning Network, Final Estimates 1994-2001. Substance Abuse and Mental Health Services Administration, Rockville, MD 2002.",
"    </li>",
"    <li>",
"     Nonmedical use of pain relievers, the NSDUH Report, Issue 22. Substance Abuse and Mental Health Services Administration, Rockville, MD.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/17\">",
"      Wilford BB, Finch J, Czechowicz DJ, Warren D. An overview of prescription drug misuse and abuse: defining the problem and seeking solutions. J Law Med Ethics 1994; 22:197.",
"     </a>",
"    </li>",
"    <li>",
"     Johnston, LD, O'Malley, PM, Bachman, JG, et, al. Monitoring the Future: national results on adolescent drug use: overview of key findings. National Institute on Drug Abuse, Bethesda, MD 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/19\">",
"      Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006; 83 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/20\">",
"      Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 2004; 47 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/21\">",
"      Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004; 28:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/22\">",
"      Parran T Jr. Prescription drug abuse. A question of balance. Med Clin North Am 1997; 81:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/23\">",
"      Coleman JJ, Bensinger PB, Gold MS, et al. Can drug design inhibit abuse? J Psychoactive Drugs 2005; 37:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/24\">",
"      Gilson AM, Kreis PG. The burden of the nonmedical use of prescription opioid analgesics. Pain Med 2009; 10 Suppl 2:S89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/25\">",
"      Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996; 11:203.",
"     </a>",
"    </li>",
"    <li>",
"     Johnston, LD, O'Malley, PM, Bachman, JG, et, al. Monitoring the Future: national results on adolescent drug use: overview of key findings, 2005, National Institute on Drug Abuse, Bethesda, MD.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/27\">",
"      Longo LP, Parran T Jr, Johnson B, Kinsey W. Addiction: part II. Identification and management of the drug-seeking patient. Am Fam Physician 2000; 61:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/28\">",
"      Isaacson JH, Hopper JA, Alford DP, Parran T. Prescription drug use and abuse. Risk factors, red flags, and prevention strategies. Postgrad Med 2005; 118:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/29\">",
"      Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/30\">",
"      Weaver MF, Bond DS, Arnold BL, et al. Aberrant drug-taking behaviors and headache: patient versus physician report. Am J Health Behav 2006; 30:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/31\">",
"      Parran TV Jr, Grey SF. The role of disabled physicians in the diversion of controlled drugs. J Addict Dis 2000; 19:35.",
"     </a>",
"    </li>",
"    <li>",
"     Doe, J. Under the counter: the diversion and abuse of controlled prescription drugs in the US, National Center on Addiction and Substance Abuse of Columbia University, New York 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/33\">",
"      Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36535/abstract/34\">",
"      Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm 2009; 15:556.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14856 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36535=[""].join("\n");
var outline_f35_43_36535=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H268753681\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H268753552\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H268753559\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268753567\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H268753576\">",
"      - Prescription drug abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H268753583\">",
"      - Prescription drug addiction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268753590\">",
"      Types of drugs abused",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268753597\">",
"      Regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H268753611\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H268753618\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H268753625\">",
"      CONTRIBUTING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268753632\">",
"      Drug characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268753639\">",
"      Patient characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268753660\">",
"      Clinician characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H268753667\">",
"      - Practices that promote drug abuse or diversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H268753674\">",
"      IMPACT OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H268753681\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14856\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14856|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/57/17309\" title=\"figure 1\">",
"      Past month illicit drug use ages 12 and older 2008",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14856|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/37/4701\" title=\"table 1\">",
"      US scheds controlled drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5562?source=related_link\">",
"      Impaired healthcare provider",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/21/7506?source=related_link\">",
"      Patient information: Prescription drug abuse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=related_link\">",
"      Prescription drug abuse and addiction: Prevention, identification, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_43_36536="Lichen planus wrists fair skin";
var content_f35_43_36536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76383%7EDERM%2F50632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76383%7EDERM%2F50632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous polygonal papules are present on the ventral wrists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Generalized lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous and hyperpigmented polygonal papules are present in a widespread distribution in this patient with generalized lichen planus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36536=[""].join("\n");
var outline_f35_43_36536=null;
var title_f35_43_36537="Overview of the diagnosis and staging of head and neck cancer";
var content_f35_43_36537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the diagnosis and staging of head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36537/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36537/contributors\">",
"     Colin S Poon, MD, PhD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36537/contributors\">",
"     Kerstin M Stenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36537/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36537/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36537/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36537/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/43/36537/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck cancers can arise in the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid, and salivary glands and include a variety of histopathologic tumors.",
"   </p>",
"   <p>",
"    An overview of the clinical presentation, diagnosis, and staging for head and neck cancer is presented here. More detailed discussions, based upon the specific primary tumor site, as well as treatment, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43959?source=see_link\">",
"     \"Overview of treatment for head and neck squamous cell cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck cancer encompasses a variety of cancers, mostly squamous cell carcinoma, arising from a variety of sites. The head and neck region consists of five anatomic areas (",
"    <a class=\"graphic graphic_figure graphicRef75396 \" href=\"mobipreview.htm?26/56/27525\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The oral cavity includes the lips, buccal mucosa, anterior tongue, floor of the mouth, hard palate, and upper and lower gingiva. The anterior border of the oral cavity is defined by the vermillion of the lips. The posterior border is defined by the circumvallate papillae of the tongue, the anterior tonsillar pillars (palatoglossus muscles), and the posterior margin of the hard palate. The hard palate defines the superior boundary of the oral cavity. Inferiorly, the oral cavity is defined by the mylohyoid muscles. The lateral boundary of the oral cavity is defined by the buccomasseteric region (buccal mucosa of the cheeks) and the retromolar trigone (which is located behind the mandibular third molar).",
"     </li>",
"     <li>",
"      The pharynx is divided into the nasopharynx, oropharynx, and hypopharynx. The nasopharynx forms the continuation of the nasal cavity. The boundary between the nasal cavity and nasopharynx is defined by the posterior choanae of the nasal cavity. The nasopharynx is defined superiorly by the basisphenoid and basiocciput (clivus) and inferiorly by the hard and soft palate. The prevertebral muscle and anterior margin of the cervical spine at C1 and C2 levels form the posterior margin of the nasopharynx. The posterolateral boundary of the nasopharynx includes several important structures. The lateral wall of the nasopharynx is elevated by the torus tubarius, a cartilaginous structure that constitutes the opening of the Eustachian tube. The Eustachian tube allows communication between the middle ear and the nasopharynx through a defect (sinus of Morgagni) of the pharyngobasilar fascia, which lines the nasopharynx. The sinus of Morgagni may allow nasopharyngeal cancer to gain access into the skull base. The fossa of Rosenmuller (lateral nasopharyngeal recess), a common site of nasopharyngeal cancer, is located posterior to the torus tubarius. The nasopharynx also includes the adenoids (nasopharyngeal tonsils), located in the midline roof of the nasopharynx. The soft palate defines the boundary between the nasopharynx and oropharynx. The oropharynx is separated anteriorly from the oral cavity by the circumvallate papillae and the anterior tonsillar pillars. The palatine tonsils, posterior tonsillar pillars, tongue base (posterior one-third of the tongue), valleculae, soft palate and the posterior pharyngeal wall are structures of the oropharynx. Inferiorly, the oropharynx is defined by the hyoid and the pharyngoepiglottic folds. The hypopharynx includes the pyriform sinuses, the posterior surface of the larynx (postcricoid area), and the inferior, posterior, and lateral pharyngeal walls.",
"     </li>",
"     <li>",
"      The larynx, which is divided into three anatomic regions: the supraglottic region, the glottic larynx (true vocal cords and mucosa of the anterior and posterior commissures), and the subglottic larynx, which extends to the inferior border of the cricoid cartilage.",
"     </li>",
"     <li>",
"      The nasal cavity and the paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal).",
"     </li>",
"     <li>",
"      The major (parotid, submandibular, and sublingual) and minor salivary glands. Minor salivary glands are found within the submucosa throughout the oral cavity, palate, paranasal sinuses, pharynx, larynx, trachea and bronchi, but are most concentrated in the buccal, labial, palatal, and lingual regions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of head and neck cancer varies widely depending upon the primary site. Examples of typical presenting manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nasopharyngeal carcinoma",
"      </strong>",
"      &ndash; The most frequent presenting complaint of is a neck mass, which occurs in nearly 90 percent of patients. Additional symptoms may include hearing loss (associated with serous otitis media), tinnitus, and pain, and symptoms associated with growth into adjacent anatomical structures, which can lead to muscle involvement and impaired function of cranial nerves II to VI.",
"     </li>",
"     <li>",
"      <strong>",
"       Oral cavity tumors",
"      </strong>",
"      &ndash; Patients may present with nonhealing mouth ulcers, loosening of teeth, ill-fitting dentures, dysphagia, odynophagia, weight loss, bleeding, or referred otalgia. Up to 66 percent of patients with primary tongue lesions have cervical nodal involvement, while the incidence is substantially lower in patients with hard palate and lip cancers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tongue cancer grows as an infiltrative lesion and may have an exophytic component, particularly for lesions arising from the tongue base. The presenting symptom is often pain, with or without dysarthria. There may be a history of longstanding leukoplakia.",
"     </li>",
"     <li>",
"      Lip cancer, the most common site of head and neck cancer (excluding skin cancer), usually presents as an exophytic or ulcerative lesion of the lower lip, occasionally associated with bleeding or pain. Some patients complain of numbness of the skin of the chin due to involvement of the mental nerve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Oropharyngeal tumors",
"      </strong>",
"      &ndash; Presenting complaints can include pain, obstructive sleep apnea or snoring bleeding, or a neck mass.",
"      <br/>",
"      <br/>",
"      Patients with HPV positive oropharyngeal cancers often present with cystic neck masses. These cystic neck masses were historically thought of as &ldquo;branchial cleft cyst carcinomas&rdquo;. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=see_link\">",
"       \"Human papillomavirus associated head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypopharyngeal tumors",
"      </strong>",
"      <em>",
"       &ndash;",
"      </em>",
"      Patients with these tumors often remain asymptomatic for a longer period and are therefore more likely to be seen in the later stages of the disease. Dysphagia, odynophagia, weight loss, and neck mass are common presenting symptoms.",
"     </li>",
"     <li>",
"      <strong>",
"       Laryngeal cancer",
"      </strong>",
"      &ndash; The symptoms associated with cancer of the larynx depend upon location. Persistent hoarseness may be the initial complaint in glottic cancers; later symptoms may include dysphagia, referred otalgia, chronic cough, hemoptysis, and stridor. Supraglottic cancers are often discovered later and may present with airway obstruction or palpable metastatic lymph nodes. Primary subglottic tumors are rare. Affected patients typically present with stridor or complaints of dyspnea on exertion.",
"     </li>",
"     <li>",
"      <strong>",
"       Sinus tumors",
"      </strong>",
"      &ndash; Common presenting symptoms of sinus tumors include epistaxis and unilateral nasal obstruction. Facial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      head pain may be seen in later stages, due to pressure or tumor infiltration into nerves or periosteum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinomas account for 90 to 95 percent of the lesions in the oral cavity and larynx. They can be categorized as well differentiated (greater than 75 percent keratinization), moderately differentiated (25 to 75 percent keratinization), and poorly differentiated (less than 25 percent keratinization) tumors. Less common histologies include verrucous carcinoma, a variant of squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12362?source=see_link\">",
"     \"Pathology of head and neck neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Squamous cell carcinoma of the head and neck cancer often develops through a series of changes from premalignant entities that include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukoplakia is characterized by hyperparakeratosis and is usually associated with underlying epithelial hyperplasia. In the absence of underlying dysplastic changes, the probability of malignant change is less than 5 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Erythroplakia is characterized by red superficial patches adjacent to normal mucosa. It is commonly associated with epithelial dysplasia and is associated with carcinoma in situ or invasive tumor in up to 40 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dysplasia is characterized histopathologically by the presence of mitoses and prominent nucleoli. Involvement of the entire mucosal thickness is usually referred to as carcinoma in situ. Dysplasia is associated with progression to invasive cancer in 15 to 30 percent of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TNM STAGING SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor node metastases (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to classify cancers of the head and neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/2\">",
"     2",
"    </a>",
"    ]. The T classifications indicate the extent of the primary tumor and are site specific; there is considerable overlap in the cervical node (N) classifications.",
"   </p>",
"   <p>",
"    TNM staging is based upon the primary tumor site:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral cavity (",
"      <a class=\"graphic graphic_table graphicRef70195 \" href=\"mobipreview.htm?38/12/39117\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/29/32217?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The oral cavity\", section on 'Anatomy and staging'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nasopharynx (",
"      <a class=\"graphic graphic_table graphicRef57392 \" href=\"mobipreview.htm?34/8/34957\">",
"       table 2",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8250?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\", section on 'Staging and classification'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oropharynx (",
"      <a class=\"graphic graphic_table graphicRef81775 \" href=\"mobipreview.htm?35/55/36733\">",
"       table 3",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3174?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The oropharynx\", section on 'Staging'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypopharynx (",
"      <a class=\"graphic graphic_table graphicRef55865 \" href=\"mobipreview.htm?36/42/37549\">",
"       table 4",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34232?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The hypopharynx\", section on 'Anatomy and staging'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Larynx (",
"      <a class=\"graphic graphic_table graphicRef66619 \" href=\"mobipreview.htm?22/14/22766\">",
"       table 5",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20552?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The larynx\", section on 'Staging and anatomy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nasal cavity and paranasal sinuses (",
"      <a class=\"graphic graphic_table graphicRef82601 \" href=\"mobipreview.htm?9/42/9902\">",
"       table 6",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39206?source=see_link&amp;anchor=H362251675#H362251675\">",
"       \"Tumors of the nasal cavity\", section on 'Diagnosis and staging'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13013?source=see_link&amp;anchor=H4#H4\">",
"       \"Cancer of the nasal vestibule\", section on 'Staging'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23241?source=see_link&amp;anchor=H5#H5\">",
"       \"Paranasal sinus cancer\", section on 'Diagnosis and staging'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Salivary glands (",
"      <a class=\"graphic graphic_table graphicRef61042 \" href=\"mobipreview.htm?34/52/35661\">",
"       table 7",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9927?source=see_link&amp;anchor=H7#H7\">",
"       \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\", section on 'Staging'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND STAGING EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6093579\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial assessment of the primary tumor is based upon a combination of inspection, palpation, indirect mirror examination, and direct endoscopy. Physical examination should include careful assessment of the nasal cavity and oral cavity with visual examination and palpation of mucous membranes, the floor of the mouth, the anterior two-thirds of the tongue, tonsillar fossae and tongue base, palate, tonsillar fossae, buccal and gingival mucosa, and posterior pharyngeal wall. In general, a metastatic work-up with appropriate imaging is recommended for all newly-diagnosed head and neck cancer patients. Patients with severe dysplasia or carcinoma in-situ who have a strong smoking, alcohol or family history of cancer also benefit from metastatic work-up.",
"   </p>",
"   <p>",
"    Visualization of lesions outside the mouth is best accomplished by mirror examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of a flexible fiberoptic endoscope with the goal of examining all of the mucosa in the nasopharynx oropharynx, hypopharynx, and larynx. Aside from mucosal irregularities, other abnormalities that should be specifically searched for are impairment of vocal cord mobility, pooling of secretions, asymmetries, and bleeding. The appropriate nodal drainage areas are examined by careful palpation (",
"    <a class=\"graphic graphic_figure graphicRef69528 \" href=\"mobipreview.htm?18/53/19285\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An examination under anesthesia often is performed to best characterize the extent of the tumor, to look for synchronous second primary tumors, and to take biopsies for a tissue diagnosis. This exam is particularly useful for patients with laryngeal and hypopharyngeal malignancies. Symptom-directed panendoscopy (laryngoscopy, bronchoscopy and esophagoscopy) reveals a 2.4 to 4.5 percent incidence of second primary tumors of the upper aerodigestive tract, but not of the lower airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Other authors have found that screening panendoscopy revealed second primary cancers only in patients with a current or past smoking history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/6\">",
"     6",
"    </a>",
"    ]. There is evidence that PET may complement panendoscopy in detecting synchronous primary cancers, although there is still a significant number of false negatives (9 in 589 patients in one study). In general, patients with a history of heavy alcohol or tobacco use undergo panendoscopy. Those with HPV positive tumors without other known risk factors are not as likely to benefit from panendoscopy.",
"   </p>",
"   <p>",
"    In early stage head and neck cancer, screening panendoscopy alone may have a role in identifying second primary malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/7\">",
"     7",
"    </a>",
"    ]. Although the incidence of second or synchronous primary tumor is low, the impact on treatment for the individual patient is significant. Many academic centers still routinely perform a full panendoscopy for at&ndash;risk patients due to the procedure&rsquo;s low morbidity, teaching value, and high potential for changing management.",
"   </p>",
"   <p>",
"    Imaging studies may augment the physical exam and evaluation of squamous cell carcinoma of the head and neck, particularly for assessing the degree of local invasion, involvement of regional lymph nodes, and presence of distant metastases or second primary malignancies. The most common metastatic sites are the lungs, liver, and bone, while the most common sites of second primary malignancies are the head and neck, followed by the lungs and esophagus. Ideally, imaging should take place prior to biopsy, which may distort anatomy and create a false positive finding on PET scanning. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Imaging studies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Evaluation for distant metastases'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fine needle aspiration biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle aspiration biopsy (FNA) is frequently used to make an initial tissue diagnosis of a head and neck cancer when a patient presents with a neck mass (metastatic cervical lymph node) without an obvious primary",
"    <span class=\"nowrap\">",
"     mucosal/upper",
"    </span>",
"    aerodigestive tract site. This technique has high sensitivity and specificity and a diagnostic accuracy that ranges from 89 to 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Nondiagnostic aspirations occur in 5 to 16 percent of cases. If FNA is negative from a suspicious neck node, the FNA may be worth repeating before doing an excisional biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19911?source=see_link\">",
"     \"Head and neck squamous cell carcinoma of unknown primary\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fine needle aspiration biopsy may provide relevant information when clinical and imaging evaluation of neck lymph nodes is equivocal and a positive or negative finding would change the clinical treatment approach (eg, RT field or dose, or the use of concurrent chemoradiotherapy versus RT alone). Several studies have compared ultrasound-guided FNA biopsy to neck computed tomography (CT); some have found that the procedures were comparable in terms of overall accuracy (88 and 85 percent in one series compared to 69 percent by palpation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], while others noted better results with FNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one report of 86 patients with clinically node-negative (N0) necks, FNA detected malignancy in five who did not fulfill radiologic criteria for malignancy by CT scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/15\">",
"     15",
"    </a>",
"    ]. Conversely, several enlarged nodes on CT scan were negative by cytology (ie, they potentially represented a false-positive finding). For these reasons, the authors recommended FNA for most patients with head and neck cancer, irrespective of the CT findings. PET may also have a role in the evaluation of cervical lymph nodes. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'PET and integrated PET/CT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another promising strategy for increasing the accuracy of overall staging is sentinel lymph node biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Like cutaneous melanoma, this technique utilizes preoperative lymphoscintigraphy, intraoperative blue dye, and handheld gamma probe. Sentinel lymph node biopsy is a reliable and reproducible method for staging the clinically and radiologically N0 neck in patients with early stage head and neck cancer. It also may have use in determining the best treatment for contralateral N0 neck in patients with midline malignancies and node positive ipsilateral disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies (computed tomography [CT] magnetic resonance imaging [MRI], positron emission tomography [PET], and integrated",
"    <span class=\"nowrap\">",
"     PET/CT)",
"    </span>",
"    are important for assessing the degree of local infiltration, involvement of regional lymph nodes, and presence of distant metastases or second primary tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT can identify tumors of the head and neck based upon either anatomic distortion or specific tumor enhancement. In general, tumors enhance more than normal head and neck structures except for mucosa, extraocular muscles, and blood vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/19\">",
"     19",
"    </a>",
"    ]. Compared with MRI, CT provides greater spatial resolution, and can be performed with faster acquisition times, thereby virtually eliminating motion artifact, and it is better for the evaluation of bone destruction.",
"   </p>",
"   <p>",
"    Modern multidetector CT technology allows scanning to be performed with slice thickness less than 1 mm. For image viewing, the source data are reconstructed into thicker slice thickness, typically around 2 to 3 mm. Coronal and sagittal images of 2 to 3 mm slice thickness are usually reconstructed from the source data, and may improve the topographical visualization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/20\">",
"     20",
"    </a>",
"    ]. Slice thickness of 3 mm is generally optimal; slice thickness less than 1.25 mm are too noisy and has not been shown to be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/20,21\">",
"     20,21",
"    </a>",
"    ] while slice thickness greater than 5 mm does not offer sufficient spatial resolution. Images should be reconstructed and viewed in both soft tissue and bone windows. Dental amalgam can create severe beam hardening image artifacts that obscure image details in the scan plane. This problem can be remedied by rescanning the obscured area with angulated gantry.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Primary site",
"      </strong>",
"      &mdash; For cancers of the oral cavity, contrast-enhanced CT can help determine the extent of tumor infiltration into deep tongue musculature and whether or not the mandible is involved. For other head and neck cancers, CT is particularly useful in upstaging cancers that have deeper local invasion or infiltration into adjacent structures that is difficult to detect on physical examination. CT can provide information on invasion of the preepiglottic space, laryngeal cartilage, paraglottic space and subglottic extension, and can evaluate retropharyngeal, parapharyngeal, upper mediastinal, and paratracheal nodes. In addition, bone and cartilage invasion, a criterion for stage T4 disease, can be more readily detected.",
"      <br/>",
"      <br/>",
"      In one review of 81 patients with head and neck cancer, CT resulted in a change in assigned clinical stage in 54 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/22\">",
"       22",
"      </a>",
"      ]. This was most likely to occur with hypopharyngeal tumors and least likely with glottic laryngeal tumors (90 and 16 percent, respectively). Similarly, in a series of 77 patients with laryngeal cancer, CT resulted in upgrading of clinical staging (as determined by endoscopic examination) in 43 percent of patients subsequently treated surgically and 33 percent of those treated with radiotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Regional nodes",
"      </strong>",
"      &mdash; Imaging by CT or MRI is complementary to the clinical examination for the staging of the neck lymph nodes. CT evaluation of regional lymph nodes primarily relies upon size criteria as well as the appearance of lymph nodes to differentiate involved from uninvolved lymph nodes. The use of size criteria alone results in frequent false positive and false negative assessment of regional nodes. CT is also highly sensitive for detection of extracapsular spread of tumor.",
"      <br/>",
"      <br/>",
"      Pathologic lymphadenopathy is usually defined radiologically as a node greater than 10 to 11 mm in diameter or one that contains central necrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Other features that suggest pathological lymph nodes include rounded shape, loss of normal fatty hilum, and increased or heterogeneous contrast enhancement. In one study, data from 47 consecutive patients with head and neck cancer (total of 53 neck dissections) were combined with findings from a 15-year MEDLINE review of the English-language literature to compare physical examination with CT scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/26\">",
"       26",
"      </a>",
"      ]. CT was superior to physical examination in terms of sensitivity (83 versus 74 percent), specificity (83 versus 81 percent), accuracy (83 versus 77 percent), and detection of pathologic cervical adenopathy (91 versus 75 percent).",
"      <br/>",
"      <br/>",
"      Although CT is superior to physical examination, the use of size criteria and the presence of central necrosis are limitations that prevent detection of borderline-sized nodes, nonnecrotic nodes, or extracapsular spread within nodes. These cannot be differentiated by CT from reactive or normal nodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/24\">",
"       24",
"      </a>",
"      ]. This is an important issue since microscopic or occult nodal adenopathy is not unusual in head and neck cancer.",
"      <br/>",
"      <br/>",
"      In one series of 957 lymph nodes from patients with head and neck cancer, 102 (11 percent) harbored malignant cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/27\">",
"       27",
"      </a>",
"      ]. The following findings were noted in terms of nodes that would not be called malignant by CT:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sixty-seven percent of tumor-containing nodes were 10 mm or smaller.",
"     </li>",
"     <li>",
"      Twenty percent of malignant nodes had extracapsular spread; almost one-third of these nodes were 10 mm or smaller and some were less than 5 mm.",
"     </li>",
"     <li>",
"      Central necrosis was found primarily in nodes larger than 20 mm, suggesting that it is a late event in metastatic adenopathy.",
"     </li>",
"     <li>",
"      Extracapsular spread of nodal metastasis is an important prognostic factor that should be assessed on imaging. Imaging findings that suggest extracapsular spread of nodal metastasis include irregular border of the lymph node, infiltration of adjacent fat planes, and loss of cleavage plane with adjacent anatomical structures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI provides superior soft tissue definition compared with CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/28\">",
"     28",
"    </a>",
"    ] and can often provide information that is complementary to CT. For example, MRI can provide more accurate definition of tumors of the tongue and is more sensitive for superficial tumors. MRI is also better than CT for discriminating tumor from mucus and in detecting bone marrow invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/29\">",
"     29",
"    </a>",
"    ]. For this reason, MRI can be useful for evaluation of cartilage invasion, particularly for non-ossified cartilage that can pose difficulty for CT. On the other hand, CT scanning is better than MRI for detection of bone cortex invasion since MRI shows no bony detail.",
"   </p>",
"   <p>",
"    MRI is superior to CT for evaluation of perineural spread, skull base invasion, and intracranial extension of head and neck cancer.",
"   </p>",
"   <p>",
"    Most important imaging sequences for head and neck imaging include non-contrast enhanced T1-weighted images, contrast-enhanced T1-weighted images with fat suppression, and T2-weighted images with fat suppression. Images in axial and coronal plane are the most useful. For general purpose, slice thickness should be no more than 5 mm. Some applications, such as evaluation of skull base and perineural spread, may require thinner slice thickness, typically around 3 mm.",
"   </p>",
"   <p>",
"    In most studies, CT scanning outperforms MRI for the detection of pathologic nodal metastases. The reported sensitivity of MRI is as low as 57 to 67 percent. However, neither test reliably detects clinically occult regional node involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     PET and integrated PET/CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;With PET, injected positron-emitting radionuclides, such as fluorine-18, are taken up by metabolically or functionally active tissues. The positrons emitted from the radionuclides join with nearby electrons and annihilate each other. The resultant photons exit the site of annihilation at 180 degrees from each other. PET images are created by detecting these emissions by an array of detectors and then using reconstruction techniques to create a three dimensional image. The most commonly used agent is 18F-flourodeoxyglucose (FDG), which is taken up into cells in different concentrations depending on the relative metabolism of different tissues. It is fairly specific for tumors because metabolic rates are very high in many tumors.",
"   </p>",
"   <p>",
"    Imaging of the primary tumor site and regional lymph nodes with PET is limited by its poor spatial resolution, which can make it difficult to localize the anatomic location of the FDG uptake. These issues can be at least partially addressed with integrated PET-CT imaging, in which PET and CT are performed sequentially during a single visit on a hybrid PET-CT scanner. The images are then coregistered using fusion software, enabling the physiologic data obtained on PET to be localized according to the anatomic CT images.",
"   </p>",
"   <p>",
"    Historically, CT images obtained from integrated PET-CT scanners had lower spatial resolution compared with dedicated CT scanners. This problem is now being overcome by new generation of PET-CT scanners that offer volumetric CT capability",
"   </p>",
"   <p>",
"    PET appears to be at least as sensitive and specific as CT and MRI in detecting primary head and neck tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/13,30-32\">",
"     13,30-32",
"    </a>",
"    ]. More importantly, PET is superior to both CT and MRI for detecting regional nodal metastases, as well as distant metastases and second primary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/30-37\">",
"     30-37",
"    </a>",
"    ]. In one study, for example, PET had a sensitivity and specificity for detecting nodal metastases of 90 and 94 percent respectively, compared with 82 and 85 percent for CT, and 80 and 79 percent for MRI, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these data, the value of PET is uncertain for patients with a clinically negative (N0) neck, a reflection of its limitations in detecting occult nodal metastases less than 5 mm. The sensitivity of PET is lower in this setting (25 to 51 percent in four separate studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/34,38-40\">",
"     34,38-40",
"    </a>",
"    ]), although at least one series reports better results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/41\">",
"     41",
"    </a>",
"    ]. Some of this disparity may be due to the detail with which resected lymph nodes are examined pathologically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When used for the initial staging of head and neck cancer, integrated PET-CT imaging appears superior to CT, MRI, or PET alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 30 patients with newly diagnosed head and neck cancer, PET-CT (98 percent) was better than CT (70 percent) and MR alone (80 percent) in identifying primary tumor invasion of specific anatomical structures. Findings on PET-CT imaging altered management in 7 of 30 patients (23 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/14\">",
"       14",
"      </a>",
"      ]. Similar findings have been reported by others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The superiority of PET-CT in evaluating the cervical nodes was shown in a series in which integrated PET-CT was compared to CT alone in 63 patients with newly diagnosed head and neck cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/45\">",
"       45",
"      </a>",
"      ]. While CT alone identified 14 of 17 diseased heminecks (82 percent sensitivity) and 9 of 9 negative heminecks (specificity 100 percent), PET-CT detected metastatic disease in all 17 diseased heminecks and in 26 of 27 nodal zones that were histologically positive at the time of dissection.",
"     </li>",
"     <li>",
"      In a second report of 68 patients (52 with a squamous cell cancer of the head or neck, 8 with a squamous cell cancer of unknown origin, and 8 with recurrent or metastatic thyroid cancer), six proven malignancies were missed by PET, but only one was missed with PET-CT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/46\">",
"       46",
"      </a>",
"      ]. Of the 157 foci with abnormal FDG uptake, the fraction of equivocal lesions decreased by 53 percent with the integration of PET and CT (from 39 of 155 with PET to 18 of 157). Findings on PET-CT changed the treatment plan in 12 patients (18 percent).",
"     </li>",
"     <li>",
"      In a retrospective report of 123 patients with previously untreated head and neck cancer who underwent pretreatment",
"      <span class=\"nowrap\">",
"       PET/CT,",
"      </span>",
"      the scan was true positive in 103 (83 percent), while 15 (12.2 percent) had a false-positive study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/47\">",
"       47",
"      </a>",
"      ]. Synchronous lesions were found in 10 patients (8.3 percent) and distant metastases in 19 (15.4 percent). Of the 40 heminecks that underwent dissection, PET was positive in 19 of the 22 involved sides (sensitivity 86 percent) and it was negative in 16 of 17 uninvolved sides (specificity 96 percent). Overall, management was altered in 38 patients (31 percent) as a result of the PET scan. The originally planned surgery was canceled (19 patients, 15 percent) because of metastatic disease or finding a primary tumor residing outside of the head and neck region.",
"     </li>",
"     <li>",
"      False negatives of PET may be seen in lymph nodes less than 5 mm, necrotic or cystic lymph nodes, and tumors of low metabolic activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data indicate that",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is accurate for detecting occult cervical nodal metastases, although it does not have the sensitivity to replace neck dissection. Its main utility is in finding occult distant metastases as well as synchronous second primary lesions, as well as altering radiation fields and doses for patients who are not undergoing neck dissection. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Evaluation for distant metastases'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to the utility in assessing patients with a known primary head and neck cancer, integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be useful to identify small or superficial primary lesions that are not seen on CT or MRI in patients with cervical lymph node metastases of a squamous cell carcinoma and an unknown primary site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19911?source=see_link&amp;anchor=H26830849#H26830849\">",
"     \"Head and neck squamous cell carcinoma of unknown primary\", section on 'Radiographic imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Evaluation for distant metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;A component of the initial staging evaluation for patients with new or recurrent head and neck cancer is the search for distant metastases. The reported incidence is between 2 and 26 percent and varies based on locoregional control, nodal involvement (number and presence of extracapsular extension), primary site (particularly hypopharynx), histologic grade, and T stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/48-51\">",
"     48-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distant metastases are usually asymptomatic; the most common sites are the lungs followed by the liver and bone. Screening tests such as chest x-ray, serum alkaline phosphatase, and liver function tests are insensitive to the presence of distant metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. This was illustrated in a study of 97 patients with head and neck cancer, 14 of whom had distant metastases at 17 sites (10 lung, 5 bone, 2 liver) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/52\">",
"     52",
"    </a>",
"    ]. The sensitivity and specificity of chest x-ray for detection of pulmonary metastases was 50 and 94 percent, respectively; the sensitivity and specificity of serum alkaline phosphatase for detection of bone metastases was 20 and 98 percent; and the sensitivity and specificity of liver function tests for detection of hepatic metastases were 50 and 81 percent, respectively.",
"   </p>",
"   <p>",
"    The lack of predictive value for liver function tests was further demonstrated in a study of 140 patients with head and neck cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/53\">",
"     53",
"    </a>",
"    ]. Approximately one-half had abnormal liver function tests; none of these patients had liver metastases and all of the abnormalities were attributed to alcohol abuse (a major risk factor for head and neck cancer). Three patients who subsequently developed liver metastases had normal liver function tests. Liver-spleen scans are nonspecific for the detection of liver metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radionuclide bone scan plays a minor role in head and neck cancer. While head and neck cancers frequently metastasize to bone, the likelihood of finding a bone metastasis in a clinically asymptomatic patient is small, and bone scans are not a normal part of the initial staging evaluation. As an example, in one study of 93 cases, 40 patients had abnormal scans; none had metastatic disease outside the head and neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until recently, CT scan was the most sensitive method to screen for distant metastases in patients with head and neck cancer, identifying malignant findings in between 4 and 19 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/54,56-61\">",
"     54,56-61",
"    </a>",
"    ]. Although chest CT detects distant metastases more frequently than chest x-ray, it fails to detect 20 to 30 percent of thoracic metastases as well as the 2 to 5 percent of patients who will develop distant metastases outside the chest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/56,62,63\">",
"     56,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PET and integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be particularly valuable in the detection of distant metastases and synchronous second primary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/43,62-67\">",
"     43,62-67",
"    </a>",
"    ]. However, false-positive findings are common, underscoring the need to undertake histologic confirmation of any sites of abnormal uptake. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'PET and integrated PET/CT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These issues can be illustrated by a series of 349 patients with head and neck tumors who underwent preoperative",
"    <span class=\"nowrap\">",
"     head/neck",
"    </span>",
"    CT or MRI and whole body PET-CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/65\">",
"     65",
"    </a>",
"    ]. Further diagnostic imaging was guided by the results of the PET-CT scan. Overall there were 14 second primary tumors (4 percent) and 26 patients with distant metastases (7.4 percent) detected during staging or within 15 months of surgery. PET-CT correctly identified all by one (a patient with CT-demonstrable metastases in the lungs and gluteus muscle). However, there were 23 false-positive PET-CT results. Overall, the sensitivity, specificity, positive predictive value and negative predictive value were 98, 93, 63, and 99.7 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Incidence of second and multiple primaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;At-risk patients (ie, those with strong tobacco and alcohol use or family history) are prone to develop second primary cancers of the upper aerodigestive tract. Such tumors may be present at presentation or develop subsequently. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15270?source=see_link\">",
"     \"Second primary malignancies in patients with head and neck cancers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Future molecular staging methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analyzing differences in gene expression patterns across individual patients with a certain type of cancer may reveal molecular differences that permit refinements in their classification, prognostication, and treatment selection. At least some data suggests that primary head and neck cancers may carry specific molecular changes that are capable of predicting the presence of (or potential for) cervical nodal metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36537/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, these approaches remain investigational. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/53/6994?source=see_link\">",
"       \"Patient information: Mouth sores (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/38/5731?source=see_link\">",
"       \"Patient information: Tongue cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/38/6755?source=see_link\">",
"       \"Patient information: Laryngeal cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/20/8515?source=see_link\">",
"       \"Patient information: Throat cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6093555\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head and neck cancer encompasses a variety of cancers, mostly squamous cell carcinomas, which can arise in the oral cavity, pharynx, larynx, or salivary glands. The initial symptoms and subsequent staging depend upon the site of the primary tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'TNM staging system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      See individual tumor sites for more detailed discussions of different primary sites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proper staging of the primary tumor, regional lymph nodes, and exclusion of distant metastases is required for developing an optimal treatment plan. The initial assessment of the primary tumor includes a combination of inspection, palpation, indirect mirror examination, and direct endoscopy. An examination under anesthesia should be performed to define the extent of the tumor and to take biopsies for a tissue diagnosis. (See",
"      <a class=\"local\" href=\"#H6093579\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging studies (computed tomography [CT] magnetic resonance imaging [MRI], positron emission tomography [PET], and integrated",
"      <span class=\"nowrap\">",
"       PET/CT)",
"      </span>",
"      are important to assess the degree of local infiltration, involvement of regional lymph nodes, and presence of distant metastases or second primary tumors. The evaluation of the regional lymph nodes has improved significantly with the development of improved imaging modalities such as integrated",
"      <span class=\"nowrap\">",
"       PET/CT,",
"      </span>",
"      but these approaches still can miss more limited degrees of tumor involvement. All patients should have a staging CT scan or MRI of the head and neck. The role of routine PET scan in staging of all patients is less clear but should be considered in patients at high risk for metastatic disease or with equivocal findings on CT or MRI scan. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/1\">",
"      Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984; 53:563.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/3\">",
"      Rennemo E, Z&auml;tterstr&ouml;m U, Boysen M. Synchronous second primary tumors in 2,016 head and neck cancer patients: role of symptom-directed panendoscopy. Laryngoscope 2011; 121:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/4\">",
"      Strobel K, Haerle SK, Stoeckli SJ, et al. Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging 2009; 36:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/5\">",
"      Hujala K, Sipil&auml; J, Grenman R. Panendoscopy and synchronous second primary tumors in head and neck cancer patients. Eur Arch Otorhinolaryngol 2005; 262:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/6\">",
"      Rodriguez-Bruno K, Ali MJ, Wang SJ. Role of panendoscopy to identify synchronous second primary malignancies in patients with oral cavity and oropharyngeal squamous cell carcinoma. Head Neck 2011; 33:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/7\">",
"      Haerle SK, Strobel K, Hany TF, et al. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma. Head Neck 2010; 32:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/8\">",
"      Feldman PS, Kaplan MJ, Johns ME, Cantrell RW. Fine-needle aspiration in squamous cell carcinoma of the head and neck. Arch Otolaryngol 1983; 109:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/9\">",
"      Tandon S, Shahab R, Benton JI, et al. Fine-needle aspiration cytology in a regional head and neck cancer center: comparison with a systematic review and meta-analysis. Head Neck 2008; 30:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/10\">",
"      Pisharodi LR. False-negative diagnosis in fine-needle aspirations of squamous-cell carcinoma of head and neck. Diagn Cytopathol 1997; 17:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/11\">",
"      Righi PD, Kopecky KK, Caldemeyer KS, et al. Comparison of ultrasound-fine needle aspiration and computed tomography in patients undergoing elective neck dissection. Head Neck 1997; 19:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/12\">",
"      Takes RP, Righi P, Meeuwis CA, et al. The value of ultrasound with ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck. Int J Radiat Oncol Biol Phys 1998; 40:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/13\">",
"      Dammann F, Horger M, Mueller-Berg M, et al. Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET. AJR Am J Roentgenol 2005; 184:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/14\">",
"      Wong WL, Hussain K, Chevretton E, et al. Validation and clinical application of computer-combined computed tomography and positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose head and neck images. Am J Surg 1996; 172:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/15\">",
"      Atula TS, Varpula MJ, Kurki TJ, et al. Assessment of cervical lymph node status in head and neck cancer patients: palpation, computed tomography and low field magnetic resonance imaging compared with ultrasound-guided fine-needle aspiration cytology. Eur J Radiol 1997; 25:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/16\">",
"      Lawson G, Matar N, Nollevaux MC, et al. Reliability of sentinel node technique in the treatment of N0 supraglottic laryngeal cancer. Laryngoscope 2010; 120:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/17\">",
"      Alkureishi LW, Ross GL, Shoaib T, et al. Sentinel node biopsy in head and neck squamous cell cancer: 5-year follow-up of a European multicenter trial. Ann Surg Oncol 2010; 17:2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/18\">",
"      Barzan L, Sulfaro S, Alberti F, et al. An extended use of the sentinel node in head and neck squamous cell carcinoma: results of a prospective study of 100 patients. Acta Otorhinolaryngol Ital 2004; 24:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/19\">",
"      Weissman JL, Akindele R. Current imaging techniques for head and neck tumors. Oncology (Williston Park) 1999; 13:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/20\">",
"      Keberle M, Sandstede J, Hoppe F, et al. [Diagnostic impact of multiplanar reformations in multi-slice CT of laryngeal and hypopharyngeal carcinomas]. Rofo 2003; 175:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/21\">",
"      Lell MM, Gmelin C, Panknin C, et al. Thin-slice MDCT of the neck: impact on cancer staging. AJR Am J Roentgenol 2008; 190:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/22\">",
"      Prehn RB, Pasic TR, Harari PM, et al. Influence of computed tomography on pretherapeutic tumor staging in head and neck cancer patients. Otolaryngol Head Neck Surg 1998; 119:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/23\">",
"      Bloom C, Just N, Remy H, et al. Laryngeal cancer: is computed tomography a valuable imaging technique? A retrospective analysis. Can Assoc Radiol J 1998; 49:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/24\">",
"      Anzai Y, Brunberg JA, Lufkin RB. Imaging of nodal metastases in the head and neck. J Magn Reson Imaging 1997; 7:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/25\">",
"      Curtin HD, Ishwaran H, Mancuso AA, et al. Comparison of CT and MR imaging in staging of neck metastases. Radiology 1998; 207:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/26\">",
"      Merritt RM, Williams MF, James TH, Porubsky ES. Detection of cervical metastasis. A meta-analysis comparing computed tomography with physical examination. Arch Otolaryngol Head Neck Surg 1997; 123:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/27\">",
"      Don DM, Anzai Y, Lufkin RB, et al. Evaluation of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Laryngoscope 1995; 105:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/28\">",
"      Sakata K, Hareyama M, Tamakawa M, et al. Prognostic factors of nasopharynx tumors investigated by MR imaging and the value of MR imaging in the newly published TNM staging. Int J Radiat Oncol Biol Phys 1999; 43:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/29\">",
"      Rasch C, Keus R, Pameijer FA, et al. The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1997; 39:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/30\">",
"      McGuirt WF, Greven K, Williams D 3rd, et al. PET scanning in head and neck oncology: a review. Head Neck 1998; 20:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/31\">",
"      Di Martino E, Nowak B, Hassan HA, et al. Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg 2000; 126:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/32\">",
"      Hannah A, Scott AM, Tochon-Danguy H, et al. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002; 236:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/33\">",
"      Adams S, Baum RP, Stuckensen T, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/34\">",
"      Stuckensen T, Kov&aacute;cs AF, Adams S, Baum RP. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 2000; 28:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/35\">",
"      Stokkel MP, ten Broek FW, Hordijk GJ, et al. Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography. Ann Surg 2000; 231:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/36\">",
"      Kau RJ, Alexiou C, Laubenbacher C, et al. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 1999; 125:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/37\">",
"      Ng SH, Yen TC, Liao CT, et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 2005; 46:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/38\">",
"      Stoeckli SJ, Steinert H, Pfaltz M, Schmid S. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck 2002; 24:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/39\">",
"      Wensing BM, Vogel WV, Marres HA, et al. FDG-PET in the clinically negative neck in oral squamous cell carcinoma. Laryngoscope 2006; 116:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/40\">",
"      Ng SH, Yen TC, Chang JT, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 2006; 24:4371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/41\">",
"      Myers LL, Wax MK. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer. J Otolaryngol 1998; 27:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/42\">",
"      Zimmer LA, Branstetter BF, Nayak JV, Johnson JT. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope 2005; 115:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/43\">",
"      Zanation AM, Sutton DK, Couch ME, et al. Use, accuracy, and implications for patient management of [18F]-2-fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope 2005; 115:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/44\">",
"      Ha PK, Hdeib A, Goldenberg D, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/45\">",
"      Schwartz DL, Ford E, Rajendran J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 61:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/46\">",
"      Sch&ouml;der H, Yeung HW, Gonen M, et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004; 231:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/47\">",
"      Fleming AJ Jr, Smith SP Jr, Paul CM, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007; 117:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/48\">",
"      Garavello W, Ciardo A, Spreafico R, Gaini RM. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/49\">",
"      Le&oacute;n X, Quer M, Or&uacute;s C, et al. Distant metastases in head and neck cancer patients who achieved loco-regional control. Head Neck 2000; 22:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/50\">",
"      Leibel SA, Scott CB, Mohiuddin M, et al. The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys 1991; 21:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/51\">",
"      Liao CT, Wang HM, Chang JT, et al. Analysis of risk factors for distant metastases in squamous cell carcinoma of the oral cavity. Cancer 2007; 110:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/52\">",
"      Troell RJ, Terris DJ. Detection of metastases from head and neck cancers. Laryngoscope 1995; 105:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/53\">",
"      Korver KD, Graham SM, Hoffman HT, et al. Liver function studies in the assessment of head and neck cancer patients. Head Neck 1995; 17:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/54\">",
"      Houghton DJ, Hughes ML, Garvey C, et al. Role of chest CT scanning in the management of patients presenting with head and neck cancer. Head Neck 1998; 20:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/55\">",
"      Ampil FL, Wood MJ, Chin HW, et al. Screening bone scintigraphy in the staging of locally advanced head and neck cancer. J Craniomaxillofac Surg 1995; 23:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/56\">",
"      de Bree R, Deurloo EE, Snow GB, Leemans CR. Screening for distant metastases in patients with head and neck cancer. Laryngoscope 2000; 110:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/57\">",
"      Loh KS, Brown DH, Baker JT, et al. A rational approach to pulmonary screening in newly diagnosed head and neck cancer. Head Neck 2005; 27:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/58\">",
"      Reiner B, Siegel E, Sawyer R, et al. The impact of routine CT of the chest on the diagnosis and management of newly diagnosed squamous cell carcinoma of the head and neck. AJR Am J Roentgenol 1997; 169:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/59\">",
"      Tan L, Greener CC, Seikaly H, et al. Role of screening chest computed tomography in patients with advanced head and neck cancer. Otolaryngol Head Neck Surg 1999; 120:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/60\">",
"      Ong TK, Kerawala CJ, Martin IC, Stafford FW. The role of thorax imaging in staging head and neck squamous cell carcinoma. J Craniomaxillofac Surg 1999; 27:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/61\">",
"      Keski-S&auml;ntti HT, Markkola AT, M&auml;kitie AA, et al. CT of the chest and abdomen in patients with newly diagnosed head and neck squamous cell carcinoma. Head Neck 2005; 27:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/62\">",
"      Brouwer J, de Bree R, Hoekstra OS, et al. Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient? Laryngoscope 2005; 115:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/63\">",
"      Brouwer J, Senft A, de Bree R, et al. Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol 2006; 42:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/64\">",
"      Schmid DT, Stoeckli SJ, Bandhauer F, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003; 113:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/65\">",
"      Kim SY, Roh JL, Yeo NK, et al. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol 2007; 18:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/66\">",
"      Teknos TN, Rosenthal EL, Lee D, et al. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 2001; 23:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/67\">",
"      Basu D, Siegel BA, McDonald DJ, Nussenbaum B. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18. Arch Otolaryngol Head Neck Surg 2007; 133:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/68\">",
"      Roepman P, Wessels LF, Kettelarij N, et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005; 37:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36537/abstract/69\">",
"      Kleer CG, Teknos TN, Islam M, et al. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2006; 12:4485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3393 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36537=[""].join("\n");
var outline_f35_43_36537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6093555\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TNM STAGING SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS AND STAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6093579\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fine needle aspiration biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - PET and integrated PET/CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Evaluation for distant metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Incidence of second and multiple primaries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Future molecular staging methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6093555\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3393\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3393|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/56/27525\" title=\"figure 1\">",
"      Anatomy of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/53/19285\" title=\"figure 2\">",
"      Lymph nodes head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3393|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/12/39117\" title=\"table 1\">",
"      TNM stage oral cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/8/34957\" title=\"table 2\">",
"      TNM stage nasopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/55/36733\" title=\"table 3\">",
"      TNM stage oropharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/42/37549\" title=\"table 4\">",
"      TNM stage hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/14/22766\" title=\"table 5\">",
"      TNM stage larynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/42/9902\" title=\"table 6\">",
"      TNM stage sinonasal sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/52/35661\" title=\"table 7\">",
"      TNM stage salivary glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13013?source=related_link\">",
"      Cancer of the nasal vestibule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19911?source=related_link\">",
"      Head and neck squamous cell carcinoma of unknown primary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43959?source=related_link\">",
"      Overview of treatment for head and neck squamous cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23241?source=related_link\">",
"      Paranasal sinus cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12362?source=related_link\">",
"      Pathology of head and neck neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/38/6755?source=related_link\">",
"      Patient information: Laryngeal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/53/6994?source=related_link\">",
"      Patient information: Mouth sores (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/20/8515?source=related_link\">",
"      Patient information: Throat cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/38/5731?source=related_link\">",
"      Patient information: Tongue cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15270?source=related_link\">",
"      Second primary malignancies in patients with head and neck cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34232?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20552?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/29/32217?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The oral cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3174?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The oropharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8250?source=related_link\">",
"      Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39206?source=related_link\">",
"      Tumors of the nasal cavity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_43_36538="Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects";
var content_f35_43_36538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36538/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36538/contributors\">",
"     Toni K Choueiri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36538/contributors\">",
"     Guru Sonpavde, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36538/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36538/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36538/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36538/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/43/36538/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36538/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/43/36538/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/43/36538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H112181231\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of angiogenesis inhibitors in cancer therapy is expanding. Following the recognition of the role of angiogenesis in promoting tumor growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/1\">",
"     1",
"    </a>",
"    ], multiple trials have shown that angiogenesis inhibitors yield incremental improvements in outcomes for a variety of advanced solid tumors.",
"   </p>",
"   <p>",
"    Several classes of agents are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      is a monoclonal antibody against vascular endothelial growth factor (VEGF) that inhibits binding of the normal VEGF ligand to its receptor. In the United States, the approval of bevacizumab for metastatic colorectal cancer (mCRC) by the Food and Drug Administration (FDA) ushered in the modern era of antiangiogenic therapy. The European Medicines Agency (EMA) granted approval for bevacizumab in mCRC in January 2006. Subsequently, bevacizumab has been approved by both the FDA and EMA for treatment of metastatic nonsquamous, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and glioblastoma multiforme. The EMA has also approved bevacizumab for treatment of ovarian cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H23212813#H23212813\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779238#H525779238\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Role of bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=see_link&amp;anchor=H24#H24\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'Bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of recurrent malignant gliomas\", section on 'Bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11832?source=see_link&amp;anchor=H11858079#H11858079\">",
"       \"The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum\", section on 'Bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"       Aflibercept",
"      </a>",
"      , another VEGF ligand inhibitor, is a VEGF receptor (VEGFR) fusion molecule that binds to and inhibits VEGF ligand binding to all classes of VEGFR as well as placenta growth factor (PlGF) binding to VEGFR1; it is approved in combination with chemotherapy for recurrent mCRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H23212877#H23212877\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Aflibercept'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple orally active tyrosine kinase inhibitors (TKIs) that block angiogenesis by inhibiting the actions of VEGF and other growth factors (eg, platelet derived growth factor) are available, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"       vandetanib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"       cabozantinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"       regorafenib",
"      </a>",
"      . These drugs have received approval for treatment of a variety of tumors, including RCC, hepatocellular cancer (HCC), gastrointestinal stromal tumors (GIST), medullary thyroid cancer (MTC), pancreatic neuroendocrine tumors (PNET), soft tissue sarcomas (STS), refractory chronic myelogenous leukemia, and refractory mCRC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=see_link&amp;anchor=H3#H3\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'VEGF TK inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H18#H18\">",
"       \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Sorafenib'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link&amp;anchor=H25772305#H25772305\">",
"       \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Alternative treatment strategies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23288?source=see_link&amp;anchor=H2#H2\">",
"       \"Chemotherapy and immunotherapy for medullary thyroid cancer\", section on 'Tyrosine kinase inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=see_link&amp;anchor=H190949089#H190949089\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Small molecule TK inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/11/41146?source=see_link&amp;anchor=H26#H26\">",
"       \"Systemic treatment of metastatic soft tissue sarcoma\", section on 'Antiangiogenic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=see_link&amp;anchor=H12149527#H12149527\">",
"       \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Ponatinib'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H56909045#H56909045\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Regorafenib'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the expanding use of agents that target the VEGF signaling pathway in cancer therapy, it is increasingly recognized that they are associated with a wide spectrum of toxicities which, in a small number of cases, may be fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. While some adverse effects are shared with conventional chemotherapeutic agents (which target cell division), many are unique and not typically observed with conventional cytotoxics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class-effects of VEGF axis inhibition by both VEGF-ligand and TKIs that target angiogenesis include cardiovascular effects (eg, hypertension, thromboembolism, left ventricular dysfunction) and non-cardiovascular effects (eg, proteinuria, bleeding, delayed wound healing, gastrointestinal perforation, fatigue, and dysphonia). Other rare class effects of VEGF axis inhibition include reversible posterior leukoencephalopathy, osteonecrosis of the jaw, and microangiopathic hemolysis.",
"     </li>",
"     <li>",
"      The antiangiogenic TKIs have additional class effects, including gastrointestinal events (diarrhea, nausea), thyroid dysfunction, fatigue, stomatitis, myelosuppression, cutaneous effects (including hand-foot skin reaction) and dysphonia. In addition, severe and occasionally fatal hepatic toxicities have been seen with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      . Rare effects include pancreatic enzyme elevations, hypoglycemia, and QTc prolongation.",
"      <br/>",
"      <br/>",
"      Some of these side effects may reflect the promiscuity of kinase inhibitors, which inhibit multiple other receptors in addition to VEGFRs (referred to as off-target activity).",
"     </li>",
"     <li>",
"      Some toxicities are mostly reported with certain agents, such as nasal septal perforation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      and",
"      <span class=\"nowrap\">",
"       sarcopenia/muscle",
"      </span>",
"      wasting with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these adverse effects are serious, and some may be fatal. (See",
"    <a class=\"local\" href=\"#H89432458\">",
"     'Risk of fatality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic review will cover cardiovascular adverse effects of the anti-VEGF agents (hypertension, thromboembolic disease, left ventricular dysfunction, myocardial ischemia, and prolongation of the QTc interval). All other (non-cardiovascular) toxicities from VEGF pathway inhibitors as well as thrombotic complications of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    , drugs that have immunomodulatory as well as antiangiogenic activity, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89432458\">",
"    <span class=\"h1\">",
"     RISK OF FATALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses have demonstrated a small risk of fatal adverse events (~1.5 to 2.5 percent, relative risk [RR] 1.5 to 2.2) with both antiangiogenic TKIs and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In one analysis, bevacizumab was associated with an increased risk of fatal events when used in combination with taxanes or platinum agents (RR, 3.49) but not in combination with other agents (RR, 0.85) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two meta-analyses, hemorrhage was the most common fatal adverse event with both classes of agents; other causes of treatment-related death were cardiac, gastrointestinal tract perforation, hepatic dysfunction, infection, and cerebrovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227378#H1651227378\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In another meta-analysis examining fatal events with antiangiogenic TKIs, fatalities from heart failure, pulmonary emboli, hepatic failure, intestinal perforation, and",
"    <span class=\"nowrap\">",
"     pneumonia/respiratory",
"    </span>",
"    failure were numerically higher on the TKI treatment arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/6\">",
"     6",
"    </a>",
"    ]. In this study, the increased RR for death with the TKIs was statistically significant for patients with renal cell cancer (RCC), but not for those with lung cancer. However, the increased risk seen in patients treated for RCC may be ascribed partly to increased exposure time to the antiangiogenic TKI in patients with RCC relative to those with lung cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291525424\">",
"    <span class=\"h1\">",
"     CLASS EFFECTS OF ALL VEGF INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21639449\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;VEGF plays a key role in the maintenance of vascular homeostasis via mediation of the production of the vasodilator nitric oxide, and decreased vascular resistance through the generation of new blood vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Both of these influences are associated with decreases in blood pressure. Thus, it is not surprising that inhibition of VEGF signaling might be associated with hypertension (HTN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Because of this, all trials evaluating inhibitors of angiogenesis have restricted eligibility to patients with controlled blood pressure at baseline.",
"   </p>",
"   <p>",
"    All commercially available angiogenesis inhibitors have been implicated in the development of hypertension, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/14,15\">",
"     14,15",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/16\">",
"     16",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/17,18\">",
"     17,18",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/19\">",
"     19",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/20\">",
"     20",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/21\">",
"     21",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/17,22\">",
"     17,22",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/23\">",
"     23",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21639456\">",
"    <span class=\"h3\">",
"     Incidence and characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following studies have addressed the incidence of HTN in patients treated with angiogenesis inhibitors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of 12,949 patients treated with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      for advanced solid tumors, the relative risk (RR) of developing &ldquo;significantly raised&rdquo; blood pressure (defined as more than one drug needed for treatment, or for a more intensive treatment than used previously, or life-threatening consequences such as hypertensive crisis; grade 3 or 4 (",
"      <a class=\"graphic graphic_table graphicRef87347 \" href=\"mobipreview.htm?36/25/37275\">",
"       table 1",
"      </a>",
"      )) among patients receiving bevacizumab was 5.38 (95% CI 3.63-7.97) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/25\">",
"       25",
"      </a>",
"      ]. Among patients receiving bevacizumab, the overall incidence of all raised blood pressure events was 24 percent (95% CI 20&ndash;29 percent), while the incidence of significantly raised blood pressure was 8 percent (95% CI 6-10 percent). Risk was dose-dependent; the RRs of severe HTN at doses of 5 and 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week were 7.17 (95% CI, 3.91-13.13) and 4.11 (95% CI 2.49-6.78), respectively.",
"     </li>",
"     <li>",
"      Another meta-analysis analyzed the incidence of HTN in 13 prospective studies with 4999 patients who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      for RCC or other malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/26\">",
"       26",
"      </a>",
"      ]. Among patients receiving sunitinib, the overall incidence of all-grade HTN was 22 percent, with severe HTN in 7 percent. When compared with control patients not receiving sunitinib, the use of sunitinib was associated with a significantly increased risk of severe HTN (RR 22.72, 95% CI 4.48-115.29).",
"     </li>",
"     <li>",
"      Almost identical findings were noted in a systematic review that analyzed the incidence of hypertension in 4599 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      in nine prospective studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among the VEGFR TKIs, it is unclear if any single agent causes HTN with greater frequency; in one meta-analysis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      was associated with higher rates of all-grade hypertension than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      (36 versus 23 and 22 percent, respectively), but similar rates of severe hypertension (6.5 versus 5.7 and 6.8 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/28\">",
"       28",
"      </a>",
"      ]. In phase III trials directly comparing TKIs in advanced RCC, pazopanib and sunitinib were associated with similar rates of all grade HTN (46 percent, 41 percent), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      was associated with somewhat more HTN compared to sorafenib (40 versus 29 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/17,29\">",
"       17,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of severe hypertension may be higher with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"       aflibercept",
"      </a>",
"      than with other VEGF-targeted therapies, but no direct comparisons of aflibercept with other VEGF inhibitors exist (19.1 percent for aflibercept compared to 1.5 percent for placebo when both were administered in combination with chemotherapy in patients with colorectal cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/16\">",
"       16",
"      </a>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dramatic increases in both diastolic (as high as 27 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/30\">",
"     30",
"    </a>",
"    ]) and systolic (as high as 29 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/30\">",
"     30",
"    </a>",
"    ]) blood pressure may be seen as early as the first week of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. It is not possible to predict which patients will have this magnitude of blood pressure elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/32\">",
"     32",
"    </a>",
"    ]. Because serious adverse events have been associated with unmanaged HTN, all patients receiving therapy with an angiogenesis inhibitor should have their blood pressure actively monitored during treatment, with more frequent measurement in the first several weeks of therapy. (See",
"    <a class=\"local\" href=\"#H21639463\">",
"     'Monitoring and management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30695629\">",
"    <span class=\"h3\">",
"     Association with antitumor efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports note an association between improved antitumor efficacy and the development of systolic or diastolic HTN during therapy with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and the antiangiogenic TKIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/15,33-39\">",
"     15,33-39",
"    </a>",
"    ]; however, this has not been seen in all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a combined series analyzing 544 patients enrolled on four prospective trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      for advanced RCC, antitumor efficacy was significantly better in patients with one or more systolic blood pressure readings &ge;140 mmHg (median overall survival, median progression-free survival, and objective response rates were 30.9 versus 7.2 months, 12.5 versus 2.5 months, and 55 versus 9 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/42\">",
"       42",
"      </a>",
"      ]. Similar results were seen using a criterion of diastolic blood pressure &ge;90 mmHg. Multivariate analysis confirmed that treatment with sunitinib was an independent factor for survival after incorporating other known risk factors (hazard ratio [HR] 0.28, 95% CI 0.22-0.37). Secondary analyses found that the improvement in efficacy was maintained in patients who were treated for HTN or had a dose reduction of sunitinib [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, a lack of association between early hypertension and clinical benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      was suggested in an analysis of seven randomized trials of bevacizumab versus no bevacizumab in patients with RCC, colorectal, breast, non-small cell lung, and pancreatic cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/41\">",
"       41",
"      </a>",
"      ]. In six of the seven studies, early hypertension (defined as an increase in systolic blood pressure of &gt;20 mm Hg or of diastolic blood pressure &gt;10 mm Hg within the first 60 days of treatment) was not predictive of clinical benefit from bevacizumab.",
"     </li>",
"     <li>",
"      Other data suggest that the apparent relationship between efficacy and toxicity may be related to increased drug exposure. In a report that systematically analyzed pharmacokinetic and pharmacodynamic data from six clinical studies of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      , sunitinib dose intensity and cumulative weekly dose correlated with both improved clinical outcomes and maximum blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hence, further studies are warranted to validate HTN as a predictive biomarker of efficacy in patients treated with angiogenesis inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21639463\">",
"    <span class=\"h3\">",
"     Monitoring and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although minimalist approaches to managing HTN for patients with incurable diseases might be favored in some circumstances, management of comorbidities, including HTN, may actually improve survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/45\">",
"     45",
"    </a>",
"    ]. Furthermore, active control of HTN should allow patients to tolerate the highest effective doses of therapy, for the longest period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Investigational Drug Steering Committee of the NCI formed a Cardiovascular Toxicities Panel, joining members of its Angiogenesis Task Force with experts in the management of HTN in cancer patients to generate consensus recommendations for risk assessment, monitoring, and safe administration of angiogenesis inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/32\">",
"     32",
"    </a>",
"    ]. Their recommendations included the following four components (",
"    <a class=\"graphic graphic_table graphicRef73373 graphicRef63338 \" href=\"mobipreview.htm?37/10/38061\">",
"     table 2A-B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform a pretreatment evaluation and screening, including formal risk assessment for potential cardiovascular complications.",
"     </li>",
"     <li>",
"      Identify and treat pre-existing hypertension before using these agents.",
"     </li>",
"     <li>",
"      Actively monitor blood pressure during treatment, with more frequent measurement in the first several weeks of therapy.",
"     </li>",
"     <li>",
"      Manage blood pressure during therapy, with a goal of keeping BP less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg for most patients; lower in those with specific preexisting cardiovascular risk factors, such as diabetes or chronic kidney disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continuous ambulatory blood pressure monitoring has been proposed for monitoring of blood pressure and management of hypertension in patients with advanced RCC receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/19\">",
"     19",
"    </a>",
"    ]. However, this approach is not in widespread use, at least in the US.",
"   </p>",
"   <p>",
"    Patients who develop HTN during treatment (defined as blood pressure &ge;140 mm",
"    <span class=\"nowrap\">",
"     Hg/90",
"    </span>",
"    mmHg or a 20 mm increase in diastolic blood pressure over baseline) should be treated with antihypertensives. The choice of agent must take into consideration the severity of the hypertension and the urgency of blood pressure control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28246?source=see_link\">",
"     \"Management of severe asymptomatic hypertension (hypertensive urgencies)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, several other considerations may influence the choice of antihypertensive therapy. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimal anti-hypertensive agents in this context have not been defined. However,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      undergo partial metabolism via cytochrome P450, a system inhibited by some antihypertensive agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/12\">",
"       12",
"      </a>",
"      ]. Therefore, these agents should probably be avoided in patients who develop HTN while receiving sorafenib or sunitinib.",
"     </li>",
"     <li>",
"      Organ dysfunction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      adverse effects on organ function may influence the choice and dose of the antihypertensive agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291526412\">",
"    <span class=\"h2\">",
"     Arterial and venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk for arterial thromboembolic events (ATEs) has been linked to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , and a number of the antiangiogenic TKIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/16,47\">",
"     16,47",
"    </a>",
"    ]. Whether the risk of venous thromboembolic events is increased in these patients is uncertain; the data are mixed. Notably, patients with prior cardiovascular or venous thrombotic events (VTEs) within 6 to 12 months were not enrolled on clinical trials of these agents in a variety of malignancy types.",
"   </p>",
"   <p>",
"    The pathophysiology underlying the increased risk of thromboembolism in patients treated with inhibitors of angiogenesis remains unresolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/48\">",
"     48",
"    </a>",
"    ]. The main hypothesis is that perturbation of tumor-associated endothelial cells can switch the endothelium from a naturally anticoagulant surface to a prothrombotic surface, thus mediating the activation of systemic coagulation in cancer patients, who are already more susceptible to thromboembolism due to their underlying disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The VEGF pathway has been reported to protect and regulate endothelial cell function via pathways that inhibit apoptosis and inflammation. VEGF-induced nitric oxide production by endothelial cells has been proposed to block antiplatelet activity and leukocyte adhesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. As a consequence, endothelial cell dysfunction may expose pro-thrombotic phospholipids and underlying stroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291526420\">",
"    <span class=\"h3\">",
"     Bevacizumab and aflibercept",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291526440\">",
"    <span class=\"h4\">",
"     Arterial thromboembolic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased incidence of potentially fatal ATEs (including transient ischemic attacks, strokes, angina, and myocardial infarction) was initially reported with the use of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing chemotherapy regimen for advanced colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/52\">",
"     52",
"    </a>",
"    ]. In randomized trials, the 4 to 5 percent incidence of serious ATEs in patients receiving bevacizumab in combination with a short-term infusional 5-FU-based chemotherapy regimen represented an approximately two- to threefold higher incidence than in the control groups receiving the same chemotherapy regimen without bevacizumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of ATEs in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    plus chemotherapy compared with chemotherapy alone in a variety of malignancies has been further clarified by the findings from at least three meta-analyses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In an individual patient level meta-analysis of data from five trials in three different tumor entities, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      with concomitant chemotherapy increased the risk of an ATE twofold (RR 2.0, 95% CI 1.05-3.75) compared with chemotherapy without bevacizumab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/54\">",
"       54",
"      </a>",
"      ]. Patients over 65 years of age (hazard ratio [HR] 2.1) and those with a prior history of ATEs (HR 4.18) appeared to be at highest risk for an ATE, particularly if they had both risk factors combined (HR 7.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The risk may also vary according to the type of malignancy. In a trial-level meta-analyses of over 13,000 patients treated on 20 randomized trials, the RR increase for ATEs in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      for a variety of advanced malignancies was 1.46 (95% CI 1.11-1.93); this translated into an incidence of 2.6 percent (95% CI 2-3.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/55\">",
"       55",
"      </a>",
"      ]. The highest ATE incidence was seen in patients treated for mCRC (3.2 percent, 95% CI 1.9-5.4), and the lowest was in patients treated for breast cancer (0.7, 95% CI 0.1-3.6), a diagnosis for which bevacizumab is no longer approved. Incidence rates for patients treated for NSCLC and RCC were 2.5 percent (95% CI 1.8-3.7) and 2.3 percent (95% CI 1.4-3.7), respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A dose-response effect has not been shown. Both trial-level meta-analyses failed to demonstrate higher rates of ATEs in patients treated with higher doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (ie, 5 versus 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fewer data are available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    . ATEs were not observed in phase I and II trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In a phase III trial of chemotherapy with and without aflibercept in patients with mCRC, the rate of all-grade ATEs in the aflibercept group was 2.6 versus 1.5 percent with chemotherapy alone, but the rate of a grade 3 or 4 event was 1.8 versus 0.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78097915\">",
"    <span class=\"h5\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not consider that a prior history of an ATE represents an absolute contraindication to use of antiangiogenic agents. We suggest caution and maintaining a low index of suspicion for drug-related ATEs in patients with a prior history of thromboembolic events. A discussion of the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in older adult patients who have a history of an ATE within the past 6 to 12 months can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41466?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The FDA-approved manufacturer&rsquo;s labeling indicates that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    should be discontinued for any severe ATE, but do not define &ldquo;severe&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/59\">",
"     59",
"    </a>",
"    ]. The labeling information for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    recommends discontinuation of the drug in patients who experience an ATE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/60\">",
"     60",
"    </a>",
"    ]. We discontinue both drugs for all grade 3 or higher (",
"    <a class=\"graphic graphic_table graphicRef87383 \" href=\"mobipreview.htm?33/30/34283\">",
"     table 3",
"    </a>",
"    ) new or worsened arterial thrombotic events during therapy, unless the clinical benefits considerably outweigh the risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/61\">",
"     61",
"    </a>",
"    ]. Continuation with concurrent anticoagulation might be considered in selected patients who are clearly benefiting from antiangiogenic therapy and who are willing to accept the hypothetical risk from continued use of bevacizumab in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291526448\">",
"    <span class=\"h4\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has been inconsistently associated with an increased risk of venous thromboembolic events (VTE) in cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/54,62,63\">",
"     54,62,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two individual patient level meta-analyses failed to identify a significant increase in risk of VTE in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      plus chemotherapy versus chemotherapy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/54,63\">",
"       54,63",
"      </a>",
"      ]. In one of these meta-analyses (n=1745 patients), the HR for VTE was 0.89 (p=0.44) and in the second study (n=6055 patients), the odds ratio was 1.14 (p=0.13).",
"     </li>",
"     <li>",
"      On the other hand, a significant risk of VTE in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      was shown in another trial-level meta-analysis of 7956 patients (RR of 1.33, p&lt;0.001), which disappeared when examining these events per unit of time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the association between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and VTE remains uncertain.",
"   </p>",
"   <p>",
"    The available data on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    are limited. In a phase III trial comparing chemotherapy with and without aflibercept in patients with mCRC, the risk of all-grade VTE was 9.3 versus 7.3 percent with chemotherapy alone, and for grade 3 or 4 VTE, it was 7.8 versus 6.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78097976\">",
"    <span class=\"h5\">",
"     Prevention and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is not enough information available to recommend for or against the use of routine anticoagulation to prevent VTE in ambulatory cancer patients receiving, or about to receive, therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    . We agree with the Clinical Practice Guidelines in Oncology from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    , which suggest stratifying recommendations for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or anticoagulant prophylaxis in patients with cancer according to the presence or absence of risk factors for VTE. The NCCN does not consider the use of angiogenesis inhibitors to represent a risk factor for VTE in cancer patients and we largely agree with this. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H10#H10\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prompt diagnosis and management is essential for patients who develop a VTE during treatment. Issues related to diagnosis and treatment of VTE in patients with malignancy are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=see_link\">",
"     \"Treatment of venous thromboembolism in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The FDA-approved manufacturer&rsquo;s package insert gives no recommendations for management of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    in patients who develop VTE while receiving the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The decision to discontinue the angiogenesis inhibitor in such cases must be individualized. Continuation of bevacizumab or aflibercept with concurrent anticoagulation is a reasonable approach for patients who are clearly benefiting from the drug.",
"   </p>",
"   <p>",
"    Angiogenesis inhibitors can be associated with an increased risk of hemorrhage, raising concern about the safety of therapeutic anticoagulation in patients who are being treated with these agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227378#H1651227378\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the concurrent administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    appeared to be safe in a large retrospective pooled analysis (risk of bleeding 1.9 versus 1.2 percent in bevacizumab and control patients, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/63\">",
"     63",
"    </a>",
"    ]. Moreover, the majority of bleeds were minor epistaxis episodes, and the rates of severe (grade &ge;3) bleeds were similar and infrequent in both groups (0.2 percent).",
"   </p>",
"   <p>",
"    A similarly low rate of bleeding events with continued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and full-dose anticoagulation was shown in another analysis of three studies, two conducted in patients with mCRC and one in advanced NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/64\">",
"     64",
"    </a>",
"    ]. There are no data on this approach for patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Low molecular weight heparins are generally preferred for the treatment of VTE in patients with cancer; their use has been associated with a lower recurrence risk than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , without significantly increasing the rate of serious bleeding. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of venous thromboembolism in patients with malignancy\", section on 'LMW heparin versus warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291526542\">",
"    <span class=\"h3\">",
"     VEGF receptor TKIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of ATEs has also been shown in patients treated with antiangiogenic TKIs that prevent VEGF receptor signaling (relative to no treatment with a TKI), but as with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , the relationship to VTEs remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1465984650\">",
"    <span class=\"h4\">",
"     Arterial thromboembolic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following data are available regarding the risk of ATEs in patients receiving antiangiogenic TKIs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a systematic review and meta-analysis that included 10,255 patients (87 percent with RCC) treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      in 10 studies (which included phase II and III trials as well as data from expanded access programs), the incidence of ATEs was 1.4 percent (RR 3.0 compared with controls) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/65\">",
"       65",
"      </a>",
"      ]. There were no differential impacts based on the underlying malignancy (RCC versus others) and specific TKI (sunitinib versus sorafenib).",
"     </li>",
"     <li>",
"      In a placebo-controlled phase III trial of 903 patients treated for advanced RCC, 2.9 percent of patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      developed myocardial ischemia or infarction compared with 0.4 percent of patients receiving placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, in a placebo-controlled randomized trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      in advanced RCC, ATEs occurred in 3 percent of pazopanib-treated patients versus none in the placebo group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      for refractory chronic myelogenous leukemia, 11 percent developed arterial thrombosis of any grade; 8 percent had serious arterial thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/68\">",
"       68",
"      </a>",
"      ]. Thirty of the 34 patients developing arterial thrombosis had one or more cardiac risk factors (coronary artery disease, stroke, transient ischemic attack, hypertension, diabetes, hyperlipidemia, history of smoking).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78098047\">",
"    <span class=\"h5\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both prevention and prompt management of an arterial thromboembolic event are critical. Prior to instituting therapy with antiangiogenic TKIs, predisposing cardiovascular risk factors (ie, hypertension, hyperlipidemia, and diabetes) should be aggressively managed. Baseline blood pressure should be controlled and the drug preferably not administered to patients with serious cardiovascular events within 6 to 12 months. Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    prophylaxis is reasonable in high-risk patients such as those with a prior ATE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who develop an ATE while receiving an antiangiogenic TKI should discontinue the antiangiogenic treatment and the ATE should be managed according to usual standards of care. Reintroduction of the agent may be considered cautiously in select cases for patients who are clearly benefiting from therapy and who are willing to accept the uncertainty of risk from continued use of the TKI in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1465984660\">",
"    <span class=\"h4\">",
"     Venous thromboembolic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between antiangiogenic TKIs and VTE is uncertain. Semaxanib (SU5416), an investigational TKI that inhibits VEGF signaling, demonstrated a potential increase in VTEs in castration-resistant prostate cancer (11 percent), multiple myeloma (15 percent), and soft tissue sarcomas (15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. However, a meta-analysis of 7441 patients from nine phase III and eight phase II trials failed to demonstrate an increase in VTE in patients with solid tumors treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/74\">",
"     74",
"    </a>",
"    ]. The summary RR for all-grade VTEs was 1.10 (95% CI 0.73-1.66) compared to no TKI controls, and for high-grade VTEs, it was 0.85 (95% CI 0.58-1.25). There was no difference in risk based upon tumor type or age.",
"   </p>",
"   <p>",
"    Similar conclusions were reached in a second meta-analysis of 14 trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291526581\">",
"    <span class=\"h5\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is not enough information available to recommend for or against the use of routine anticoagulation to prevent VTE in ambulatory cancer patients receiving, or about to receive, therapy with antiangiogenic TKIs. We agree with the Clinical Practice Guidelines in Oncology from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    , which suggest stratifying recommendations for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or anticoagulant prophylaxis in patients with cancer according to the presence or absence of risk factors for VTE. The NCCN does not consider the use of angiogenesis inhibitors to represent a risk factor for VTE in cancer patients and we largely agree with this. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H10#H10\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a patient undergoing therapy with an antiangiogenic TKI develops a VTE, prompt diagnosis and treatment are essential. Issues related to diagnosis and treatment of VTE in patients with malignancy are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=see_link\">",
"     \"Treatment of venous thromboembolism in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A brief withdrawal of the TKI may be prudent, while anticoagulation is being attained. Resumption of the TKI once anticoagulation is established is reasonable assuming the patient is receiving antitumor benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21640522\">",
"    <span class=\"h2\">",
"     Left ventricular dysfunction and myocardial ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Declines in left ventricular function can be seen in patients treated with VEGF-targeted therapies; they are predominantly seen in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    . In addition, myocardial ischemia has been seen in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21640884\">",
"    <span class=\"h3\">",
"     VEGF receptor TKIs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78098454\">",
"    <span class=\"h4\">",
"     Sunitinib and sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;In retrospective series and clinical trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    has been associated with a decline in left ventricular ejection fraction (LVEF) in up to 28 percent of treated patients and clinical heart failure in 3 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/76-80\">",
"     76-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the pivotal randomized trial that led to approval of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    for advanced renal cell cancer, 21 percent of patients experienced a decline in LVEF, but this was symptomatic in only 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/79\">",
"     79",
"    </a>",
"    ]. All cases were reversible and not associated with an adverse clinical outcome. In an early study of patients receiving sunitinib for a gastrointestinal stromal tumor (GIST), left ventricular dysfunction developed in 10 versus 3 percent of the sunitinib and placebo-treated patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of the published literature that included 6936 patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    for a variety of oncologic indications and who had regular cardiac function monitoring, the summary incidence of all grades of heart failure was 4.1 percent (95% CI 1.5-10.6 percent) and of grade 3 or 4 heart failure (",
"    <a class=\"graphic graphic_table graphicRef58345 \" href=\"mobipreview.htm?18/59/19387\">",
"     table 4",
"    </a>",
"    ) was 1.5 percent (95% CI 0.8-3.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/81\">",
"     81",
"    </a>",
"    ]. There were no differences in subgroups of patients receiving sunitinib for renal cell versus nonrenal cell cancer indications. Both hypertension and a history of coronary artery disease (CAD) are thought to increase the risk of sunitinib cardiotoxicity.",
"   </p>",
"   <p>",
"    However, these data from clinical trials probably underestimate the risk of LVEF decline and clinical heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/82\">",
"     82",
"    </a>",
"    ]. It is now thought that the vast majority of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    (29 of 36 in one analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/76\">",
"     76",
"    </a>",
"    ]) experience an LVEF drop during therapy that approximately one in five have LVEF reductions of 15 percent or more, that 11 percent of patients receiving repeated cycles of sunitinib a cardiovascular event, mostly heart failure, and that preexisting hypertension and coronary artery disease are risk factors for cardiac toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have had a cardiovascular event (eg, myocardial infarction,",
"    <span class=\"nowrap\">",
"     severe/unstable",
"    </span>",
"    angina,",
"    <span class=\"nowrap\">",
"     coronary/peripheral",
"    </span>",
"    artery bypass graft, symptomatic heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism) within 12 months prior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    administration have been excluded from the sunitinib studies. If sunitinib is administered to such patients, they should be carefully monitored for clinical signs and symptoms of heart failure, and undergo periodic reevaluation of LVEF during therapy.",
"   </p>",
"   <p>",
"    Less data on cardiotoxicity are available with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one phase III trial of patients treated for advanced renal cell cancer, 2.9 percent of patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      developed myocardial ischemia or infarction compared with 0.4 percent of patients receiving placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      in advanced HCC, the incidence of cardiac ischemia or infarction with sorafenib was 2.7 versus 1.3 percent in the placebo group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major problem with defining the precise rate of cardiotoxicity associated with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and its reversibility is that phase III trials have not pursued cardiac endpoints, and the identification of cardiac side effects with both drugs has predominantly been based on the occurrence of clinical symptoms. Potentially, the most comprehensive data on the range and frequency of cardiotoxicity with these drugs come from an observational series of 86 consecutive patients with renal cell cancer who were treated with either sunitinib or sorafenib at a single Austrian center over a 15-month period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/84\">",
"     84",
"    </a>",
"    ]. During treatment, 25 of 74 assessable patients (34 percent, including 11 receiving sunitinib and 14 treated with sorafenib) experienced a cardiovascular event, as defined by new elevation in cardiac enzymes, symptomatic arrhythmia requiring treatment, new left ventricular dysfunction, or acute coronary syndrome. Reported ECG changes included changes in rhythm, conduction disturbance, change in axis or QRS amplitude, ST or T wave changes, and QTc prolongation (which has been reported by others with sunitinib). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All symptomatic patients discontinued use of the TKI and began medical cardiovascular treatment. All recovered, although three had persisting abnormal cardiac enzymes through the entire TKI treatment period.",
"   </p>",
"   <p>",
"    However, the high rate of cardiotoxicity in this series could have been related to the broad (and unconventional) definition of a cardiac event. In a preliminary report of cardiac toxicities with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    use for the adjuvant therapy of renal cell carcinoma (ASSURE phase III trial), cardiac function in patients starting with normal LVEF was not impaired significantly over placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/85\">",
"     85",
"    </a>",
"    ]. Ischemic events were uncommon and not clearly associated with treatment. However, it should be noted that cardiac function was assessed at the six month time point and therefore excluded many patients who stopped treatment earlier due to side effects.",
"   </p>",
"   <p>",
"    The nature of myocardial damage from antiangiogenic TKI treatment has not been extensively investigated, although hypotheses as to an underlying off-target pathophysiologic mechanism of cardiotoxicity caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/86-88\">",
"     86-88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78098554\">",
"    <span class=\"h4\">",
"     Regorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a placebo-controlled clinical trial in patients with metastatic colorectal cancer,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    was associated with an increased incidence of myocardial ischemia and infarction (1.2 versus 0.4 percent with placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/89\">",
"     89",
"    </a>",
"    ]. Heart failure has not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87979669\">",
"    <span class=\"h4\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;In trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    , cardiac dysfunction (decreased LVEF and clinical heart failure) has been observed. As an example, in a trial in advanced soft tissue sarcoma, myocardial dysfunction (symptomatic, or &ge;15 percent absolute decline in LVEF compared to baseline, or decrease in LVEF &ge;10 percent to below the lower limit of normal) was observed in 6.7 percent of patients treated with pazopanib compared to 2.4 percent of placebo-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    has also been associated with QTc prolongation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651224896#H1651224896\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Class effects of VEGF inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063205050\">",
"    <span class=\"h4\">",
"     Ponatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 4 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    have developed serious heart failure or left ventricular dysfunction, with some fatalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87977512\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has been sporadically reported in several trials of bevacizumab given in conjunction with anthracyclines or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    in women with metastatic breast cancer, an indication for which bevacizumab is not longer approved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/91-93\">",
"     91-93",
"    </a>",
"    ]. It has not been reported in patients treated with bevacizumab for other advanced cancers.",
"   </p>",
"   <p>",
"    In contrast with heart failure, ischemic cardiac events are increased in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H291526440\">",
"     'Arterial thromboembolic events'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The specific incidence of cardiac ischemia was addressed in a meta-analysis of five controlled trials conducted in patients with mCRC or advanced RCC that separated out risks of cardiac events and strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/56\">",
"     56",
"    </a>",
"    ]. The summary relative risk of high-grade cardiac ischemia in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was 2.14 (95% CI 1.12-4.08), and the overall incidence was 1.5 percent (95% CI 1-2.1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1465984881\">",
"    <span class=\"h3\">",
"     Monitoring and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline assessment of LVEF by echocardiogram or MUGA scan and an ECG are suggested variably by the manufacturers of the different agents. Some have suggested that patients receiving these drugs be treated as \"stage A\" heart failure patients, ie, at risk for heart failure, but without structural heart disease or symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/94\">",
"     94",
"    </a>",
"    ]. The 2005 American Heart Association (AHA) heart failure guidelines (with 2009 focused update), which include recommendations for stage A patients, recommend that patients receiving potentially cardiotoxic agents undergo noninvasive assessment of left ventricular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/95\">",
"     95",
"    </a>",
"    ]. Other recommendations for stage A patients at high risk for heart failure include monitoring for symptoms and signs of heart failure and management of cardiovascular risk factors including control of blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link&amp;anchor=H2#H2\">",
"     \"Prognosis of heart failure\", section on 'Stages of HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, obtaining a baseline assessment of LVEF in all patients receiving these drugs is not supported by compelling data. We obtain a baseline LVEF evaluation only in older adult patients and those with a history of prior cardiovascular disease or prior anthracycline exposure.",
"   </p>",
"   <p>",
"    Caution and close serial monitoring of LVEF is warranted during therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and VEGFR TKIs for older adult patients and for those with a history of poorly-controlled hypertension, heart disease, or anthracycline exposure. However, in our view, routine serial monitoring of ECGs and cardiac enzymes during therapy in the absence of symptoms is not warranted for other patients. The clinical significance of asymptomatic increases in cardiac enzymes or ECG changes to detect myocardial ischemia remains undefined. Clinicians should maintain a low threshold for cardiac evaluation in symptomatic patients.",
"   </p>",
"   <p>",
"    The US FDA-approved manufacturer&rsquo;s labeling recommends discontinuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    in the presence of clinical manifestations of heart failure, and interruption of therapy or dose reduction in patients without clinical evidence of heart failure, but with an ejection fraction &lt;50 percent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    &gt;20 percent below baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US FDA manufacturer&rsquo;s labeling information for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    recommends temporary or permanent discontinuation of the drug in any patient who develops cardiac ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Labeling information for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    suggests discontinuation of the drug in any patient who develops &ldquo;serious&rdquo; heart failure.",
"   </p>",
"   <p>",
"    Guidance is not available for the other agents of this class. However, in general we hold the TKI for cardiotoxicity, and if the event was not major and the patient recovered, we would consider restarting therapy if there was evidence of clinical benefit. For patients who develop heart failure during treatment, it is reasonable to switch to an alternative, less cardiotoxic anti-VEGF agent, if one is available (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for patients with RCC who develop heart failure while receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063205212\">",
"    <span class=\"h1\">",
"     CLASS EFFECTS OF VEGF TYROSINE KINASE INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063204941\">",
"    <span class=\"h2\">",
"     Prolongation of the QTc interval and cardiac arrhythmias",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063205064\">",
"    <span class=\"h3\">",
"     Vandetanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    has been associated with prolongation of the QTc interval (",
"    <a class=\"graphic graphic_waveform graphicRef77018 \" href=\"mobipreview.htm?26/24/27008\">",
"     waveform 1",
"    </a>",
"    ), torsades de pointes, and sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. The magnitude of risk can be illustrated by a meta-analysis of nine phase II or III trials of vandetanib in a variety of malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/99\">",
"     99",
"    </a>",
"    ]. The overall incidence of all-grade (&gt;0.45 seconds) and high-grade (&gt;0.5 seconds or symptomatic and requiring treatment) QTc interval prolongation was 16.4 and 3.7 percent, respectively, among nonthyroid cancer patients (predominantly breast and lung cancer), and 18 and 12 percent, respectively, among thyroid cancer patients who received treatment for a substantially longer period of time (median 18.8 versus 1.8 to 3 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Largely because of its cardiovascular risk,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    is only available through a restricted distribution program (the Vandetanib Risk Evaluation and Mitigation Strategy [REMS] Program). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23288?source=see_link&amp;anchor=H10576313#H10576313\">",
"     \"Chemotherapy and immunotherapy for medullary thyroid cancer\", section on 'Vandetanib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    should not be initiated in a patient with a QTc interval &gt;450 milliseconds (ms) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/100\">",
"     100",
"    </a>",
"    ]. Because of the risk of cardiotoxicity, the FDA-approved labeling includes a black box warning to correct hypocalcemia, hypokalemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypomagnesemia prior to drug administration. In addition, given the long half life of the drug (19 days), EKGs are recommended to monitor the QT interval at baseline, at two to four weeks, and 8 to 12 weeks after starting treatment, and every three months thereafter. Monitoring of serum potassium, calcium, and magnesium levels as well as TSH is recommended on the same schedule. Concurrent administration of drugs known to prolong the QTc interval should be avoided (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients who develop a QTc interval greater than 500 ms during treatment should stop taking the drug until the QTc returns to &lt;450 ms; dosing should be resumed at a reduced dose. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063205071\">",
"    <span class=\"h3\">",
"     Sunitinib and sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    also has a dose-dependent effect on the QTc interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/84,101,102\">",
"     84,101,102",
"    </a>",
"    ]. In contrast, the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    on changes in the QTc interval appears modest and unlikely to be of clinical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific guidelines for monitoring with EKGs during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    therapy and managing the dose in patients who develop QTc prolongation are lacking. In general, we obtain a baseline EKG in patients treated with sunitinib and monitor with EKGs during therapy only if the patient is also receiving therapy with other drugs that have the potential to prolong the QTc interval (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063205152\">",
"    <span class=\"h3\">",
"     Ponatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    have developed symptomatic bradyarrhythmias and 5 percent supraventricular tachyarrhythmias (predominantly atrial fibrillation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1556580909\">",
"    <span class=\"h3\">",
"     Monitoring and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, specific guidelines are available for assessing and monitoring the QTc interval in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    . Formal guidelines are not available for any of the other antiangiogenic TKIs.",
"   </p>",
"   <p>",
"    For any patient receiving therapy with an antiangiogenic TKI, careful review of concomitant medications is warranted, especially drugs that are associated with increased QTc (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 5",
"    </a>",
"    ). Patients with a history of QT interval prolongation, those who are taking antiarrhythmics, and those with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances may be more prone to develop a prolonged QTc. Concomitant treatment with strong CYP3A4 inhibitors (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 6",
"    </a>",
"    ), which may increase plasma concentrations of antiangiogenic TKIs, may require a dose reduction of the TKI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21640979\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several classes of molecularly-targeted antiangiogenic agents are available for the treatment of cancer, including the vascular endothelial growth factor (VEGF) ligand inhibiting agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"       aflibercept",
"      </a>",
"      ) and tyrosine kinase inhibitors (TKIs) that target angiogenesis by blocking VEGF signaling (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"       cabozantinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"       vandetanib",
"      </a>",
"      ). VEGF-targeting agents have unique toxicities that differ from those of traditional chemotherapy. Toxicities of antiangiogenic agents may be classified as VEGF class-specific, drug class-specific (eg, associated with antiangiogenic TKIs), or agent-specific. (See",
"      <a class=\"local\" href=\"#H112181231\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many of these adverse effects, particularly the cardiovascular effects, can be serious and potentially fatal. (See",
"      <a class=\"local\" href=\"#H89432458\">",
"       'Risk of fatality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful selection of patients for therapy with angiogenesis inhibitors (ie, reasonable performance status, controlled blood pressure and lack of serious cardiovascular events within 6 to 12 months) as well as close monitoring and prompt intervention are necessary to alleviate the risks posed by these toxicities.",
"     </li>",
"     <li>",
"      All commercially available angiogenesis inhibitors have been implicated in the development of hypertension. The overall incidence of all-grade hypertension is approximately 22 to 25 percent, with severe hypertension in 7 to 8 percent. (See",
"      <a class=\"local\" href=\"#H21639456\">",
"       'Incidence and characteristics'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The development of either systolic or diastolic hypertension may represent a surrogate marker for response or improved outcomes with both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      and the antiangiogenic TKIs. (See",
"      <a class=\"local\" href=\"#H30695629\">",
"       'Association with antitumor efficacy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Recommendations for monitoring and management of hypertension from a National Cancer Institute Cardiovascular Toxicities Panel include the following four components (see",
"      <a class=\"local\" href=\"#H21639463\">",
"       'Monitoring and management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Perform a pretreatment evaluation and screening, including formal risk assessment for potential cardiovascular complications.",
"     </li>",
"     <li>",
"      Identify and treat preexisting hypertension before using these agents.",
"     </li>",
"     <li>",
"      Actively monitor blood pressure during treatment, with more frequent measurement in the first several weeks of therapy.",
"     </li>",
"     <li>",
"      Manage blood pressure during therapy, with a goal of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg for most patients; lower in those with specific preexisting cardiovascular risk factors such as diabetes or chronic kidney disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased risk for arterial thromboembolic events (ATEs) has been linked to the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      and a number of the antiangiogenic TKIs. Given that the risk appears to be highest in patients with a prior history of an ATE and, in some reports, in those over age 65, bevacizumab should be used with caution in this group. The drug should be discontinued for grade 3 or higher (",
"      <a class=\"graphic graphic_table graphicRef87383 \" href=\"mobipreview.htm?33/30/34283\">",
"       table 3",
"      </a>",
"      ) new or worsened arterial thrombotic events during bevacizumab therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/43/36538/abstract/61\">",
"       61",
"      </a>",
"      ]. Continuation with concurrent anticoagulation might be considered in selected patients who are clearly benefiting from bevacizumab, and who are willing to accept the uncertainty of risk from continued use of bevacizumab in this setting. (See",
"      <a class=\"local\" href=\"#H291526440\">",
"       'Arterial thromboembolic events'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients being considered for an antiangiogenic TKI, low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      prophylaxis is reasonable for high-risk patients (eg, prior ATE). Patients who develop an ATE should discontinue the TKI and the ATE managed according to current standards of care. Reintroduction of the TKI may be considered cautiously in selected cases if the patient was deriving benefit from the drug. (See",
"      <a class=\"local\" href=\"#H78098047\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The aggregate of data suggest no significant increase in the risk of venous thromboembolic events (VTEs) with VEGF-targeted therapy. (See",
"      <a class=\"local\" href=\"#H291526448\">",
"       'Venous thromboembolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1465984660\">",
"       'Venous thromboembolic events'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The decision to continue",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in a patient who develops a VTE during therapy must be individualized. Continuation of bevacizumab with concurrent anticoagulation is a safe approach for patients who are clearly benefiting from bevacizumab. (See",
"      <a class=\"local\" href=\"#H78097976\">",
"       'Prevention and management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If a patient undergoing therapy with an antiangiogenic TKI develops a VTE, a brief withdrawal of the TKI may be prudent while anticoagulation is being attained. (See",
"      <a class=\"local\" href=\"#H291526581\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Declines in left ventricular ejection fraction can be seen in patients treated with VEGF-targeted therapies; they are predominantly seen in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      . In addition, myocardial ischemia has been seen in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"       regorafenib",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      A baseline assessment of left ventricular ejection fraction (LVEF) prior to treatment is warranted in older adult patients and for those with a history of prior cardiovascular disease or anthracycline exposure. Caution and close serial monitoring of LVEF are warranted during therapy with bevacizumab and antiangiogenic TKIs in older adult patients and those with a history of prior hypertension or heart disease or anthracycline exposure. (See",
"      <a class=\"local\" href=\"#H21640522\">",
"       'Left ventricular dysfunction and myocardial ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prolongation of the QTc interval has been described with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"       vandetanib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      , but not with other antiangiogenic TKIs. Specific guidelines for managing QTc prolongation during vandetanib therapy are available. (See",
"      <a class=\"local\" href=\"#H1063204941\">",
"       'Prolongation of the QTc interval and cardiac arrhythmias'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For any patient receiving therapy with an antiangiogenic TKI, careful review of concomitant medications is warranted, especially drugs that are associated with increased QTc (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"       table 5",
"      </a>",
"      ). Patients with a history of QT interval prolongation, those who are taking antiarrhythmics, and those with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances may be more prone to develop a prolonged QTc. Concomitant treatment with strong CYP3A4 inhibitors (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"       table 6",
"      </a>",
"      ), which may increase plasma concentrations of the antiangiogenic TKIs, may require a dose reductions of the antiangiogenic TKI.",
"     </li>",
"     <li>",
"      A multi-disciplinary approach that includes the treating oncologist and cardiologist can provide highly specialized care to patients receiving antiangiogenic therapy and lead to a comprehensive approach to potential cardiovascular toxicities.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/1\">",
"      Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency website is file://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp&amp;mid= (Accessed on December 13, 2012).",
"    </li>",
"    <li>",
"     Tabernero J VCE, Lakomy R, et al. Results from VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC). ESMO Congress November 2011, Late Breaking Abstract #6, Stockholm, Sweden.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/4\">",
"      Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/5\">",
"      Schutz FA, Je Y, Richards CJ, Choueiri TK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012; 30:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/6\">",
"      Sivendran S, Liu Z, Portas LJ Jr, et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012; 38:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/7\">",
"      Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003; 107:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/8\">",
"      Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274:H1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/9\">",
"      Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 2005; 90:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/10\">",
"      Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 2004; 255:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/11\">",
"      Robinson ES, Khankin EV, Choueiri TK, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010; 56:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/12\">",
"      Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006; 24:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/13\">",
"      Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/14\">",
"      Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/15\">",
"      Mir O, Coriat R, Cabanes L, et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 2011; 16:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/16\">",
"      Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30:3499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/17\">",
"      Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/18\">",
"      Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/19\">",
"      Bamias A, Manios E, Karadimou A, et al. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer 2011; 47:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/20\">",
"      Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/21\">",
"      Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/22\">",
"      Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17:3841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/23\">",
"      Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA approves Cometriq to treat rare type of thyroid cancer. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm (Accessed on December 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/25\">",
"      An MM, Zou Z, Shen H, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010; 66:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/26\">",
"      Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009; 48:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/27\">",
"      Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/28\">",
"      Qi WX, Lin F, Sun YJ, et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol 2013; 71:431.",
"     </a>",
"    </li>",
"    <li>",
"     Motzer RJ HT, Reeves J, et al. Randomized, open label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC); Results of the COMPARZ trial. Proc European Society of Medical Oncology Congress LBA8, Vienna, Austria September 28-October 2, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/30\">",
"      Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15:6250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/31\">",
"      Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/32\">",
"      Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/33\">",
"      Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010; 28:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/34\">",
"      Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26:4672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/35\">",
"      Ryanne Wu R, Lindenberg PA, Slack R, et al. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer 2009; 40:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/36\">",
"      Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/37\">",
"      Goodwin R, Ding K, Seymour L, et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 2010; 21:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/38\">",
"      Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103:763.",
"     </a>",
"    </li>",
"    <li>",
"     Harzstark AL HS, Stadler WM, et al. Hypertension is associated with clinical outcome for patients(pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206. Genitourinary Cancer Symposium 2010 (abstr 351).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/40\">",
"      Wick A, Sch&auml;fer N, D&ouml;rner N, et al. Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. J Neurooncol 2010; 97:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/41\">",
"      Hurwitz HI, Douglas PS, Middleton JP, et al. Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies. Oncologist 2013; 18:273.",
"     </a>",
"    </li>",
"    <li>",
"     Rini BI, Cohen DP, Lu D, et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (abstract). American Society of Clinical Oncology (ASCO) 2010 Genitourinary Cancers Sympsoium.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/43\">",
"      Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol 2009; 27:6152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/44\">",
"      Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/45\">",
"      Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/46\">",
"      Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/47\">",
"      Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009; 27:4865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/48\">",
"      Mir O, Mouthon L, Alexandre J, et al. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 2007; 99:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/49\">",
"      Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/50\">",
"      Gonz&aacute;lez-Pacheco FR, Deudero JJ, Castellanos MC, et al. Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am J Physiol Heart Circ Physiol 2006; 291:H1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/51\">",
"      Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/52\">",
"      Tebbutt NC, Murphy F, Zannino D, et al. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol 2011; 22:1834.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/SAFETY/2004/safety04.htm#avastin (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/54\">",
"      Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/55\">",
"      Schutz FA, Je Y, Azzi GR, et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011; 22:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/56\">",
"      Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/57\">",
"      Van Cutsem E, Khayat D, Verslype C, et al. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer 2013; 49:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/58\">",
"      Tang PA, Cohen SJ, Kollmannsberger C, et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res 2012; 18:6023.",
"     </a>",
"    </li>",
"    <li>",
"     FDA-approved manufacturer's package insert for bevacizumab available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e#section-5-5 (Accessed on December 14, 2012).",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f6725df6-50ee-4b0a-b900-d02ba634395d#section-5.6 (Accessed on February 01, 2013).",
"    </li>",
"    <li>",
"     Common Toxicity Criteria of the National Cancer Institute available online at file://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/62\">",
"      Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/63\">",
"      Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011; 29:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/64\">",
"      Leighl NB, Bennouna J, Yi J, et al. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer 2011; 104:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/65\">",
"      Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/66\">",
"      Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.",
"     </a>",
"    </li>",
"    <li>",
"     Sternberg CN, Szczylik C, Lee ES, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) (abstract #5021). J Clin Oncol 2009; 27:240s.",
"    </li>",
"    <li>",
"     US FDA-approved manufacturer's package insert available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=807f988e-117b-4497-934d-73aa78baac71 (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/69\">",
"      Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:234S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/70\">",
"      Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/71\">",
"      Stadler WM, Cao D, Vogelzang NJ, et al. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 2004; 10:3365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/72\">",
"      Zangari M, Anaissie E, Stopeck A, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004; 10:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/73\">",
"      Heymach JV, Desai J, Manola J, et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 2004; 10:5732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/74\">",
"      Sonpavde G, Je Y, Schutz F, et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/75\">",
"      Qi WX, Min DL, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis. Int J Cancer 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/76\">",
"      Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/77\">",
"      Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/78\">",
"      Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009; 20:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/79\">",
"      Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/80\">",
"      Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/81\">",
"      Richards CJ, Je Y, Schutz FA, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 2011; 29:3450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/82\">",
"      Witteles RM, Telli M. Underestimating cardiac toxicity in cancer trials: lessons learned? J Clin Oncol 2012; 30:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/83\">",
"      Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/84\">",
"      Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26:5204.",
"     </a>",
"    </li>",
"    <li>",
"     Haas NB MJ, Ky B, et al. Cardiac safety analysis for a phase III trial of sunitinib or sorafenib or placebo in patients with resected renal cell carcinoma. J Clin Oncol 30, 2012 (suppl; abstr 4500).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/86\">",
"      Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/87\">",
"      Hsieh PC, MacGillivray C, Gannon J, et al. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006; 114:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/88\">",
"      Cheng H, Force T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis 2010; 53:114.",
"     </a>",
"    </li>",
"    <li>",
"     FDA-approved manufacturer's labeling information available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7#section-6.5or= (Accessed on October 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/90\">",
"      van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/91\">",
"      Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011; 29:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/92\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23:7685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/93\">",
"      Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/94\">",
"      Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/95\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     FDA-approved manufacturer's package insert for sunitinib available at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c (Accessed on December 18, 2012).",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0 (Accessed on February 01, 2013).",
"    </li>",
"    <li>",
"     US FDA drug approval summary for vandetanib in medullary thyroid cancer available online at file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/99\">",
"      Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One 2012; 7:e30353.",
"     </a>",
"    </li>",
"    <li>",
"     FDA-approved manufacturer's package insert for vandetanib available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525 (Accessed on January 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/101\">",
"      Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007; 25:3362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/102\">",
"      Bello CL, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res 2009; 15:7045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/43/36538/abstract/103\">",
"      Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 2011; 67:751.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14250 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36538=[""].join("\n");
var outline_f35_43_36538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21640979\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112181231\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89432458\">",
"      RISK OF FATALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H291525424\">",
"      CLASS EFFECTS OF ALL VEGF INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21639449\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21639456\">",
"      - Incidence and characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30695629\">",
"      - Association with antitumor efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21639463\">",
"      - Monitoring and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H291526412\">",
"      Arterial and venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H291526420\">",
"      - Bevacizumab and aflibercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H291526440\">",
"      Arterial thromboembolic events",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H78097915\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H291526448\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H78097976\">",
"      - Prevention and management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H291526542\">",
"      - VEGF receptor TKIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1465984650\">",
"      Arterial thromboembolic events",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H78098047\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1465984660\">",
"      Venous thromboembolic events",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H291526581\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21640522\">",
"      Left ventricular dysfunction and myocardial ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21640884\">",
"      - VEGF receptor TKIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H78098454\">",
"      Sunitinib and sorafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H78098554\">",
"      Regorafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H87979669\">",
"      Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1063205050\">",
"      Ponatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87977512\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1465984881\">",
"      - Monitoring and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1063205212\">",
"      CLASS EFFECTS OF VEGF TYROSINE KINASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1063204941\">",
"      Prolongation of the QTc interval and cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1063205064\">",
"      - Vandetanib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1063205071\">",
"      - Sunitinib and sorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1063205152\">",
"      - Ponatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1556580909\">",
"      - Monitoring and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21640979\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14250\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14250|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/25/37275\" title=\"table 1\">",
"      NCI CTCAE hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/7/22652\" title=\"table 2A\">",
"      HTN with VEGF inhib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/36/33356\" title=\"table 2B\">",
"      Risk factors BP VSP rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/30/34283\" title=\"table 3\">",
"      NCI CTCAE v40 grading for thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/59/19387\" title=\"table 4\">",
"      NCI CTCAE Heart Failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/48/2830\" title=\"table 5\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/45/9950\" title=\"table 6\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14250|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?26/24/27008\" title=\"waveform 1\">",
"      Prolonged QT interval tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23288?source=related_link\">",
"      Chemotherapy and immunotherapy for medullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28246?source=related_link\">",
"      Management of severe asymptomatic hypertension (hypertensive urgencies)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=related_link\">",
"      Systemic treatment for advanced hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11832?source=related_link\">",
"      The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41466?source=related_link\">",
"      Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=related_link\">",
"      Treatment of venous thromboembolism in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_43_36539="Spectrum of IgG4 systemic disease";
var content_f35_43_36539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spectrum of IgG4 systemic disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pancreas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bile ducts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG4-associated cholangitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Salivary gland",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic sclerosing sialadenitis (K&uuml;ttner's tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mikulicz's disease (IgG4-related plasmacytic exocrinopathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patchy ground glass, nodular, and consolidative lung opacities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mediastinal fibrosis, adenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Retroperitoneum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Chronic periaortitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic retroperitoneal fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Kidneys",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tubulointerstitial nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Orbits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG4-associated pseudolymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36539=[""].join("\n");
var outline_f35_43_36539=null;
var title_f35_43_36540="Pediatric ulcerative colitis activity index";
var content_f35_43_36540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric ulcerative colitis activity index",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Item",
"      </td>",
"      <td class=\"subtitle1\">",
"       Points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Abdominal pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       No pain",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pain can be ignored",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pain cannot be ignored",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Rectal bleeding",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       None",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Small amount only, in &lt;50 percent of stools",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Small amount with most stools",
"      </td>",
"      <td>",
"       20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Large amount (&gt;50 percent of the stool content)",
"      </td>",
"      <td>",
"       30",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Stool consistency of most stools",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Formed",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Partially formed",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Completely unformed",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Number of stools per 24 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       0 to 2",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3 to 5",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       6 to 8",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;8",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Nocturnal stools (any episode causing wakening)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Yes",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Activity level",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       No limitation of activity",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Occasional limitation of activity",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Severe restricted activity",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Sum of PUCAI (0 to 85)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Turner, D, Otley, AR, Mack, D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study. Gastroenterology 2007; 133:423. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36540=[""].join("\n");
var outline_f35_43_36540=null;
var title_f35_43_36541="Global mortality by age";
var content_f35_43_36541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Estimated global mortality rates from fire-related burn injuries in 2004, by age and gender.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 326px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mortality rates are expressed as deaths per 100,000 population. Mortality rate is the greatest in the group age 60 and greater. Overall, mortality rates are higher for females in all age categories. These data include high income, middle income, and low income countries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     World Health Organization. The Global Burden of Disease: 2004 Update. World Health Organization, Geneva 2008. Available online at: www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.(Accessed on April 2, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36541=[""].join("\n");
var outline_f35_43_36541=null;
var title_f35_43_36542="Asthma education";
var content_f35_43_36542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivery of asthma education by clinicians during patient care visits",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Assessment questions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Information",
"       </td>",
"       <td class=\"subtitle1\">",
"        Skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Recommendations for initial visit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Focus on:",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        Teach in simple language:",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        Teach or review and demonstrate:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Expectations of visit",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; What is asthma? Asthma is a chronic lung disease. The airways are very sensitive. They become inflamed and narrow; breathing becomes difficult.",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Inhaler and spacer or valved holding chamber (VHC) use. Check performance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Asthma control",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; The definition of asthma control: few daytime symptoms, no nighttime awakenings due to asthma, able to engage in normal activities, normal lung function.",
"       </td>",
"       <td class=\"sublist2_start\">",
"        &bull; Self-monitoring skills that are tied to a written action plan:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Patients' goals of treatment",
"       </td>",
"       <td class=\"sublist2_start\">",
"        &bull; Asthma treatments: two types of medicines are needed:",
"       </td>",
"       <td class=\"sublist2\">",
"        - Recognize intensity and frequency of asthma symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Medications",
"       </td>",
"       <td class=\"sublist2\">",
"        - Long-term control: medications that prevent symptoms, often by reducing inflammation.",
"       </td>",
"       <td class=\"sublist2\">",
"        - Review the signs of deterioration and the need to reevaluate therapy:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Quality of life",
"       </td>",
"       <td class=\"sublist2\">",
"        - Quick relief: short-acting bronchodilator relaxes muscles around airways.",
"       </td>",
"       <td class=\"sublist3\">",
"        Waking at night or early morning with asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"What worries you most about your asthma?\"",
"        </em>",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Bring all medications to every appointment.",
"       </td>",
"       <td class=\"sublist3\">",
"        Increased medication use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"What do you want to accomplish at this visit?\"",
"        </em>",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; When to seek medical advice. Provide appropriate telephone number.",
"       </td>",
"       <td class=\"sublist3\">",
"        Decreased activity tolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"What do you want to be able to do that you can't do now because of your asthma?\"",
"        </em>",
"       </td>",
"       <td rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Use of a written asthma action plan that includes instructions for daily management and for recognizing and handling worsening asthma.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"What do you expect from treatment?\"",
"        </em>",
"       </td>",
"       <td rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"What medicines have you tried?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"What other questions do you have for me today?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"Are there things in your environment that make your asthma worse?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Recommendations for first followup visit (2 to 4 weeks or sooner as needed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Focus on:",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        Teach in simple language:",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        Teach or review and demonstrate:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Expectations of visit",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Use of two types of medications.",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Use of written asthma action plan. Review and adjust as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Asthma control",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Remind patient to bring all medications and the peak flow meter, if using, to every appointment for review.",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Peak flow monitoring if indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Patients' goals of treatment",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Self-assessment of asthma control using symptoms and/or peak flow as a guide.",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Correct inhaler and spacer or VHC technique.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Medications",
"       </td>",
"       <td rowspan=\"8\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"8\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Patient treatment preferences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Quality of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ask relevant questions from previous visit and also ask:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"What medications are you taking?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"How and when are you taking them?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"What problems have you had using your medications?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"Please show me how you use your inhaled medications.\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Recommendations for second followup visit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Focus on:",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        Teach in simple language:",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        Teach or review and demonstrate:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Expectations of visit",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Self-assessment of asthma control, using symptoms and/or peak flow as a guide.",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Inhaler/spacer or VHC technique.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Asthma control",
"       </td>",
"       <td class=\"sublist2_start\">",
"        &bull; Relevant environmental control/avoidance strategies:",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Peak flow monitoring technique.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Patients' goals of treatment",
"       </td>",
"       <td class=\"sublist2\">",
"        - How to identify home, work, or school exposures that can cause or worsen asthma",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Use of written asthma action plan. Review and adjust as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Medications",
"       </td>",
"       <td class=\"sublist2\">",
"        - How to control house-dust mites, animal exposures if applicable",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Confirm that patient knows what to do if asthma gets worse.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Quality of life",
"       </td>",
"       <td class=\"sublist2\">",
"        - How to avoid cigarette smoke (active and passive)",
"       </td>",
"       <td rowspan=\"8\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ask relevant questions from previous visits and also ask:",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Review all medications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"Have you noticed anything in your home, work, or school that makes your asthma worse?\"",
"        </em>",
"       </td>",
"       <td rowspan=\"6\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"Describe for me how you know when to call your doctor or go to the hospital for asthma care.\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"What questions do you have about the asthma action plan?\" \"Can we make it easier?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"Are your medications causing you any problems?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"Have you noticed anything in your environment that makes your asthma worse?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"Have you missed any of your medications?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Recommendations for all subsequent visits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Focus on:",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        Teach in simple language:",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        Teach or review and demonstrate:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Expectations of visit",
"       </td>",
"       <td class=\"sublist2_start\">",
"        &bull; Review and reinforce all:",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Inhaler/spacer or VHC technique.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Asthma control",
"       </td>",
"       <td class=\"sublist2\">",
"        - Educational messages",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Peak flow monitoring technique, if appropriate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Patients' goals of treatment",
"       </td>",
"       <td class=\"sublist2\">",
"        - Environmental control strategies at home, work, or school",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Use of written asthma action plan. Review and adjust as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Medications",
"       </td>",
"       <td class=\"sublist2\">",
"        - Medications",
"       </td>",
"       <td class=\"indent1\">",
"        &bull; Confirm that patient knows what to do if asthma gets worse.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Quality of life",
"       </td>",
"       <td class=\"sublist2\">",
"        - Self-assessment of asthma control, using symptoms and/or peak flow as a guide",
"       </td>",
"       <td rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ask relevant questions from previous visits and also ask:",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"How have you tried to control things that make your asthma worse?\"",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         \"Please show me how you use your inhaled medication.\"",
"        </em>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36542=[""].join("\n");
var outline_f35_43_36542=null;
var title_f35_43_36543="Prevention of VAP";
var content_f35_43_36543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    The relationship between pathogenesis and preventive strategies for hospital-associated pneumonia (HAP) and ventilator-associated pneumonia (VAP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 421px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Prevention strategies that should be limited to specific patient populations according to available clinical data.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004; 32:1396. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_43_36543=[""].join("\n");
var outline_f35_43_36543=null;
